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ABSTRACT
Atherosclerosis is a chronic inflammatory process occurring within arterial blood
vessels. Clinical sequelae of atherosclerotic plaque build up include angina,
myocardial infarction and ischaemic stroke, imposing a massive burden on
healthcare provision. The retention and subsequent oxidative modification of low-
density lipoprotein within the subintimal space provides a persistent stimulus for
inflammation throughout atherosclerotic plaque development. Understanding the
inflammatory mechanisms of oxidised LDL-induced endothelial cell injury will be
necessary before devising therapies that intercept, reverse and prevent atherosclerotic
plaque development. The work in this thesis is based on a conviction that strategies
aimed at augmenting endogenous anti-inflammatory and repair mediators through
local gene delivery have the potential to provide lasting effectiveness with low
toxicity.
An in vitro model of atherosclerotic endothelial cells was established using
cultured human umbilical vein endothelial cells and oxidised LDL. Gene expression
profiling identified angiopoietin-2 as a target gene up regulated by oxidised LDL
incubation in endothelial cells. High levels of this angiogenic factor were also found
in endothelial cell culture supernatants following oxidised LDL incubation and
within zones of neointimal angiogenesis in atherosclerotic human coronary arteries.
Gene expression profiling failed to identify candidate 'endothelial protective'
mediators and attention focused on elafin and secretory leucocyte protease inhibitor
(SLPI), two low molecular weight elastase inhibitors. Elafin has been demonstrated
within human coronary arteries although its function as a locally active antiprotease,
II
antagonising the inflammatory effects of human neutrophil elastase (HNE) and
bacterial injury has been characterised best within the lung.
Here we have used adenovirus as a vector to deliver elafin and SLPI genes to
human endothelial cells and macrophages. We have devised a protocol involving
precomplexing of adenovirus with lipofectamine to enhance gene delivery and
subsequent gene expression in human endothelial cells and to facilitate gene delivery
to human macrophages.
Elafin and SLPI overexpression were associated with reduced inflammatory
cytokine production in endothelial cells and macrophages in response to a range of
atherogenic stimuli including oxidised LDL. This anti-inflammatory activity was
associated with reduced activation of the transcription factor NF-kB and preservation
of its inhibitory sub-unit IkBcl Furthermore, elafin overexpression protected
endothelial cells from HNE mediated injury and attenuated FINE mediated
impairment of macrophage apoptotic cell recognition.
In summary, angiopoietin-2 was identified as a novel mediator produced by
endothelial cells in response to oxidised LDL and may contribute to plaque
development through facilitation of neointimal angiogenesis. Adenoviral
overexpression of elafin and SLPI exhibited therapeutic potential through reducing
inflammatory responses and protecting the structure and function of endothelial cells
and macrophages in the presence of atherogenic stimuli.
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Atherosclerosis is a chronic inflammatory disease of arterial blood vessels that
can begin in fetal life. The rate of atherosclerotic plaque development determines the
time of onset of plaque erosion or rupture, the events responsible for morbid and fatal
clinical sequelae including myocardial infarction and ischaemic stroke. The work
described in this thesis has two principle aims. The first is to identify and if possible
characterise key mediators responsible for driving plaque development and
protecting the endothelium from inflammatory insult. The second is to investigate a
strategy for slow ing or halting endothelial inflammation through gene transfer of the
antiproteases elafin and secretory leucocyte protease inhibitor.
Against this background, the importance of low-density lipoprotein, its
retention and oxidative modification in the subendothelial space as initiating and
driving forces in atherosclerotic plaque development, is outlined in the following
sections. Methods to characterise diseased cells and tissues using gene expression
profiling will be examined and strategies to augment endothelial defence against
inflammatory insult using gene transfer techniques, in particular, the use of
recombinant adenoviral vectors, will be discussed.
1.2 Chronic Inflammation
Inflammation is described by the sequence of events involving leukocytes




other noxious stimuli. Inflammatory responses have evolved to counter microbial
infection, cellular damage and necrosis. It is useful to recall these principles when
trying to understand processes within the arterial wall that lead to inflammation.
Although inflammatory cells were first recognised within the endothelium of rabbits
with experimental atheroma almost half a century ago (Poole et al 1958), focus on
atherosclerosis as an inflammatory process has only intensified in the last 15 years
(Ross 1986; Ross 1999). Atheroma is characterised by persistent inflammation,
beginning insidiously with later concomitant cellular injury, necrosis and repair in
the form of connective tissue replacement and angiogenesis within the arterial wall.
Macrophages and lymphocytes predominate within the cellular infiltrate and
persistent exposure to a noxious stimulus in the form of oxidised low-density
lipoprotein (oxidised LDL) occurs along with evidence of an adaptive immune
response and autoimmune mechanisms together evoking a self-perpetuating immune
reaction. These features illustrate why atherosclerosis may be considered a paradigm
of chronic inflammatory disease (Cotran et al 1999).
Atherosclerosis is a maladaptive process serving no benefit to the host. This is
in contrast to chronic inflammatory responses to microbial pathogens such as
tuberculosis. Clinical manifestations usually occur after the procreational period and
genetic predisposition to early plaque development and complications do not exert
strong selection pressures. Important factors responsible for the inexorable climb in
atheroma related disease across the world include the decline in other (infectious)
diseases, allowing sufficient lifespan to develop atheroma related complications and
the adoption of a diet and lifestyle conducive to unfavourable lipid profiles with





1.3. LIPOPROTEINS AND ATHEROGENESIS
1.3.1 Low-density lipoprotein: retention and oxidative modification within the
subendothelial space
Serum cholesterol is carried by several lipoprotein particles that perform the
complex physiological tasks of transporting dietary and endogenously produced
lipids (Tall et al 1999). Chylomicrons provide the primary means of transport of
dietary lipids, while very low-density lipoproteins (VLDL), low-density lipoproteins
(LDL), and high-density lipoproteins (HDL) function to transport endogenous lipids.
Triglyceride-rich VLDL particles containing apolipoprotein B-100 (apo B-100) and
apolipoprotein E (apo E) are synthesized by the liver and transport fatty acids to
adipose tissue and muscle. After triglyceride removal in peripheral tissues, a fraction
of the remaining VLDL remnants is metabolised to LDL particles by further removal
ofcore triglycerides and dissociation of apolipoproteins other than apo B-100. In
humans, most of the serum cholesterol is carried by LDL particles.
LDL is taken up by cells via LDL receptors that recognise an N-terminal
domain of apo B-l 00. The circulating level of LDL is determined in large part by its
rate ofuptake through the hepatic LDL receptor pathway, as evidenced by the fact
that lack of functional LDL receptors is responsible for the massive accumulation of
LDL in patients with homozygous familial hypercholesterolemia (Anderson et al
1977). Targeted disruption of the apolipoprotein E or LDL receptor genes in mice,
results in marked increases in VLDL and/or LDL cholesterol levels. When such
animals are fed high cholesterol diets, plasma cholesterol levels are greatly increased
(Breslow 1996; Smithies et al 1995). Although mice are resistant to the development
of atherosclerosis, the combination of these genetic and dietary manipulations results
in massive hypercholesterolemia leading to extensive atherosclerotic disease that


















Figure 1.1 Initiating events in the development of an atherosclerotic
fatty streak lesion
Key to figure 1.1
Adhesion molecules: VCAM-1, ICAM-1, P-Selectin, E-selectin
A |li| Chemokines: MCP-1, IL-8
Chemokine receptors: CXCR-2, CCR-2





Figure 1.1 Initiating events in the development of an atherosclerotic fatty streak
lesion (continued)
This diagram illustrates the central role of entrapment of circulating LDL within the
intimal space with subsequent oxidative modification to minimally modified (mm-
LDL) and fully oxidised LDL (ox-LDL). Candidate oxidant generating systems
within the intimal space include 15-lipoxygenase, myeloperoxidase and inducible
NO synthase. Both mm-LDL and oxidised LDL are recognised by scavenger
receptors resulting in adhesion molecule expression and chemokine release by
endothelial cells. Monocytes are recruited into the intimal space in regions with high
chemokine and adhesion molecule expression. Uptake of oxidised LDL results in
macrophage foam cell formation. There exists the potential for cholesterol efflux and
reverse cholesterol transport through membrane transporters (not shown). Oxidised
LDL epitopes are immunogens and contribute to the cellular and humoral immune
responses that help perpetuate the chronic inflammatory state. There is evidence of T
cell activation within the plaque with the production of Thl cytokines such as
interferon y and Th2 cytokines such as IL-4. Continued oxidised LDL uptake by
macrophages and vascular smooth muscle cells (stimulated to proliferate and migrate
into the intima), combined with the local cytokine environment result in apoptotic
and necrotic cell death. The subsequent release of insoluble lipid material leads to the




The development ofmurine models of atherosclerosis has facilitated evaluation
of specific genes and the proteins they encode in lesion development. The crossing of
these animals with mice that have been engineered to overexpress or lack genes of
interest has led to a growing list of mediators that accelerate or retard the rate at
which lesions develop, and/or alter lesion composition.
Atherosclerotic lesions begin as fatty streaks underlying the endothelium of
large arteries. Figure 1.1 summarises initiating events in the development of
atheroma. Factors responsible for retention of LDL in the matrix within the
subendothelial space are important. Early accumulation of atherogenic lipoproteins
within the arterial wall is concentrated in areas such as bifurcations, known to be
prone to later development of atheroma, although the rates of LDL entry into
susceptible and resistant sites are the same (Schwenke et al 1989a; Schwenke et al
1989b). Recently the matrix proteoglycan binding site in apo B-100 was identified
(Boren et al 1998) and atherosclerotic mice expressing proteoglycan binding
defective LDL have reduced plaque burden (Skalen et al 2002).
Many lines of evidence suggest that oxidative modifications in the lipid and
apo B-100 components of LDL drive the initial formation of fatty streaks (Navab et
al 1996; Steinberg et al 1989a). Indeed, immunological evidence of LDL oxidation is
observed even in human fetal arteries prior to the presence of macrophages (Napoli et
al 1997). The specific properties of oxidised LDL, usually studied following
oxidation of native LDL in vitro, depend on the extent ofmodification. This can
range from "minimal" modification, (mm-LDL) in which the LDL particle can still be
recognized by LDL receptors (Navab et al 1996). to extensive oxidation, in which the
apo B-100 component is fragmented and lysine residues are covalently modified with
reactive breakdown products of oxidised lipids (Steinberg et al 1989a). Endothelial




potential oxidant-generating systems within the subendothelial space have been
investigated that could directly or indirectly target LDL lipids, including
myeloperoxidase, nitric oxide synthase and 15-lipoxygenase (15-LO) (Daugherty et
al 1994; Steinberg et al 1989b)
1.3.2. Proatherogenic properties of oxidised LDL
Both mm-LDL and oxidised LDL elicit inflammatory responses from
endothelial cells, vascular smooth muscle cells and macrophages. The oxidation-
specific neo-epitopes within oxidised LDL are recognised by pattern-recognition
receptors (PRRs) that have evolved within the host innate immune defences to
identify conserved motifs on pathogens. Such PRRs typically recognise a restricted
pattern of ligands called pathogen-associated molecular patterns (PAMPs) (Janeway,
Jr. et al 2002). In addition to being ligands on microbes PAMPs come from a diverse
array of compounds including bacterial lipopolysaccharide, aldehyde derived
proteins and necrotic cell debris (Janeway, Jr. et al 2002; Medzhitov et al 2002).
Many of the proatherogenic properties of oxidised LDL previously identified in vitro
probably reflect interaction with PRRs (Binder et al 2002). The defining property of
oxidised LDL is its ability to bind and be taken up by scavenger receptors A (SR-A)
and CD 36 on macrophages and smooth muscle cells (Navab et al 1996). The lectin-
like oxidised LDL receptor (LOX-1) receptor, a further PRR on endothelial cells,
mediates inflammatory activation in response to oxidised LDL (Cominacini et al
2000b; Li et al 2003b; Moriwaki et al 1998). Table 1.1 provides a summary of the
inflammatory actions of oxidised LDL on various intimal cells. The recruitment of
monocytes to lesion-prone sites depends upon endothelial cell up regulation of







Increasedexpressionofadhemol culeICAM-I(P t t1992).Incr as dchem kinesL-8,MCP-lanincr asedmacrophagec lony stimulatingfactorf cilitatinleu ocy e(m nocyte)recr itm tCla sel1996;L2000;Rajava h sthel19 ).In re s dPAl-l tissuefactorexpressionf vo ingthr mbusformati(Alli tl1999).Incr asedMMP-lxpres ionfacil tatingatrixremo ellingwi hthe intima(Huangetal1999).Apoptoticndnecroticcelld a hossiblyleadingt o el ald nu onp e udetc tthr mbusformation (Harada-Shibaetl1998). OxidisedLDLexhibitsdirectch motacticac vitytowar smonocytesnhanc dup akebcrophagesl ngtchole t r les rnric ment andfo mcellormation(Quint1987).Up-regulationofscave gerCD36rec ptofu hen a cesoxidis dLDLuptake(H ntl1997). Inductionofapoptoticndnecr tcelldea hleadingtformationfn raln c otic,li ir hplaquer(Ki s herf1998).P ese t ion oxidisedLDLantig ni associationw thMHCclassIIm leculesanCD40timulation(Bind rl2002). Smoothmusclecelligra ionandproliferation(H ry1995).Pr du ti nfpl t letderiv drowthf c r,moothmusclelli gen (Stiko-Rahmetal1992).OxidisedLDLuptakeanfocellf rm ion(P s1 90).V scularmoothm sclellp ptoticde(Okura 2000). Tcellsarepr s ntinearlyndl tesion .Pres tationfoxidi edLDLa tig nbym crophagesl st tivationfcy k nepr ducingCD4+ T-helpercells(Bindtal2002).H,ce spr ominatepr ducingint rferonywhichamultipleproatherogenicropert esc ud ngactivatio ofmacrophages.Bcellsrelesnumerousndp esentithdv ntitia.T ret ngid ncef rce l-pla mallm i t dh ral responsetooxidisedLDLpit pes(Shawtal2000;Yla-Herttuala1994).
Table1.1.hpro-atherogeniceff ctsfxidisedLDLndiffer tc lltypwithinneointima Thistableindicat stscopeofpro-atherogenicacti nscrsev rallltypndin txhaustivesummaryflublish dd t .
8
Endothelialc l Macrophage Vascularmooth musclece l Lymphocyte
Chapter 1: Introduction
1.3.2.1. Activation of the inflammatory transcription factor NF-kB
Activated NF-kB has been identified in situ in human atherosclerotic plaques
but is virtually absent in vessels devoid of atherosclerosis (Brand et al 1996). NF-kB
activates a variety of genes relevant to pathophysiology of the vessel wall including
cytokines, chemokines and leucocyte adhesion molecules, as well as genes that
regulate cell proliferation and mediate cell survival. NF-kB is composed of members
of the Rel family that share a 300 amino acid domain, known as the Rel homology
domain. Fhis mediates dimerisation, nuclear translocation, DNA binding and
interaction with NF-kB inhibitors (Karin 1999). NF-kB activation is controlled by a
family of inhibitors or IkBs that bind NF-kB dimers masking the nuclear localisation
sequence, thus retaining the entire complex in the cytoplasm. Diverse stimuli activate
NF-kB. through phosphorylation and activation of the IkB kinase (IKK) complex.
This complex consists of IKK-a and IKK-J3 heterodimers, and a number of IKK-y
subunits. The activated IKK complex specifically phosphorylates the IkBs, which are
rapidly polyubiquinated, targeting them for degradation by the proteosome.
Following release from the IkB inhibitor, NF-kB dimers translocate from the
cytoplasm to the nucleus, where they bind target genes and stimulate transcription
(Karin 1999). NF-kB also activates the IkB-cc gene thus replenishing the cytoplasmic
pool of its own inhibitor and facilitating an autoregulatory system that tends to push
the activated cell back to the quiescent state.
Multiple genes involved in the atherosclerotic process are regulated by NF-kB.
Leucocyte adhesion molecules such as VCAM-1, ICAM-1 and E-selectin as well as
chemoattractant cytokines, monocyte chemoattractant protein-1 (MCP-1) and
interleukin-8 (IL-8). regulate leucocyte recruitment. The induction of tissue factor
could tip the endothelial pro/anticoagulant balance towards coagulation. Further
target gene products such as cyclin D1 may induce cell proliferation or stimulate cell
survival. NF-KB-dependent genes exert a substantial atherogenic effect on the vessel




and to subsequent amplification steps during expansion and progression of lesions.
Activation ofNF-kB by oxidised LDL is discussed in detail in chapter 3. Other
candidates for induction ofNF-kB activity within the atherosclerotic plaque include
cytokines such as TNF-a, advanced glycation end products, angiotensin-2,
haemodynamic forces and heat shock proteins (Collins et al 2001)
1.3.2.2. Adhesion molecule and chemokine expression
Several cell adhesion molecules have been shown to have roles in leucocyte
recruitment. VCAM-1 was implicated because of its increased expression on
endothelial cells over lesion-prone areas, its preferential recruitment ofmonocytes,
and its pattern of regulation by proinflammatory stimuli (Cybulsky et al 1991).
Studies to confirm a role ofVCAM-1 in atherosclerosis in the mouse have been
complicated by the fact that systemic deletion of the VCAM-1 gene results in early
embyronic death. E selectin and P selectin appear to play quantitative roles in
monocyte entry based on a 40% to 60% decrease in atherosclerosis in apo E—
deficient mice lacking both genes (Dong et al 1998). Similarly, gene deletion of
ICAM-1 resulted in small but significant reductions in monocyte recruitment to
atherosclerotic lesions in apo E-deficient mice (Collins et al 2000). Together, these
findings suggest the involvement of several adhesion molecules in the recruitment of
monocytes and T cells to the atherosclerotic lesion.
Monocyte entry into the artery wall is stimulated in part by oxidised LDL,
which can directly attract monocytes (Quinn et al 1988) and can also induce the
expression of chemotactic molecules by endothelial cells, such as monocyte
chemotactic protein 1 (MCP-1) and interleukin-8 (IL-8) (Claise et al 1996; Li et al
2000a). Monocyte expression ofCCR2, the receptor for MCP-1, is stimulated by
hypercholesterolaemia and monocytes derived from hypercholesterolaemic patients
exhibit increased chemotactic responses to MCP-1 (Han et al 1999). Disruption of




apoE knockout mice (Gosling et al 1999; Gu et al 1998). IL-8 is present in large
quantities within atherosclerotic tissue and has predominantly been characterised as a
neutrophil chemoattractant. This is surprising given that paucity of neutrophils is a
characteristic of atherosclerotic lesions. These seemingly disparate observations may
be reconciled by evidence for an active role for neutrophil derived proteins within
atheroma and this is discussed in detail in Chapter 6. IL-8 can promote firm
adherence of rolling monocytes to endothelial cell monolayers expressing E-selectin
(Gerszten et al 1999) and may be involved in stimulating endothelial cell migration
and angiogenesis within the atherosclerotic plaque. Although a clear homologue of
IL-8 has not been established in the mouse, reconstitution of the hematopoietic
system of LDL R knockout mice with bone marrow cells lacking CXCR2, one of two
high-affinity receptors for IL-8, resulted in significantly less atherosclerosis than
mice reconstituted with wild-type bone marrow cells (Boisvert et al 1998). In concert,
these findings suggest that inhibition of macrophage chemotaxis mediated by MCP-
1, IL-8 and their respective receptors may be of therapeutic potential.
1.3.2.3. Oxidised LDL uptake by macrophages and foam cell formation
Interaction of oxidised LDL with scavenger receptors on macrophages (SR-A
and CD36) results in internalisation, massive accumulation of cholesterol and foam
cell formation (de Villiers et al 1999), a hallmark of both early and late
atherosclerotic lesions. Apo E knockout mice lacking the SR-A or CD36 scavenger
receptors developed significantly less atherosclerosis than control apo E knockout
mice, with quantitatively greater reductions in lesion area observed in CD36/ApoE
double knockout mice (Febbraio et al 2000; Suzuki et al 1997). Foam cells are a
source of inflammatory mediators including cytokines, proteases and growth factors
that modulate plaque development. The factors controlling progression from fatty
streak to complicated atherosclerotic plaque with fibroproliferative stenosis or
development of a central necrotic core with a propensity to intraluminal rupture have





Firstly, the ability ofmacrophages to function as antigen presenting cells is
related to the generation of a variety of autoantibodies to oxidatively modified lipids
and an adaptive immune response. There is abundant evidence for immune activation
within atherosclerotic lesions with activation ofT cells and a florid Thl response
associated with interferon y expression (Binder et al 2002). There have been several
antigens proposed including bacterial components and heat shock proteins although
the data support oxidised LDL itself as the most important antigen. Intriguingly, the
cloning of autoantibodies from Apo E knockout mice led to identification of the E06
clone that binds both oxidised LDT and apoptotic cells (Shaw et al 2000). It was later
discovered to be identical to T15 natural antibodies to phosphorylcholine that
provide protection against S. pneumoniae in mice (Briles et al 1982). These findings
lend further support to the theory that oxidised LDE is subject to a concerted innate
immune response through recognition by PRRs.
Secondly, necrotic death of lipid-laden macrophages and vascular smooth
muscle cells contributes to the formation of'gruel' characterising advanced lesions.
Oxidised LDL can induce apoptosis in all intimal cell types and whereas apoptosis
may be a pathway to the resolution of inflammation, clearance of apoptotic cells is
likely to be impaired, their build up contributing to the necrotic core (Bennett 1999).
Finally, cholesterol accumulation is not irreversible. Mechanisms for cholesterol
efflux from lipid laden macrophages have been identified involving ABC Al, a
member of the ATP binding cassette family ofmembrane transporters (Bodzioch et
al 1999) and HDL as the extracellular receptor.
The next two sections will review evidence indicating involvement of proteases




1.4. Atherosclerotic lesion progression: the role of inflammatory
proteases
A variety of proteases have been identified within atherosclerotic tissue. Their
activity is responsible for structural and functional changes that facilitate plaque
development including breaching of the basement membrane of the neointima and
internal elastic lamina, migration and proliferation of vascular smooth muscle cells,
influx of macrophages and weakening of vulnerable shoulder regions of complicated
plaques prior to rupture.
1.4.1. Matrix metalloproteases
Matrix metalloproteinases (MMPs) are a family of zinc dependent
endopeptidases capable of cleaving all components of the extracellular matrix.
Interstitial collagenases MMP-1, MMP-13 and MMP-8 are produced at sites of
interstitial collagen cleavage and MMPs 2, 3, 7, 9, 12 and 14 also localise in human
atherosclerotic plaques (Jones et al 2003). MMPs are produced by intimal cells
(macrophages, endothelial cells and vascular smooth muscle cells) and
transcriptional regulation is in response to a range of inflammatory stimuli including
inflammatory cytokines TNF-a and interleukin-1 P (IL-ip), hypoxia, heat shock
protein 60 (HSP 60) and oxidised LDL. MMPs are produced as proenzymes
requiring proteolytic cleavage, most commonly after release into the extracellular
space, for activation and this is performed by other proteases such as plasmin or by
active MMPs. The effects ofmetalloproteases on plaque development are complex
and relate to their action on matrix degradation and the tensile strength of the vessel
wall. The accumulation ofmacrophage foam cells in atherosclerotic lesions
correlates on immunohistochemical examination with increased local release of
MMPs and a thin fibrous cap (Galis et al 1995a; Moreau et al 1999). MMPs may
reduce plaque volume. Concentration ofMMP activity at the shoulder regions of
plaques where they are most prone to rupture has implicated them in this process




It may be of clinical benefit to alter the expression or activities of
metalloproteinases. To date, there are no animal models of atherosclerosis in which
plaque rupture and acute thrombotic events contribute to plaque growth. This has
prevented testing the hypothesis that MMP inhibition may prevent plaque rupture
and has led to a focus on whether MMPs contribute to plaque growth.
Atherosclerotic mice deficient in an endogenous inhibitor of matrix metalloproteases
(Tissue inhibitor ofmetalloprotease-1; TIMP-1) had reduced plaque burden (Silence
et al 2002). In contrast, MMP-1 knockout mice backcrossed onto the same
atherosclerotic apoE knockout background had increased plaque burden with a
greater fibrillar collagen content. Although vessel ectasia and aneurysm formation
were reduced compared to control ApoE knockout mice. This suggests an important
effect of MMP-1 on the structural integrity of the vessel wall (Silence et al 2001).
1.4.2. The plasminogen-plasmin system
The blood fibrinolytic system comprises an inactive proenzyme (plasminogen)
that can be converted to the active enzyme plasmin (a serine protease) that degrades
fibrin. Two plasminogen activating enzymes have been characterised: tissue
plasminogen activator (t-PA) and urokinase plasminogen activator (u-PA). u-PA
binds a cell surface receptor, resulting in cleavage of cell-bound plasminogen. This
in turn facilitates pericellular proteolysis, including degradation of matrix and the
activation of latent growth factors and proteases. Expression of u-PA is increased in
human atherosclerotic coronary arteries (Kienast et al 1998). Overexpression of u-PA
cDNA in the carotid arteries of cholesterol fed rabbits (a further experimental model
of atherosclerosis) led to increased intimal growth and degradation of elastic laminae
(Falkenberg et al 2002). Similarly, Apo E:u-PA double knockout mice had less
elastin fibre degradation and media destruction than Apo E knockout mice although
total plaque burden was no different (Carmeliet et al 1997). Plasmin has no capacity






Cathepsins are cysteine proteases with potent collagenolytic and elastolytic
activity. Professor Libby's group has identified cathepsin S and cathepsin K
production with human atherosclerotic tissue (Sukhova et al 1998). In vitro
experiments demonstrated production of cathepsin S by macrophages, vascular
smooth muscle cells and endothelial cells, following exposure to inflammatory
cytokines found within atheroma. Cathepsin S knockout mice backcrossed on the
atherogenic LDL receptor knockout background had reduced plaque burden and
reduced intimal content ofmacrophages, smooth muscle cells, CD4 T lymphocytes
and interferon y expression (Sukhova et al 2003). The latter finding possibly
reflected the role of cathepsin S in antigen presentation (Shi et al 1999) and the
striking quantitative and qualitative changes in plaque composition illustrate the
influence of proteolytic activity in plaque growth.
1.4.4. Other sources of elastolytic activity within atherosclerotic tissue
Elastin is one of the most proteolytically resistant matrix components and
proteases with elastase activity may generally exhibit a broad range of substrates
including extracellular matrix components, cell surface receptors and cytokines.
Cathepsins and metalloproteases contribute to the elastolytic activity within human
atheroma. Elastolytic activity increases in human aortas with age and degree of
atheromatous involvement (Hornebeck et al 1975). In diseased vessels, the
appearance of elastin degradation fragments correlates with an increase in collagen to
elastin ratio and also with loss of elastance and windkessel effect responsible for
smoothing and hydraulic filtering of pulsatile blood flow from the heart. In addition
to changes in the physical properties of the vessel wall, recognition of elastin-derived
fragments by the elastin receptor (Hinek et al 1988; Mochizuki et al 2002) leads to a
range of proatherogenic effects including monocyte and vascular smooth muscle cell
chemotaxis (Robert et al 1998). Identification and regulation of the proteases
predominantly responsible for elastolytic activity within atherosclerotic tissue are




elastase activity from atherosclerotic tissue and cultured vascular smooth muscle
cells. Professor Rabinovitch's group in Toronto isolated a 20-kDa molecule with
serine elastase activity from cultured rat pulmonary artery smooth muscle cells which
they designated endovascular elastase (EVE) (Rabinovitch 1999; Thompson et al
1996; Zhu et al 1994). This protein is immunoreactive with adipsin, a serine protease
previously characterised from adipose tissue. The protein and gene sequences of
EVE have yet to be published.
More recently, another serine elastase, human neutrophil elastase (HNE), has
been demonstrated within human atherosclerotic tissue (Dollery et al 2003). The
enzyme was strongly expressed and co-localised with plaque macrophages. In-situ
hybridisation also identified expression in cultured human saphenous vein
endothelial cells and peripheral blood derived macrophages. HNE had hitherto been
considered solely as a neutrophil derived enzyme and the presence of such a potent
inflammatory protease within atherosclerotic tissue is surprising. HNE has a broad
range of substrates including elastin and collagen. It also activates metalloproteases
and regulates inflammatory cytokines, activating pro-IL-l-P and IL-8 and
inactivating TNF-a by proteolytic cleavage (Owen et al 1997; Padrines et al 1994).
In addition to direct cellular toxicity, HNE can degrade inter-endothelial junctional
proteins (Carden et al 1998) and surface receptors (Le Barillec et al 1999). HNE
degradation of elastin produces peptide fragments that are chemotactic for
monocy tes (Senior et al 1984) and disruption of the endothelial basement membrane
may facilitate invasion of inflammatory cells into the vessel wall (Watanabe et al
1990b; Watanabe et al 1990c).
Finally, HNE induces proliferation of vascular smooth muscle cells in a
mechanism involving release of matrix bound fibroblast growth factor (Thompson et
al 1996). HNE's wide spectrum of activity makes it an interesting therapeutic target
and its inflammatory actions on endothelial cells and macrophages are considered in




1.5. Antiproteases and atherosclerosis
All endogenous proteases have their activities checked in varying degrees by
antiprotease molecules. Excessive or unbalanced protease activity is a prominent
feature of both acute inflammatory pathologies such as acute pancreatitis and chronic
disease such as emphysema and liver cirrhosis in patients deficient in the circulating
antiprotease, al -antitrypsin. The host response to inflammatory insult includes up
regulation of antiproteases. This response assists resolution of inflammation by
containing and neutralising injurious proteases. Some antiproteases are released into
the circulation from the liver (systemically) and production of others is heightened
locally at sites of inflammation and tissue injury. This mechanism has best been
elicited in the lung, an organ prone to acute infection and inflammation and
exhibiting a spectrum of locally produced antiproteases that form a protective shield
against unchecked protease activity (Sallenave et al 1999; Sallenave 2000).
The preceding sections outlined the growing evidence implicating various
protease families in atherosclerosis. By contrast, less is known about the role and
identity of inhibitory antiproteases within the vessel wall and the following sections
will introduce this topic which forms a central investigative theme in the following
work.
1.5.1. Metalloprotease inhibitors
Tissue inhibitors ofmetalloproteases (TIMPs) are specific inhibitors that bind
MMPs in a 1:1 stoichiometry. Four TIMPs (TIMP-1, TIMP-2, TIMP-3, and TIMP-4)
have been identified in vertebrates (Bode et al 1999; Bode et al 2003; Visse et al
2003). Their expression is regulated during development and tissue remodelling. In
pathological conditions associated with unbalanced MMP activity, changes of TIMP
levels are considered to be important through directly affecting the level ofMMP
activity. TIMPs inhibit all MMPs tested to date, except that TIMP-1 fails to inhibit




encompassing members of the disintegrin and metalloproteinase (ADAM) family.
TIMPs 1-3 have been characterised in vascular tissue (Brophy et al 1991; Galis et al
1994b). Production of T1MP-1 and TIMP-2 from vascular smooth muscle cells is
constitutive (Galis et al 1994a) and their secretion is increased twofold in the aortic
explants of cholesterol fed rabbits (Zaltsman et al 1999). An excess ofMMPs over
TIMPs is believed to promote extracellular matrix turnover and has been
demonstrated directly in tissue sections from human atherosclerotic plaques (Galis et
al 1994b) and plaques from balloon injured arteries from cholesterol fed rabbits
(Galis et al 1995b) using in situ zymography.
The regulation of TIMP production and MMP/TIMP balance are important
determinants of plaque development and stability. In this regard, it is relevant that
both oxidised LDL and IL-8 are associated with attenuated macrophage TIMP-1
production (Moreau et al 1999; Xu et al 1999). TIMPS 1-3 exhibit in vitro properties
that protect against plaque development, including inhibition of vascular smooth
muscle cell migration and proliferation. Adenoviral overexpression of TIMP-1 in
Apo E knockout mice reduced lesion development (Rouis et al 1999). In conflict
with this result, ApoE:TIMP-l double knockout mice also exhibited decreased
plaque development (Silence et al 2002). The role of TIMPs in atheroma
development is complex in part because of their broad ranging interference with all
MMPs. The opposing results observed in the latter two studies may reflect changing
actions for MMPs during plaque development, serving both facilitatory and
inhibitory roles at different stages of plaque growth.
TIMPs are the best characterised inhibitors ofMMPs. Recently, tissue factor
pathway inhibitor-2 (TFPI-2) was identified as an inhibitor of several MMPs within
human arterial vessels (Herman et al 2001a). That a serine protease inhibitor should
have activity against MMPs is novel and breaks the dogma that protease inhibitors
exhibit inhibitory activity within certain structural classes of proteases. TFPI-2




heavily expressed in non-diseased vessels and exhibiting reduced expression in
diseased vessels (Herman et al 2001a). Circulating a-macroglobulin exhibits strong
binding and inhibition ofMMP-1 (Cawston et al 1986) and the role of circulating
proteinase inhibitors in atherosclerosis is largely unknown with published work
remaining scant.
1.5.2. Elatln and secretory leucocyte protease inhibitor
Elafin and secretory leucocyte protease inhibitor (SLPI) are two serine protease
inhibitor members of the antileukoprotease family. Elafin expression has been
identified within the intima of human atherosclerotic arteries (Sumi et al 2002a) and
Professor Rabinovitch's group in Toronto has been singularly successful in
characterising the impressive therapeutic potential of elafin augmentation in various
models of vascular disease including transplant arteriosclerosis, myocarditis, vein
graft degeneration and myocardial infarction. By contrast, SLPI has yet to be studied
directly in the context of vascular disease but in terms of structure and function, it is
closely related to elafin.
Elafin and SLPI are relatively low molecular mass molecules (10 kDa and 11.7
kDa respectively) sharing 40% sequence homology. They contain similar reactive
sites (Ala-Met and Leu-Met respectively) and have a high content of cysteine
residues arranged as disulfide bonds in their C-terminal protease inhibiting regions
making them compact, proteolytically resistant molecules. The NH2-terminal domain
of elafin contains VKGQ motifs (Sallenave et al 1993). This sequence acts as a
substrate for transglutaminase with the resultant formation of covalent isopeptide
bonds between glutamine and lysine. Transglutaminase has been shown to effect
polymerization of elafin and the covalent binding of elafin to laminin in vitro (Nara
et al 1994), raising the possibility that tissue transglutaminase may anchor elafin to




colocalising with tissue transglutaminase within human coronary arteries (Sumi et al
2002a).
Elafin and SLPI were originally characterised in the search for molecules
responsible for the anti-elastase activity from human bronchial secretions
(Hochstrasser et al 1972; Sallenave et al 1991). Elafin and SLPI are produced widely
by epithelial tissues including bronchial, cervical and seminal secretions (SLPI) and
lung and skin (elafin) (Sallenave et al 1999). Both elafin and SLPI are produced by
neutrophils and macrophages. SLPI is induced by LPS and phagocytosis of apoptotic
cells in murine macrophages (Jin et al 1997; Odaka et al 2003) and is the main
elastase inhibitor present within the cytosol of human neutrophils (Sallenave et al
1997b). Low levels of elafin expression have also been identified in neutrophils
(Sallenave et al 1997). macrophages (Sallenave 2000) and vascular smooth muscle
cells (Nara et al 1994).
The cytokines IL-1 and TNF-a effect up regulation of SLPI and elafin
production from epithelial cells (Sallenave et al 1994; Sallenave et al 1997b). HNE is
also capable of increasing their gene expression implying a central role for both
antiproteases in protection of the airway epithelium during the earliest phase of the
inflammatory response. SLPI inhibits HNE, cathepsin G, trypsin, chymotrypsin and
mast cell chymase. HNE and elafin or SLPI form fully reversible 1:1 stoichiometric
complex (Ying et al 1993) but the bond is tight with a slow rate of dissociation and
they may therefore be regarded as a "pseudo-reversible inhibitors". Elafin's spectrum
of activity is less broad, inhibiting HNE, porcine pancreatic elastase and proteinase 3.
Inhibition ofHNE is believed to be the major physiological function of both
SLPI and elafin. Their importance in the clinical setting has been examined largely in
patients with pulmonary disease including cystic fibrosis, chronic obstructive




deficiency state resulting in disease has been described for either antiprotease. SLPI
knockout mice exhibit impaired cutaneous wound healing with increased
inflammation and elastase activity (Ashcroft et al 2000). No murine orthologue of
elafin has been identified.
Elafin and SLPI have additional anti-inflammatory actions. Direct
antimicrobial activity has been demonstrated for both molecules (Simpson et al 1999;
Wiedow et al 1998). SLPI also reduces activation of the transcription factor NF-kB
and macrophage cytokine production (Jin et al 1997; Lentsch et al 1999a). These
properties are discussed in chapter 5.
In order to characterise the roles of elafin and SLPI, several groups have
applied these molecules in animal models of inflammatory injury. SLPI and elafin
have beneficial effects in models of pulmonary inflammation. Topical instillation of
SLPI reduced extra-vascular leakage of albumin, up regulation of ICAM-1 and lung
homogenate NF-kB activity in a rat model of acute lung injury induced by IgG
immune complexes (Lentsch et al 1999a). Similar protective, anti-inflammatory
effects for elafin have been demonstrated. Adenoviral overexpression in murine
lungs reduced markers of pulmonary injury following intratracheal instillation with
Pseudomonas aeruginosa (Simpson et al 2001b). Transgenic mice overexpressing
human elafin under the control of the murine CMV promoter exhibit altered
responsiveness to LPS challenge (Sallenave et al 2003). Serum TNF-a levels were
lower in elafin compared to wild type mice following intraperitoneal administration
of LPS. Similarly, TNF-a production by peritoneal macrophages to LPS challenge
ex-vivo was reduced in elafin expressing mice.
Elafin has also shown great potential as a therapeutic target in models of
vascular inflammation. Post-cardiac transplant arteriopathy is particularly associated




(Billingham 1994). Continuous intravenous infusion of recombinant elafin leads to
an impressive decline in the intimal thickening and involvement of coronary arteries
in rabbits post-cardiac transplant. This effect was associated with reduced vascular
wall elastolytic activity as judged by fewer breaks in the internal elastic lamina
(Cowan et al 1996). In a related study examining jugular vein grafts interposed into
rabbit carotid arteries, elafin gene transfer (using haemagglutinating virus of Japan
liposomes) reduced vein graft degeneration, neointimal formation and leucocyte
infiltration (O'Blenes et al 2000).
Elafin transgenic mice expressing elafin under the control of the pre-
proendothelin promoter were protected from viral myocarditis (Zaidi et al 1999) and
hypoxia induced pulmonary hypertension (Zaidi et al 2002). They also exhibit less
intimal and medial thickening following wire-induced endothelial denudation of the
carotid artery (Zaidi et al 2000) and preserved myocardial chamber size and function
following experimentally induced myocardial infarction (Ohta et al 2004).
The models of vascular disease listed above share the common mechanism of
heightened elastase activity within the diseased tissue following acute injury,
whether it is immune rejection of transplanted tissue, wire induced endothelial
denudation or acute myocardial infarction. Infiltrating leucocytes are one source of
elastase activity including HNE from neutrophils. Smooth muscle cells may also
release endogenous elastase (Zhu et al 1994). The pro-inflammatory actions ofHNE
within the vessel wall have been outlined in the preceding section and it seems likely
that elafin's protective effect in these models of acute vascular injury is mediated
through neutralisation of HNE. It is particularly noteworthy that in the vein graft
degeneration model, gene transfer of elafin conferred protection out to 3 months with
lipid and macrophage accumulation being less in the elafin treated animals on a high
fat diet (O'Blenes et al 2000). This finding is an indication that elafin's protective




1.5.3. Inhibitors of fibrinolysis
Variation in levels of several coagulation factors, including fibrinogen and
factor VII, are associated with increased risk of cardiovascular disease. Extensive
fibrin deposition is observed in most complex human atherosclerotic lesions and
decreased fibrinolytic activity has been proposed to accelerate atherogenesis by
facilitating thrombosis and fibrin deposition within developing atherosclerotic lesions
(Lee et al 1997). However. Apo E-deficient mice lacking fibrinogen develop lesions
that are similar in size and complexity to control apo E knockout mice (Xiao et al
1998).
Inhibition of the fibrinolytic system may occur either at the level of
plasminogen activators by specific plasminogen activator inhibitors (PAIs; PAI-1
and PAI-2) or at the level of plasmin through a,2-antiplasmin. LDL receptor knockout
mice lacking plasminogen activator inhibitor-1 (PAI-1), should have the balance
shifted toward greater fibrin hydrolysis, but they also develop typical atherosclerotic
lesions (Sjoland et al 2000). Overexpression of PAI-1 reduced aneurysm formation
in a guinea pig to rat aortic xenograft model. In this model, PAI-1 overexpression
was associated with reduced activation ofMMPs and consequently reduced
degradation ofmatrix components including fibronectin and laminin (Allaire et al
1998). Oxidised LDL increases expression of PAI-1 in human endothelial cells and
vascular smooth muscle cells (Allison et al 1999; Dichtl et al 1999). PAI-1
expression is increased in human atherosclerotic arteries compared to healthy arteries
(Schneiderman et al 1992). This would be expected to confer a prothrombotic effect
on the endothelium.
In summary, despite evidence of increased expression of inhibitors of the
fibrinolytic pathway in atherosclerosis, the few studies performed to date (on animal
models of atherosclerosis) have failed to demonstrate substantial effects on plaque




not a prominent feature of murine plaques and this important difference between
human atheroma and experimental, murine atheroma may have explained the
negative findings following overexpression ofPAI-1 (Sjoland et al 2000).
1.5.4. Circulating antiproteases; ai-antitrypsin
The liver releases a series of molecules termed 'acute phase reactants' in
response to signals emanating from distant sites of inflammatory injury. This acute
phase response is regulated by inflammatory cytokines including IL-1 and TNF-a
that induce IL-6 production, an important initiator of hepatic acute phase reactant
production. Associations between atherosclerotic disease and the acute phase
reactants C-reactive protein and serum amyloid protein A are well established
(Johnson et al 2004; Ridker et al 2003). ai-antitrypsin is an acute phase reactant
synthesised in the liver with serine protease inhibitory activity and high circulating
levels are associated with progression of human carotid artery atheroma (Zureik et al
2002). A major physiological function is to inhibit HNE, although it has inhibitory
action against a wide range of serine proteases and the human deficiency state is
associated with emphysema. Mutations resulting in reduction of circulating ai-
antitrypsin activity are also associated with more angiographically advanced
coronary artery disease (Talmud et al 2003). Monocytes also produce ai-antitrypsin
and studies in vitro support direct inflammatory actions of the carboxyl terminal,
having an activating effect on monocytes through the TDT and CD36 receptors
(Janciauskiene et al 2001). a i-antitrypsin is responsible for a large proportion of the
HNE inhibitory capacity of serum and it would be expected to impact on HNE
activity within atherosclerotic lesions assuming it could access the vascular space. To
date, there is no published information from human or animal studies on the presence




1.6. The application of gene expression profiling to atherosclerosis
The precise combination of environmental and genetic factors driving
atheroma may vary between patients, producing phenotypically similar
manifestations but potentially requiring different interventions to correct them. More
detailed characterisation of pathological processes at the molecular and cellular
levels will enhance understanding of underlying mechanisms. Cellular phenotype is
determined by the set of proteins translated from the small fraction of the genomic
information that is expressed. Proteins form the cellular machinery, regulating
responses to stimuli and generally there is a good correlation between the amount of
messenger RNA (mRNA) and the production of corresponding protein by the cell.
Profiling of gene expression may therefore provide insights into the functional state
of the cell in health and disease. Sequence databases, generated by genome
sequencing programs, have provided the opportunity to characterise cells and tissues
in terms of the pattern and relative quantity ofmessenger RNA they produce. This
analysis has been termed gene expression profiling (Duggan et al 1999).
1.6.1 Gene expression profiling methodology
Differential display, subtraction suppression hybridisation and DNA
microarrays are three methods used for expression profiling. Microarrays facilitate
parallel quantification of thousands of specific mRNAs in a sample through
hybridisation to a complementary sequences placed at specified positions on glass or
silicon supports (Gerhold et al 1999). In contrast to differential display and
subtractive hybridisation the sequence of the target gene or expressed sequence tag
(EST) is known, obviating the need for further cloning steps for identification. Two
techniques for high density spotting ofDNA molecules on glass or silicone surfaces
have become available. One format involves robotic deposition of PCR fragments
amplified from cDNA clones and was developed at Stanford University (Schena et al
1995). 10,000 genes may be arrayed on a compact area of 3.6cm . Affymetrix adopt
an alternative approach based on photolithographic synthesis of oligonucleotides in




400,000 oligos on one silicone chip (Gerhold et al 1999). Specific oligo design
allows the user to avoid regions of repetitive or homologous sequence between
different genes.
Microarrays work on a principle that is the reverse to that ofNorthern blot
analysis. Instead of labelling a specific cDNA probe and hybridising to a pool of
mRNAs immobilised on a membrane, a pool of labelled mRNAs is hybridised to
numerous cDNA probes immobilised on a solid support in specific positions. The
cDNA populations from two experimental samples are labelled with different
fluorescent dyes and hybridised to the same microarray allowing direct comparison
of signal intensity. Smaller amounts of RNA are required for the analysis of a greater
number of genes than is possible with Northern blotting without a big loss of
sensitivity. In one study comparing the two methods, a microarray was able to detect
90% of the expression changes demonstrated in one sample by Northern blotting
(Taniguchi et al 2001).
The array fabrication technique is critical for producing high resolution and
minimising background "noise' and cross hybridisation signals. For cDNA arrays,
signals vary depending on the slide surface, the spotting buffer and the temperature
and humidity during array printing (Flegde et al 2000). Following hybridisation and
image processing the data must be normalised to adjust for labelling and detection
efficiencies for different fluorescent labels and differences in the quantity of starting
RNA between samples.
Normalisation strategies (reviewed in (Hegde et al 2000) include correcting for
total intensity by assuming that although fluorescence varies between individual
transcripts, this should even out over many thousands and be identical for the same
quantity ofRNA labelled with two different fluorescent markers. A second approach




expression levels of which are assumed not to vary between samples. A third uses the
fact that the predicted slope of a scatterplot of housekeeping and added equimolar
controls for the two probes should be unity. The data can be rescaled using this slope
with regression analysis.
1.6.2. Expression profiling and models of atherosclerosis
The above techniques have wide application in the study of developmental and
pathophysiological processes in the cardiovascular system. Difficulties may arise in
the interpretation of gene profiles from tissues containing multiple cell types. This
can be circumvented in part by the use of in vitro single cell models of disease.
Professor Gimbrone's group used differential display to isolate genes which are up
regulated in cultured endothelial cells in response to laminar or turbulent flow shear
stress (Topper et al 1996). The genes for manganese superoxide disnrutase and
cyclooxygenase-2 (COX-2) were up regulated in cells exposed to laminar shear
stress and these findings were confirmed by reverse northern blotting. Importantly,
the investigators confirmed that enhanced gene expression was translated into
increased protein synthesis by immunoblotting. The contribution of turbulent flow to
endothelial dysfunction and atheromatous plaque development at 'lesion prone
areas', such as arterial bifurcations and curvatures, is well established. The putative
protective effects of an antioxidant enzyme and prostacyclin (the major product of
endothelial COX-2) induced by laminar shear stress are particularly interesting in
this regard. The failure of differential display to detect enhanced expression of
endothelial cell nitric oxide synthase (eNOS) in endothelial cells exposed to laminar
flow illustrated the limited sensitivity of this technique. The influence ofmechanical
stimuli has also been studied on vascular smooth muscle cells grown on fibronectin
coated supports using cDNA microarrays (Feng et al 1999). Only a handful of the
5000 genes monitored at two time points after the onset of mechanical stretch varied
by more than the 2.5-fold threshold change in expression set by the investigators.




majority of genes varied by less than 2-fold in their expression and quantitatively
small but functionally important changes in expression may have been overlooked.
PAI-1 and Tenascin-C were induced following stretch. These findings were
confirmed with Northern blotting, ELISA and Western blotting for corresponding
changes in RNA and protein production. Tenascin-C is prominent in remodelling
tissues and has anti-adhesive properties. Whether a stretch stimulus applied to
endothelial cells growing in a monolayer reproduces the mechanical environment of
a vessel wall is questionable and studies on ex-vivo vessel preparations to follow up
the array findings form in vitro experiments would have been instructive.
Foam cell formation within the atherosclerotic plaque has been modelled by
incubating the monocytic THP-1 cell line with oxidised TDL and comparing
expression profiles to untreated cells using microarrays (Shiffman et al 2000). Of the
6805 genes arrayed. 268 (4%) altered their expression, a minimum of 2 fold, at one
of the time points ranging up to 4 days. Data was presented in clusters according to
temporal expression patterns and results were confirmed using quantitative real time
PCR. Genes previously demonstrated to be responsive to oxidised LDL loading of
macrophages such as thrombomodulin, were induced in the THP-1 cells offering
some validation of the model. The scavenger receptors A and CD36 involved in
oxidised LDL uptake were up-regulated along with nuclear receptors that control
lipid metabolism reflecting a lipid storage phenotype similar to maturing adipocytes.
Vascular smooth muscle cell (VSMC) behaviour in an atheromatous plaque has
been modelled by treating cultured VSMCs with the cytokine, tumour necrosis factor
a (Haley et al 2000). Eotaxin, a chemokine characterised by its chemotactic
properties for eosinophils was induced greater than 20-fold on a cDNA nricroarray.
Eosinophils are not present within atherosclerotic plaques and the finding prompted




smooth muscle cells and its receptor, present on plaque macrophages and mast cells.
The latter study demonstrated how transcriptional profiling can complement
traditional hypothesis driven research through producing unexpected findings, in this
case the presence of a signalling pathway in atherosclerotic plaques.
1.6.3. Conclusions: scope and limitations of gene expression profiling
Complex interactions between multiple cell types and matrix are lost with in
vitro systems. Further information may be gained by summative expression profiles
obtained directly from animal model tissues or clinical specimens. Gene expression
changes associated with unstable plaques were identified using total RNA extracted
from coronary atherosclerotic plaques by directional atherectomy (Randi et al 2003).
A central difficulty with interpreting gene expression changes in two different
diseased tissues is understanding to what degree expression changes merely represent
different cellular content rather than changes in gene expression within the same cell
type. This is particularly pertinent when comparing an unstable or ruptured coronary
plaque with associated influx of inflammatory cells to a stable plaque.
The interpretation of data from any expression profiling technique requires
caution. The risk of false positive signals or bands is high. In microarray studies this
may arise through cross hybridisation of homologous or conserved repeat sequences.
One study demonstrated that for a specified cDNA sample the ability of a DNA chip
to distinguish correctly, the presence of any sequence, was 90% per run (Lee et al
2000b). Costly repeat analysis of the same sample is therefore required and ideally
all findings should be confirmed in a separate system such as Northern blotting and
quantitative PCR. Secondly, attaching functional significance to changes in gene
expression level alone is difficult. No information is provided on alternative splice
variants, post translational modifications or the rate of protein degradation. Studies in
yeast indicate that expression of important growth regulatory genes may not vary




can be extrapolated to eukaryotes then expression profiling may only be capable of
detecting subpopulations of functionally important genes whose transcription level is
subject to regulation.
Setting these caveats aside, the potential uses for systematic expression
profiling on a genome wide scale in atherosclerosis research are clear. The enormous
amounts of data produced by profiling studies pose challenges for publication and
journals frequently use supplemental web pages to release data fully. The
development of expression databanks akin to the sequence databanks already
available will facilitate more rapid comparisons between cells and tissues in health
and disease.
1.7. Principles of Gene Therapy
1.7.1. Overview and comparison with recombinant protein
Gene therapy may be defined as a strategy of delivering beneficial genes either
systenrically or directly into tissue. The initial concept of delivering replacements for
defective genes in monogenetic disorders has been expanded to include delivery or
augmentation of therapeutic genes in both inherited and acquired diseases. In spite of
effective drug treatments, poor patient compliance affects our ability to control
chronic disorders such as atherosclerosis and hypertension. The side effect profile
from systemic actions ofmany drugs is a further limitation. From the few studies that
have been performed in conditions such as Type 2 Diabetes Mellitus it seems that
regular drug compliance may be practised in fewer that 50% of patients (Morris
2002). In addition to having adverse effects on disease control, this problem has




A central question in considering a gene therapy strategy for atherosclerosis is
whether it offers advantages over more direct delivery of drug or therapeutic protein.
Firstly, recombinant protein and drug treatments have limited half-lives with
attendant problems of peak and trough levels as a result of repeat administrations.
Recombinant proteins in particular have short half-lives usually measured in hours
and techniques for preparation are often expensive.
Secondly, it is hard to target specific cells or to control levels of drug or
recombinant protein in tissues. In contrast gene therapy offers the possibility of using
promoters which may be inducible (Gossen et al 1992; No et al 1996) or tissue and
cell specific (Strayer et al 1998). The targeting of gene vectors in the case of
adenovirus through modifying viral capsid proteins or using bispecific antibodies
(Nicklin et al 2000; Wickham et al 1996; Wickham 2003) allows cell specific
expression.
Vascular catheterisation is a routine diagnostic and therapeutic procedure in
patients with cardiovascular disease offering direct access to much of the venous and
arterial vasculature. During cardiac surgery further access is obtained to the
myocardium, epicardial surface of coronary arteries and vein grafts during harvesting
for bypass surgery. Gene therapy protocols require a period of contact between the
target cell and gene vector and this is not easily afforded in the coronary artery bed
where blood flow across the endothelium is rapid and under high pressure. In order
to circumvent this problem investigators have employed arterial occlusion with
balloons to temporarily interrupt flow, delivery of vectors through the balloon while
it is opposed to the vessel wall during angioplasty and impregnation of gene vectors
onto stents allowing more prolonged juxtaposition and release into the vessel wall
(Sharif et al 2004a; Walter et al 2004; Yuan et al 2001). Of necessity these
approaches are invasive, involving heavy instrumentation of the target blood vessel.




By offering the potential of targeted and time controlled delivery, gene therapy
is attractive in chronic disease processes such as atherosclerosis. Gene therapy
strategies may be classed as viral or non-viral according to the vector system.
1.7.2. Non-viral gene therapy
Naked plasmid DNA can be added to cultured cells or injected directly into
tissues. Cardiac myocytes are one of the few cell types receptive to this form of gene
delivery although low transfection efficiency is an important drawback (Lin et al
1990). Naked DNA has also been used to transduce cells in the arterial wall of
rabbits after introduction on a hydrophilic gel-coated catheter albeit with very low
efficiency (Riessen et al 1993). Plasmid DNA has a number of attractions being
inexpensive and easy to construct in large quantities. The injection of pure plasmid
DNA is not generally associated with immune responses either to the DNA or
transgene product making it possible to readminister (Tripathy et al 1996). Clinical
trials with naked DNA have had limited success. However, for ischaemic leg ulcers
where the target tissue is both receptive and accessible, intramuscular injection of
plasmid DNA encoding the VEGF gene led to significant improvement
(Baumgartner et al 1998). Low transduction efficiency limits the use of naked DNA
alone but complexing with cationic or neutral lipids reduces this problem. DNA-lipid
liposomes increase the stability ofDNA and facilitate cellular entry by promoting
fusion with the plasma membrane. Liposomes are relatively easy to prepare and
facilitate gene transfer to a range of cell types. Alteration of the lipid structure
(Feigner 1996) and incorporation of adenoviral or fusogenic viral proteins into the
complexes (Dzau et al 1996) can improve transfection efficiency and even allow
targeting of the vectors. Although transfection efficiency is improved compared to
naked DNA, particularly for proliferating cells in culture, it is still low when




1.7.3. Viral gene therapy
Mammalian viruses have evolved efficient mechanisms for infecting and
transducing a wide variety of cell types. Vectors derived from viruses are effective in
delivering therapeutic transgenes to human tissues. The host immune system has
evolved to respond to and destroy viruses. Circumventing the immune response to
allow persistent transgene expression within the host, without a damaging
inflammatory response, remains the most important obstacle to viral gene therapy.
The vast majority of clinical trials and animal studies in cardiovascular disease have
used recombinant adenovirus as a viral vector. This is discussed in a separate section.
The remainder of this section will consider briefly other viruses important to gene
therapy protocols.
Retroviruses are single stranded, enveloped RNA-viruses whose viral genes
can be removed and replaced with transgene sequences and transcriptional regulatory
elements (Miller 1992). Retroviruses enter mammalian cells through specific surface
receptors. Once inside the cytosol. the RNA genome is reverse transcribed into
double-stranded DNA which typically requires a break in the nuclear membrane
during mitosis before it can translocate to the nucleus and integrate into the host cell
genome. This is problematic for cells with low proliferation rates such as vascular
smooth muscle cells and endothelial cells. Within the retrovirus family, lentiviruses
are exceptional in that their double stranded DNAs can pass through the pores of
intact nuclear membranes in non-dividing cells. Retroviruses are difficult to produce
in the large quantities needed for gene therapy. Although they integrate producing
long term gene expression in vitro the transcription may be shut off in vivo after a
short time. Random integration of wild type lentiviral vectors also poses the threat of
insertional mutagenesis and in particular of neoplastic transformation (Vanin et al
1994). Gene therapy of children with X-linked severe combined immune deficiency
resulted in impressive levels of immune reconstitution although two patients
developed leukaemia (Kohn et al 2003). Multiple factors could have contributed to
the development of leukaemia in the patients involved in this trial. These include the




properties of the haematopoietic stem and progenitor cells in bone marrow ofX-
l inked SCID patients, the immune deficiency of the X-linked SCID patients and/or
the transferred gene itself.
The adeno-associated virus (AAV) is an integrational vector that infects a
broad range of cell types and can be produced at high titres (Muzyczka 1992). It
displays the useful property of becoming integrated in a site-specific manner into a
single, seven-kilobase region on human chromosome 19 (Kotin et al 1992).
Recombinant AAV is stable and has low immunogeneicity although its carrying
capacity is also relatively low (around 4.7 kb). Production ofAAVs is dependent on
the use of a helper virus (usually adenovirus) and producing sufficient quantities of
AAV free of contamination from helper virus is technically challenging. However,
AAV vectors have been used successfully to provide long term gene expression.
Infusion of an AAV containing cDNA for factor IX into the portal vein of factor IX
deficient dogs led to 5% of normal factor IX levels within the plasma (Wang et al
2000).
1.7.4. Adenovirus as a vector for gene delivery to the endothelium
Adenoviruses are double-stranded DNA viruses. Serotypes 2 and 5 are most
commonly modified for use in gene therapy protocols. The adenoviral genome
comprises early regions (El A, El B, E2A, E2B, E3 and E4, which are transcribed
prior to viral replication) and the late regions (LI-5, which are transcribed after viral
replication). Late regions generally encode structural proteins whereas the gene
products of the early regions are concerned with viral transcription and evading the
host immune response (Kremer et al 1995; Russell 2000). The El region initiates
viral transcription and is the only region not controlled by trans activators encoded
by the adenovirus. Deletion of the El segment renders the virus replication-deficient




Wi ld-type adenovirus capsid takes the form of an icosahedron. approximately
80 nm in diameter. Adherent to the capsid are penton subunits, from which project
fibre protein. Studies have demonstrated the role of the knob protein engaging a
specific coxsackie adenovirus receptor (CAR) on the cell surface (Bergelson et al
1997). Internalisation of the virus also depends on recognition of an RGD motif
exposed on the penton base that interacts with cellular aV integrins (Wickham et al
1993). Interaction of the virus with the plasma membrane induces a number of
signalling pathways including the Rho family of GTPases and the polymerisation and
re-organistation of actin filaments to facilitate endocytosis (Li et al 1998; Rauma et
al 1999). Once inside the cell, the adenoviral DNA is transported to an
epichromosomal location within the nucleus (reviewed by Russell. 2000).
An efficient method for generating recombinant adenovirus deleted in El has
been described by Professor Frank Graham's group at McMaster University,
Hamilton, Ontario (Bett et al 1994; Graham et al 1991). The method was used to
generate most of the adenovirus vectors used in this work (Sallenave et al 1998).
Briefly, two plasmids were used to co-transfect the 293 cell line, an embryonal
kidney cell line which produces El in trans (Graham et al 1977). One plasmid
contains all adenoviral sequences required to produce infectious virus when
transfected into the 293 cells with the important exception of the packaging sequence
required for encapsidation of adenoviral DNA (Bett et al 1994). A second plasmid
contains left-ended sequences less the El domain and part of the E3 domain which
are not essential for viral replication (Haj-Ahmad et al 1986). The second plasmid
contains a packaging signal, a promoter, a polylinker sequence and further short
adenoviral sequences sharing homology with DNA in the first plasmid. Transgenes
of interest of up to 8.3 kb in size can be cloned into the polylinker site. Homologous
recombination occurs within the common segment shared by both plasmids when
they are cotransfected into 293 cells resulting in an El deleted construct with
transgene and packaging sequences. El products are provided in trans by the 293




Following recombination, lytic plaques develop within the 293 cell culture as
high yields of replication deficient adenovirus are produced. The process of
homologous recombination is inefficient and can be improved through Cre-mediated
site-specific recombination between two plasmids, each bearing a loxP site.
Adenovirus vectors are generated as a result of Cre-mediated site-specific
recombination between the two plasmids after their cotransfection into 293 cells
expressing Cre recombinase. The frequency of adenovirus vector rescue by Cre-
mediated site-specific recombination is significantly higher (approximately 30-fold)
than by homologous recombination (Ng et al 1999). This approach was used to
generate the murine SLPI vector used in this work.
Recombinant adenoviruses can infect efficiently both dividing and non-
dividing cells including endothelial cells and smooth muscle cells both in vitro and
after catheter-mediated delivery (Guzman et al 1993; Lee et al 1993). Adenoviral
vectors do not integrate into the host genome, can be produced in high yield in the
laboratory and are relatively stable (Hitt et al 1995). Wild type adenovirus has no
association with malignancy and provides a favourable safety profile in humans,
having been used to vaccinate military recruits (Gurwith et al 1989).
The biggest hurdle to successful adenoviral gene therapy is the host immune
response preventing any form of prolonged transgene expression. The innate immune
system recognises and responds to adenoviral infection. Adenoviral infection may
lead to release ofmultiple chemokines that in turn recruit neutrophils invoking an
inflammatory response in the liver or heart (Muruve et al 1999). Cytotoxic
lymphocytes recognise neoproteins in complex with class I proteins of the MHC on
the surface of infected cells (Yang et al 1994; Yang et al 1996a). This leads to
perforin release and host cell lysis. Macrophages internalise adenovirus and present
viral antigen in association with class II MHC, activating CD4 helper T cells and the
adaptive wing of the immune response (van Ginkel et al 1997). Helper T cells can




neutralising antibodies. Antibodies are directed against epitopes on the fibre and
penton base and the efficacy of the humoral response depends on the nature of pre¬
existing immunity as well as the route and target of infection (Harvey et al 1999).
The immune response may also be directed towards the transgene. The bulk of
evidence for anti-adenoviral immunity has been generated from experiments in
rodents and it is possible that different mechanisms may take precedence in human
hosts.
1.8. An overview of gene therapy for atherosclerosis
1.8.1. Targets for gene therapy in atherosclerosis
Development of atherosclerotic vascular disease is slow, (usually) occurring
over many decades and the clinical manifestations of obstructive arterial disease
producing symptoms of angina and intermittent claudication or atherosclerotic
plaque rupture leading to arterial occlusion and myocardial infarction occur late in
the natural history of the disease. A preventive strategy could reduce disease
progression by targeting risk factors such as hypercholesterolaemia and
hypertension. This would require long-term gene expression either through stable
transfection or repeated gene delivery.
Repair of the diseased vessel wall represents an alternative direction, inducing
plaque regression or changing plaque properties making it is less 'vulnerable' or less
prone to rupture (Naghavi et al 2003b; Naghavi et al 2003a). The processes occurring
immediately following balloon angioplasty or stent deployment when arterial wall
remodelling produces a proliferative vascular smooth muscle cell response with




Finally, in patients with advanced obstructive atherosclerotic disease the focus
of treatment could move away from prevention or repair to creating new vessels.
This approach is arguably the most ambitious of the directions outlined above. To
date, gene therapy for angiogenesis in patients with coronary artery disease and
peripheral limb ischaemia makes up the vast majority of human gene therapy trials in
patients with atherosclerotic disease. In relation to the findings in this thesis, the
following sections will examine the potential of gene therapy as a strategy to prevent
and modulate atherosclerotic plaque development, drawing on animal studies and
early clinical trials.
1.8.2. Lipid metabolism and risk factor modification
Inherited defects in lipid metabolism such as LDL receptor deficiency in
familial hypercholesterolaemia culminate in premature ischaemic heart disease. Gene
therapy approaches have focused on replacing normal LDL receptors in the liver.
Adenoviral delivery of both the low density lipoprotein and very low density
lipoprotein receptors led to correction of serum LDL cholesterol and slowed
development of atheromatous changes in LDL receptor deficient mice (Ishibashi et al
1993; Kozarsky et al 1996). In both studies, therapeutic transgene effect was
transient lasting less than 40 days as a result of immune responses against both
adenovirus and transgene proteins. The first clinical trial used transplantation of
autologous hepatocytes that had been genetically corrected with a recombinant
retrovirus carrying the LDL receptor. Reductions of between 6% and 23% in plasma
LDL levels were observed in 3 of the 5 patients (Grossman et al 1995). Susceptibility
to atherosclerosis in humans is correlated inversely with plasma F1DL and adenoviral
overexpression of apolipoprotein A-l led to increased HDL levels and a strong
antiatherogenic effect for up to 10 weeks in atherosclerotic mice (Benoit et al 1999).
Murine models have illustrated the feasibility of correcting genetic defects in lipid





Hypertension is a major risk factor for atherosclerosis and a significant cause
ofmorbidity and mortality in its own right. A complex and multifactorial aetiology
led some investigators to question the feasibility of gene therapy for this disorder.
Overexpression of vasodilator genes including atrial natriuretic peptide and
endothelial nitric oxide synthase (eNOS) reduced blood pressure over a 12 week
period in hypertensive rats (Lin et al 1997; Lin et al 1998). In order to have an
impact on atherosclerosis prevention in humans, gene expression would have to
persist.
Hypertension and hyperlipidaemia are continuous variables and in most
patients they equate to only a fraction of the total risk of future atherosclerotic related
events. Correction of rare genetic deficiencies like familial hypercholesterolaemia
aside, preventive gene therapy approaches for these disorders would entail treatment
of large numbers of patients. Mechanisms would need to be devised to switch
therapeutic gene expression offwhen the patient develops an intercurrent illness: for
example. With improvements in vector design and increasing clinical experience
with gene therapy this approach may become feasible in the future.
1.8.3. Protection and repair of the arterial wall.
Treatment and stabilisation of atherosclerotic lesions would entail either direct
gene delivery to the arterial wall or, possibly, distant expression of a therapeutic
transgene in skeletal muscle or the liver, the product ofwhich could reach diseased
vessels through the circulation. The hurdles for direct gene transfer to cells lining
arterial vessels carrying blood under high pressure were outlined earlier.
Modifications of vascular catheters will be required to facilitate juxtaposition of
vectors against the endothelium for more prolonged periods and progress has been




Cell proliferation is a prominent feature of atherosclerotic lesions. Gene
therapy strategies directed at inhibiting vascular smooth muscle cell proliferation and
migration, by interfering with intracellular transduction pathways, has been shown to
be effective in retarding the development of intimal disease, particularly with respect
to restenosis following angioplasty. Adenoviral overexpression of the cell cycle
inhibitor p21 limited vascular smooth muscle cell proliferation and neointimal
formation following arterial balloon injury in rats and pigs (Chang et al 1995; Yang
et al 1996b). An alternative is to augment local production of endothelial factors that
prevent VSMC proliferation and neointimal formation. Gene transfer of eNOS and
PGI synthase inhibited luminal narrowing following balloon angioplasty
(Numaguchi et al 1999; Varenne et al 1998).
Acceleration of re-endothelialisation following balloon injury was proposed by
Isner's group as an approach to limit VSMC migration and proliferation (Losordo et
al 2003). Periadventitial gene transfer of VEGF has been demonstrated to reduce
neointima formation via a NO-mediated mechanism (Laitinen et al 1997). There is a
close relationship between endothelial integrity and neointimal thickening in human
coronary arteries (Davies et al 1988) and poor re-endothelialisation is associated with
adverse outcomes following angioplasty (Gravanis et al 1989). This array of
information has led to clinical trials of VEGF gene therapy with adenoviral vectors to
prevent restenosis after coronary stenting. The phase II results have been reported
indicating good safety and tolerability (Fledman et al 2003).
To date, all clinical studies and the majority of animal studies have examined
gene delivery in the context of acute vessel injury during angioplasty and stent
deployment. Genetic augmentation of protective factors to modulate atherosclerotic
plaque development is an alternative preventive strategy, facilitating plaque
regression and stabilisation. Augmentation of the anti-inflammatory cytokine IL-10
in LDL receptor knockout mice with adenovirus led to reduced atherosclerotic lesion




2001). This effect was associated with reduced activation ofmonocytes and the
unexpected finding of reduced serum cholesterol levels. Similarly, adenovirus
mediated overexpression of platelet-activating factor-acetylhydrolase led to
significant reductions in aortic arch atheroma in apoE mice (Quarck et al 2001).
Systemic gene delivery of adiponectin an adipocyte derived anti-inflammatory
cytokine, and TIMP-1 have both been demonstrated to reduce atherosclerotic
development in murine models (Okamoto et al 2002; Rouis et al 1999).
All the preceding studies were based on adenoviral gene delivery to the liver
with subsequent release of therapeutic transgene products into the circulation. Local
production of gene products within the atherosclerotic lesion may be preferable and
was achieved in part by adenovirus mediated heme-oxygenase-1 gene transfer to the
arterial wall in apoE knockout mice through injection of adenovirus into the left
ventricle of anaesthetised animals (Juan et al 2001).
Murine models of atherosclerosis have repeatedly been shown to be amenable
to gene delivery or knockout strategies, often resulting in dramatic reductions in the
rate of disease development and atherosclerotic burden. Earlier sections have alluded
to the multiple growth factors, cytokines and proteases implicated in atherosclerosis
and aetiological factors in humans may be more complex compared to the primarily
lipid driven disease in murine models. There may be greater redundancy where
multiple factors are involved giving rise to concern that genetic augmentation of a
single factor would be less successful in humans.
The majority of large myocardial infarctions arise from thrombus development
within the proximal third of one of the three main coronary arteries (Wang et al
2004) and these regions can readily be accessed by cardiac catheterisation. Improved
methods for assessing the composition of atherosclerotic plaques will be required to




Quantitative coronary angiography effectively identifies fixed obstructive stenoses
but development in additional imaging modalities such as intravascular ultrasound
(Newby et al 2002) will be required to identify vulnerable plaques, the target of
therapy.
1.9. Summary
This introduction highlights the importance of oxidised low density lipoprotein
as a central cause at all stages of atherosclerotic plaque development. Inflammatory
chemokines and proteases produced within the artery wall are instrumental in the
inflammatory changes that occur. The hypothesis that elafin augmentation may
reduce endothelial cell and macrophage inflammatory responses to atherogenic
stimuli was introduced. Finally, the rationale for gene delivery as a treatment for
coronary artery disease was outlined.
2.0. Aims
The principal aim of the experiments cited in succeeding chapters is the
identification of mediators of damage and repair in atherosclerosis The initial aim,
after establishing an in vitro model of endothelial cell injury, is to identify novel
candidates exhibiting altered expression through gene expression profiling of
endothelial cells incubated with oxidised LDL. A further aim is to establish whether
overexpression of the protease inhibitors elafin and SLP1 could attenuate the
inflammatory responses to atherogenic stimuli of human endothelial cells and
macrophages.
The experiments described in chapter 3 and 4 seek to characterise the in vitro
model of atherosclerosis. The work in chapters 5 and 6 is directed towards












2.1.1. Source of chemicals and reagents
Unless stated otherwise, chemicals and reagents were obtained from Sigma,
Poole. UK
2.1.2. Native and oxidised LDL
Human plasma was obtained from the Department of Transfusion Medicine,
Royal Infirmary of Edinburgh. LDL isolation and oxidation was performed by
Professor Rudolph Riemersema (Cardiovascular Research Unit, University of
Edinburgh). LDL was isolated by sequential ultracentrifugation, followed by dialysis
against PBS and 0.2 g/L chelex (pH 7.4). The LDL was oxidised against CuCLand
the degree of oxidation was monitored by the formation of conjugated dienes at 234
nm (Lewin et al 2002). At maximum absorbance (usually 60-90 min after initiation)
oxidation was terminated by the addition of 10% excess EDTA. Both native and
oxidised LDL were concentrated in an ultrafiltration unit (Amicon 52. Millipore
(UK) Limited. Watford, UK) using polyethersulfone membranes (Dia:44.5 mm-
NMWL: 30 000, Millipore) to yield 5 ml of concentrated material. Traces of Cu2+
were then removed by gel filtration chromatography over a Sephadex G25 column
(PD-10, Amersham Pharmacia, Uppsala, Sweden). Protein concentrations were
measured by the Lowry method (Fryer et al 1986).
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2.1.3. Adenoviral Constructs
Production and purification of adenoviral vectors was not part of the
experimental work in this thesis. All adenovirus vectors described below were
available in-house or were obtained or produced in collaboration with other workers
during the course of this work.
2.1.3.1. Ad-elafin
The Ad-elafin vector was produced as described by Sallenave et al (1998).
Briefly, full length elafin cDNA (538 bp) was obtained by RT-PCR from total RNA
extracted from bronchial epithelial cell line NCI-H322. Elafin cDNA was cloned into
a shuttle plasmid (pDK6) containing adenovirus type 5 sequences from 0-1 mu and
9.8-15.8 mu, a polyadenylation signal and a 1.4 kb fragment from the murine
cytomegalovirus (mCMV) promoter. The resulting plasmid was cotransfected with
pBHCilO in 293 cells. PBHG10 lacks a packaging sequence and is partially E3-
deleted (i.e. it contains the entire Ad5 gene sequence apart from 0.5-3.7 mu and 78-
85.6 mu). Homologous recombination resulted in El, partially E3-deleted adenovirus
encoding elafin cDNA downstream of the mCMV promoter. Plaque forming unit and
particle concentrations from the batch of virus used were as follows; 4.8 x 1010
pfu/ml. 5.3x 1012 particles/ml.
2.1.3.2. Ad-murine SLPI (Ad-mSLPI)
Cloning ofmSLPI cDNA was performed in the lab by other investigators.
Briefly, fresh lung from a murine C57B16/CBA hybrid was obtained, snap-frozen in
liquid nitrogen and total RNA was prepared using Trizol reagent as a template for
mSLPI RT-PCR. Amplified products were then analysed on 0.8 % agarose gels, cut
from the gel and purified and ligated by conventional methods into pGEM T-easy
(Promega, Southampton. UK). An EcoRl mSLPI cDNA digest was then subcloned
into pDK6. The correct orientation was assessed and sequencing performed to rule
45
Chapter 2
Chapter 2: Materials and Methods
out any unwanted mutagenesis. Further directional cloning was performed by
subcloning the Xbal-EcoRV mSLPI cDNA fragment into Nhel-EcoRV digested
plRESGFP2 (gift from Drs F. Graham and R.Marr, McMaster University, Ontario,
Canada) to generate pIRESmSLPI-GFP2. Ad-mSLPI was prepared by Mrs Alyson
Harris in collaboration with Dr Mary Hitt. McMaster University. pIRES-mSLPI-
GFP2 and pBHGloxAEl,3Cre were used to cotransfect 293 cells. Cre mediated site
specific recombination resulted in the generation ofEl, E3-deleted adenovirus
encoding mSLPI and green fluorescent protein (Ng et al 1999a). Plaque forming unit
and particle concentrations from the batch of virus used were as follows; 6.1x 1010
pfu/ml, 7.8x 1012 particles/ml.
2.1.3.3. Ad-murine eotaxin (Ad-meotaxin)
The Ad-meotaxin vector was prepared by Professor Zhou Xing's team,
McMaster University, m-eotaxin cDNA was amplified by RT-PCR from total RNA
extracted from female Balb/c murine lung that had been subjected to induced allergic
airway eosinophilia (Xing et al 1996). An 800-bp EcoRI/BamHI fragment of full-
length m-eotaxin was ligated into the multicloning site of the shuttle vector pDK6 to
generate pDK6-meotaxin. The pDK6m-eotaxin plasmid was co-transfected into 293
cells along with the rescuing vector pBHGlO. Homologous recombination resulted in
the generation of El, E3-deleted adenovirus encoding m-eotaxin under the control of
the mCMV promoter. Plaque forming unit and particle concentrations from the batch
of virus used were as follows; 1,7x 1010 pfu/ml, 5.6x 1012 particles/ml.
2.1.3.4. Ad-lKBa, Ad-dl703 and Ad-GFP
The construction of the vector expressing a mutant form of IkBcx protein (the
super repressor where serines 32 and 36 are replaced by alanine residues, therefore
preventing inducible IkBcx phosphorylation) has been described before (Jobin et al
1997). The Ad-IxBa vector differs from the other vectors used in that it contains the
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human CMY promoter. Ad-lKBa was a kind gift from Dr R. Balfour Sartor,
University ofNorth Carolina, NC, USA. The generation by homologous
recombination of an empty viral vector containing deletions in the El and E3
regions, using the same protocol as for Ad-elafin has been described previously (Bett
et al 1994). Ad-GFP was also an El, E3 deleted serotype 5 adenovirus encoding the
green fluorescent marker protein. Ad-dl703 and Ad-GFP were kindly provided by
Professor Jack Gauldie and Dr Mary Hitt, McMaster University. Plaque forming unit
and particle concentrations from the batches of viruses used were as follows; Ad-
1kBcc-3.5x 1010 pfu/ml, 5.6x 10" particles/ml; Ad-dl703-2.7x 1011 pfu/ml, 2.1x 1012
particles/ml; Ad-GFP-1.1 x 1010 pfu/ml, 7.3x 1011 particles/ml.
2.1.4. Recombinant human elafin
A truncated recombinant human elafin (57 amino acids in length, FUN-
39AQE...'bQ-OH, approximately 6kDa, representing the COOFI-terminus of pro-
elafin) was available in-house and was originally a kind gift from Dr J Fitton, ICI
Pharmaceuticals, Macclesfield, UK.
2.1.5. Primers
The primers chosen for sense (3'-5') and antisense (5'-3') respectively were for
human angiopoietin-2 (GenBank™ accession number AF004227)
ggatctggggagagaggaac and ctctgcaccgagtcatcgta (535 base pair product); for human
IL-8 (GenBank™ accession number Y00787) aatgagagtggaccacactgcgcc and
cactgattcttggataccacagag (181 base pair product); for human midkine (GenBank™
accession number M69148) caaggattgcggcgtgggtttccg and tgtgacaccaggggctccttggca
(323 base pair product); for human matrix metalloprotease-1 (MMP-1) (GenBank™
accession number X05231) ttgccaagagcagatgtggac and gctgaacatcaccactgaagg (369
base pair product); for human GAPDH (GenBank™ accession number M33197)
ccacccatggcaaattccatggca and tctagacggcaggtcaggtcaacc (599 base pair product); for
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human HPRT (GenBank™ accession number V00530) acattgtagccctctgtgtgctca and
gcgaccttgaccatctttggatta (300 base pair product). IL-8 and GAPDH primers were
kind gifts from DrNik Hirani Rayne Laboratory, University of Edinburgh. All other
primers were ordered from MWG Biotech, Ebersberg, Germany.
2.1.6. IL-8 promoter constructs
The IL-8 promoter constructs were based on the pXP2 vector and were a kind
gift from Professor Naofumi Mukaida, Cancer Research Institute, Kanazawa
University, Japan. XL-1 Blue bacteria were transformed with the plasmids using a
heat shock protocol as follows. Plasmid DNA (500 ng) was added to a 50 pi
suspension ofXL-1 Blue bacteria and incubated on ice for 20 min. The mix was then
heated at 42 °C for 45 s and returned to ice for a further 2 min. SOC medium (900
pi) was added to the mix and incubated at 42 °C for 5 min. The mix was then
incubated at 37 °C in a shaker for 30 min. The mix (100 pi) was plated out on an LB
plate containing ampicillin as a selection antibiotic. The LB plate was incubated at
37 °C over night and colonies were picked for maxi-prep (see section 2.2.4.6.) the
following day.
2.1.7. Source of other reagents used
Oxidised LDL and native LDL obtained commercially were from Intracel
Corporation, Rockville, MD. USA.
Panorama Cytokine Gene Arrays and specific Human Cytokine Labelling Primers
were form Sigma Genosys, Haverhill, UK.
Penicillin-streptomycin, trypsin-EDTA, Trizol, and Iscove's medium were from
Gibco BRL, Paisley, Scotland. UK.
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X-Vivo 10 serum-free medium was from Cambrex, Nottingham, UK
Dextran and Percoll were from Pharmacia. Uppsala. Sweden.
HNE was from Elastin Products, Owensville, MO, USA.
LPS (from E. coli 0127:B8 in all experiments) was from Difco laboratories, Detroit,
MI. USA.
The Celltiter 96 One Solution cell Proliferation Assay and Cytotox 96 non¬
radioactive cytotoxicity assay were obtained form Promega, Southampton, UK.
Iononmvcin was obtained from Calbiochem, Nottingham. UK.
Nitrocellulose membrane was from Millipore, Watford, UK.
Dried skimmed milk was from Marvel, Premier Brands UK, Moreton. UK.
Western Lightning Chemiluminescence Reagent Plus (ECL) was from Perkin-Elmer
Life Sciences, Cambridge, UK.
ELISAs for human IL-8, TNF-a and MCP-1 were from R&D Systems, Abingdon,
UK.
The assay for protein concentration was NHS-LC-Biotin kit from Pierce, Rockford,
IL, USA.
Diff-quik was from Dade Diagnostika, Germany.
Normal Goat serum was from the Scottish Antibody Production Unit, Edinburgh,
UK.
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2.1.8. Plastic Ware
All tissue culture plates were from Corning Costar, Cambridge, MA, USA.
Polyurethane intravenous venflon cannulas were obtained form Becton Dickinson




2.2.1.1. Preparation and culture of human umbilical vein endothelial cells
(HUVECs).
Ethical approval was obtained from Lothian Research and Ethics Committee
(LREC No. 2001/R/UO/01) for the procurement of human umbilical veins from
healthy term pregnancies during elective caesarean sections (Appendix I). The
preparation ofHUVECs has been described previously (Gimbrone, Jr. et al 1974).
Human umbilical cord was collected in a container in PBS and transferred on ice to
the laboratory. The cord was clamped at one end and the vein was cannulated at the
other using an 18 gauge intravenous cannula (Venflon, Becton Dickinson Ltd,
Oxford, UK). A solution containing collagenase type IV (0.1%) in PBS was infused
(approximate volume 5ml) into the vein and the cord was clamped, with cannula in
situ, at both ends. Following a 20 min incubation at 37 °C, the cord was gently
massaged and the distal clamp was released. The vein was flushed through with
sterile PBS and the effluent containing HUVECs was collected. The effluent was
centrifuged at 700 x g for 6 min at room temperature and the cell pellet was
resuspended in 10 ml of EBM-2 culture medium. The cells were allowed to adhere
for 6 hours to a T75 culture flask before replenishment with 15 ml of fresh medium.
On average cells from a cord preparation would take around 5-6 days to grow to
confluence in a T75 flask with this protocol. Cells were grown in EBM2 culture
medium containing growth supplements at 37 °C, 5 % CO2. Medium was changed
every other day and cells were not grown beyond 5 passages.
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2.2.1.2. Preparation of peripheral blood-mononuclear cells
Mononuclear cells were isolated from peripheral blood as described
(McCutcheon et al 1998). Freshly citrated blood was centrifuged at 400 X g for 20
min and the platelet-rich plasma supernatant was used to prepare autologous serum
by addition of CaCL (10 mM final concentration). Leukocytes were isolated after
removal of erythrocytes by sedimentation using 6 % (w/v) dextran T500 in saline by
fractionation on a discontinuous gradient of isotonic Percoll solutions made in
Ca2+/Mg2+- free PBS (CMF-PBS). Percoll concentrations of 55 %, 68 % and 79 %
were used and the leukocytes were centrifuged at 700 X g for 20 min. Mononuclear
cells were aspirated from the 55 %/68 % interface and washed three times in CMF-
PBS prior to culture. Monocytes were enriched from the mononuclear fraction by
selectively attaching them to 48 or 12-well plates for 40 min at 37 °C. Non-adherent
lymphocytes were removed and adherent monocytes were washed twice in PBS.
Monocytes were then cultured in Iscove's modified DMEM containing 10 %
autologous serum, penicillin G (final concentration 100 U/ml) and streptomycin
sulphate (final concentration 100 pg/ml). For serum-free experiments, cells were
cultured in X-vivo 10 serum-free medium with antibiotic. Incubator conditions were
the same as for HUVECs. Maturation into macrophages with this culture protocol
has previously been demonstrated using myeloid specific markers including CD 16
and CD51/CD61 (McCutcheon et al 1998).
2.2.1.3. Preparation of A549 cells
A549 cells (Lieber et al 1976) were available in-house. Cells were suspended
in DMEM containing 10% FCS, penicillin G (final concentration 100 U/ml),
streptomycin sulphate (final concentration 100 pg/ml) and L-glutamine (2 pM)
before seeding onto multi-well plates or culture flasks. Incubator conditions were the
same as for HUVECs.
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2.2.1.4. Preparation of apoptotic Mutu I cells
The group I Burkitt lymphoma cell line Mutu I, is an established target cell for
macrophage interaction assays (Devitt et al 1998) and was available in house. The
Mutu I cells were induced into apoptosis by 16h incubation with 1 pg/ml of the
calcium ionophore ionomycin.
2.2.2. Gene transfer protocols
2.2.2.1. Transfection of HUVECs with plasmid DNA: calcium precipitate method
HUVECs were grown in 6-well Costar plates to 60% confluence in usual
growth medium. The dsRed2 plasmid (kindly provided by Dr J King, from our
group) encoding red fluorescent protein was used to establish the efficiency of
transfection. DNA (3 pg) was mixed with 4.3 pi 3 M CaCEto a final volume of 64
pi. The mixture was diluted with 2 x Hank's Balanced Salt Solution, vortexed for 15
s and allowed to stand for 1 min before being vortexed again and added to 1 ml
DMEM containing 10 % FCS. The precipitates could be visualised under light
microscopy over the surface of the HUVEC culture. DMEM containing the
precipitates was incubated with the HUVECs for 5 h, removed and replenished with
usual growth medium. The cell culture was examined for red fluorescence at 14 and
24 h.
2.2.2.2. Transfection of HUVECs with plasmid DNA: lipofectin method
HUVECs were grown in 6-well Costar plates to 60% confluence in usual
growth medium. 1 pg of DNA was diluted in 100 pi OptiMEM I reduced serum
medium (Invitrogen, Paisley, UK). 6 pi of Lipofectin reagent (Invitrogen) was mixed
in 100 pi of OPTI-MEM medium and the 2 solutions were combined and mixed
gently with a Gilson pipette at room temperature for 15 min. A further 800 pi
OptiMEM I was added directly to the mix, the cell culture was washed once with
OptiMEM I and the mix was applied for 2 h before removing and replenishing with
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usual medium. The cultures were examined for red fluorescence according to the
protocol above.
2.2.2.3. Adenoviral infection of HUVECs, macrophages and A549 cells.
All adenoviral work was performed in the Adenoviral Facility Class II
Ventilation Flood. Adenoviral infections were initially performed without
precomplexing. Adenovirus was incubated with the cells for 2 h in the usual culture
medium for each cell type before removing and replenishing with fresh medium.
2.2.2.3.1. Adenovirus infection in association with calcium precipitates
Calcium precipitates were generated in Eagle's MEM (Sigma). This contains
C'a2F (1.8 mM) and PO42" (0.86 mM). Calcium chloride (stock solution 2.5 M) was
added to Eagle's MEM (serum-free) to increase the Ca2n~ concentration to form
calcium phosphate precipitates. Unless indicated otherwise the final total
concentration of Ca2+ ion used for precipitate formation was 8.3 mM. Adenovirus
was precomplexed in the Eagle's MEM precipitate suspension for 15 min with gentle
mixing at room temperature before adding to the cell culture. Adenoviral infections
were performed (200 pi volume) on HUVECs and A549 cells grown to confluence in
48-well Costar plates. Macrophages were also matured on 48-well Costar plates and
infected on culture day 6 (following initial plating of 4 x 106 mononuclear cells on
day 1). Adenoviral incubations were for 2 h unless stated otherwise.
2.2.2.3.2. Adenovirus infection in association with lipofectamine
HUVECs and A549 cells were grown to confluence and one well was used for
cell count determination. Adenovirus vectors were pre-incubated for 15 min at room
temperature in OptiMEM I reduced serum medium (Invitrogen) with lipofectamine
(Invitrogen) at a ratio of 5 x 104 lipofectamine molecules to each adenovirus particle.
Particle concentration was determined from absorbance at 260 nm for each
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adenovirus construct according to published protocols (Maizel, Jr. et al 1968).
HUVECs and A549s were incubated in the virus-containing medium for 2 h before
replenishment with their respective usual growth media. Peripheral blood derived
macrophages were infected using the same protocol on culture day 4 before
replenishment with normal growth medium
2.2.3 Cell based assays
2.2.3.1. Flow cytometric analysis of CD31 and annexin V in HUVECs.
HUVECs were cultured in 12-well Costar plates. Culture medium was
removed and the cells were washed with PBS before being detached with trypsin.
For CD31 staining, the cells were pelleted (1000X g for 5 min) and resuspended in
PBS (100 pi) in polystyrene round bottom test tubes (BD Falcon). This step was
repeated and 1 pi of phycoerythrin conjugated murine anti-human CD31 IgG (BD
PharMingen, Oxford, UK) or FITC conjugated murine anti-human polyclonal IgG
(BD Pharmingen), as control, was added to the cell suspension. The antibody cell
suspension mix was incubated at room temperature for 30 min prior to analysis with
FACS analysis (FACSCalibur, BD Biosciences, San Jose, US).
Phosphatidylserine translocation, a process ocurring early in apoptotic cell
death and later in both apoptotic and necrotic cell death was analysed by annexin V
staining after incubation with stimulus (Vermes et al 1995). Cells were washed with
PBS and trypsinised as above. Following a further wash, they were pelleted again
and resuspended in Hanks' Balanced Salt Solution (HBSS: 200 pi) containing CaC^
(5 mM) and FITC conjugated Annexin-V-FLUOS (Boehringer-Mannheim
Biochemicals, Mannheim. Germany: diluted 1 pi in 3 ml HBSS). Control cells were
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2.2.3.2. Measurement of cell lysate luciferase activity
HUVECs were cultured to 60% confluence in 12-well Costar plates.
Transfections with the IL-8 promoter-luciferase plasmids were performed with
lipofectin according to the protocols described except that a transfection volume of
500 pi was used. The pGL3 plasmid encoding luciferase under the control of the
SV40 promoter (Promega, kind gift from Dr Karen Chapman, Molecular Medicine
Centre, University ofEdinburgh) was also transfected as a positive control. Cells
were cultured for 48 h following transfection and stimuli (TNF-a, PMA, oxidised
LDL and LPS) were added for a period of 8 h. Cells were then lysed in ice cold cell
lysate buffer (Tris base adjusted to pH 7.8 with phosphoric acid, 8 mM MgCU, 1 mM
DTT, 1% Triton x 100. 15% Glycerol). Lysates were centrifuged at 12 000 x g for 5
min and supernatants removed for analysis of luciferase activity. The assay was
performed on a Luminometer (Lumac, Biocounter M2500, MWG). The
Luminometer injected luciferin reagent (1 mM ATP, 0.25 mM Luciferin, 1% bovine
serum albumin in lysis buffer) into a 50 pi assay volume and the mean of 3
recordings was calculated from each sample.
2.2.3.3. Lactate dehydrogenase assay
The CytoTox Non-radioactive Cytotoxicity Assay (Promega) quantitates
lactate dehydrogenase (LDH) released into culture supernatants upon cell lysis. LDH
activity is measured through formation of a coloured product following hydrolysis of
o-nitrophenyl-(3-D-galactopy-ranoside. The colour intensity measured at 420 nm is
proportional to the number of lysed cells. This technique is sensitive for LDH release
and has been used previously to quantify cell death after treatment with cytotoxic
agents and can indicate low levels of cell membrane damage missed using other
approaches (Decker et al 1988). Assays were performed according to manufacturer's
protocol with a spectrophotometer (MR5000 Plate Reader, Dynatech, Dynex,
Billinghurst, UK). Supernatant LDH activity was expressed (after correction for
background within the culture medium) as a percentage of the activity resulting from
total cell lysis produced using 1% Triton X-100.
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2.2.3.4. Cell Titer Aqueous One Solution Cell Proliferation Assay
This assay uses a tetrazolium compound and electron coupling agent
(phenazine ethosulfate; PES). The MTS tetrazolium compound is reduced by cells
into a coloured formazan product that is soluble in tissue culture medium. Production
of the coloured agent can be measured directly by recording absorbance at 490 nm.
This reduction is mediated by NADPH and NADH produced by dehydrogenase
enzymes in metabolically active cells. The assay can reliably discriminate changes in
viable cell number caused by proliferation or necrotic and apoptotic cell death (Cory
et al 1991). The reduction of the tetrazolium compound is also affected by
interference with cell mitochondrial activity (Berridge et al 1993). In experiments
examining the effects ofHNE incubation on viable cell number, cells were exposed
to HNE for 24 h. HNE-containing culture medium was then replenished with fresh
culture medium and 20 pi of Cell Titer Aqueous One Solution reagent was added and
incubated at 37 °C for a further 4 h. Absorbance was then measured directly at 490
nm. Results are presented after correction for absorbance from medium alone.
2.2.3.5. Elafin ELISA
The ELISA was performed on 96-well plastic plates. Wells were coated
overnight at 4 °C with anti-elafin IgG in carbonate buffer, pH 9.6 (final concentration
IgG 7.7 pg/ml), with the exception that blank wells received buffer alone. The plate
was washed with wash buffer (0.1% Tween-20 in PBS, pH 7.4). Gelatin (final
concentration 1% in PBS, pH 7.4) was added to all wells (as a blocking agent) for 2 h
at 37 °C and the plate washed with wash buffer, prior to addition of samples and
standard. Standards comprised recombinant human elafin diluted in 1% gelatin and
were applied in duplicate at a dose range from 0.5 to 30 ng/ml (blanks received 1%
gelatin alone). Samples were serially diluted in 1% gelatin and for each sample 2
different dilutions were applied in duplicate. The volume of each standard and
sample was 100 pi, and incubation proceeded for 2 h at 37 °C, after which all wells
were washed with wash buffer. Anti-elafin IgG, biotinylated using an NHS-LC-
Biotin kit was diluted in 1% gelatin and added to each well (except blanks which
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received 1% gelatin alone) for 2 h at 37 °C. The plate was then washed with wash
buffer. Streptavidin-biotin-horeseradish peroxidase complex (final concentration 10
ng/ml in 1 % gelatin) was added to each well (except blanks which received 1%
gelatin alone) for 2 h at 37 °C. The plate was washed with wash buffer. Substrate
(comprising 0.006% H2O2 and lmg/ml 2,2'azino bis 3-ethyl benzthiazolidine
sulfonic acid, in 0.1M citric acid, pH 4.0) was added to all wells and absorbance
against elafin concentration in samples determined by extrapolation from the curve.
2.2.3.6. Staining ofmacrophages and HUVECs for P-galactosidase
Macrophages and HUVECs infected with Ad-pGal were fixed for 10 min at
room temperature in a solution comprising 0.2% glutaraldehyde, 0.8% formaldehyde
and 2 mM MgCf> in PBS. Fixative was discarded and 200 pi of staining solution was
added for 5 h at 37 °C (staining solution comprised 5 mM K4Fe(CN)6, 2 mM MgC^,
0.05% Triton X-100, 0.5 mg/ml X-gal, in PBS). Cells were washed with PBS to
remove residual stain, air dried and photographed.
2.2.3.7. 1L-8, MCP-1 and TNF-a ELISAs
Culture supernatants were collected and either used in an assay directly or frozen at -
20 °C. The human IL-8, MCP-1 and TNF-a ELISAs were commercial kits (R&D
Systems, Abingdon, UK) containing optimised capture and biotinylated detection
antibody pairs along with recombinant protein standard and manufacturer's protocols
were followed.
2.2.3.8. Limulus Amebocyte Lysate Assay for LPS contamination
The COAMATIC Chromo-LAL kit was purchased (Chromogenix, Milan, Italy).
This contained extract from the blood cells of the horseshoe crab, L. polyphemus.
This extract contains enzymes that are activated in a series of reactions in the
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presence of LPS. The last enzyme activated in the cascade splits the chromophore,
para-nitro aniline (pNA) producing a yellow colour. Samples were diluted in
endotoxin free water (Chromogeneix), transferred to a microplate (100 pi) at 37 °C
and the Chromo-LAL reagent (containing lysate and chromogen) was added to each
well (100 pi). The microplate was then placed in a plate reader and LPS content was
calculated from the change in absorbance at 405 nm plotted against time. Endotoxin
standard (Escherichia coli 0113:H10, Chromogeneix) was used to produce a standard
curve to estimate LPS contamination in endotoxin units.
2.2.4. RNA based assays and plasmid preparation
2.2.4.1. Preparation of total RNA from HUVECs
RNA for semi quantitative RT-PCR and the miniarray experiments was
prepared using TRIzol reagent (Gibco BRL). TRIzol reagent is a monophasic
solution of phenol and guanidine isothiocyanate and works through disrupting cell
membrane while maintaining the integrity ofRNA (Chomczynski 1993). TRIzol was
added directly to HUVECs cultured in multi-well plates following removal of culture
medium (600 pi for 48-well plates, 800 pi for 24-well plates and 1 ml for 6-well
plates). The samples were transferred to Eppindorf tubes and chloroform was added
to produce phase separation (0.2 ml of chloroform was added per 1 ml of TRIzol)
and the mix was centrifuged at 12000 X g at 4 °C for 10 min. The colourless upper
aqueous phase was transferred to a fresh eppindorf with care taken to avoid
disturbing the interphase. RNA precipitation was performed with isopropyl alcohol
(IPA, 0.5 ml of IPA per ml of TRIzol) for 30 min at -20 °C. A further centrifugation
(12000 x g at 4 °C for 10 min) was performed. The aqueous phase was removed
from the eppindorf leaving a visible pellet against the side of the eppindorf tube. This
was washed with a 75% ethanol/DEPC water solution, gently agitated and
centrifuged again at 7500 x g for 5 min. The 75% ethanol/DEPC water was removed
and the eppindorf was inverted and allowed to dry for 5 min. The pellet was then
dissolved in between 50 and 100 pi of DEPC water. RNA integrity was checked by
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assessing the ratio of 28s to 16s subunits on a 1% agarose gel. A ratio of greater than
or equal to 2 was taken to indicate absence of significant degradation. RNA was
quantified by measuring the absorbance at 260 nm in a spectrophotometer and
concentration was calculated from the formula (ODimjts x dilution factor x 40 pg/ml).
Protein contamination was considered to be absent if the 260nm/280nm absorbance
ratios were between 1.6 and 1.9.
2.2.4.2. Miniarray protocols
2.2.4.2.1. Prepartion of labelled cDNA
Total RNA form untreated native LDL and oxidised LDL treated cells (2 pg)
was mixed with Human Cytokine cDNA Labelling Primers (4 pi) and diluted to 15
pi with DEPC water. The primers were annealed by incubating at 90 °C for 2 min
and then programming a temperature ramp to 42 °C over 20 min. Once the thermal
cycler (MJ Research. DNA Engine, MJ Research, Ma, US), had reached 42 °C the
components for cDNA synthesis and labelling were added as follows; RT buffer (6
pi of 5x buffer), dATP. dGTP, dTTP (all 333 pM) and dCTP (1.67 pM) along with
20 pCi [a-'l2P] dCTP (3000 Ci/mmol), 20 U ribonuclease inhibitor and 50 U AMV
reverse transcriptase to a final volume of 30 pi with DEPC water. The mix was
pippetted carefully and incubated for 3 h. Unincorporated label was removed by
purification over a Sephadex G-25 gel filtration column centrifuged at x 11 OOg for 4
min. A 0.5 pi sample was taken before and after purification for determination of
percent incorporation on a scintillation counter. Labelled nucleotide incorporation
was between 20 and 30 %.
2.2.4.2.2. Hybridisation and array analysis
The arrays were rinsed in 50 ml of 2 x SSPE (0.18 M NaCl. 10 mM sodium
phosphate pH7.7. 1 mM EDTA) at room temperature for 5 min. Incubations with 5
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ml hybridisation solution (5 x SSPE, 2% SDS, 5 x Denhardfs reagent, 100 tig/ml
sonicated denatured salmon testes DNA) were performed at 65 °C in a hybridisation
oven for 60 min rotating at 6 r.p.m. Labelled sample (cDNA) was denatured with a
10 min incubation at 95 °C, suspended in 5 ml hybridisation solution and incubated
with the array in the hvbrisdisation oven for 14 hr. The hybridisation mix was then
decanted and the array washed for 2-3 min by gently agitating in 20 ml ofwash
solution I (0.5 x SSPE, 1% SDS). This step was repeated 3 times and then a further 3
times with a more stringent wash solution II (0.1 x SSPE, 1% SDS). The final wash
with wash solution II was for 20 min. The wash solution was discarded and the array
removed form the hybridisation bottle and placed onto blotting paper. After 2 min
exposure to air it was wrapped in plastic food wrap and exposed to a phosphor screen
(Molecular Dynamics. Sunnyvale, Ca, US) for 14 hr. The phosphorimaging was
performed with a Storm 860 phosphorimager and ImageQuant software (Molecular
Dynamics). Scanning resolution was set at 50 pM and a quantitation template was set
up to analyse pixel intensity for each spot of the array. Background signal was
selected from a clear area of the array and subtracted from each spot. Signal values
were exported to a spreadsheet (Microsoft Excel) and average signal intensity was
determined for each duplicate spot pair representing a gene. A simple normalisation
approach of comparing housekeeping gene expression between arrays was employed
to account for differences in hybridisation efficiency and sample loading. Normalised
signals were then compared between different array hybridisations to determine fold
change in gene expression between the different samples.
2.2.4.2.3. Washing and repeat hybridisation with the nriniarray
The nylon miniarrays were stripped and used again once only. The arrays were
placed together in a boiling stripping solution (10 mM Tris-HCL, pH 8.0, 1 mM
EDTA, 1% SDS) in an autoclaved pyrex flask on a hot plate for 20 min. The
stripping solution was drained off and the arrays were covered with plastic food wrap
and re-exposed against the phosphor screen to check that signal had been removed.
The arrays were stored at -20°C between hybridisations.
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2.2.4.3. Semi-quantitative reverse transcription polymerase chain reaction
Total RNA was isolated from HUVECs as described in section 2.2.4.1. For IL-
8 semiquantitative RT-PCR. 0.35pg of total RNA was reverse transcribed. For other
RT reactions 1 pg of total RNA was used. RNA was heated to 93°C for 5 min and
added to the mix containing 3.0 mM MgCL, 0.5 pg oligodT, 16 U RNasin, 1 mM of
each dNTP and 200 U ofMoloney murine leukaemia virus (MMLV) reverse
transcriptase (all Promega) to a total volume of 20 pi. The mix was incubated at 42
°C for 45 min and then heated at 95 °C for a further 5 min. For PCR a 30 pi reaction
containing 3 pi cDNA. 0.2 mM of each dNTP, 2 mM MgCL, 1.5 U Taq polymerase
(all Promega) and 1 pM each oligonucleotide primer was subjected to the following
temperature cycles; denaturating at 95 °C for 30 s, annealing at 55 °C for 1 min and
extension at 72 °C for 1 min for 35 cycles with a final 5 min extension period. For
IL-8 semiquantitative RT-PCR, GAPDFI was used as a reference with GAPDH
primers (0.5 pM) added in a multimix with IL-8 primers (1 pM). Temperature cycles
of 95°C for 30s, 60°C for 1 minute and 72°C for 1 minute for 31 cycles were
performed.
Semi-quantitative RT-PCR for Ang2 was performed using the housekeeping
gene. HPRT as reference. Briefly, 1 pg of total RNA was used in the RT reaction (37
°C for 45 min) with 0.5 pg oligo dT, 0.1 mM of dNTPs, 10 U/pl of reverse-
transcriptase (MMLV) and 1 U/pl of RNAsin in PCR buffer containing 3 mM of
MgCL- After a 5 min incubation at 95 °C, 2 pi of RT-mixture was added for PCR
(final volume 28 pi of PCR buffer; 1 ng/pl of reverse and forward primers, 0.03 U/pl
Taq polymerase, 0.5 mM MgCL).
Amplifications of HPRT and Ang2 were carried out for 26 and 30 cycles
respectively in a thermal cycler (MJ Research, DNA Engine), using the following
conditions for each cycle; 94 °C for 30s, 55 °C for 60 s, 72 °C for 60 s. These cycle
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numbers had previously been determined to allow quantification within the
curvilinear phase of PCR amplification. PGR products were analysed on a 1.2%
agarose gel with ethidium bromide staining and densitometry was performed using a
gel documentation system (Ultra Violet Products, Cambridge, UK).
2.2.4.4. Northern blotting for angiopoietin-2, midkine, MMP-1 and HPRT
Angiopoietin-2, midkine, MMP-1 and HPRT cDNA generated by PCR were
used to amplify cDNA for use as template to produce radiolabelled cDNA probe for
Northern blotting. cDNA bands were cut out of agarose gels with a scalpel and
purified using the QIAquick Gel extraction kit (Qiagen, Crawley, UK). Excess
agarose was trimmed away and the gel slice containg the cDNA was weighed. 3
volumes of Buffer QG (Qiagen) were added to 1 volume gel and incubated (50 °C
for 10 min) until the gel slice was solubilised. Isopropanol (1 gel volume) was added
and the mixture was applied onto a spin column containing a DNA binding resin
(QIAquick spin-column) and centrifuged (17000 x g for 1 min). The flow through
was discarded and a further centrifugation was performed with Buffer QG (0.5 ml) to
remove all trace of agarose. The centrifugation was repeated with wash Buffer PE
(0.75 ml, Qiagen), the flow through discarded and a further centrifugation performed
to remove all trace of alcohol. The QIAquick spin-column was placed into a fresh
centrifuge tube and DNA was eluted from the column by centrifugation (17000 x g
for 1 min) with Buffer EB (10 mM Tris-CL, pH 8.5). Radiolabelled cDNA probe was
synthesised using a Ready-to-Go kit (Amersham, Little Chalfont, UK). cDNA
template (50 ng) was denatured at 94 °C for 4 min and added to a reaction mix
containing Klenow Fragment (7-12 Units), dATP, dGTP, dTTP and random
oligodeoxyribonucleotides. 5 pi of [a-32P] dCTP (3000 Ci/mmol) was added to a
final 50 pi reaction volume. The mix was incubated at 37 °C for 30 min and then
allowed to cool to room temperature for 2 h. Unincorporated nucleotides were
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The Northern blotting protocol was based on a method previously described to
improve sensitivity (Fourney et al 1988). Total RNA was dissolved in 25 mM
EDTA, 0.1% SDS. The RNA sample was adjusted to a volume of 5 pi and added to
25 pi Electrophoresis Sample Buffer (0.75 ml deionised formamide, 0.15 ml 10x
MOPS/EDTA buffer, 0.24 ml formaldehyde, 0.1 ml DEPC water, 0.1 ml glycerol,
0.08 ml 10% (w/v) bromophenol blue). The mix was heated at 65 °C for 15 min and
placed on ice. 1 pi ethidium bromide solution (1.0 mg/ml) was added to the sample
and mixed thoroughly prior to loading onto the gel. The gel was prepared as follows;
1 g agarose, 10 ml 1 Ox MOPS/EDTA and 87 ml DEPC water were added to an
autoclaved flask. The mixture was heated to dissolve the agarose and cooled to 50 °C
to allow addition of 5.1 ml 37% formaldehyde. The solution was gently mixed and
poured into a gel tray and allowed to set for 1 h. Prior to loading, sample wells were
flushed and the gel was run in lx MOPS/EDTA buffer. The gel was run at 30V at
room temperature overnight (14 h). The gel was prepared for transfer by soaking it in
10 x SSC with gentle shaking. The nylon membranes (Genescreen Plus, DuPont,
Wilmington, USA) were pre-soaked in DEPC water and then 10 x SSC for 5 min.
RNA was transferred in 10 x SSC using a sponge to enhance capillary attraction. The
sponge had been washed thoroughly, was made from polyurethane foam and had
been obtained from a camping bed mattress. The gel was sandwiched between 3MM
Whatmann paper on top of the sponge sitting in a tank of 10 x SSC with paper towels
and a weight on top.
RNA transfer was performed overnight (14 h) and the gel was examined under
UV light for residual RNA. RNA was fixed to the membrane by baking at 80 °C for
2 h. Hybridisation was performed using ULTRAhyb buffer (Ambion, Huntingdon,
UK). ULTRAhyb was preheated to 68 °C to dissolve all precipitated material. The
blot was soaked in buffer for 30 min at 68 °C with enough volume to keep it
uniformly wet in the hybridisation bottle. Radiolabeled probe was added (106
cpm/ml buffer) and hybridised overnight (14 h) at 68 °C. Hybridisation buffer and
probe were then discarded and the blot was washed twice with 2x5 min washes (2 x
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SSC, 0.1% SDS) at 68 °C. a further 2x15 min washes were performed (0.1 x SSC,
0.1% SDS) at 68 °C. The blot was then wrapped in sandwich wrap and exposed to a
phosphor screen. The phosphor screen was analysed with a Storm 860
Phosphorimager and ImageQuant software.
2.2.4.5. Preparation of plasmids for angiopoietin-2, midkine, HPRT and MMP-1.
The PGEM-T Easy Vector System (Promega) was used to clone PCR inserts
for generation of cDNA and riboprobes. This vector contains T7 and SP6 RNA
polymerase promoters flanking a multiple cloning region. The multiple cloning
region is also flanked by recognition sites for restriction enzymes EcoR 1, BsfL 1 and
Not 1 facilitating single enzyme digest release of insert. Angiopoietin-2, MMP-1.
HPRT and MMP-1 cDNA were extracted form PCR mixes using the following
protocol. PCR mix was added (1:1 vol ratio) to a phenol/chloroform mix (25:1 vol
ratio), vortexed and centrifuged for 5 min at 12000 xg.A further volume of
chloroform (0.9 vol of original PCR mix) was added and centrifuged at 12000 x g for
5 min. The upper aqueous phase was transferred to a clean tube and cDNA was
precipitated for 40 min at -20 °C with 3 M sodium acetate pH 4.3 (0.1 vol original
PCR mix) and 100 % cthanol (2.5 vol original PCR mix). A further centrifugation
(12000 x g for 5 min) was performed, the supernatant removed and the pellet washed
with 70% ethanol. A final spin centrifugation (12000 x g for 5 min) was performed,
the ethanol was removed, the pellet air dried and resuspended in 20 pi of DEPC
water. cDNA concentrations were measured from absorbance at 240 nm in a
spectrophotometer.
Ligations were performed overnight at 4 °C using pGEM-T easy vector (50 ng)
and cDNA products in a 3:1 molar ratio with ligation buffer and T4 DNA ligase (3
Weiss units). A negative ligation with no PCR product and a positive control ligation
with a control insert DNA provided with the pGEM-T Easy vector were also set up.
DH5a competent cells (Life Technologies, Invitrogen, Paisley, UK) were
64
Chapter 2
Chapter 2: Materials and Methods
transformed with vector. Electroporation was performed with 2 pi of vector mix
(approx 25 ng) added to 50 pi DH5a E. Coli stock (25 pF, 200 Ohms, 2.5 kV:
Equibo ;EasyJect Plus" electroporator Eurogentec, Liege. Belgium). Following the
shock, 300 pi of SOC medium was added immediately and the mix was further
incubated for 40 min at 37 °C. The mix (100 pi) was then plated onto Luria-Bertani
(LB) agar plates containing ampicillin (100 pg/ml).
2.2.4.6. Isolation of plasmid DNA from DH5a E. Coli
Single, well isolated colonies from LB agar plates containing ampicillin were
picked and inoculated into 10 ml of LB culture medium containing ampicillin (0.5
mg/ml). The tip from a colony was also placed in a sterile microfuge tube with 30 pi
of LB agar. The tube was vortexed vigorously and 10 pi was transferred to a PCR
tube and boiled at 100 °C for 5 min to liberate plasmid. This suspension was used as
template for PCR to screen colonies for angiopoietin-2. midkine, MMP-1 and HPRT
inserts. Colonies containing inserts were incubated overnight (10 ml) on a shaker at
37 °C. The Wizard Plus SV Miniprep DNA purification System (Promega) was used
to isolate plasmid DNA from transformed bacteria. 5 ml of bacterial culture was
harvested and centrifuged (10,000 x g for 5 min at 21 °C). Supernatant was poured
off and the tube was inverted onto blotting paper to remove excess media. Cell
Resuspension Solution (250 pi. Promega) was added and the cells were resuspended
by vortexing and transferred to a 1.5 ml microfuge tube. Cell Lysis Solution (250 pi,
Promega) was added and the tube inverted gently 4 times and incubated at room
temperature for 4 min. The pitfall in the lysis step to be avoided was that the SDS
within the lysis solution might not be fully dissolved. The solution clarified during
this period and Alkaline Protease Solution (10 pi, Promega) was added, the tube
inverted 4 times and incubated for 4 min. The Wizard Plus Neutraliastion Solution
(350 pi, Promega) was then added and mixed immediately by inverting 4 times.
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The bacterial lysate was then centrifuged (14000 x g for 10 min at room
temperature). Cleared lysate was transferred to a Spin Column by pipette without
disturbing or transferring any of the white precipitate. Supernatant was then
centrifuged (14000 x g for 1 min) at room temperature and the flow-through was
discarded. Column Wash Solution (750 pi, Promega) was then added and a further
centrifugation performed. The wash was repeated with 250 pi of Column Wash
Solution (14000 x g for 2 min). The spin column containing bound plasmid DNA
was then transferred to a fresh microfuge tube with care taken to avoid transferring
any wash solution. Plasmid DNA was eluted with 100 pi ofNuclease Free Water
(Promega) by centrifugation (14000 x g for 1 min at room temperature).
2.2.4.7. Generation of riboprobes for ribonuclease protection assays
The vectors containing HPRT and angiopoietin-2 PCR fragment inserts were
sequenced to ascertain orientation and verify sequence of the insert. Riboprobes were
generated using the Maxiscript In Vitro Transcription Kit (Ambion). The
angiopoietin-2 and HPRT inserts could be linearised with Sph I following incubation
at 37 °C for 2 h. The linearised plasmid was then digested with proteinase K (200
pg/ml, 0.5% SDS at 50 °C) for 30 min. Linearised plasmid was then phenol
chloroform extracted and resuspended in DEPC water. Transcription reactions were
set up with 1 pg of DNA template, transcription buffer, ATP, CTP, GTP (all 0.5
mM), UTP and al2P-[UTP] (2 pM and 1 pM respectively) to a final limiting
concentration of 3 pM. In riboprobe synthesis a balance exists between probes
generated with high specific activity, where the ratio of radiolabelled to cold
nucleotide is high but overall concentration is lower, limiting full chain synthesis.
SP6 RNA polymerase was added to the transcription mix and diluted to a final
volume of 20 pi. The mix was incubated at 37 °C for 15 min and template DNA was
digested with DNase I (2U) for 15 min at 37 °C. Free nucleotides were removed by
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2.2.4.8. Ribonuclease protection assays
The ribonuclease protection assay is a sensitive method for detecting RNA
transcripts (Lee and Costlow, 1987). Radiolabeled antisense RNA transcripts
(riboprobes) were generated from the vectors containing PCR fragment inserts
according to the method in section 2.2.4.7. The assay works on the principle that
hybridisation of riboprobe to complementary sequences in the RNA sample will
protect it from digestion by ribonuclease. The greater the amount of complementary
RNA the more probe is protected and the higher the signal.
Sample RNA and labelled riboprobe were mixed together (approximately 5 x
104 cpm per 10 jug RNA sample) and co-precipitated by adding ammonium acetate
(0.5 M) and 2.5 vol of ethanol and incubating at - 20 °C for 15 min. For each probe,
2 additional control reactions were set up using yeast RNA (1 jug). RNA was pelleted
by centrifugation (12000 x g for 15 min at 4 °C) and pellets were washed with 70%
ethanol. Eluants were monitored for radioactivity to ensure that probe was not being
removed from the mix. The pellets were then resuspended in 10 pi of hybridisation
buffer, vortexed and centrifuged briefly to mix and collect the reaction at the bottom
of the tube. RNA was denatured (94 °C for 4 min) and hybridised overnight (42 °C
for 14 h). A mix of RNase A and RNase T1 (250 U/ml and 10,000 U/ml
respectively) was diluted 100-fold in RNase digestion 111 buffer (Ambion) and then
added (150 pi) to each hybridisation reaction and to one of the yeast control
reactions. RNase digestion III buffer was added alone to the other control yeast
reaction. The tubes were briefly vortexed and centrifuged to collect the reaction mix
and incubated at 37 °C for 30 min. RNase Inactivation/Precipitation III Solution
(Ambion) was added (225 pi) and the reaction was incubated at -20 °C for 20 min.
The precipitated RNA was then centrifuged (12,000 x g for 15 min at 4 °C) and
supernatants were carefully removed from each tube and monitored for radioactivity.
The pellets were washed with 70% ethanol and resuspended in 5 pi of Gel loading
Buffer II (Ambion). The samples were run on 6% acrylamide gels (Sequagel-6,
National Diagnostics. Georgia, US) 15 cm wide and 25 cm long with wells 5 mm in
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width. The acrylamide was polymerised with ammonium persulphate and run
between two siliconised glass plates separated by plastic spacers and sealed with
autoclave tape. Around 35 ml of acrylamide was required to fill the sequencing gel.
The gel was placed in a sequencing gel tank (Base Runner, GENEQ inc.
Montreal. Canada) consisting of two tanks each containing 500 ml TBE buffer
connected to the gel plates and sealed with gel grease. The gel was run at 600 V for
20 min and urea was flushed out of the wells prior to sample loading. Prior to
loading, the samples were heated at 94 °C for 3 min to solubilise and denature the
RNA. The gel was run at 250V for 2.5 h until the leading dye band had reached the
bottom of the gel. The gel was then blotted onto Whatmann paper and dried on a gel
drier before exposure overnight to a phosphor screen. The phosphor screen was
analysed with a Storm 860 Phosphorimager and ImageQuant software.
2.2.5. Protein based assays
2.2.5.1. Immunoprecipitation and SDS-PAGE to detect angiopoietin-2 from HUVEC
culture supernatants
The immunoprecipitation protocol was developed by Mr Charlie Mayor,
Department of Cardiovascular Sciences, University of Edinburgh. Mr Mayor also
performed the majority of immunoprecipitation experiments. HUVECs were cultured
with oxidised LDL (100 pg/ml), native LDL (100 pg/ml) and TNF-a (R&D Systems,
Abingdon, UK - lOng/ml) for 8 h. Conditioned HUVEC supernatant (1 ml) was
incubated at room temperature for 30 min with goat polyclonal anti-Ang2 (N-18)
antibody (Santa Cruz Biotechnology, Santa Cruz, Ca, US) at a concentration of 200
ng/ml. 50 pi of ProteinG sepharose (Amersham) that had been washed three times in
lysis buffer (1% Triton-XlOO, 150 mM NaCl, 50 mM Tris.HCl pH 7.4, 0.2 mM
PMSF, 1 mM EDTA. 0.2 mM sodium orthovanadate, 0.1 pg/ml pepstatin) was added
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overnight at 4°C under rotation. The pellet was washed three times with lysis buffer
and immmunoprecipitates eluted by boiling for 5 min in 40 pi sample buffer.
Equal volumes of sample were diluted with 30 pi distilled water and separated
by SDS-PAGE. Proteins were resolved by electrophoresis on 10 % polyacrylamide
gels (100 V/50-100 mA for 2h) and transferred to a polyvinylidene difluoride
membrane in 25 mM Tris, 190 mM glycine, 0.05 % SDS, 20 % methanol (100 V/400
mA for 2h). Membranes were blocked in Tris-buffered saline (TBS pH 7.6) with 0.1
% Tween, 5 % non-fat dry milk overnight at 4° C prior to a 2 h incubation at room
temperature with anti-Ang2 antibody (1:1000). After washing, membranes were
incubated (1 h at room temperature) with anti-goat-IgG conjugated to horseradish
peroxidase (Dako, Ely, UK; 1:2500). After washing, immunoreactive bands were
visualised by enhanced chemiluminescence (ECL). Recombinant Ang2 (rAng2-R&D
Systems) was run as a positive control.
2.2.5.2. Immunostaining of human coronary arteries
All immunostaining was performed by Mrs Frances Rae, Department of Pathology,
University of Edinburgh. The work was conducted in collaboration with Dr Lee
Jordan, Specialist Registrar and Lecturer in Flistopathology, University of
Edinburgh. A series of human tissues including four coronary arteries were obtained
(following clearance from the relevant ethics committee) from the University of
Edinburgh Department of Pathology living (non-post mortem) archive of patients
with atherosclerosis undergoing coronary artery bypass surgery. Non-diseased
vascular tissues including temporal and splenic arteries, renal and umbilical/placental
tissues were also obtained for comparison. Full local Lothian Research and Ethics
Committee (LREC) approval was received. The tissue was in formalin fixed (10%
aqueous solution of formaldehyde), paraffin embedded blocks. Traditional
haematoxylin and eosin stained sections were viewed by the histopathologist for
morphological description. A series of 5-7 micron thick sections were exposed to a
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panel of immunohistochemical agents to establish the cell type within vessel walls.
These included: CD3 (rabbit polyclonal anti-human CD3, clone A452 - Dako, UK);
CD31 (mouse monoclonal anti-human endothelial cell CD31, clone JC/70A- Dako,
UK); CD68 (mouse monoclonal anti-human macrophage CD68, clone PG-M1 -
Dako, UK); Smooth Muscle Actin (mouse monoclonal anti-human SMA, clone 1A4
- Dako, UK). Ang2 immunohistochemistry was performed using goat polyclonal
antihuman Ang2, (Santa Cruz). Manufacturers' protocols were used. Recommended
positive and negative controls were used where possible (Lymph node - CD3, CD68;
Small Intestine - SMA. Vascularised tissue - CD31). The control tissue for Ang2
was placenta, previously recognised as a site of Ang2 expression (Wulff et al 2002).
2.2.5.3. Extraction of nuclear fractions from HUVECs and macrophages
Nuclear protein analysis was performed according to published protocols (Staal
et al 1990) with some modifications as follows. Cells were grown in 12-well Costar
plates and following treatments, culture medium was removed and 400 pi of ice cold
buffer A (10 mM HEPES-KOH; pH 7.9, 10 mM KC1, 2 mM MgCl2. 1 mM DTT, 0.1
mM EDTA, 0.2 mM NaF, 0.2 mM NasVCf and proteinase inhibitors; 0.5 mM
PMST, and 1 pg/nrl of leupeptin and aprotinin added immediately prior to use) was
added. The cells were scraped off and suspended in an eppindorf. Buffer B (25 pi,
10% NP-40) was added and the suspension was vortexed vigorously for 15 s. The
suspension was then centrifuged (12000 x g for 45 s) and cytoplasmic fractions were
removed with care taken not to disturb the pellet. Pelleted nuclei were then
resuspended in 50 pi of Buffer C and incubated on ice on a shaker for 20 min
vortexing for 15 s every 5 min. The suspensions were then centrifuged (13000 x g
for 5 min) and the supernatants collected for analysis. Protein concentrations were
measured using the Bio-Rad Protein Assay (Bio-Rad, Hemel Hempstead, UK) which
had been shown to be compatible with the extraction buffers used in this protocol.
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2.2.5.4. Electromobility shift assay
This assay is based on the principle that complexes of protein and DNA migrate
more slowly on polyacrylamide gel than free DNA or double stranded
oligonucleotides. Consensus NF-kB oligonucleotide, antisense (5'-3') AGT-TGA-
GGG-GAC-TTT-CCC-AGG-C (2.5 pmol; Promega) or a mutant consensus oligo
containing a single base pair substitution antisense AGT-TGA-GGC-GAC-TTT-
CCC-AGC-C (Santa Cruz) were mixed with T4 polynucleotide kinase. [y"32P]ATP (1
pi, 3000 Ci/mmol at 10 mCi/ml) and reaction buffer to a final volume of 10 pi. The
reaction was incubated at 37 °C for 30 min and then terminated with 1 pi EDTA (0.5
M). The mix was then diluted to 100 pi with TE buffer. Nuclear protein (7 pg) was
added to a 10 pi binding reaction containing radiolabeled consensus or mutant oligo
(1 pi) 10 mM Tris-CL. 10 mM KCL, 1 mM EDTA, 0.5 mM MgCl2 8% glycerol,
ImM DTT and 0.5 pi of stock poly(dI-dC)poly(dI-dC) (1 mg/ml).
The binding reaction was incubated at room temperature for 20 min. An
additional control binding reaction was set up with 2.5 pmol of excess unlabelled
consensus oligo as a further control for specific binding to compete with the
radiolabeled probe. The protein-oligo binding mix was then added to a 6%
polyacrylamide gel. Dye was added to a separate well to visualise migration without
interfering with nuclear protein binding. The gel was run at 100 volts until the dye
had migrated to the bottom end. The gel was dried on Whatman paper, wrapped in
sandwich wrap and exposed to a phosphor screen.
2.2.5.5. SDS PAGE and Western blotting for IkBcc (and angiopoietin-2)
For angiopoietin-2. cell culture supernatants were collected and cell lysates
taken in RIPA buffer (10 mM sodium phosphate buffer pH 7.5, 150 mM NaCl, 1
mM DTT, 1% Nonidet P-40, 1% sodium deoxycholate, 0.1% SDS, 10 pg/ml
aprotinin. 10 mg/ml PMSF). Lysates were collected in an eppindorf and centrifuged
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(12000 x g at 4 °C for 5 min). The soluble component of the lysate was removed and
loaded (50 pg) onto a 12% SDS polyacrylamide gel. SDS-PAGE was performed
using a vertical electrophoresis tank Mini-Protean II system. Samples were
electrophoresed at 100 V using SDS-Tris-Glycine electrode buffer for 2 hours beside
prestained molecular weight markers (Life Technologies) and using 20 ng of
angiopoietin-2 (R&D Systems) protein as a positive control. Following separation,
proteins were transferred onto Hybond ECL nitrocellulose membrane (Amersham),
at 100 V for 1 h. Non-specific protein binding sites were blocked overnight at 4 °C
with PBS/0.1% Tween 20 containing 5% skimmed milk. The membrane was then
incubated with 1:1000 dilution of goat anti-angiopoietin-2 IgG (Santa Cruz) in
blocking solution for 2 h at room temperature and washed thoroughly with PBS/0.1%
Tween. HRP conjugated rabbit anti-goat immunoglobulin diluted 1:5000 (Dako) in
blocking solution was added for 30 min at room temperature, and then the membrane
was washed as above. Finally, immunoreactive bands were detected by ECL and
membrane developed on X-omat film.
For IkBoc, HUVECs and macrophage extracts were prepared as above with cell
lysate buffer (10% glycerol, 2% SDS, 62.5 mM Tris-Cl, 2 pg/ml leupeptin, 2 pg/ml
aprotinin, and 1 mM PMSF) after 10 min of LPS (100 ng/ml) or TNF-a (100 pg/ml)
stimulation. Pilot studies were performed to determine the optimum time point for
observing IkBcc degradation in response to stimulus. Cell extracts were analysed for
IkBoc protein content by SDS-PAGE. The majority of these gels were performed by
Miss Tara Sheldrake (from our group). Briefly, equal volumes were loaded onto a
prefabricated 12% Bis-Tris/MES polyacrylamide gel (Nu-PAGE, Invitrogen) and
electrophoresis was performed as above. Electroblotting was then conducted on
nitrocellulose and membranes were treated with rabbit anti-lxBa antibody, 1/1000
dilution (Cell Signaling Technology, New England Biolabs, Hitchin, UK), for either
16 h at 4°C or 2 h at room temperature and subsequently with goat anti-rabbit,
1/2000 dilution (Dako) for 1.5 h at room temperature. The Western blots were then
developed by ECL and exposed to film as above.
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Formulations: 4 x SDS-PAGE sample buffer: 0.5 M Tris-HCl, 40% (v/v)
glycerol, 8% (w/v) SDS, 0.2 M EDTA, 0.5% (v/v) bromphenol blue and 4% (v/v)
mercaptoethanol. Separating gel (angiopoietin-2): ph 8.8, 0.375 M Tris-HCL, 2 mM
EDTA, 0.1% (w/v) SDS. 12% acrylamide, 0.1% (v/v) APS and 0.05% (v/v)
TEMED. Electrode buffer: 0.6% (w/v) Tris base, 2.9% (w/v) glycine, 0.7% (w/v)
EDTA. 0.1% (w/v) SDS. Transfer buffer: 24.7 mM Tris base, 210 mM glycine and
20% (v/v) methanol.
2.2.6. Techniques related to human neutrophil elastase (HNE) assays
2.2.6.1. Treatment of HUVECs with HNE
For HNE mediated injury experiments HUVECs were washed with PBS to
remove serum (because of the presence of HNE inhibitors in serum) and incubated in
serum-free EBM2 containing HNE for 8 h (at the concentration indicated), after
which photomicrographs were taken. For HNE pretreatment studies, HUVECs were
washed in PBS and pre-incubated with HNE for 1 h before replenishment with
serum-containing EBM2 containing the second TPS (100 ng/ml) or oxidised LDL
stimulus (100 pg/ml). All incubations with LPS, TNF-a (1 ng/ml) and oxidised LDL
were for 8 h.
2.2.6.2. Treatment of macrophages with HNE and flow cytometric analysis
On culture day-4 macrophages were removed with cold CMF-PBS and plated
at 70000 cells/ well on 48-well plates in X-Vivo 10 serum-free culture medium
(Cambrex Bio Science). Where indicated, HNE (1 pM) was added directly the
following day and incubated for 1 hour prior to removal. Following HNE treatments,
cells were washed with ice cold CMF-PBS and suspended in 2 % goat serum
(Serotec Ltd. Oxford. UK). Cells were incubated with 61D3, a CD 14 blocking
monoclonal antibody (Devitt et al 1998), for 30 min, washed twice and then
incubated with phycoerythrin-conjugated goat anti-mouse IgG secondary antibody
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(Dako) for 15 minutes. Washed macrophages were then analysed on a FACScan
cytometer (BD Biosciences).
2.2.6.3. HNE inhibition assay
The FINE activity ofmacrophage supernatants, following incubation with
HNE, was examined to determine any inhibitory effect conferred by infection with
Ad-elafm or incubation with r-elafin. Briefly, all dilutions were performed in assay
buffer (50 mM Tris. 0.5M NaCl, 0.1% Triton X-100, pH 8.0). Cell culture
supernatant (90 pi) was incubated in a 96-well microtitre plate for 30 min at 37 °C
before addition of the chromogeneic substrate N-methoxysuccinyl-Ala-Ala-Pro-Val-
p-nitroanilide. The change in absorbance measured spectrophotometrically at 405 nm
(MR5000 Plate Reader), was expressed as a function of time.
In a separate experiment to measure HNE activity within apoptotic Mutu cells,
two independent batches of apoptotic Mutu cells (3 million cells) were pelleted and
washed with PBS and lysed in 0.4 ml of FINE buffer assay. Cell lysate (50 pi) was
added to a microtitre plate and HNE activity recorded according to the protocol
above.
2.2.6.4. Apoptotic cell recognition assay
Macrophages were cultured in 48-well plates. Adenovirus infections were
performed in X-vivo 10 serum-free using the precomplexing protocol with
lipofectamine, described in section 2.2.2.3.2. Macrophages were treated 24 h after
adenoviral infection. Where indicated, FINE (1 pM) and r-elafin (15 pg/ml) were
added directly for 1 hour prior to the interaction assay with apoptotic cells. The
group I Burkitt lymphoma cell line Mutu I, induced into apoptosis by 16 h incubation
with 1 pg/ml of the calcium ionophore ionomycin was used as a source of apoptotic
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cells. Typically, around 70% of cells were apoptotic following this treatment as
determined by FACS analysis of annexin V staining. For some experiments the 61D3
CD14-blocking monoclonal antibody was mixed with the apoptotic Mutu cells. The
culture medium was removed and 750000 apoptotic Mutu cells were added to each
48-well for 1 h at 37 °C before being washed extensively with ice cold CMF-PBS to
remove unbound apoptotic cells. Cells were then fixed in 1% paraformaldehyde and
stained with Diff-quick for counting. Cultures were scored by light microscopy
according to the proportion of macrophages that had internalised or bound apoptotic
Mutu cells by established criteria (Devitt et al 1998). At least 300 macrophages were
assessed per sample.
2.2.7. Statistical analysis
Results are reported either as pooled data from a series of n separate
experiments and presented as mean ± SD or as individual experiments, carried out in
triplicate and presented as mean ± SD. Statistical significance was analysed using the
Student /-test except for data except for data in Figure 5.12 which were analysed
using oneway ANOVA with post-hoc Boneferrpni correction. Statistical significance
was assigned to data returning a P value of less than 0.05.
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Chapter 3
An experimental system to study human endothelial
cell inflammatory responses to oxidised LDL
3.1. Aims
The central aim is to create and characterise an in-vitro culture system to model
endothelial injury occurring during the development of atherosclerosis.
Firstly, primary endothelial cell cultures were established from human
umbilical cord veins. The purity of these cultures was demonstrated.
The purity of LDL preparations and in particular, the presence of
contaminating LPS was then investigated.
The effects of oxidised LDL on endothelial cell survival and inflammatory
cytokine production were established.
Finally, the signalling events associated with oxidised LDL stimulation of
endothelial cells were investigated.
3.2. Results
3.2.1. Preparation of a pure culture of human endothelial cells from umbilical veins.
The Lothian Research and Ethics Committee (LREC/R/UO/Ol) gave approval
to obtaining consent from pregnant mothers for donation of the umbilical cord
following healthy term pregnancies delivered by Caesarean section. The information
sheet for this study, given to expectant mothers prior to obtaining consent, is shown
in Appendix I at the end of this chapter. Cells were extracted according to techniques
outlined in the methods section. Human endothelial cells, obtained by collagenase
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treatment of term umbilical cord veins were cultured in EBM-2 medium with 4.5%
fetal calf serum and growth factor supplements (see Materials and Methods, section
2.2.1.1). Small clusters of cells, initially spread out in the 75 cl culture flask,
coalesced and grew to form confluent monolayers of polygonal cells within 5 to 7
days. Endothelial cells were recognised morphologically by their cobblestone
appearance in culture and staining for the CD31 antigen was performed (Figure 3.1).
CD31 expression is limited to endothelial cells and leucocytes (Newman 1997)
and is absent from the major possible contaminating cell types, vascular smooth
muscle cells and fibroblasts. After 2 passages, cells were dislodged from culture
plastic and suspended following trypsin treatment. FACS analysis demonstrated a
homogeneous population of cells with greater than 99% positivity for CD31 antigen
(Figure 3.1). The homogeneous appearance of the cultures was in keeping with
results of FACS analysis, indicating an essentially pure culture.
3.2.2. Characterisation of native (non-oxidised) and oxidised LDL preparations and
their effects on endothelial cell cultures.
Fluman plasma was obtained from the Department of Transfusion Medicine,
Royal Infirmary of Edinburgh. LDL was isolated by sequential ultracentrifugation
and oxidised against CuCL The degree of oxidation was monitored by the formation
of conjugated dienes at 234 nm (Lewin et al 2002). The effect of incubation with
native and oxidised LDL on endothelial cell inflammatory cytokine production was
examined (Figure 3.2). Both preparations of LDL stimulated interleukin-8 (1L-8) and
monocyte chemoattractant protein-1 (MCP-1) production in endothelial cell culture
supernatants. Oxidised LDL was the more potent stimulus for these chemoattractant
cytokines (Figure 3.2A. B).
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Figure 3.1. Collagenase digestion of human umbilical cords produced a pure
yield of CD31+ endothelial cells on FACS analysis.
A. Cells were suspended in a single cell suspension and sorted by charge and
granularity using fluorescent activated cells sorting analysis (FACS). A population of
intact cells uncontaminated by debris was identified within the scatter plot. This
population was termed region 1 (Rl) and selected for further interrogation. B.
Histogram analysis of region 1 following incubation of cells with an isotype matched
PE labelled antibody. There was little if any staining in the Rl population of cells
with 100% of cells lying in area 2 (A2). C. Incubation with an anti-CD31 PE
conjugated antibody produced a shift in the fluorescence of the Rl population with
99.77% of cells lying in area 2 (A2).
Similar results were seen form different umbilical vein preparations.
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This result indicates the importance of oxidative modification of LDL for its
inflammatory properties. A central theme of this chapter is the characterisation of
signalling events responsible for induction of inflammatory cytokine production by
oxidised LDL. Firstly, the possibility of LPS contamination of LDL during
preparation was investigated. LPS would be expected to produce a similar cytokine
response from endothelial cells (von Asmuth et al 1991). The sensitive limulus
amebocyte lysate (LAL) assay was used to detect LPS. LDL preparations produced
by Professor Riemersma (Cardiovascular Research Unit, University ofEdinburgh)
and obtained commercially from Intracel were analysed (Table 3.1). Both
commercial and locally produced native and oxidised LDL contained LPS. There
was considerable variation in the LPS content between different preparations. It is
important to note that the LPS content of the locally produced native LDL (batch 1)
was higher or similar to the corresponding oxidised LDL batch (batch 2) despite the
more involved processing associated with oxidised LDL preparation. The LPS
content of sterile PBS was also measured to provide a negative control for the LAL
assay and as an indication of a minimum level of endotoxin contamination for tissue
culture grade material.
This magnitude of endotoxin contamination in the LDL preparations was
surprising and experiments were devised to find where LPS was being introduced in
the LDL preparation process and to what degree LPS was contributing to the
observed stimulatory effect of LDL on endothelial cell cytokine production (Figure
3.1). In order to identify the source of contamination, LPS levels were measured in
aliquots from different stages of the LDL preparation (Figure 3.3). LPS levels were
undetectable in donor human plasma. Following ultracentrifugation (and oxidation)
to produce native (and oxidised) LDL, low levels of LPS were found. Passage
through the Amicon ultrafiltration unit produced the biggest step up in LPS
concentration for the native LDL component of the analysed batch (Figure 3.3). The
Amicon ultrafiltration unit was the only component of the LDL preparation apparatus
that could not be autoclaved and had been identified as a likely source for LPS
contamination prior to the experiment.
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Figure 3.2. Both oxidised LDL and native LDL induced HUVEC production of
IL-8 and MCP-L
Confluent HUVECs in 48-well format at passage 4 were incubated in EBM-2 (2.5%
fetal calf serum) alone or with locally produced preparations of native LDL or
oxidised LDL for 16 hours. Supernatants were removed and IL-8 (Panel A) and
MCP-1 (Panel B) levels were quantified by ELISA. Results for IL-8 and MCP-1 are
mean ± SD from 3 experiments performed in triplicate representing 2 different
HUVEC donors and LDL preparations (batches 2 and 3). * Significantly greater than
native LDL,p < 0.05.
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Lipid batch (#) LPS EU/ml (approx. pg/ml)
Local nLDL # 1 1340 (111667)
Local oxLDL # 1 4.97 (414)
Local nLDL # 2 46.8 (3900)
Local oxLDL # 2 44.7 (3725)
Intracel oxLDL #351 1.38 (115)
Intracel oxLDL # 353 189.2 (15767)
Intracel oxLDL #354 187.2 (15600)
Intracel oxLDL # 356 13.5 (1125)
Sterile PBS 0.009 (0.75)
Table 3.1. LPS concentration within different preparations of locally produced
and commercial LDL.
The LPS content of LDL was measured against a standard LPS (United States
standard endotoxin EC-6). Results are in endotoxin units/ml (EU/ml) where 12 EU
approximates 1000 pg LPS.
Chapter 3
81
Chapter 3: Human endothelial cell inflammatory responses to oxidised LDL
The contribution of contaminating LPS to LDL's stimulatory effect on inflammatory
cytokine production was assessed by incubating LDL with polymyxin-B (Figure
3.4). Polymyxin-B is a naturally occurring antibiotic known to bind and inhibit
various biological activities induced by LPS (Pier et al 1981). Pre-incubation of a
batch of locally produced native and oxidised LDL with polymyxin B significantly
reduced subsequent MCP-1 production by endothelial cells (Figure 3.4). This is
consistent with a significant contribution from LPS to MCP-1 production. In a
further experiment the effect on MCP-1 production of spiking a sample of locally
produced oxidised LDL with LPS was examined. MCP-1 production was heightened
considerably and the effect was attenuated by pre-incubating the spiked sample with
polymyxin-B (Figure 3.5).
A saturating dose of polymyxin-B reduced but did not annul completely the
stimulatory effect of LPS alone (Figure 3.5). The negative control limb of this
experiment produced an unexpected result. Polymyxin-B had an inhibitory effect on
TNF-a induced MCP-1 production by endothelial cells suggesting an inhibitory
action that extends beyond neutralisation of LPS (Figure 3.5).
Together, these results indicated the potential for LPS contamination of LDL
preparations produced locally or obtained commercially. With locally produced LDL
the Amicon ultrafiltration unit appeared to be a particularly important source of
contamination. The studies with polymyxin-B suggested that contaminating LPS
may be contributing to LDL stimulated cytokine production although this conclusion
was weakened by an apparent LPS independent inhibitory effect of polymyxin-B on
endothelial MCP-1 production. Because doubt remained it was clear that the amount
of contaminating LPS in LDL had to be reduced for further experiments.
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Figure 3.3. LPS levels at different stages from an LDL preparation.
Results are in endotoxin units/ml (EU/ml) from the mean ± SD of 3 measurements
from one LDL preparation. LPS levels are shown in plasma, following
ultracentrifugation (native: nLDL). oxidation with copper sulphate (oxidised LDL:
oxLDL) and following passage through the concentrator.
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Polymyxin B (20 pg/ml)
Figure 3.4. Polymyxin B reduces both oxidised LDL and native LDL induced
HL1VEC MCP-1 production.
LDL was pre-incubated with 20 pg/ml polymyxin B for 30 minutes at room
temperature. MCP-1 levels were measured in the supernatants following 8 h
incubations with the different treatments. The results from one locally produced
batch of lipid are shown. Results are presented as mean ± SD from one experiment


















Polymyxin B 20 pg/ml
Figure 3.5. Polymyxin B attenuates LPS and TNF-a signalling in HUVECs.
Polymyxin B was pre-incubated with TNF-a, LPS or oxidised LDL that had been
spiked with LPS to a final concentration of 100 ng/ml. MCP-1 levels were measured
in the supernatants following 8 h incubations with the different treatments. Results
are presented as the mean ± SD from one experiment performed in triplicate. *, t
significantly less following incubation with polymyxin B,p< 0.05, p < 0.01.
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The effort to reduce levels of contaminating LPS focused on the Amicon
ultrafiltration unit, the only component of the LDL preparation process that had to be
reused between preparations. Although the Amicon ultrafiltration unit was rigorously
cleaned between preps it could not withstand autoclaving. The protocol to remove
LPS by soaking the concentrator in potassium hydroxide was employed for all
further LDL preparations. Where possible, a switch to disposable equipment was
made and LPS levels were measured in fresh LDL preparations (Table 3.2). The
changes to the preparation protocol reduced LPS contamination from the Amicon
ultrafiltration unit in LDL preparations. LPS levels were measured for all subsequent
batches of locally produced LDL. LDL was diluted in culture medium prior to use
and working concentrations of LPS became less than 25 pg/ml. This level of
contamination for native and oxidised LDL was accepted for the remaining
experiments described in this thesis
3.2.3. The inflammatory effects of oxidised LDL on cultured endothelial cells
Following detection of significant LPS contamination within early LDL
preparations, with the possibility that this may have contributed to the impressive
stimulation of endothelial cell chemokine production (Figure 3.2), it was important to
assess the inflammatory effects of LDL produced after introduction ofmeasures to
reduce LPS contamination. Oxidised LDL induced up-regulation of IL-8 message
was demonstrated using semi-quantitative RT-PCR (Figure 3.6). Endothelial cells
incubated with oxidised LDL had increased amount of IL-8 mRNA within 4 hours.
Incubation with native LDL for this period also produced a faint but discernible
signal indicating an increase in IL-8 transcription over basal levels of activity (Figure
3.6).
The amount of IL-8 released into culture supernatants following 16 h
incubations with oxidised and native LDL was quantified by ELISA. A dose
relationship was seen with oxidised LDL (Figure 3.7A). For the same concentration,
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Batch no. (#) EU/ml (approx pg/ml)
Local nLDL # 7-9 0.75 +/-0.14 (62.5 +/- 12.5)
Local oxLDL # 7-9 0.98+/- 0.18 (81.6+/- 15.0)
Table 3.2. LPS contamination levels in LDL following cleaning of Amicon
ultrafiltration unit.
Results are mean and standard deviation of three separate LDL preparations.
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native LDL was a much less potent stimulus for IL-8 production (after preparation
using the method to reduce LPS contamination) and there was a trend towards
increased IL-8 over untreated cells only at the highest concentration (100 pg/ml,
Figure 3.7A). Similar results were seen with different preparations of LDL using
different endothelial cell donors. The variation in IL-8 production from 4 LDL
batches incubated with 2 different endothelial cell donors is shown (Figure 3.7B).
Oxidised LDL also stimulated MCP-1 production by human endothelial cells.
Native LDL had a weaker stimulatory effect. These results closely paralleled their
effects upon IL-8 production (Figure 3.8). The experiments with LDL produced with
the modified protocol designed to reduce LPS contamination demonstrated that
oxidised LDL retained its ability to stimulate endothelial cell production of the
chemokines IL-8 and MCP-1. The quantity of cytokine production appeared to be
less with oxidised LDL prepared using the modified protocol (compare Figure 3.2A
with Figure 3.7A) and although LPS content data for one of the lipid batches used in
Figure 3.2A are not available, the higher potency of earlier LDL preparations was
probably related in part to LPS contamination (Table 3.1).
Oxidised LDL exerted its effect on IL-8 release in part through up regulating
IL-8 transcription and indeed. IL-8 production is regulated primarily at the level of
gene transcription (Roebuck 1999). The work described in the rest of this chapter
was directed towards the inflammatory signalling mechanisms of oxidised LDL.
Because native LDL had at most, a very weak effect on inflammatory cytokine
production, the remaining work compared oxidised LDL with untreated cells only.
Functional studies indicate that IL-8 transcriptional responses to proinflammatory
mediators are rapid and require only 100 nucleotides of 5' flanking DNA upstream of
the TATA box. Binding sites for the inducible transcription factors AP-1. NF-IL-6
and NF-kB are contained within the promoter. Deletion constructs of the IL-8
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500bp
250bp
Figure 3.6. Semi-quantitative RT-PCR for IL-8 gene expression in HUVECs
treated with oxidised LDL.
HUVECs were incubated at confluence in medium alone (lane 1) or in the presence
ofnLDL 100 pg/ml (lane 2) or oxLDL 100 pg/ml (lane 3) for 4 hours. Total RNA
was extracted using TRIZOL reagent and 0.5 pg was used in a reverse transcription
reaction. 2 pi of resulting cDNA was then used from each reaction condition to
perform semi-quantitative PCR in a multiplex reaction with primers for the
housekeeping gene GAPDH (product 545bp) and IL-8 (product 180bp). A reaction
was also performed in the absence of reverse transcriptase (-RT) to check for the
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100 pg/ml
Figure 3.7. Oxidised LDL stimulated release of IL-8 from HUVECs exhibited
dose dependence.
A. HUVECS were stimulated with clean preparations of oxidised LDL or native
LDL at the concentrations indicated for 16 hours. Supernatants were retrieved and
IL-8 concentration measured by ELISA. Results shown are from a single LDL
preparation and HUVEC donor (n=3). B. The pooled results (mean ± SD) from 4
separate lipid preparations and HUVEC donors (performed in triplicate) are shown. *
significantly greater than native LDL,p < 0.05.
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Figure 3.8. MCP-1 production is increased in HUVECs incubated with oxidised
LDL
HUVECS were incubated with native LDL and oxidised LDL for 16 hours.
Supernatants were retrieved and MCP-1 levels were measured by ELISA. Results are
mean and standard deviation from one donor performed in triplicate. * significantly
greater than native LDL. < 0.01.
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promoter tagged to a luciferase reporter gene were generously donated by Professor
N Mukaida (Kanazawa University, Japan) in order to dissect out transcriptional
mechanisms responsible for oxLDL induced IL-8 production. A schematic of the
different plasmids is shown (Figure 3.9).
XL-1 Blue bacteria were transformed with the IL-8 promoter constructs in a
pXP2 backbone. In comparison to many cell lines, HUVECs are relatively refractory
to transfection. They are susceptible to toxicity from lipids used in lipofection and
are readily damaged during electroporation (Segura et al 2001). The efficiency of
different transfection methods was established using pDsRed2-Cl (Clontech),
containing the red fluorescent protein (RFP) reporter gene DsRed2 under the simian
virus promoter (SV40). High transfection efficiency ofHUVECs has been reported
using both calcium phosphate precipitates (Segura et al 2001) and liposomes (Kaiser
et al 2001). Both methods were compared using the DsRed2 reporter plasmid (Figure
3.10).
Lipofectin provided a transfection efficiency of around 20-25%, estimated by
inspection, compared to calcium phosphate (5-10%). The calcium phosphate protocol
was also directly cytotoxic, producing rounding and detachment of cells following
incubation with the precipitates. No toxicity was seen with calcium phosphate
precipitates alone and this effect may have been caused by the larger quantity of
DNA used in this protocol.
Lipofectin provided the highest transfection efficiency without toxicity and
was therefore chosen as method of delivery for the IL-8 promoter constructs. In a
preliminary experiment. HUVEC luciferase activity was compared following
transfection with pGL3 vector, expressing luciferase under the control of the SV40
promoter and the full length IL-8 promoter construct 1 (-1481 bp) following
treatment with PMA, TNF-a and oxidised LDL (Figure 3.11). This was a pilot
experiment and no corrections were made for transfection efficiency or cell lysate
92
Chapter 3
Chapter 3: Human endothelial cell inflammatory responses to oxidised LDL
Figure 3.9. A schematic of the IL-8 promoter constructs.
Transcription factor binding sites and the luciferase promoter are shown. Construct 1
is the full length IL-8 promoter (-1481 to + 44) constructs 2 and 3 are deletion
constructs that contain nucleotides (-546 to + 44) and (-133 to +44) respectively.
Construct 3 was also used with site directed mutations in the AP-1, NF-IL-6 and NF-
kB binding sites (indicated by arrows; AAP-1, ANF-IL6, ANF-kB). IRF: Interferon
regulatory factor; AP: Activator protein, HNF-1: Hepatocyte nuclear factor; GRE:
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Figure 3.10. Comparison of liposome and calcium phosphate mediated
transfection of HUVECS.
HUVECs were grown to 60% confluence in 12-well plate format. Pictures were
taken 24 hours after transfection at low power in light microscopy and fluorescent
views (left and right slides respectively). A. Transfections of DsRed2 (3 pg plasmid
DNA) with calcium phosphate were as described in Materials and Methods. B.
Liposome transfections using Lipofectin (Invitrogen). Cells were washed in serum-
free medium (OptiMEM I, Gibco Brl) and DsRed2 (0.4pg plasmid DNA) was pre-
incubated with Lipofectin in OptiMEM I prior to incubation with the HUVECs. C.
Neither liposome nor calcium phosphate (not shown) treatment induced red
fluorescent activity in the absence ofDsRed2. Slides shown are representative from
one experiment performed in triplicate wells.
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Figure 3.11. Comparison of induction of luciferase activity by PMA, TNF-a and
oxidised LDL in HUVECs transfected with the -1481 IL-8 promoter-Luc
construct.
HUVECs were grown to 60% confluence in 12-well plates and transfected with
plasmid DNA in complex with lipofectin. The cells were allowed to grow to
confluence and treated with the stimuli for 14 hours. Following stimulation with
PMA (1 x 10"7M), TNF-a (100 ng/ml) and oxidised LDL (100 pg/ml) cell lysates
were harvested for luciferase activity. Results are mean and standard deviation,
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concentration. A construct containing only the luciferase gene (-44bp) was included
as a negative control. PMA treatment of cells transfected with the —1481 bp plasmid
and transfection with the pGL3-Luc plasmid produced strong luciferase activity in
the cell lysates. Activity in the lysates from cells transfected with the mock plasmid
(-44 bp) was negligible. Stimulation of cells transfected with the full length plasmid
(-1481 bp) with high concentrations of TNFa (100 ng/ml) produced considerably
less luciferase activity than the potent PMA stimulus and incubation with oxidised
LDL did not increase luciferase activity above baseline levels in unstimulated
transfected cells. Similarly, no increase in luciferase activity could be detected
following incubation of oxidised LDL with cells transfected with the -546bp and -
133bp plasmids (not shown). TNF-a and PMA are established as powerful stimuli
for inflammatory cytokine production (data on TNF-a induced IL-8 production from
endothelial cells is presented later in chapter 5). The observation that a high
concentration of TNF-a was required to produce detectable luciferase levels
suggested that absence of a detectable increase in luciferase activity in response to
oxidised LDL was probably a combined result of low plasmid transfection efficiency
and relatively low potency as a stimulus for IL-8 production.
The potential of this approach for dissecting out the DNA binding sites
modulating IL-8 transcription was demonstrated for TNF-a stimulation (Figure
3.12). TNF-a induced luciferase activity was less in the full length promoter
construct than in the -546 and -133 bp constructs. This is consistent with the
possibility of an upstream negative regulatory element. Mutation of the NF-IL6, NF-
kB and AP-1 binding sites reduced luciferase activity compared to the intact -133
promoter construct. Activity was least in the promoter constructs with AP-1 and NF-
kB binding site mutations. This is consistent with the cooperative role of these
transcription factors in IL-8 message production (Roebuck 1999).
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Despite optimising a protocol for plasmid delivery to HUVECs, the
experiments using reporter constructs to elucidate oxidised LDL transcriptional
mechanisms were limited by failure to detect luciferase reporter gene activity from
any of the constructs following oxidised LDL stimulation. The importance ofNF-kB
for IL-8 transcription following TNF-a was indicated by the absence of luciferase
activity in cells transfected with the luciferase reporter containing a mutated NF-kB
binding site (A NF-kB. Figure 3.12). For this reason, nuclear fractions from
HUVECs stimulated with oxidised LDL were examined directly for active NF-kB
using electromobility shift assays (EMSA).
Incubation of oxidised LDL with endothelial cells for 1 hour resulted in
increased binding activity within nuclear extracts for a consensus NF-kB
oligonucleotide. The specificity of binding was demonstrated by competing out
radiolabelled probe in the presence of excess unlabel led (cold) oligonucleotide and
by the failure of a radiolabelled consensus oligonucleotide with a single base
substitution to bind nuclear extracts. The intensity of the NF-kB band varied among
the 3 different preparations of oxidised LDL. NF-kB activity was not detected in
untreated cells and a discernible NF-kB band could only be seen in one (Figure 3.13,
lane 7) of the three batches of native LDL, indicating at most, slight activation of
NF-kB above baseline levels.
There are several NF-kB proteins and most can dimerise with themselves
(homodimers) or other family members (heterodimers) to form active NF-kB (Tak et
al 2001). NF-kB complexes can be incubated with antibodies against specific NF-kB
proteins and further retardation of the complex on a gel (supershift) indicates the
presence of the specific protein within the active NF-kB complex. Supershift
analysis on NF-kB complexes induced by oxidised LDL, TNF-a and LPS was
performed using antibody against the p50 protein (Figure 3.14). The p50 antibody
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Figure 3.12. Luciferase activity following TNF-a stimulation of HUVECs
transfected with IL-8 promoter-luciferase plasmids 1-7.
Cells were transfected and treated as for figure 3.11. Luciferase activity was
expressed after correction for the quantity of cell lysate placed in the luminometer
(RLU/pg of cell lysate). Results for the different promoter constructs including the -
133 promoter constructs containing mutations in the NF-IL6, NF-kB and AP-1 (A
NF-IL6. ANF-kB and AAP-1 respectively) are shown. Results are mean and standard
deviation from one experiment performed in triplicate.
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Figure 3.13. EMSA demonstrating oxidised LDL induced activation of the
transcription factor NF-kB in HUVECs.
HUVECs were incubated for 1 h with TNF-a (1 ng/ml) as a positive control ofNF-
kB activation (lanes 1-3). medium alone (lane 4), 3 different preparations of native
LDL (100 pg/ml, lanes 5, 7. 9) and oxidised LDL (100 pg/ml, lanes 6, 8, 10). NF-kB
was assayed in nuclear extracts (7 pg) from HUVECs by electromobility shift assays
op
(EMSA) with "P-labelled, double stranded consensus NF-kB oligonucleotides. The
specificity of binding was demonstrated by incubating with both 100-fold excess
cold oligo (lane 2) and a scrambled oligo containing a single base pair substitution
(lane 3). The results are from 3 separate batches of LDL on the same HUVEC donor.
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Figure 3.14. Supershift analysis of active NF-kB
Supershift analysis of oxidised LDL (100 pg/ml lanes 1, 2), TNF-a (1 ng/ml lanes 3,
4) and LPS (5 pg/ml lanes 5, 6) induced complexes using a specific antibody against
p50 (Santa Cruz). Antibody was pre-incubated with the nuclear binding mix for 50
min before being run on the polyacrylamide gel.
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was effective at supershifting complexes induced by all 3 stimuli, indicating a
prominent role for p50 either in the form of a homodimer or possibly as a
heterodimer with other NF-kB family members. It is important to note the low
concentration of TNF-a used to demonstrate NF-kB activation (1 ng/ml, Figure
3.14) compared to the concentrations required to observe a strong luciferase signal
from the IL-8 promoter constructs (100 ng/ml, Figure 3.12). Preliminary experiments
indicated that NF-kB activation could be observed in HUVECs with TNF-a
concentrations as low as 100 pg/ml (Figure 5.16). This discrepancy probably
reflected the relatively poor transfection efficiency of the IL-8 promoter plasmids
and is discussed further on.
After establishing temporal and quantitative aspects of oxidised LDL regulated
transcription and release of the chemokine IL-8 from endothelial cells, experiments
were planned to assess the impact of prolonged LDL incubations on cell viability. A
working LDL concentration of 100 pg/ml provided a clear differential in response
with respect to IL-8 transcription, release and NF-kB activation. Although the
experiments examining IL-8 message up-regulation and NF-kB activation involved
incubations lasting 4 hours, it was important to account for any impact on cell
necrosis or apoptosis following the more prolonged 16 h experiments examining IL-8
release.
3.2.4. Oxidised LDL induced endothelial cell death
Cellular necrosis and apoptosis within the atherosclerotic plaque contribute to
lesion instability and rupture. Oxidised LDL is cytotoxic and has been shown to
induce both apoptosis and necrosis in vascular cells. Oxidised LDL causes the
release of lactic dehydrogenase (LDH) from cultured vascular smooth muscle cells,
endothelial cells and fibroblasts (Morel et al 1984). Oxidised LDL has been shown to
induce apoptosis in smooth muscle cells, endothelial cells (Harada-Shiba et al 1998)
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(Dimmeler et al 1997) and macrophages. The effects of LDL preparations on
HUVEC LDH release and annexin V positivity were therefore examined.
LDH activity was measured from the decay in absorbance at 340nm following
oxidation of nicotinamide adenine dinucleotide (NADH) by LDH. This assay tests
for major disruption of cellular membranes occurring during necrosis when
cytoplasmic LDH leaches into the culture supernatant. After 16-hour incubations
there was no difference in cytoplasmic LDH activity between oxidised LDL, native
LDL and untreated samples (Figure 3.15). This result was surprising in view of
previously published data on oxidised LDL cytotoxicity. LDH is not a sensitive
indicator ofmore subtle aspects of cellular toxicity such as depressed metabolic
function or apoptosis. The LDH assay did not lend itself to high sample throughput
(each sample had to have activity measured in a spectrophotometer cuvette over 3
minutes) and because of these concerns annexin V was pursued as a marker of
cellular injury. Annexin V is a calcium dependent phospholipid binding protein with
a high affinity for the phospholipid phosphatidylserine (PS). PS translocation is the
movement of PS from the inner to the outer cellular membrane leaflet and is an early
event during apoptosis, also occurring during cell necrosis (Koopman et al 1994).
The binding of FITC-conjugated annexin V to human endothelial cells
following incubations with varying concentrations of oxidised LDL was examined
(Figure 3.16). Untreated cells and cells incubated with native LDL (100 pg/ml) for
16 hours had levels of annexin V binding below 4%. Hydrogen peroxide was
included as a positive control inducing necrosis and etoposide was included as an
inducer of apoptosis. These produced rates of annexin V binding of 70.1% and
20.1 % respectively. The relatively low rate of annexin V binding for etoposide was
in accordance with the microscopic appearance of the cell culture after treatment.
There was evidence of cell rounding and lifting although the majority of cells
appeared intact. Oxidised LDL exhibited a dose relationship for annexin V staining.
A 24 h incubation with 100 pg/ml of oxidised LDL produced 9.3% annexin V
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Figure 3.15. Incubation with native LDL or oxidised LDL did not increase
HUVEC LDH supernatant activity.
HUVECs were incubated for 24 hours in medium alone or in the presence of native
LDL or oxidised LDL at concentrations of 50 pg/ml (not shown) and 100 pg/ml
(above). Supernatants were removed after the incubations and LDH activity was
recorded. The results are expressed as a percentage rate of absorbance change of
wells that had been completely lysed with PBS 1% Triton X. The data are mean and













n 1 A2 100
|
'
| t| | , , 1 | | , | |M|
50
native LDL 100 pg/ml
°10° 10' 102 103 104 0 10° 10* 102 103 104











100 1 1 A2
# 1
50 k. .
10° 101 102 103 104


















10° 10' 102 103 104






100 1 1 A2
n, ■ 50
1
r . ' rifffff | --
0° 101 102 103 104 ° 10° 10' 102 103 104














Chapter 3: Human endothelial cell inflammatory responses to oxidised LDL
E oxidised LDL 400 pg/ml
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10° 10' 102 103 104
No annexinV stain
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Figure 3.16. The effect of increasing concentrations of oxidised LDL on annexin
V staining in HUVECs.
HUVECs were incubated for 16 hours in medium alone or with oxLDL at the
concentrations indicated. Etoposide (15 pM) and HLCL (2 pM in PBS) treatments for
6 h were included as positive controls of apoptotic and necrotic stimuli respectively.
Following the treatments, supernatants were removed and the cells washed,
trypsinised, and resuspended in annexin V binding buffer. The results are presented
in histograms representing 5000 counts for each experiment. The percentage of dead
or necrotic cells was taken as 100A2/(A1+A2). A. Untreated cells and native LDL
(100 pg/ml) produced low levels of annexin V staining (mean 3.20%, and 4.25%). B.
Treatment with etoposide and LLCb resulted in cell death at rates of 21.1% and 70.1
% respectively. C-E. Concentrations of 100, 200 and 400 pg/ml oxidised LDL
produced mean percentages of annexin V staining of 9.3%, 80.1% and 99.8%
respectively after 16 h. F. The background fluorescence in the FL1 -H channel in the
absence of annexin V was 0.9%.
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binding and this increased to almost 100% following incubations with 400 pg/ml.
This experiment illustrated the damaging effects of the oxidised LDL on endothelial
cells, increasing annexin V binding rates above levels observed with untreated or
native LDL treated cells. No firm conclusion could be drawn over the nature of
cellular damage, whether it was in the form of necrosis or apoptosis, although the
results from LDH supernatant analysis (Figure 3.15) suggested no excess necrosis in
the oxidised LDL treated cultures.
3.3. Discussion
The data presented in this chapter demonstrate the isolation of a pure culture of
human umbilical vein endothelial cells (HUVECs, Figure 3.1) and characterisation of
a preparation of LDL with minimal LPS contamination as a model for inflammatory
endothelial injury in atherosclerosis. Mechanisms of oxidised LDL inflammatory
injury are also illustrated including release into the culture supernatants of the
chemokines IL-8 and MCP-1. For IL-8, part of this increased production was through
increased gene transcription and this was associated with activation of the
transcription factor NF-kB. The importance of oxidation for LDL's effect was also
demonstrated, with native LDL proving to be relatively inert, producing only a small
increase in cytokine production above untreated cells. Finally, the damaging effects
of oxidised LDL on endothelial cells cultures was examined. Concentrations that
produced heightened cytokine production and NF-kB activation also had excessive
rates of apoptosis or necrosis compared with native LDL and untreated cultures.
3.3.1. The use of cultured endothelial cells in an in vitro model of atherosclerosis
A fundamental question is the validity of venous endothelial cells (HUVECS)
in a model of a pathological process affecting arterial vessels. HUVECS remain the
most prevalent model for studying human endothelial cells in vitro. Advantages
include the ability to isolate pure populations of primary cells that can be expanded
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in culture prior to freezing for future use. Criticisms of the use of these cells include
the fact that venous vessels do not develop atheroma and more appropriate cell
populations including human coronary artery endothelial cells (HCAECs) and bovine
aortic endothelial cells are available. However, a study comparing HCAECs and
HUVECs found qualitatively similar cytokine responses to inflammatory stimuli
(Briones et ah, 2001). The loss of arterial pressure and turbulent flow effects are
more significant deficiencies of in vitro models of atheroma. The potential for
venous vessels to develop atheroma when exposed to high arterial pressures is also a
significant clinical problem following saphenous vein grafting for coronary artery
bypass surgery.
HUVECs were chosen as a model owing to the favourable properties outlined
above and the extensive international laboratory experience already available on this
cell type. Possible cell contaminants in HUVEC cultures that had been passaged
following collagenase digestion from umbilical cords included pericytes, fibroblasts
and smooth muscle cells from the vessel wall (Gimbrone, Jr. et al 1974; Jaffe et al
1973). The CD31 antigen, platelet endothelial cell adhesion molecule-1 (PECAM-1)
was chosen to identify endothelial cells by flow cytometry (Figure 3.1) (Newman
1997). Expression of PECAM-1 is confined to endothelial cells and leucocytes
(Newman et al., 1997) and failure of a proportion of the cell population to stain with
the antibody would have indicated the presence of a contaminating cell type. Greater
that 99% of cells were CD31 positive indicating a relatively pure culture (Figure
3.1).
3.3.2. The inflammatory effects of native and oxidised LDL on endothelial cells
A central tenet of this thesis is the role of oxidised LDL as an inflammatory
stimulus, present and bound to matrix within the intimal space, driving the formation
of atheroma through interaction with endothelial cells. Having established an
endothelial cell culture, a source of both native and oxidised LDL had to be
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identified and characterised. Professor Riemersma's laboratory was producing LDL
and oxidising it against copper sulphate within the University. Native and oxidised
LDL preparations could also be bought commercially. An initial experiment
demonstrated MCP-1 and IL-8 production by endothelial cells in response to both
native and oxidised LDL produced within the University (Figure 3.2). IL-8 and
MCP-1 are members of the CXC and CC chemokine families respectively (Rossi et
al 2000). They are important chemoattractants for neutrophils and monocytes and
have been implicated in a variety of inflammatory diseases. At a concentration of
100 pg/ml, oxidised LDL is a potent inducer of cytokine production with native LDL
producing small increases above untreated conditions. A key unknown is the
biologically relevant amount of oxidised LDL trapped within the extracellular space
of the subendothelium and how this could be translated into a concentration in
solution within tissue culture medium. Oxidised LDL is not found in the circulation
or lymphatic systems (Steinberg et al 1999) and information on the specific
quantities of different components of LDL within atheromatous tissue is not
available (Tabas et al 1999). The choice of LDL concentration to use in the initial
experiment was therefore heavily influenced by work published by other groups
studying oxidised LDL"s effects on various cell types in culture. There is a close
correlation between in vitro observations of oxidised LDL's effects on endothelial
cell activation and immunohistochemical examination of endothelial cells from
atheromatous vessels demonstrating chemokine production and NF-kB activation
(Brand et al 1996; Claise et al 1996; Cominacini et al 2000; Koch et al 1993;
Simonini et al 2000). Having demonstrated a clear differential in biological activity
between native LDL and oxidised LDL, at concentrations of 100 pg/ml (Figure 3.2)
that was in accordance with previously published work with respect to IL-8
production in an endothelial cell line (Claise et al 1996), it was decided to conduct
further LDL studies using this concentration.
In order to be sure that it was the inflammatory activity of LDL that was being
examined it was important to eliminate any LPS contamination occurring during
preparation that might be contributing to cytokine production. Problems with LPS
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contamination of biological reagents, including LDL have been described frequently
in the past (Rickles et al 1979; Sata et al 1998) and significant quantities of LPS
ranging up to 1 pg/ml were identified within LDL preparations produced locally or
obtained commercially using the Limulus Amebocyte Lysate (LAL) assay (Table
3.1). Specific LPS binding has been demonstrated for all lipoprotein family members
(Levels et al 2001) including LDL, very low density lipoprotein (VLDL) and high
density lipoprotein (HDL). The levels observed (Table 3.1) were much higher than
those quoted for LDL prepared using similar protocols by other workers and
suggested contamination during preparation. Grafe et al (1998) and Claise et al
(1996) found no evidence of contaminating LPS using the LAL assay within the
oxidised LDL in their studies. In contrast, levels as high as 800 pg per mg of
lipoprotein have been detected by other workers (Terkeltaub et al 1994). Importantly,
the data sheet for the commercial LDL purchased from Intracel © stated that the
product was 'prepared aseptically but not guaranteed sterile'. By analysing aliquots
of the LDL preparation from each step in the process, the Arnicon ultracentrifugation
unit was identified as one major source of contamination (Figure 3.3).
The contribution to endothelial cell activation of any LPS contamination was
difficult to quantify for two reasons. Firstly, the LAL assay provided no information
on LPS serotype, an important variable for determining the magnitude of response
(Rietschel et al 1990). However, at the higher concentrations listed in Table 3.1, E
Coli 0127b8 LPS, a serotype used within our laboratory, would result in activation of
HUVECS and human monocyte derived macrophages (see chapters 5 and 6).
Secondly, the biological activity of LPS bound within LDL is reduced (Flegel et al
1993; Netea et al 1996) and this has been proposed as a mechanism whereby
lipoproteins facilitate safe clearance from the circulation (Rauchhaus et al 2000).
Polymyxin B was pre-incubated with a batch of LDL in an attempt to neutralise the
biological activity of any contaminating LPS (Figure 3.4). Polymyxin B is a naturally
occurring antibiotic with powerful disrupting properties on cell membranes of gram
negative bacteria. Its properties of binding, neutralising and inhibiting inflammatory
signalling by LPS has been used by investigators for over 20 years (Pier et al 1981).
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Cytokine production to both oxidised and native LDL was significantly reduced
following pre-incubation with polymyxin B (Figure 3.4). This was also effective in
reducing cytokine production in response to LPS alone and oxidised LDL containing
a spiked quantity of LPS (Figure 3.5). The interpretation of these results was clouded
by the inhibitory activity of polymyxin B on TNF-a induced cytokine production in
an LPS-free control limb of the experiment (Figure 3.5). In eukaryotic cells,
polymyxin B has additional effects and has been used specifically as an inhibitor of
protein kinase C (Gandhi et al 1992). It is not clear whether protein kinase C
inhibition was responsible for attenuating the response to TNF-a but this property
prevented any assessment of specific LPS signalling blockade by polymyxin B.
LPS contamination levels within the LDL were measured in fresh preparations
after modification of the protocol for LDL production and in particular, introduction
of a new method to clean the Amicon ultracentrifugation unit between preparations.
LPS content was markedly reduced from previous levels (to less than 100 pg/ml
within the LDL preparation, prior to dilution in culture medium for use in
experiments, Table 3.2) and compared very favourably with levels of contamination
between 80 and 3200 pg/ml reported by some authors: (Fischer et al 2002;
Terkeltaub et al 1994). Oxidised LDL prepared with minimal LPS contamination
retained the ability to stimulate IL-8 production and after 4 h incubations, IL-8
message was up regulated in oxidised LDL treated cells compared to native LDL or
untreated cells (Figure 3.6). IL-8 production has been characterised in a range of cell
types including leucocytes, fibroblasts, epithelial and endothelial cells in response to
specific inflammatory stimuli (reviewed by Roebuck 1999). IL-8 induction by TNF-
a. IL-ip and LPS is primarily at the level of gene transcription (Blease et al 1999;
Chaly et al 2000; Yeh et al 2001) and my own observation of oxidised LDL
regulation of endothelial cell IL-8 transcription was in accordance with this.
The IL-8 promoter contains binding sites for several inducible transcription
factors characterised as pro-inflammatory responsive elements (Mukaida et al 1994).
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The increased transcription correlated with increased release of IL-8 protein into the
culture supernatants of endothelial cells and oxidised LDL demonstrated a dose
effect with respect to IL-8 production (Figure 3.7A). These experiments were
conducted using LDL with minimal LPS contamination (Table 3.2) and it was
notable that total amounts of cytokine production were reduced compared to levels
seen with an earlier lipid batch, prepared using the old protocol (Figure 3.2). This
provides further evidence that contaminating LPS may have been contributing to the
activity of the old LDL preparations. Oxidised LDL and minimally modified LDL
(MM-LDL) have been shown to activate an immortalised endothelial cell line (Claise
et al 1996) and human aortic endothelial cells to produce IL-8 (Lee et al 2000a).
Claise et al (1996) used oxidised LDL at a concentration of 100 pg/ml to
demonstrate increased IL-8 release after 24 h but not at an earlier timepoint of 4 h.
MM-LDL is produced using a much shorter incubation with copper and although it
attains new biological properties (Berliner et al 1990) it has not undergone the major
oxidative changes seen with oxidised LDL and is still recognised by LDL but not by
scavenger receptors (Navab et al 1996). In line with the identification of biological
activity in minimally or non-modified LDL, 16 h incubations of non-oxidised native
LDL with FlUVECs produced a non-significant trend towards increased IL-8 release
(Figure 3.7A) in contrast to the lack of effect seen on IL-8 transcription after 4 hours.
The literature contains conflicting reports on the biological activity of native
LDL. Claise et al (1996) demonstrated a non-significant trend towards heightened
IL-8 release in cells incubated with native LDL. Using higher concentrations for 4-
day incubations, monocyte adhesiveness towards FlUVECs was increased through a
mechanism involving increased intercellular adhesion molecule-1 (ICAM-1)
expression (Snralley et al 1996). Native LDL activity may arise from oxidation in
culture during prolonged incubations (Fang et al 1998; Steinberg et al 1989).
However, shorter 5-hour incubations using high concentrations (700 pg/ml) of native
LDL have been shown to trigger a transient calcium influx and to increase vascular
cell adhesion molecule-1 (VCAM-1) expression in human coronary artery
endothelial cells, indicating the possibility of a more direct action (Allen et al 1998).
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Prepared with the new protocol, oxidised LDL retained its ability to stimulate
HUVEC MCP-1 production (Figure 3.7B) although native LDL had no significant
effect. Once again, levels ofMCP-1 were less than those seen with earlier LDL
preparations (Figure 3.2B). Both MM-LDL (Berliner et al 1990) and oxidised LDL
(Li et al 2000) have been shown to increase MCP-1 release from endothelial cell
cultures. The finding of elevated IL-8 and MCP-1 production by endothelial cells
exposed to oxidised LDL correlates well with pathological studies of human
atherosclerotic tissue (Koch et al 1993; Simonini et al 2000) demonstrating
heightened production of both chemokines.
Both IL-8 and MCP-1 production are regulated primarily at the level of gene
transcription and have regulatory sites for NF-kB. For this reason, experiments were
designed to investigate transcriptional events associated with oxidised LDL
signalling on HUVECs. IL-8 transcriptional mechanisms for an active oxidised
phospholipid moiety found within oxidised LDL and MM-LDL have previously been
elicited using reporter plasmids under the control of the IL-8 promoter (Yeh et al
2001). A series of plasmids, containing the luciferase reporter gene, with different
components of the IL-8 promoter removed either through truncation or mutation,
were obtained (Figure 3.9) in order to perform a similar analysis on our own locally
prepared oxidised LDL. A reporter plasmid encoding red fluorescent protein DsRed2
(Baird et al 2000) was used initially to facilitate optimisation of a transfection
protocol through rapid quantification of transfection efficiency by fluorescent
microscopy. HUVECs have been found to be relatively refractory to transfection
techniques with maximal transfection rates as low as 2% being reported for
lipofection and electroporation (Teifel et al 1997). Modified protocols have produced
improved transfection efficiencies in HUVECs with calcium phosphate (Segura et al
2001) and liposomes (Kaiser et al 2001). The latter transfection methods were
compared in HUVECs (Figure 3.10) and lipofectin proved to be a more efficient
delivery vehicle giving transfection rates of around 25%. Toxicity as evidenced by
cytopathic microscopic appearances was a particular problem with calcium
phosphate precipitates and concern about inflammatory activation of endothelial cells
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made this protocol an unattractive option for studying oxidised LDL signalling
mechanisms.
IL-8 reporter plasmids were transfected into HUVECs that were subsequently
incubated with oxidised LDL (Figure 3.11). A vector constitutively expressing
luciferase (pGL3) was included as a positive control for luciferase expression. PMA
and TNF-a were also included as potent inducers of IL-8 activation and although all
three positive controls lead to appreciable increases in luciferase activity, oxidised
LDL failed to induce enough luciferase to register on the luminometer (Figure 3.11)
with any of the plasmids. This result contrasts with the strong luciferase activity
induced in FleLa cells transfected with the same IL-8 promoter-luciferase construct
following stimulation with oxidised phospholipid, oxidised 1 -palitoyl-2-
arachidonoyl-5f7-glycero-3-phosphorylcholine (OX-PAPC) (Yeh et al 2001). OX-
PAPC was found to be a relatively potent stimulus for IL-8 production at the
concentration used, leading to IL-8 levels within 50% of those seen with TNF-a in
this study. Data comparing HUVEC IL-8 production are presented in chapter 5 and
oxidised LDL induced levels of IL-8 production are less than 10% those of TNF-a
(Figure 5.12). Similarly, a low concentration of TNF-a (1 ng/ml) was a much more
potent stimulus for NF-kB activation in HUVECs than oxidised LDL (Figures 3.13
and 3.14).
It seems likely that the comparatively low potency of oxidised LDL as a
stimulus for IL-8 production combined with relatively low levels of transfection in
HUVECs (compared to the more readily transfectable HeLa cells) resulted in failure
to detect luciferase activity in these experiments. The IL-8 reporter constructs were
tested in HUVECs with TNF-a (Figure 3.12) to demonstrate the potential of this
approach for elucidating transcriptional mechanisms. In particular, the importance of
active NF-kB and AP-1 for IL-8 transcription were illustrated when these sites were
mutated in the -133 bp plasmid. This finding corresponds to previous promoter
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mutation studies in a range of cell types (Roebuck 1999) including HUVECs
(Wagner et al 1998). The relatively low luciferase activity in the full length (-1481
bp) IL-8 promoter construct was surprising (Figure 3.12). It suggests the possibility
of an active negative regulatory element, requiring the presence of a segment in
region -1481 to -561 bp to exert its effect. Following failure to gain information on
oxidised LDL transcription mechanisms from the IL-8 promoter constructs, EMSAs
were employed to directly examine for NF-kB activation. This was because of the
latter's close association with IL-8 transcription and numerous studies demonstrating
endothelial cell NF-kB activation in response to oxidised LDL in endothelial cells
(Cominacini et al 2000; Parhami et al 1993) and macrophages (Flamilton et al 1998;
Janabi et al 2000).
The concentration of active NF-kB within HUVEC nuclear extracts rose
significantly following 1 h incubations with oxidised LDL (Figure 3.13). Native LDL
had no activating effect within this time period, supporting the view that it was non¬
inflammatory over shorter incubation periods. Li et al (2000) also demonstrated
degradation of inhibitory subunit IkBcx and active NF-kB within human coronary
artery endothelial cell nuclear extracts following incubation with oxidised LDL.
Cominacini et al (2000) demonstrated NF-kB activation in bovine aortic endothelial
cells and used a blocking antibody to show that this action was dependent on lectin-
like oxidised LDL receptor-1 (LOX-1), originally cloned from this cell type
(Sawamura et al 1997). Another scavenger receptor, CD36 also regulates oxidised
LDL induced NF-kB activation in peripheral blood monocyte derived macrophages
(Janabi et al 2000). Macrophages from patients who are CD36 deficient have
diminished NF-kB activation in response to oxidised LDL. The relationship in
monocytes may be more complex with short incubations increasing NF-kB
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The NF-kb/Rel transcription family has several members including NF-kB1
p50/pl05, p65 RelA. NF-kB2p52/pl00, RelB and c-Rel (Chen et al 1999). Most of
these proteins can form hetero- or homodimers and the most prevalent activated form
ofNF-kB is a heterodimer consisting of a p65 and a p50 or p52 subunit (Tak et al
2001). Supershift analysis of the active NF-kB was performed on HUVEC nuclear
lysates following oxidised LDL. LPS and TNF-a stimulation. The p50 antibody
resulted in complete supershift ofNF-kB induced by all three stimuli, suggesting a
preponderance of p50 homo- or heterodimers. In contrast, Li et al (2000) performed
Western blots demonstrating the presence of active p65 in nuclear lysates but did not
search for other NF-kB proteins. Oxidised LDL induced NF-kB complexes in human
monocytes could also be supershifted by p50 and p65 antibodies but not an antibody
to c-Rel (Brand et al 1997a).
Activated NF-kB has been identified in situ in human atherosclerotic plaque
endothelial cells but is absent or nearly absent in vessels devoid of atherosclerosis
(Brand et al 1996). This observation coupled with the regulatory relationship of this
transcription factor with so many genes putatively involved in the atherosclerotic
process, including leukocyte adhesion molecules such as ICAM-1 and chemokines
such as IL-8, suggest it plays a pivotal role (Brand et al 1997b). The data presented
in this chapter support the idea that oxidised LDL located within the subendothelial
space acts as a persistent stimulus to endothelial cell NF-kB activation. The parallels
between experimental findings from HUVEC cultures and immunohistochemical
observations from atherosclerotic specimens lend credence to the in vitro model of
atherosclerosis introduced in this chapter and continued as a workhorse throughout
the remainder of this thesis.
3.3.3. Oxidised LDL effects on endothelial cell survival
One final aspect of LDL's inflammatory effects, its impact on cell survival,
required further analysis. Several studies have documented the cytotoxic nature of
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oxidised LDL on cultured endothelial cells (Colles et al 2001). Culturing HUVECs
with oxidised LDL (25 jLig/ml) for 10 hours led to an apoptosis rate of 8% increasing
to 16% after 50 hours (Harada-Shiba et al 1998). The corresponding background
rates of apoptosis in this study were less than 1% and 5% indicating increased
apoptosis induced by oxidised LDL. Incubation with oxidised and native LDL led to
no detectable increase in LDH activity in the supernatants of cultured HUVECs
(Figure 3.15). LDH release occurs during major cellular disruption and necrosis and
this result was in keeping with absence of any gross cytopathy on microscopic
examination of the cultures following incubations. FACS analysis for fluorescently
labelled annexin V. a marker of apoptosis and necrosis was performed. Following a
16-hour incubation with oxidised LDL at a concentration of 100 pg/ml, 9.3% of cells
were annexin positive (Figure 3.16). The rate of cell death increased sharply with
increasing concentrations of oxidised LDL to 21.1% (200 pg/ml) and 99.1% (400
pg/ml). These apoptosis levels compared to 3.20 and 4.25% rates of annexin V
staining in untreated or native LDL treated cultures respectively. Hydrogen peroxide
was included as a positive control inducer of necrosis and it was striking that this
produced less cell death (70.1%) albeit for a shorter incubation period than the
highest concentration of oxidised LDL. It seems very unlikely that the small
differences in cytopathy between native and oxidised LDL at 100 pg/ml was
responsible for the observed differences in cytokine release.
No further characterisation was performed to assess the nature or mechanism
(apoptotic or necrotic) of cell death leading to annexin V positivity. Other workers
have identified apoptotic pathways influenced by oxidised LDL in human endothelial
cells including caspase activation, ceramide accumulation (Harada-Shiba et al 1998)
and sensitisation to Fas mediated apoptosis (Sata et al 1998). The latter mechanism
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Taken together, the results of this chapter characterise a model of endothelial
injury involving the incubation of oxidised LDL with HUVECs that is pertinent to
the study of atherogenesis. The nature of oxidised LDL's inflammatory activation of
endothelial cells observed with LDL and HUVECs prepared and set up within our
laboratory correlated closely with the behaviour of endothelial cells studied under
similar conditions in other laboratories and studies of endothelial cells from
atherosclerotic plaque specimens. This provided the necessary proof of principle to
proceed towards further characterisation of the system and a model for testing the
effects of therapeutic gene augmentation
Chapter 3
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Appendix I
Characterisation of oxidised LDL mediated endothelial cell injury.
Explanation of research project- for patient
This study aims to identify new genes responsible for the cause of atherosclerosis
('hardening of the arteries'). This disease is responsible for heart attacks and strokes.
The aim is to establish cultures of endothelial cells (the cells lining the blood vessels)
and study their responses to stimuli which model those stimuli occurring during the
development of atherosclerosis. These cells can be purified from umbilical cords
which form the connection between the baby and placenta during pregnancy.
Normally the cord and placenta are disposed for incineration following childbirth. If
you give consent, the cord will be removed for purification of endothelial cells.
Neither you nor the baby will require additional tests or treatments as a result of
agreeing to release the cord.
It is important for you to know that neither you nor the baby's name will be shown to
any researchers, appear on any documents or any publication. Please feel free to
discuss any of these aspects w ith the doctor who gives you this letter or the principal
investigator whose name appears at the bottom of this sheet. If you have further
queries you may contact an independent advisor listed below. This is a doctor who is
independent of the study and can provide additional advice. This study has been
approved by the Research Ethics Committee in this hospital, (which has a
responsibility for reviewing and approving any research projects that involve
patients).
Please understand that you are under no obliuation to take part in this study. If you
do consent to release of the cord you may change your mind at any time and do not
need to give a reason for doing so. Finally whether the cord is released or not the
routine care for you and your baby will be unaffected
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Chapter 4
Gene expression profiling of oxidised LDL stimulated
endothelial cells
4.1. Aims
The aim of the work in this chapter is to identify further genes responsible for
oxidised LDL endothelial injury by comparing gene expression profiles, using
commercial nylon miniarrays.
Expression changes observed in individual genes needed confirmation by
separate methods ofmRNA quantification such as semiquantitaive RT-PCR and
Northern blotting. Demonstrating a correlation of changes in gene expression with
translation and protein expression is important in order to interpret functional
significance.
The angiogenic factor angiopoietin-2 emerged as a target gene and preliminary
array findings correlated with semi-quantitative RT-PCR and ribonuclease protection
assays. The remaining work in this chapter is therefore directed towards detecting
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4.2.1. Expression profiling ofHUVECs under basal conditions and following
incubation with oxidised and native LDL.
The nylon human cytokine miniarrays (Sigma Genosys, UK) consist of 375 cDNA
sequences of cytokines, growth factors and their receptors printed in dot pairs at
specific locations. DNA was printed in 2 dot pairs at the four corners of each array to
provide a positive hybridisation control and orientation for design of an analysis grid
to determine signal intensity for each dot pair using image analysis software. Nine
positive control housekeeping genes including human pyrophosphate
phosphoribosyltransferase (HPRT) and glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) were included on the array. Housekeeping genes are transcripts that are
considered to have constant levels of expression in different physiological
conditions.
The relative signal intensity of housekeeping genes between different samples
may therefore provide information to facilitate correction for the amount of target
(radiolabelled cDNA) used in the hybridisation reaction. Negative controls including
chromosomal DNA from E. Coli, 1 x TE spotting buffer and the pUC19 plasniid
were also printed to provide information about the efficiency of hybridisation and the
contribution of any non-specific binding to the observed signal. The broad similarity
of signal pattern between different treatment conditions can be seen on visual
inspection of the four hybridisations in figure 4.1. The signal from housekeeping
genes was similar across the different hybridisations.
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A B
native LDL oxidised LDL
• »
C untreated D oxidised LDL (2)
Figure 4.1. Cytokine Miniarray gene expression profiles of HUVECs in basal
(untreated) conditions and following incubation with native and oxidised LDL.
mRNA was extracted from HUVECs grown to passage 4 in 6-well Costar plates
incubated under basal conditions and following incubations with oxidised LDL (100
pg/ml) and native LDL (100 pg/ml). Two nylon arrays were stripped and reused in
two separate hybridisations; A v B and C v D. A: array ' 1' hybridised with
radiolabeled cDNA (2.5 pg) from native LDL treated cells. B: array '2' hybridised
with radiolabelled cDNA (2.5 pg) from oxidised LDL treated cells. C: array '2'
hybridised with radiolabelled mRNA (2.5 pg) from cells grown under basal
(untreated) conditions. D: array '1' hybridised with radiolabelled mRNA (2.5 pg)
from cells treated with oxidised LDL.
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The mean ratio and standard deviation for 9 paired housekeeping gene signal
intensity ratios was 1.01 ± 0.32 (array '1' v array '2') for the first hybridisation and
0.99 ± 0.28 for the second hybridisation. These figures suggested that the quantity of
target hybridised to each filter was similar for each experiment. This method of
signal normalisation was recommended by the manufacturer although variation in
housekeeping gene transcript abundance between samples is possible and the
existence of genes whose transcript abundance is truly invariant in different
physiological conditions has been questioned (Dheda et al 2004).
Background signal was selected from a clear area of the array and subtracted
from each spot. This basic method of normalisation did not account for important
differences in hybridisation properties between the two arrays. The signal from the
four negative controls (the plasmid pUC19 and 3 bacterial DNAs) was different
between miniarray 1 and 2. The negative control signal for array 1 (figure 4.1) was
negligible and comparable to signal on non-printed areas of the filter for both
hybridisations. In contrast, array 2 had significant signal from all negative control
spots following both hybridisations. The net signal (the signal put forward for
comparative analysis between hybridisations) from a significant minority of probes
on array 2 was nullified following subtraction of the negative control signal. In
addition, 'blank' spots that had been printed with TE spotting buffer consistently had
signal in some areas of both arrays. The signal from the TE buffer blanks illustrated
how factors unrelated to DNA hybridisation, including physical characteristics of the
nylon miniarray surface may contribute to signal intensity.
These limitations led to a significant number of probe signals being
inconsistent between the two hybridisations demonstrating both up and down-
regulation in response to oxidised LDL. The high (background) negative control
signal from array 2 was probably responsible although it is conceivable that some of
the discrepancy was related to the use of different controls in each hybridisation:
native EDL sample and untreated sample. Many probes were therefore excluded and
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only genes with high signal (greater than 25000 densitometric units on
phosphorimager analysis) were suitable for comparisons between hybridisations.
Genes of interest were identified by expressing the corrected signal intensity from
the oxidised LDL treated sample as a ratio against native LDL or untreated samples.
Genes that exhibited greater than 1.8 fold up or down-regulation reproducibly, in
both hybridisations, were selected as genes of interest (Table 4.1). Several genes
were reproducibly up regulated in the oxidised LDL treated samples. These included
matrix metalloprotease-1 (MMP-l), placental growth factor and angiopoietin-2. The
growth factor midkine was down regulated in oxidised LDL treated samples
compared to untreated or native LDL treated samples. The vast majority of probes
had less than 1.4 fold variation between treatments or, following correction for
background, produced insufficient signal. The signals for IL-8 and MCP-1 fell into
the latter category, illustrating a potential weakness of expression profiling. It is a
useful technique for providing global changes in gene expression with many probes
providing strong and reproducible signals but its sensitivity as a tool for following
expression changes of a predetermined gene of interest (such as IL-8) will depend on
interaction of the IL-8 probe and labelled IL-8 transcripts within a complex
hybridisation mixture. One of the strongest signals on the array came from MMP-l
both from native LDL, untreated and oxidised LDL.
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Matrix metalloprotease-1 1.59 2.67 2.13
Placental growth factor 2.79 3.47 3.13
Angiopoietin-2 2.11 2.16 2.14
Midkine 0.63 0.40 0.52
Table 4.1. A summary of the results from two miniarray hybridisations.
Signal intensities from target genes in oxidised LDL treated samples were
expressed as a ratio of native LDL or untreated samples.
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Two genes from Table 4.1 were selected for further study by Northern blotting.
Angiopoietin-2 expression was increased and midkine expression decreased
following oxidised LDL stimulation. Neither midkine (Figure 4.2) nor angiopoietin-2
(Figure 4.3) could be detected by this technique following electrophoresis of 20 pg
ofHUVEC RNA. It is important to note that the probes used in the miniarray studies
were different from those used for Northern blotting (see Materials and Methods
section). The relatively high abundance housekeeping transcript GAPDH was readily
detected by Northern blot and could be used to compare sample loading between
lanes (Figures 4.2, 4.3).
Angiopoietin-2 cDNA probe (80 ng) was dot blotted onto the nylon filter as a
positive control and produced a strong signal following hybridisation. The probe
would be expected to hybridise more efficiently to itself than a native angiopoietin-2
sequence although the absence of signal for genes of interest within the samples and
the presence of a strong GAPDH signal suggested that low sequence abundance and
the relatively weak sensitivity ofNorthern blotting were the reasons for failure to
detect midkine and angiopoietin-2 signal.
The absence of signal on Northern blotting for two target genes that had
exhibited high signal intensity on the arrays illustrated the comparably high
sensitivity of arrays working on a reverse principle to Northern blotting where the
sample is radiolabelled and hybridised to a fixed probe. More sensitive techniques
were going to be required to corroborate changes in transcript abundance observed
on the arrays and efforts were focused on detecting angiopoietin-2 by
semiquantitative RT-PCR and ribonuclease protection assay.
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Figure 4.2. Northern blot for midkine and GAPDH
RNA was extracted form HUVECs grown in 6-well Costar plates that had been
incubated with oxidised LDL for 4 h using TRIzol according to a protocol outlined in
Materials and Methods (section 2.2.4.4). 20 pg of total RNA was loaded onto a
denaturing formaldehyde agarose gel and separated by electrophoresis according to
the protocol in Materials and Methods. LEFT PANEL: An image taken of the gel
following ethidium bromide staining under ultraviolet light prior to RNA blotting
and transfer to a nylon filter. 28s and 18s ribosomal subunits are clearly seen in an
approximate intensity ratio of 2:1 indicating the absence of any significant RNA
degradation. RIGHT PANEL: After blotting the nylon filter was hybridised in
Ultrahyb buffer overnight with radiolabelled midkine probe (target transcript size 4.6
kB). Following washes and exposure to a phosphor screen, no signal was seen
(exposure not shown) and the filter was then probed without any further washing for
GAPDH. In addition to the intense band for GAPDH, faint bands representing non¬
specific signal from 18s and 28s subunits can be seen.
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Figure 4.3. Northern blot for angiopoietin-2 and GAPDH
LEFT PANEL: As a positive control for hybridisation around 80 ng of
angiopoietin-2 cDNA probe was denatured by boiling at 95°C for 5 min and dot
blotted onto a nylon filter. Subsequent hybridisation with radiolabeled angiopoietin-
2 cDNA produced a strong signal following exposure on a phosphorimager screen.
RIGHT PANEL: HUVECs were grown as for figure 4.2. RNA was extracted from
cells grown in basal conditions, after incubation with TNF-a (lng/ml), a known
inducer of angiopoietin-2, and following incubations with oxidised LDL and native
LDL (both 100 pg/ml) for 4 h. 20 pg of total RNA was loaded and Northern blotting
performed according to the protocol in figure 4.2. The nylon filter was hybridised
initially with angiopoietin-2 probe (target transcript size 2.3 kB) and then for
GAPDH. The images shown are following the second hybridisation. Position of the
28s and 18s ribosomal subunits are indicated.
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Primers were designed for the housekeeping gene HPRT and angiopoietin-2
that produced 300 base pair and 535 base pair PCR products respectively. PCR was
performed with a fixed quantity of cDNA and different cycle numbers to ascertain an
optimum cycle number for maximum sensitivity without saturation. The effect of
increasing PCR cycle number on signal intensity is shown in figure 4.4A. HPRT
began to saturate at a lower PCR cycle number consistent with it being a high
abundance transcript in comparison to angiopoietin-2. In order to produce non-
saturated PCR products that could be used in semi-quantitative comparisons, cycle
numbers of 26 and 30 were chosen for HPRT and angiopoietin-2 respectively.
Angiopoietin-2 signal was increased in oxidised LDL treated samples compared to
native LDL or untreated samples (figure 4.4B).
Further quantification of angiopoietin-2 transcript was performed using a
ribonuclease protection assay. This method has no signal amplification step in
contrast to quantitative PCR and allows linear quantification of transcript abundance.
Compared to hybridisation protocols that rely on RNA bound to solid supports (i.e.
Northern blots) low abundance mRNAs are detected more readily by using a solution
hybridisation protocol (Lee et al 1987). Riboprobes for angiopoietin-2 and HPRT
(for reference) were generated and an initial experiment to determine signal intensity
from RNAase protected angiopoietin-2 transcripts for different loading quantities of
HUVEC RNA was determined (Figure 4.5). The full length probe (lane 2, Figure
4.5) was demonstrated and protected probe fragments after hybridisation with
HUVEC RNA and RNAase digestion could be seen (lanes 3-6, Figure 4.5). A faint
band of protected angiopoietin-2 transcript could be seen following loading with 5
pg of HUVEC RNA (Lane 3, Figure 4.5). This result is in contrast to the failure to
detect angiopoietin-2 transcript in 20 pg of HUVEC RNA using Northern blotting
(Figure 4.3). Protected probe fragments of varied lengths were seen following
RNAase digestion (arrows, Figure 4.5). This result may reflect premature termination
of transcription during probe synthesis or degradation of the probe. Shorter probe
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fragments still hybridise and protect their complement sequences within the sample
RNA and the resulting multiple bands have been described previously (Zinn et al
1983). A small increase in angiopoietin-2 signal was seen in RNAase protected
samples form oxidised LDL treated cells compared to native LDL and untreated cells
(Figure 4.6). HPRT transcript abundance was also quantified to demonstrate
equivalent loading between lanes (lanes 3-5, Figure 4.6). Although the data presented
for semi-quantiative RT-PCR and ribonuclease protection assay are qualitative, they
appear to confirm the original finding from the array indicating increased
angiopoietin-2 expression in oxidised LDL treated cells.
Angiopoietin-2 is a member of a novel family of angiogenic factors (Carmeliet
2000). Increased gene expression in the context of oxidised LDL mediated
endothelial cell injury would have broad implications for angiogenesis within the
atherosclerotic plaque and this gene was selected from the original array findings for
further study. The remaining work in this chapter sought to establish any associated
increase in FIUVEC angiopoietin-2 protein production and whether there was
evidence of angiopoietin-2 production within human atherosclerotic specimens.
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Figure 4.4. Semi-quantitative RT-PCR for angiopoietin-2 gene in HUVECs
treated with oxidised LDL.
Semi-quantitative was performed using primers for the housekeeping gene, HPRT
and angiopoietin-2. A. Titration of PCR cycle number for HPRT and angiopoietin-2
using 2 pi out of a 20 pi RT reaction performed on 1 pg ofHUVEC RNA. RT and
PCR were performed according to protocols outlined in the Material and Methods
(section 2.2.4.6). Primers for HPRT and angiopoietin-2 produced 300 and 565 base
pair products respectively. B. Semiquantitative RT-PCR was performed separately
for HPRT (26 PCR cycles) and angiopoietin-2 (30 PCR cycles) using total RNA
prepared from HUVECs according to experimental protocol outlined in figure 4.2.
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Figure 4.5. Ribonuclease protection assay for angiopoietin-2
HUVECs were grown to passage 4 in 6-well Costar plates and total RNA was
extracted using TRIzol. The method for RNAase protection is outlined in Materials
and Methods (sections 2.2.4.7-8) and was briefly as follows. An angiopoietin-2 PCR
fragment was subcloned into a PGEMT Easy vector and a radiolabeled riboprobe
was generated using SP6 RNA polymerase. Probe and sample were co-precipitated
and resuspended in hybridisation buffer. After an overnight hybridisation (14 hours)
the mix was digested with RNAase, precipitated again and the resulting RNA pellet
was resuspended in loading buffer. Samples were run in a polyacrylamide gel
(Sequagel) and dried to Whatman paper before exposure on a phosphorimaging
screen. 1. 20 pg Yeast RNA and RNAase. 2. Yeast RNA alone (Full length probe). 3.
5 pg HUVEC RNA. 4. 10 pg HUVEC RNA. 5. 20 pg HUVEC RNA. 6. 40 pg
FIUVEC RNA. The full length undigested probe (arrowhead) and protected
angiopoietin-2 riboprobes (arrows) are shown.
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Figure 4.6. Ribonuclease protection assay for angiopoietin-2 gene expression in
oxidised LDL treated HUVECs.
HUVEC total RNA was prepared as for Figure 4.2. HUVECs were incubated for 4 h
with oxidised LDL (100 pg/ml), native LDL (100 pg/ml) or left untreated in basal
conditions. RPAs were performed using 15pg ofRNA in each lane, for the
housekeeping gene, HPRT (left panel) and angiopoietin-2 (right panel). 1. HPRT
probe + 15 pg yeast RNA. 2. HPRT probe + 15 pg yeast RNA + RNAase. 3.
Untreated. 4. Oxidised LDL. 5. Native LDL. 6. Angiopoietin-2 probe + 15 pg yeast
RNA, 7. Angiopoietin-2 + 15 pg yeast RNA + RNAase, 8. Untreated, 9. Oxidised
LDL, 10. Native LDL. Arrowheads; full length probes. Arrows, protected fragments
following RNAase digestion.
Chapter 4 133
Chapter 4: Gene expression profiling of endothelial cells
4.2.2. Characterisation of angiopoietin-2 protein production, by endothelial cells
and within human atheroma.
Angiopoietin-2 protein could not be detected in HUVEC supernatants (data not
shown) or cell lysates (Figure 4.7) by Western blotting. Previous workers have used
concentrators (Witzenbichler et al 1998) or loaded large quantities (50 pg) of cell
lysate (Kim et al 2000b) in order to detect HUVEC angiopoietin-2 production
suggesting that it is present in low abundance. More recently, angiopoietin-2 signal
has been demonstrated with the same Santa Cruz antibody used in the present work
in 15 pg ofHUVEC cell lysate (Chang et al 2003) indicating that differences in
technical aspects relating to the immunoblotting protocol may also explain the
absence of signal using a direct approach. An immunoprecipitation protocol was
therefore devised in order to detect angiopoietin-2 protein in HUVEC culture
supernatants. Angiopoietin-2 activity could be detected in HUVEC supernatants
using this approach. Both oxidised LDL and TNF-a, a known stimulus for
angiopoietin-2 production (Kim et al 2000b), led to impressive increases in
angiopoietin-2 release compared to untreated or native LDL treated cells (Figure
4.8). Production of angiopoietin-2 in vivo has been found in pathological states
characterised by disordered angiogenesis including the vasculature of tumours
(Ahmad et al 2001). New blood vessel formation within the neointima or neointimal
angiogenesis is a feature of advanced atherosclerotic plaques (Barger et al 1984) and
the in vitro data with oxidised LDL, led to the question of whether angiopoietin-2
was present within human atheroma.
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Figure 4.7. Western blot for angiopoietin-2 in HUVEC cell lysates
HUVECs at passage 4 were grown to confluence in 6-well Costar plates and
incubated in medium alone (lanes2-3) with oxidised LDL (100 pg/ml, lanes 4-5),
native LDL (100 pg/ml. lanes 6-7) and TNF-a (1 ng/ml. lanes 8-9). Cell lysates were
extracted with RIPA buffer and equal quantities from each treatment were separated
on a 12% SDS polyacrylamide gel according to protocols set out in Materials and
Methods (section 2.2.5.5). Recombinant angiopoietin-2 (20 ng) was included as a
positive control (lane-1). UPPER PANEL: A Coomasie stain illustrates protein
loading and migration of recombinant angiopoietin-2. LOWER PANEL:
Angiopoietin-2 immunoblot of the above gel.
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untreated LDL LDL TNF-a rAng2
Figure 4.8. Identification of angiopoietin-2 production in HUVECs using
immunoprecipitation.
Immunoprecipitation of Angiopoietin-2 from HUVEC supernatants following
stimulation with TNF-a (10 ng/ml), oxidised LDL (100 pg/ml) and native LDL (100
pg/ml) for 8 hours. rAng2, recombinant angiopoietin-2 (100 ng). Similar results were
seen in 2 independent experiments. The band running in front of angiopoietin-2 is an
immunoglobulin chain, the faster migrating band is Protein G.
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A series of human tissues including four coronary arteries were obtained from the
living (non-post mortem) archive of patients with atherosclerosis undergoing
coronary artery bypass surgery from the University of Edinburgh Department of
Pathology. Non-diseased renal artery and umbilical vein specimens were also
obtained for comparison. Full local research ethics committee approval was received.
Angiopoietin-2 expression was limited to the luminal endothelial cells of non-
diseased renal artery and umbilical vein samples. These vessels had no neointimal
expansion. By contrast, immunohistochemical staining demonstrated strong
angiopoietin-2 expression within the cells of human coronary artery atherosclerotic
plaque neointima in addition to endothelial cells lining the vascular lumen (Figure
4.9). Staining for the endothelial cell (CD31), lymphocyte (CD3), macrophage
(CD68) and vascular smooth muscle cells (Smooth muscle actin, SMA) specific
markers was performed on sequential sections (Figure 4.9C-F) and there was
significant overlap of expression with Ang2 and CD31 (Figure 4.9C) and the smooth
muscle antigen SMA (Figure 4.9F). Angiopoietin-2 expression was frequently seen
within cells with smooth muscle morphology that stained for SMA (Figure 4.10).
Not all SMA positive smooth muscle cells were positive for Ang2 and variation both
within different regions of the same sample and between samples was noted.
Angiopoietin-2 staining from a further atherosclerotic coronary artery specimen with
a complex plaque is shown in Figure 4.11 A. Strong expression from the small
capillaries and neointimal vessels can be seen co-localising with CD31 (Figure
4.1 IB, C). Positive and negative controls for immunoperoxidase staining of SMA,
CD31, CD3, CD68 and angiopoietin-2 are given in Figure 4.12.
The immunohistochemistry studies indicated high angiopoietin-2 expression
within the neointima of human atherosclerotic plaques. In addition to localisation
within the endothelial cells of neointimal vessels, smooth muscle expression was also
identified.
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Figure 4.9. Immunoperoxidase staining for angiopoietin-2 in human
atherosclerotic specimens
Immunohistochemical analysis of atherosclerotic human coronary arteries obtained
during cardiac surgery or at autopsy was performed. Immunohistochemistry was
performed on paraffin embedded sections according to protocols outlined in Material
and Methods (section 2.2.5.2). A. Immunoperoxidase staining for angiopoietin-2 in a
human coronary artery with an eccentric atherosclerotic plaque. B. Higher
magnification of the boxed region highlighted in slide A. Staining was performed on
sequential sections for specific cellular markers. C. CD31 (endothelial cells). D. CD3
(T lymphocytes). E. CD68 (macrophages). F. Smooth muscle cell actin (SMA).
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Figure 4.10. Immunostaining of atherosclerotic coronary artery for
angiopoietin-2 and SMA.
A. Representative cross section of an atherosclerotic coronary artery stained for
angiopoietin-2. B. Sequential slice from the same coronary artery stained for SMA.
Results are representative of findings in four diseased human coronary arteries.
Magnification * 200
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Figure 4.11. Immunoperoxidase staining of angiopoietin-2 in an area of
neointimal angiogenesis within a complex human atherosclerotic plaque.
A. Low power view of human coronary artery. B. Representative cross section from
region outlined in B stained for angiopoietin-2. Magnification * 100. C. sequential
slice from the same coronary artery stained for endothelial CD31 Magnification x
100. Results are representative of findings in four diseased human coronary arteries.
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Figure 4.12. Positive and negative controls of immunoperoxidase staining for
SMA, CD3, CD31, angiopoietin-2 (Ang-2) and CD68.
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Figure 4.12. Positive and negative controls of immunoperoxidase staining for
SMA, CD3, CD31, angiopoietin-2 (Ang-2) and CD68 (contd)
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CD68
Figure 4.12. Positive and negative controls of immunoperoxidase staining for
SMA, CD3, CD31, angiopoietin-2 (Ang-2) and CD68.
Tissue from human trachea (SMA, smooth muscle actin), haemagioendothelioma
(angiopoietin-2 and CD31) and lymph node (CD3 and CD68) were used as positive
controls. Negative control staining included the secondary peroxidase conjugated
antibody only.
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4.3. Discussion
The angiogenic factor, angiopoietin-2, displays differential expression in
human endothelial cells in response to oxidised LDL. Furthermore, endothelial cell
release of angiopoietin-2 is increased in response oxidised LDL and
immunohistochemistry demonstrated strong angiopoietin-2 staining in endothelial
cells and vascular smooth muscle cells within atherosclerotic neointima.
This line of investigation arose from a gene expression profiling study using
nylon miniarrays and the following section will consider practical issues associated
with designing, interpreting and following up data from this kind of experiment.
4.3.1. Discussion ofminiarray results
The various methods for profiling gene expression including differential
display, subtractive hybridisation and microarrays are reviewed in the introduction
(section 1.6.1). Miniarrays were chosen because of their relative ease of use
compared to the other techniques. In contrast to differential display and subtractive
hybridisation the sequence of the target gene is known and although relatively
expensive this technique obviates the need for further laborious identification of
unknown sequences.
The nylon miniarrays used in this chapter contained 375 different cDNAs from
relatively well characterised human cytokines, growth factors and their receptors
printed at defined locations as PCR products. An additional modification of the
standard array reverse transcription step was to use a mixture of specific primers in
place of random primers. The Panorama cDNA labelling mixture had been
developed by Sigma Genosys in order to improve cytokine labelling efficiency.
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The hybridisations (Figure 4.1) illustrate the potential of this approach for
unlocking vast quantities of information. They also reveal problems that can be
encountered with respect to background noise and correcting for signal differences
arising form extraneous factors such as hybridisation efficiency. An initial
observation on visual inspection of the hybridisations was the close similarity
following different treatments. This is a common finding in expression profiling
studies using cDNA arrays (personal communication from Dr Paul Dickinson, The
Scottish Centre for Genome Technology and Informatics, University of Edinburgh)
and the vast majority of sequences probed in any array experiment will typically vary
in abundance by less than a factor of two.
Visual inspection also revealed a fundamental difference in signal between the
two nylon arrays used in these experiments. Array 2 (Figure 4.IB, C) consistently
produced signal in more genes compared to array 1 (Figure 4.1 A, D). The
discrepancy was unlikely to reflect the samples used or hybridisation conditions as it
occurred over two hybridisations. Spotting buffer (with no cDNA) and the bacterial
DNA plasmid pUC19 were spotted on the arrays as negative controls. Faint signal
was detected from the buffer controls on both arrays and some signal was also
detected from areas designated as blank (more intense from array 1). There appeared
to be a difference in the binding quality of array 2 leading to higher signal even from
spots that had no printed cDNA. The signals from these negative controls were
quantified by densitometry as being between 1000 and 6000 units and by contrast,
the reading from a gene exhibiting a strong signal, angiopoietin-2, was 33027
(untreated sample). This background may have arisen from regional variation in
physical qualities of the nylon membrane rather than differences in preparative
procedures such as blocking prior to hybridisation. This was supported by the
observation that blanks producing signal tended to be the same between
hybridisations.
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The effect of re-use following washing of the nylon membranes on
hybridisation signal is also seen in Figure 4.1. Comparing Figures 4.1 A and B with
Figures 4.1C and D it can be seen that the genomic DNA signal at the four corners of
each array was markedly reduced in the second hybridisation. Following the first
hybridisation, both arrays were washed stringently and exposed again. Signal was
still present in the genomic controls at each corner indicating failure to remove all
bound sample. Further washes to remove remaining signal were not performed
owing to a concern that array probes (which had no residual signal following the
initial wash) might be damaged by further washes. The decline in genomic signal
intensity following the second hybridisation indicated the potential for array
sensitivity to fall during re-use.
These findings made decisions on how to correct for background signal
difficult. The signal from non-printed regions of the array was very low and this was
used to correct signal intensity. It was clear that low gene expression signals would
have to be interpreted with care and because of concerns regarding non-specific
signal outlined above, interest focused on genes with high expression signals.
Comparisons of expression profiles under different conditions were performed
following signal normalisation.
The existence of (housekeeping) genes, whose mRNA transcript quantity
remains unchanged under different conditions and can therefore be used to compare
loading and hybridisation efficiency between different experiments, has been
questioned (Dheda et al 2004) although this principle is still widely applied both in
quantitative PCR and array analysis. The ratio of signals for each housekeeping gene
between hybridisations was calculated and a mean ratio for all eight was used as a
correction factor for signal intensities when comparing hybridisations. In practice
this correction made little numerical difference to overall results because of the
similarity in housekeeping gene signal between hybridisations.
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Using a cut off for gene expression change of 1.8 fold, four genes were
identified with increased expression following oxidised LDL treatment and one gene
had relatively higher expression in native LDL or untreated cells. The use of two
different controls is a further criticism of these experiments and native LDL or
untreated were assumed to be similar for the purpose of investigating oxidised LDL
specific effects. The level of change in gene expression used as a cut off has varied
between different investigators. For example 2.5 (Feng et al 1999), 2.0 (Shiffman et
al 2000) and 1.8 (Stanton et al 2000) have been used in previous studies. The higher
the cut off, the greater the chance that quantitatively small but functionally important
gene expression changes will be missed. The lower the cut off, the greater the
potential exists for positive or false positive findings. There were too few
observations to analyse statistically. In fact, expression changes in all target genes
could be confirmed retrospectively by visual inspection of the exposed arrays.
Oxidised LDL has previously been shown to have a positive regulatory effect
on MMP-1 transcription in HUVECs and human coronary artery endothelial cells
(Huang et al 1999). Its regulatory influence over MMP-1 expression has been used to
investigate oxidised LDL signalling mechanisms (Huang et al 1999; Li et al 2003)
and the finding that it was also up regulated following oxidised LDL treatment in our
system provided further indication that our model was comparable to that used by
investigators in other laboratories (see chapter 3). Midkine expression was reduced
consistently in samples treated with oxidised LDL in contrast to increased expression
observed with two angiogenic factors: angiopoietin-2 and placental growth factor.
Midkine is an angiogenic factor (Choudhuri et al 1997) whose production has been
identified previously in HUVECs (Sumi et al 2002b). The angiogenic roles of
placental growth factor and angiopoietin-2 have been characterised in greater detail
and both are associated with angiogenesis in response to tissue injury and
pathologies including cancers (Carmeliet 2000; Carmeliet et al 2001).
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Initial attempts to confirm expression changes by Northern blotting were
unsuccessful for midkine (Figure 4.2), angiopoietin-2 (Figure 4.3) and placental
growth factor (data not shown). Angiopoietin-2 expression changes were confirmed
using semiquantitaive RT-PCR (Figure 4.4) and following development of a
ribonuclease protection assay (Figures 4.5, 4.6). Having demonstrated up regulation
of this angiogenic factor in response to oxidised LDL attention focussed on its
production in HUVECs and whether it was present in atherosclerotic plaques.
4.3.2. Angiopoietin-2 protein is increased in endothelial cells incubated with oxidised
LDL and human atherosclerotic plaques
Efforts to detect angiopoietin-2 directly in culture supernatants by Western
blotting were unsuccessful (Figure 4.7). An immunoprecipitation protocol was
therefore developed and this demonstrated increased angiopoietin-2 release into the
culture medium of endothelial cells incubated with oxidised LDL compared to native
LDL or untreated cells (Figure 4.8). TNF-a was also an effective stimulus for
angiopoietin-2 release in these cells in keeping with previous studies demonstrating
regulation by inflammatory stimuli and vascular endothelial growth factor (Kim et al
2000b; Oh et al 1999).
Angiopoietin-2 and its receptor Tie-2 are closely involved along with the other
angiopoietin family members in blood vessel development. Angiopoietin-2 was
initially regarded as a natural antagonist of angiopoietin-1 having no activating effect
on their shared Tie-2 receptor. More recently, angiopoietin-2 has been shown to exert
concentration and context dependent effects on Tie-2. At low concentrations the
receptor may be bound but not activated by autophosphorylation (Maisonpierre et al
1997). In this situation it may block Tie-2 activation by other ligands such as
angiopoietin-1 and prevent chemotactic, sprouting and pro-survival messages
(Papapetropoulos et al 1999; Witzenbichler et al 1998). At high concentrations,
angiopoietin-2 binding is conversely associated with Tie-2 phosphorylation and
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activation (Kim et al 2000a). In the embryo, over-expression of angiopoietin-2 is
associated with disruption of blood vessel development, possibly through
antagonising the effects of angiopoietin-1 and during vascular development
angiopoietin-2 expression is associated with loosening of peri-endothelial cell
contacts and increased permeability prior to new blood vessel formation
(Maisonpierre et al 1997).
The angiopoietin system has recently been implicated in the development of
atheroma. Angiopoietin-1 was shown to be protective against the apoptotic effects of
oxidised LDL on porcine coronary artery endothelium, in vitro, at relatively high
concentrations (Kim et al 2001). Heightened expression of angiopoietin-2 is seen in
diseases characterised by disordered blood vessel formation including the vasculature
of tumours and following cerebral infarction (Ahmad et al 2001; Beck et al 2000).
New blood vessel formation within the neointima (Barger et al 1984) is also a feature
of atherosclerosis and following the demonstration of oxidised LDL as a regulator of
angiopoietin-2 expression, immunohistochemical analysis of human atheroma
specimens was performed to examine whether angiopoietin-2 expression was
associated with neointimal angiogenesis.
Angiopoietin-2 staining of a coronary artery with progressive atherosclerosis is
shown in Figure 4.9A. The plaque has an extensive fibroproliferative cap best
illustrated by the vascular smooth muscle staining (Figure 4.9F) with evidence of a
small necrotic core system and cholesterol clefts. Angiopoietin-2 staining cells can
clearly be seen both within the neointima and lining the vascular lumen (Figure
4.9B) in a high power field selected from Figure 4.9A. Sequential sections were
taken to stain for endothelial cell, lymphocyte, macrophage and vascular smooth
muscle cell markers, the predominant cell types within atheroma. CD31 staining
confirmed that the angiopoietin-2 signal from cells lining the vascular lumen was
endothelial in origin (Figure 4.9C) although in this section there were no endothelial
cells within the neointima. CD3 staining for lymphocytes was relatively scarce from
Chapter 4 152
Chapter 4: Gene expression profiling of endothelial cells
this fibroproliferative zone (Figure 4.9D) and macrophage CD68 staining (Figure
4.9E) was concentrated around the necrotic core in keeping with studies
demonstrating their part in lipid laden foam cell formation and necrosis (Libby,
2001). Although alveolar macrophage angiopoietin-2 expression has been described
previously (Kim et al 2000b) co-localisation with plaque leucocytes was not seen.
The predominant cell type within the fibroproliferative cap was vascular
smooth muscle (Virmani et al 2000) and comparing Figures 4.9B and 4.9F it seems
probable that a subpopulation of vascular smooth muscle cells was responsible for
angiopoietin-2 expression observed within the neointima. Although the sequential
sections do not provide perfect overlay, the spindle shape morphology of the
angiopoietin-2 positive intimal cells (Figure 4.9B) and the virtual absence of markers
for other cell types within this zone support this conclusion. High power micrographs
from a different donor demonstrated further evidence of smooth muscle expression
within the fibroproliferative cap (Figure 4.10). A more advanced and complex
atherosclerotic plaque in a coronary vessel from a separate donor is shown, stained
for angiopoietin-2, in Figure 4.11. The low power orientation view demonstrates at
least two foci of necrosis and cholesterol clefts. The area to the bottom left of the
micrograph contained a dense acellular necrotic area and there was associated non¬
specific uptake of secondary HRP conjugated secondary antibody. The zone
examined under high power shows dense staining of small vessels for angiopoietin-2
(Figure 4.1 IB) and CD31 (Figure 4.11C). In contrast, angiopoietin-2 expression was
limited to the luminal endothelial cells of human umbilical veins and non-diseased
segments of human renal artery. One caveat to interpretation of the
immunohistochemistry was the use of secondary antibody alone as a control. Ideally
an isotype matched primary antibody should be used in addition to exclude non¬
specific staining although this step is frequently missed out in the analysis of clinical
specimens (personal communication; Dr Lee Jordan, Department ofPathology,
University of Edinburgh). These control tissues had no neointimal formation and
coronary artery specimens with varying degrees of plaque development would have
been preferable controls. (The work was conducted during a period of upheaval with
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respect to the access and use of human tissues in research and access to coronary
artery tissue was restricted as a result.)
4.3.3. The role of angiopoietin-2 in atherosclerotic plaque development
Taken together, these findings indicate significant angiopoietin-2 expression
within the atherosclerotic plaque, both from a subtype of vascular smooth muscle
cells and from endothelial cells within zones of neointimal angiogenesis. During the
writing of this thesis, an Italian group published work demonstrating increased
angiopoietin-2 gene expression and protein content in extracts from human
atherosclerotic plaques (Calvi et al 2004). Immunofluorescence was performed to
illustrate angiopoietin-2 localisation within the neointima but surprisingly, the cell
types expressing angiopoietin-2 were not identified and in particular, smooth muscle
stains were not performed. An earlier study examining non-atheromatous porcine
coronary arteries found limited angiopoietin-2 expression within luminal endothelial
cells with no evidence of vascular smooth muscle cell expression (Kim et al 2001).
In adult tissues, angiopoietin-2 expression tends to be localised to endothelial cells
and closely related supporting cells at sites of vascular re-modelling (Maisonpierre et
al 1997: Yuan et al 2000b). The original description of angiopoietin-2 documented
high expression in murine embryonal vascular smooth muscle (Maisonpierre et al
1997) and others have confirmed smooth muscle specific expression during
development (Yuan et al 2000a). The potential for adult vascular smooth muscle
cells and fibroblasts to produce angiopoietin-2 has recently been demonstrated (Kelly
et al 2003) and angiopoietin-2 protein expression from rat cardiomyocytes was also
shown to be increased in an experimental model ofmyocardial infarction. The
variable staining in vascular smooth muscle cells, observed in the present work, is
consistent with preferential induction of angiopoietin-2 in these cells by
inflammatory signals, possibly at sites of vascular remodelling or injury.
Heterogeneity of smooth muscle within atheroma is well described and may reflect
differing phenotypes or possibly different sources of smooth muscle cells
(Gittenberger-de Groot et al 1999).
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Vascular smooth muscle cell expression of angiopoietin-2 may play a role in
plaque development. In cancers, high angiopoietin-2 expression by tumour cells is
associated with increased invasion and angiogenesis (Hu et al 2003; Ochiumi et al
2004). Angiopoietin-2 was recently shown to regulate the invasiveness of human
glioma cells through induction ofmatrix metalloprotease-2 (Hu et al 2003). A similar
action on vascular smooth muscle cells within the plaque might be expected to
promote both angiogenesis and plaque instability (Rajavashisth et al 1999a;
Rajavashisth et al 1999b).
The extensive network of fine blood vessels within the plaque provides an
expansive surface area for the transit of inflammatory cells and mediators. The
neointimal vessels are fragile and susceptible to rupture with ensuing haemorrhage,
leading to sudden plaque expansion or even rupture (Barger et al 1984). Treatment
with angiogenesis inhibitors is effective in reducing plaque burden in murine models
of atheroma (Moulton et al 1999; Moulton et al 2003). Recently, adenoviral gene
delivery of angiopoietin-1 was shown to reduce arterial wall thickening in a rat
model of transplant arteriosclerosis (Nykanen et al 2003). The investigators did not
examine angiopoietin-2 in this study but the implication that angiopoietin-1 may be
working, at least in part, through antagonism of angiopoietin-2 expression is
intriguing.
The possibility that angiopoietin-2 may be acting in synergy with vascular
endothelial growth factor (VEGF) was not examined in this chapter. This is an
important question for VEGF is present within human atheroma (Calvi et al 2004)
and administration of exogenous VEGF has been shown to enhance atherosclerotic
plaque progression in apolipoprotein E knockout mice and cholesterol fed rabbits
(Celletti et al 2001). Furthermore, VEGF has also been shown to be a facilitator of
angiopoietin-2 induced endothelial cell proliferation, migration and capillary
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formation (Lobov et al 2002). VEGF is a stimulus for angiopoietin-2 production by
endothelial cells (Oh et al 1999) and because it was present in the endothelial cell
culture medium, possible co-operativity with oxidised LDL induced angiopoietin-2
production cannot be excluded.
In summary, gene expression profiling identified oxidised LDL as a stimulus
for angiopoietin-2 production in human endothelial cells. Subsequent
immunohistochemical analysis of human atheroma identified extensive angiopoietin-
2 staining within endothelial cells lining neointimal blood vessels and also within
vascular smooth muscle cells from human coronary arteries with advanced atheroma.
These findings lead to two further questions. Firstly, to what degree does oxidised
LDL contribute to angiopoietin-2 production within the plaque? Given the central
role of oxidised lipid throughout plaque development and its presence within the
earliest lesions its role is likely to be important. Other inflammatory stimuli such as
VEGF or TNF-a may also contribute, particularly in more advanced atheroma.
Secondly, the association of angiopoietin-2 with pathological angiogenesis and the
observation of high expression within zones of neointimal angiogenesis suggest it
may be a key mediator and possible therapeutic target for plaque growth. This is an
important hypothesis for future study.
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Chapter 5
Adenoviral gene delivery of elafin and SLPI attenuates the
inflammatory responses of endothelial cells and
macrophages to atherogenic stimuli
5.1. Aims
The work in chapter 3 demonstrated that oxidised LDL induced
proinflammatory gene expression in endothelial cells through a mechanism involving
NF-kB mediated transcription. A fundamental aim of this chapter is to determine
whether two homologous endogenous antiproteases, elafin and secretory leucocyte
protease inhibitor (SLPI), could attenuate pro-inflammatory signalling in human
endothelial cells and macrophages.
Several lines of evidence, described in detail in the introduction, point to an
anti-inflammatory role for these peptides that extends beyond inhibition of
extracellular proteases. The studies demonstrating blockade ofNF-kB activation in a
range of tissues following delivery of SLPI (Lentsch et al 1999a; Lentsch et al
1999b) are particularly important in this respect. No such broad ranging anti¬
inflammatory properties have been identified for elafin although its homology with
SLPI indicated this to be a possibility. While the experimental work in this chapter
was being performed, members of the laboratory team were characterising the
inflammatory responses of elafin transgenic mice and demonstrated reduced
inflammatory cytokine production in response to systemically delivered LPS
(Sallenave et al 2003 ).
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The protective property of elafin against vascular inflammation in elafin
transgenic mice targeted to express elafin in vascular tissues under the control of the
preproendothelin promoter has been demonstrated by Professor Rabinovitch's group
in Toronto (Zaidi et al 1999; Zaidi et al 2000). A human elafin continuous
intravenous infusion was also shown to attenuate the intimal thickening and
arteriopathy occurring following orthoptic cardiac transplant in rabbits (Cowan et al
1996). The localisation of elafin within human coronary arteries by
immunohistochemistry was a further intriguing finding (Sumi et al 2002a) reported
while the work described in this chapter was in progress. This study raised the
additional possibility that endogenous elafin contributes to vessel wall defences
against inflammation in addition to the anti-inflammatory effects of exogenously
delivered or genetically overexpressed protein.
The work in this chapter had two objectives. Firstly, to develop techniques for
high efficiency gene delivery using adenoviral vectors to endothelial cells and
macrophages. Secondly, to examine the effects of overexpression of human elafin
and the murine orthologue of SLPI (mSLPI) on inflammatory cytokine production
and NF-kB activation in macrophages and endothelial cells.
A gene augmentation strategy was chosen because of evidence indicating that
the inhibitory activity of murine SLPI on NF-kB activation was dependent on
intracellular expression of the protein (Jin et al 1997; Zhu et al 1999). The
requirement for a continuous infusion of peptide to achieve therapeutic delivery of
elafin and SLPI in vivo was an additional concern. This would be impractical and
expensive and development of a gene based treatment that would facilitate targeted
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5.2.1. Development of a protocol to optimise adenoviral infection ofHUVECs and
macrophages
Staining for p-galactosidase activity and quantification of elafin production by
ELISA were the principal methods utilised in the following section to quantify
adenovirus infection efficiency and transgene expression following infection with
Ad-p-Gal and Ad-elafm respectively. P-galactosidase staining and elafin production
were low in HUVECs (Figure 5.1) and macrophages (Figure 5.2) compared to those
reported for the A549 epithelial cell line (Simpson 2001) (compare 1.5 ng/ml from
HUVECs to 120 ng/ml from A549 cells infected with Ad-elafin at an MOI 50). The
latter cell type demonstrates high tropism for adenovirus and previous work within
our group at similar multiplicities of infection had produced close to 100 % infection
rates measured by P-galactosidase positivity. Elafin supernatant concentrations are in
the lOOng/ml range compared to l-10ng/ml for HUVECs and even less for
macrophages. In HUVECs, infection efficiencies (p-galactosidase positive cells)
were estimated at 10%, 20%, 50% and 80% for MOIs of 25, 50, 100 and 1000
respectively (Figure 5.1 A). For macrophages, infection efficiencies with Ad-P-Gal
were estimated at 2%. 5% and 10% for MOIs of 25, 50 and 100 respectively (Figure
5.2A). No elafin was detected in supernatants from uninfected HUVECs. By
contrast, an elafin signal was detected from uninfected macrophages (Figures 5.IB,
5.2B). It must be emphasised that the macrophage experiments were performed using
autologous human serum that contains elafin (Molhuizen et al 1995). The levels of
elafin observed in uninfected macrophage supernatants approximate the 1.7ng/ml
quantity described in culture medium containing 10% human serum described by Dr
A.J. Simpson (Simpson 2001).
The relatively poor infection efficiency and gene expression levels for
HUVECs (at low MOI) and macrophages needed to be improved before the effects
of elafin and SLPI gene delivery could be studied. Fasbender et al. (1998) described
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a protocol of precomplexing adenovirus with calcium phosphate precipitates (CaPi)
to enhance infection efficiency to primary epithelial cells both in vitro and in vivo.
This protocol was adapted for use in human endothelial cells and macrophages
(Figures 5.3 and 5.4).
Precomplexing with CaPi dramatically improved infection efficiencies for Ad-P-Gal
in HUVECs (Figure 5.3). Infection efficiency was close to 100% at MOI 5 for
HUVECS and the increased intensity of P galactosidase staining with MOI 10 was
consistent with higher expression levels per cell. There was a dramatic increase in
elafin production with an MOI 20 in the presence of CaPi leading to production of
over 30-times the levels of elafin observed with an MOI 200 and virus alone. Similar
increases in infection efficiency and gene expression levels were seen for
macrophages (Figure 5.4). The latter finding was particularly striking given the
hitherto reported refractory nature of this cell type to any form of gene delivery
(Kaner et al., 1999). Macrophage morphology changed following adenoviral-CaPi
gene delivery. Examination with light microscopy demonstrated coalescing and
increased giant cell formation. This finding appeared to be more marked for P-
galactosidase cells compared to elafin expressing cells although giant cell formation
occurred following infection with both adenoviruses. A cytopathic effect consisting
of lifting and rounding had been observed in FIUVECs following infection with CaPi
and higher MOIs of 100 (data not shown). These observations raised the concern that
high levels of gene delivery came with the price of cytotoxicity and staining with
propidium iodide was performed to elucidate any evidence of cell death (Figures 5.5
and 5.6).
CaPi alone did not produce any increase in propidium iodide staining above
basal levels in HUVEC cultures (Figure 5.5, first 2 panels). Propidium iodide
staining was increased in adenovirus-CaPi exposed cells and this effect was more
pronounced with higher viral MOIs despite the cells appearing viable under light
microscopy in terms of shape, confluence and adherence (Figure 5.5). Macrophages
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Figure 5.1. P galactosidase staining and elafin production in HUVECs infected
with Ad-Pgal and Ad-elafin at varying MOI.
Adenovirus was left in contact with cells for 1 h before washing and replenishing
with normal growth medium. P galactosidase staining and elafin ELISAs were
performed 24 h after infection. A. HUVECs exhibited increasing p-galactosidase
positivity with greater viral MOI (multiplicity of infection). B. The effect of viral
MOI on elafin production in supematants from Ad-Elafin infected cells. Results are
mean ± SD from one experiment performed in triplicate.
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Figure 5.2. (3 galactosidase staining and elafin production in human peripheral
blood monocyte derived macrophages infected with Ad-3gal and Ad-elafin.
Macrophages were prepared as outlined in Materials and Methods (section 2.2.1.2).
They were matured on tissue culture plastic in 10% autologous serum for 5 days with
a wash on day 2 to remove non-adherent cells. Adenoviral infections were performed
in serum-free media for 1 h before replenishing with normal medium. A.
Macrophages were infected with Ad-pGal on day 5 and stained for 3-galactosidase
activity on day 6. Micrographs are representative of two experiments from a single
donor. B. Elafin production by Ad-elafin infected macrophages, data are mean ± SD
from one experiment performed in triplicate.
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showed a slight increase in propidium iodide staining when exposed to CaPi alone
(Figure 5.6) and adenovirus-CaPi led to a large increase in cytotoxic effect.
The levels of propidium iodide staining indicated high rates of cell death in
both macrophages and 1 lUVECs. Propidium iodide staining was conducted at the
same time interval following infection that the quantifications of elafin and [)-
galactosidase activity were performed and several conclusions could be drawn with
respect to the mechanism of toxicity. Firstly, cell death occurred several hours after
viral entry and gene expression had taken place and propidium iodide positive cells
also stained strongly for (3-galactosidase. Secondly, although there was an impression
of higher toxicity with P-galactosidase in macrophages, toxicity did not appear to be
transgene specific and was observed with several different adenoviral gene vectors
and importantly, an empty vector (Ad-dl703) expressing no transgene (Figure 5.6).
Finally, viral dosing (MOI) was a factor with higher adenovirus-CaPi doses giving
increased toxicity.
The levels of cell death were too high for this protocol to be used and the
effects of altering the calcium concentration for precipitate formation on gene
expression and cytotoxicity were therefore examined. Reducing the calcium
concentration led to a fall in HUVEC elafin production (Figure 5.7). A similar result
was seen for macrophage elafin production (not shown). Cytotoxicity was also
reduced in both FIUVECs (data not shown) and macrophages (Figure 5.8) with lower
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Figure 5.3. The effect on gene expression levels of precomplexing adenovirus
with calcium phosphate precipitates prior to infection ofHUVECs.
Adenoviral infections were performed in Eagle's minimal essential medium (cat
M2770 Sigma) without serum. CaCl2 was added to a final concentration of 8.3mM
allowing calcium precipitate (CaPi) formation. Adenovirus was pre-incubated with
the CaPi suspension for 20 min prior to addition to the cells at the required MOI. A.
(3-galactosidase staining ofHUVECs following Ad-p-Gal-CaPi delivery. B. Elafin
production in the supernatants from HUVECs 24 h after infection with Ad-elafin-
CaPi. Results are mean ± SD from one experiment performed in triplicate.
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Figure 5.4. The effect on gene expression levels of precomplexing adenovirus
with calcium phopshate precipitates prior to infection of macrophages.
Adenoviral infections were performed according to the protocol described in Fig.5.3.
A. (3-galactosidase staining ofmacrophages following Ad-P-Gal-CaPi infection. B.
Elafin production in the supernatants from macrophages infected with Ad-elafin-
CaPi. Results are mean ± SD from one experiment performed in triplicate.
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Figure 5.5. Propidium iodide staining for cytotoxicity in HUVECs following
Adenoviral-CaPi delivery.
Paired micrographs ofHUVECs taken under light (left panels) or green fluorescence
(right panels) immediately after adding propidium iodide stain. There were very few
propidium iodide positive cells following incubation in medium alone, medium and
CaPi and following infection with a high dose of Ad-elafin (MOI 200). Adenoviral-
CaPi resulted in more cell death, demonstrating dose dependence with viral MOI
increasing with Ad-elafin and Ad-(3-Gal at MOI 20.
Figure 5.6. Propidium iodide staining for cytotoxicity in macrophages following
Adenoviral-CaPi delivery.
Paired micrographs of day 7 macrophages infected on day 6 and taken under light
(left panels) or green fluorescence (right panels) for propidium iodide staining.
Increasing MOI of virus together with CaPi resulted in clumping, the formation of
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could be achieved in the absence of overt increases in toxicity by reducing the
calcium concentration. The effect of reducing calcium concentration on toxicity and
P-galactosidase staining in macrophages is evident in Figure 5.8. A calcium
concentration of 4.3 mM (Figure 5.8, middle panel) produced an estimated 70%
infection rate with no discernible increase in propidium iodide staining.
Because of the concerns regarding CaPi mediated cytotoxicity, lipofectamine,
another cationic adjuvant was assessed. Preliminary studies indicated that this was
also effective in boosting adenoviral infection efficiency and microscopic
appearances of cytopathy were notably absent in HUVECs at high viral MOIs
compared to CaPi. The effects of duration of viral incubation and precomplexing
with CaPi and lipofectamine were compared in HUVECs. For the same viral MOI of
100, lipofectamine had a similar effect to CaPi, increasing infection and elafin
production (Figure 5.9). Interestingly the action on adenoviral infection was rapid
with high levels of transgene expression following only a brief incubation of 30
minutes. There was a trend towards a further increase in elafin production after a 2-
hour incubation for both CaPi and lipofectamine. Extending the length of incubation
to 24 hours for virus precomplexed with either CaPi or lipofectamine did not increase
elafin production in contrast to virus alone (Fig. 5.9). The latter finding was of
particular interest indicating that for virus on its own, the length of incubation was a
determining factor for successful infection. Previous laboratory protocols with
adenovirus receptive cell types such as A549 cells had advocated a 1-hour incubation
period but this may be too short for the kinetics of virus-cell interaction in HUVECs.
Precomplexing with lipofectamine similarly enhanced adenoviral infection of
macrophages. An adenovirus vector encoding green fluorescent protein (Ad-GFP)
was available for these experiments (a kind gift from the laboratory of Professor J.
Gauldie, McMaster University, Hamilton, Ontario, Canada) and Ad-GFP was used to
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Figure 5.7. The effect of Ca2+ concentration on elafin production in HUVECs
following Ad-elafin-CaPi infection.
Ad-elafin-CaPi infections were performed as for Fig. 5.3 and the concentration of
CaCE added to form precipitates was varied as indicated. Elafin levels in
supernatants were measured by ELISA 24 h after infection. Results are mean ± SD
from one experiment performed in triplicate.
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Figure 5.8. Propidium iodide staining examining the effect of varying the Ca2+
concentration on cytoxicity and gene expression for adenovirus-CaPi delivery in
macrophages.
Ad-P-Gal-CaPi infections were performed at an MOI of 50 with precipitates formed
with different Ca2+concentrations according to the protocol in Fig 5.4. Micrographs
in light (left panel) and green fluorescence (middle panel) from the same field and
following p-galactosidase staining (right panel) from the well were taken.
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Figure 5.9. A comparison of the effect of duration of viral incubation period and
precomplexing virus with cationic liposomes or CaPi on elafin production.
Endothelial cells were infected with Ad-elafm at an MOI 100 alone (A) or following
precomplexing with CaPi and lipofectamine according to protocols set out in
Materials and Methods (sections 2.2.2.3.1-2). Adenovirus was incubated with
HUVECs for the length of time indicated. Virus containing medium was then
removed and the cells were incubated in normal culture medium for a further 24 h
and supernatant elafin concentrations were quantified by ELISA. Results are the
mean ± SD from two HUVEC donors performed in triplicate.
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demonstrate infection efficiency directly by green fluorescent protein expression
(Fig. 5.1 OA). Ad-elafin infection and elafin production were affected by varying the
ratio of lipofectamine to adenovirus particles. Elafin production increased with
increasing lipofectamine ratios with no additional increase above 5 x 104
1 ipofectamine particles to each adenoviral particle (Fig. 5.10B). The latter ratio was
chosen for all further infections involving precomplexing with lipofectamine.
Lipofectamine produced similar augmentation of infection efficiency and
transgene expression to CaPi but an important question was whether this was
associated with less toxicity. Because macrophages appeared to be most susceptible
to CaPi toxicity the effect of lipofectamine precomplexing was evaluated closely on
this cell type. There was no increase in propidium iodide uptake in macrophages that
had been infected with adenovirus in precomplex with lipofectamine compared to
non-infected cells (Fig 5.11). A similar result was observed following infection of
HUVECs with adenovirus-lipofectamine. Lipofectamine facilitated efficient non¬
toxic adenoviral transgene delivery to primary human endothelial cells and
macrophages and it was now possible to study the effects of elafin and murine
secretory leucocyte protease inhibitor on these cell types.
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Figure 5.10. Precomplexing adenovirus with lipofectamine improved infection
efficiency in macrophages
A. Ad-GFP infection ofmacrophages. Micrographs comparing the effect of
precomplexing adenovirus with lipofectamine on green fluorescent protein
expression following infection with virus at an MOI 100. Infections were performed
according to protocols in Materials and Methods (section 2.2.2.3.1). The micrographs
shown are representative of experiments performed on three separate donors. B. The
effect of varying the ratio of lipofectamine to adenoviral particle number on infection
efficiency and elafin transgene expression for Ad-elafin MOI 100. Results are mean









Figure 5.11. Precompiexing adenovirus with lipofectamine facilitates non-toxic
high efficiency gene delivery in macrophages
Paired micrographs taken under light (left panel) or green fluorescence for propidium
iodide staining (right panel) of day 7 macrophages following infection on day 6 with
the different Ad vectors shown at an MOI 100. Ad-GFP infected macrophages were
photographed under blue fluorescence to illustrate GFP expression. Macrophages
were prepared and infected according to protocols in Figure 5.10.
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5.2.2. The effect of elafin and mSLPI overexpression on the inflammatory cytokine
responses of human endothelial cells and macrophages to atherogenic stimuli.
The anti-inflammatory activities of elafin and murine secretory leucocyte
protease inhibitor (mSLPI) were studied on HUVECs, macrophages and lung
alveolar epithelial cell tumour cell line (A549 cells). The mSLPI vector was
developed in preference to its human orthologue because the literature indicating
anti-inflammatory actions for murine SLPI (Jin et al 1997; Zhu et al 1999) and
because of future applicability of this vector in murine models of atheroma.
Epithelial cells are not relevant to atherosclerosis (although lung epithelial cells
produce both elafin and SLPI) and were included to test whether the potential effect
demonstrated cellular specificity. A model of inflammatory activation of endothelial
cells in atherosclerosis involving activation ofNF-KB and production of IL-8 in
response to oxidised LDL has been described in chapter 3. Bacterial
lipopolysaccharide (LPS) and TNF-a were included as further stimuli relevant to the
development of atheroma (Barath et al 1990; Lehr et al 2001) and both increased
endothelial cell IL-8 release (Figure 5.12A). LPS induced TNF-a and IL-8
production were chosen as models of inflammatory activation ofmacrophages and
A549 cells respectively.
The effects of both Ad-elafin and Ad-mSLPI, were examined on responses to
LPS, TNF-a and oxidised LDL in HUVECs. In addition to the empty adenovirus
construct Ad-dl703 and in order to effect complete control for adenovirus and
transgene effects, a further control adenovirus expressing murine eotaxin (Ad-m-
eotaxin). a secreted chemokine of similar molecular weight to elafin and mSLPI with
no known anti-inflammatory activity in the cell types, was studied.
In HUVECs, Ad-elafin and Ad-mSLPI produced small but significant
reductions in basal IL-8 production, an effect not observed in Ad-IxBa infected cells
(Figure 5.12B). Ad-elafin and Ad-mSLPI had comparable inhibitory effects to Ad-
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IkBoc following stimulation ofHUVECs with LPS and oxidised LDL when
compared to control vectors (Figure 5.12D, E). TNF-a stimulation led to a large
increase in IL-8 production that was significantly attenuated by Ad-IxBa, Ad-mSLPI
and Ad-elafin (Fig. 5.12C). TNF-a was chosen as a marker for the ability of
macrophages to respond to LPS. Stimulation ofmacrophages with LPS produced a
response in both non-infected and virally infected cells (Fig. 5.13A). Ad-mSLPI and
Ad-elafin significantly reduced the TNF-a response to LPS compared with Ad-dl703
and Ad-m-eotaxin (Fig. 5.12C). In contrast to IL-8 production in HUVECs there was
no significant difference in the basal level of TNF-a production among the five
adenovirus constructs (Fig. 5.13B).
This result differs from others that have demonstrated inflammatory effects of
adenovirus on macrophages with increased TNF-a production following infection.
Intratracheal administration of an Ad-(3Gal in mice resulted in elevated TNF- a
message in alveolar macrophages detected by in situ hybridisation, 30 minutes after
infection (Zsengeller et al 2000). The same workers also demonstrated augmented
TNF-a production by the murine RAW264.7 macrophage cell line 2 hours after
infection with virus (Zsengeller et al 2000). In contrast, Foxwell et al (1998) did not
observe any increase in basal NF-kB activity or TNF-a production 3 days after
infection of primary human macrophages with an empty adenoviral vector
comparable to Ad-dl703, compared to uninfected cells. The use of a longer time
courses in the latter study and the work presented in this chapter may explain the
absence of evidence for adenovirus induced inflammation which could represents an
early and transient event.
To assess whether the properties of elafin and mSLPI extended to all cell types,
similar experiments were conducted on the A549 epithelial tumour cell line. In
comparison with their inhibitory effect on stimulated cytokine production in
HUVECs and macrophages, Ad-elafin and Ad-mSLPI had no effect on IL-8
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5.12. Ad-elafin and Ad-mSLPI reduce IL-8 production in HUVECs in basal
conditions and following stimulation with TNF-a, LPS and oxidised LDL.
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5.12. Ad-elafin and Ad-mSLPI reduce IL-8 production in HUVECs in basal
conditions and following stimulation with TNF-a, LPS and oxidised LDL.
Stimuli were applied 24 h after Ad-infection and left for 8 h before removal of
conditioned medium for IL-8 ELISA. A. IL-8 response to the three stimuli. B. Ad-
elafin, Ad-mSLPI, Ad-dl703, Ad-IicBa and Ad-meotaxin infected cells under basal
(untreated) conditions. C. TNF-a 1 ng/ml. D. LPS 100 ng/ml. E. oxidised LDL 100
pg/ml. IL-8 production is expressed as a percentage of uninfected cells. Data in B-E
are means and standard deviations from 3 separate donors performed in














































5.13. Ad-elafin and Ad-mSLPI reduced macrophage TNF-a production in
response to LPS stimulation.
Adenoviral infections were performed (100 PFU/cell) as described in Materials and
Methods and LPS was added on day 7 of culture. Conditioned medium was removed
after 3 h for TNF-a ELISA. A. Representative experiment from one donor (mean
and standard deviation from triplicate wells) showing TNF-a production from
untreated cells and the response following stimulation with LPS (1 ng/ml) in
uninfected and Ad-dl703 infected macrophages. B. TNF-a production in infected,
non-stimulated cells. C. TNF-a production in response to infected and LPS
stimulated macrophages (1 ng/ml). TNF-a production is expressed as a percentage of
uninfected cells. Data in B-C are means and standard deviations from 3 donors

































































Figure 5. 14 Ad-elafin and Ad-mSLPI had no effect on IL-8 production by A549
epithelial cells in response to LPS stimulation.
A549s were grown to confluence in 48-well Costar plates, infected with adenovirus
vectors (100 PFU/cell) and stimulated with LPS using the HUVEC protocol. A. IL-8
production in response to LPS stimulation (100 ng/ml). Data represent the mean and
standard deviation from triplicate wells. B. Basal IL-8 release from infected non-
stimulated A549s. C. IL-8 production from infected A549s in response to LPS (100
ng/ml). Data represent the means and standard deviations from 3 experiments
performed in triplicate. IL-8 concentration is expressed as a percentage of uninfected
cells. *,** significantly lower than Ad-meotaxin infected cells p < 0.05, p < 0.001.
182
Chapter 5
Chapter 5: Adenoviral gene delivery of elafin and SLPI attenuates inflammation
production by A549s in basal conditions or following stimulation with LPS (Figs.
5.14B.C).
However, Ad IkBoc retained an inhibitory effect, significantly reducing basal
IL-8 production and attenuating the response to LPS in A549 cells. This finding was
intriguing given that the A549 cell is the only one of the three studied that produces
endogenous elafin and SLPI protein in large quantities. This result was expected
from previous work conducted on A549 cells in our lab (Dr Sallenave, unpublished
data). In seeking a possible explanation for the different response of the A549 cells it
is important to consider that they may behave differently as an immortalised cell line
and one would need to assess the effect of elafin and mSLPI on primary epithelial
cells before concluding that that their effect was cell type specific.
5.2.3. Effect of elafin and mSLPI overexpression on NF-kB activation
IL-8 and TNF-a are strongly regulated by NF-kB transcription in endothelial
cells (Roebuck 1999) and macrophages (Foxwell et al 1998). The observation that
elafin and mSLPI overexpression inhibited inflammatory cytokine production in
response to three different stimuli points to an intracellular mechanism at a point of
signalling convergence. NF-kB activity was therefore examined using
electromobility shift assays. In HUVECs and macrophages the level ofNF-kB
activity in unstimulated cells was very low. In preliminary studies, there was no
difference between virally infected and uninfected cells. In HUVECs, stimulation
with LPS led to an increase in NF-kB activity that was reduced by Ad-elafin and Ad-
mSLPI but only at the lowest concentration of LPS used (100 ng/ml) (Fig. 15A).
Inhibitory effects disappeared at higher LPS concentrations (1 and 5 pg/ml) by
comparison with the inhibitory effect of Ad-hcBa that remained constant (Fig.
5.15A). A similar trend was seen following incubation ofHUVECs with oxidised
LDL (Fig. 5.16A). Ad-hcBa was most inhibitory, Ad-mSLPI attenuated
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Figure 5.15. Ad-elafin, Ad-mSLPI and Ad-IicBa reduced NF-kB activation in
HUVECs following stimulation with LPS.
HUVEC nuclear proteins were prepared for EMSA 1 h after stimulation with LPS.
Specificity of binding was demonstrated by disappearance of the NF-kB band with a
mutated NF-kB oligo (A probe). Nuclear proteins from two separate experiments
were run in pairs on the same gel. EMSAs of nuclear proteins (7 pg) from cells
infected with Ad-vectors and stimulated with LPS at 100 ng/ml, 1 pg/ml and 5
pg/tn 1. The mean intensities of the corresponding NF-kB bands for uninfected and
adenovirus infected cells were determined using ImageQuant software and expressed
as arbitrary densitometric units on the y-axis.
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TNF 10 ng/ml TNF 10 ng/ml
Figure 5.16. Ad-elafin, Ad-mSLPI and Ad-lKBa reduced NF-kB activation in
HUVECs following stimulation with oxidised LDL and TNF-a.
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Figure 5.16. Ad-elafin, Ad-mSLPI and Ad-lKBa reduced NF-kB activation in
HUVECs following stimulation with oxidised LDL and TNF-a (continued).
EMSAs were performed on nuclear proteins prepared according to protocols in Fig.
5.14 A, oxidised LDL stimulated cells, B, TNF-a stimulated cells. EMSAs are
shown with corresponding densitometry.
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Figure 5.17. Ad-elafin, Ad-mSLPI and Ad-lKBa reduced NF-kB activation in
macrophages following stimulation with LPS.
Macrophages were cultured in 12-well Costar plates and infected with adenovirus
vectors as for Fig. 5.12. Cells were stimulated with LPS (1 ng/ml) for 1 hour on day
7 and EMSAs performed on nuclear extracts (7 jag) as for Fig. 5.14 (representative
gel from an experiment repeated on 2 separate donors). Corresponding densitometry
ofNF-kB bands is also shown.
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NF-kB activation to a lesser degree but the effect of Ad-elafin was marginal
compared with control vectors.
Similarly, there was a trend towards reduced NF-kB activity following
stimulation with TNF-a (100 pg/ml) in Ad-elafin and Ad-mSLPI infected cells. In
parallel with their inhibitory effects on LPS signalling (Fig. 5.15A), this effect
disappeared with a higher concentration (1 ng/ml) ofTNF-a (Fig. 5.16B). In
contrast, the inhibitory effect of Ad-lKBa was much stronger and retained at the
higher TNF-a concentration. The observation that the effect of both elafin and
mSLPI overexpression could be overridden by higher concentrations of stimulus was
intriguing, suggesting that the inhibitory mechanism could be consumed or saturated
in contrast to overexpression ofmutated IicBa that remains resistant to proteosomal
degradation and continues to bind NF-kB at higher concentrations of stimulus.
In macrophages, Ad-elafin and Ad-mSLPI significantly attenuated NF-kB
activity following LPS stimulation when compared with control vectors although
Ad-lKBa was the most effective (Fig. 5.17).
To investigate the mechanism ofNF-kB inhibition by Ad-elafin and Ad-
mSLPI further, adenovirus infected HUVECs and macrophages were stimulated with
TNF-a and LPS respectively. Total cell lysates were then analysed for iKBa content
by Western Blot analysis. Ad-mSLPI and Ad-elafin significantly protected HUVECs
and macrophages from TNF-a and LPS-induced IKBa degradation respectively
(Figure 5.18). Ad-lKBa produced overexpression of mutated IKBa (as evidenced by
its higher molecular weight) but in accordance with other studies (Heimberg et ah,
2001) did not completely prevent endogenous IxBa degradation.
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To summarise the findings from this section: adenovirus mediated expression
ofelafin and mSLPI reduced inflammatory cytokine production in human endothelial
cells and macrophages in response to several stimuli through a mechanism involving
inhibition of the transcription factor NF-kB and preservation of cell IkBoi.
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Figure 5.18. Ad-elafin, Ad-mSLPI and Ad-IicBa protected HUVECs and
macrophages from IkBcc degradation.
HUVECs and macrophages (uninfected or infected with adenovirus constructs) were
stimulated with TNF-a (100 pg/ml, upper panel) or LPS (lng/ml, lower panel)
respectively, for 10 min (preliminary experiments were performed to determine
optimal timing, not shown). Total cell extracts were obtained and Western Blot
analysis was performed for IkBoi content as outlined in Materials and Methods
(section 2.2.5.5). Ad-derived IkBcc migrates slightly higher than endogenous IkBcx.
Results are representative of experiments performed in duplicate.
Chapter 5
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5.3. Discussion
The principal novel observations arising from this chapter are the development
of an inexpensive, non-toxic method to enhance adenoviral gene delivery to
HUVECs and facilitate gene delivery to human macrophages, a cell type refractory
to gene therapy and the characterisation of elafin and mSLPI as multifaceted innate
immunity molecules regulating the inflammatory responses of human endothelial
cells and macrophages to atherogenic stimuli. Discussion will focus on the methods
used to augment adenoviral gene delivery, the mechanism of effects of elafin and
mSLPl on endothelial cell and macrophage inflammatory functioning and the
potential of these peptides as targets for gene therapy in atherosclerosis.
5.3.1. Enhancing adenoviral infection of human endothelial cells and macrophages.
HUVECs are receptive to adenoviral infection. They express the
coxsackie/adenovirus receptor (CAR) (Jornot et al 2002). Previous workers have
demonstrated efficient adenoviral infection and transgene expression (Takahashi et al
1997). A viral MOI of 100 produced an infection efficiency of around 50% estimated
by P-galactosidase staining (Figure 5.1 A). By contrast, macrophages are less
susceptible to adenoviral infection, expressing low levels of CAR (Kaner et al 1999)
and in accordance with this, infection efficiency was 10% with a viral MOI of 100 in
human macrophages (Figure 5.2A). Improved infection efficiency was therefore
deemed to be an important goal, not only to facilitate gene delivery but also to reduce
viral dosing, a particular concern in clinical studies. Entry of human adenovirus into
host cells involves initial binding of the adenovirus fibre protein to the CAR receptor
(Bergelson et al 1997). Following attachment, virus entry into cells is mediated by
viral penton base binding to aV integrins (Bai et al 1993). Huang et al (1995) used
stimulation with granulocyte macrophage colony-stimulating factor (GM-CSF) to up
regulate aV integrin expression on the surface of freshly prepared human monocytes.
This modification produced significant increases in transgene expression rates with
around 54% infection with a viral MOI of 1000. This approach is relatively costly,
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impractical for in vivo use and through altering the macrophage phenotype with a
growth factor has the potential disadvantage of altering cell function.
The efficiency of adenoviral infection has been improved previously through
using a noncovalent complex consisting of a cationic component (calcium
precipitates or cationic lipid) and adenovirus in NIH 3T3 cells and murine epithelium
in vivo (Fasbender et al 1997; Fasbender et al 1998) and human monocytes in
suspension (Schleef et al 2001). Calcium precipitates enhanced infection efficiency
in HUVECs (Figure 5.3) and dramatically increased infection and gene expression of
macrophages (Figure 5.4). The calcium precipitates may be attracted by charge to
adenovirus particles that carry a net negative charge (Alenrany et al 2000; Mei et al
1995), facilitating attachment to the negatively charged cell membrane. The
mechanism of improved infection does not involve fibre knob-CAR or penton base-
exV integrin interactions and may occur through non-specific endocytotic pathways
(Walters et al 1999). In this regard it is noteworthy that prolonged contact with
adenovirus alone, heightened cell infection and transgene expression (Figure 5.9).
That the mechanism is receptor independent probably contributes to its success with
cell types demonstrating low tropism for adenovirus.
Although gene expression was increased following precomplexing adenovirus
with calcium precipitates in HUVECs and macrophages, propidium iodide staining
led to the surprise finding of increased cell injury and death (Figures 5.5, 5.6).
Calcium precipitates did not account for the toxicity alone and cell death occurred
late on, following transgene expression through a mechanism that appeared to be
independent of the transgene expressed with similar levels of cell injury being
observed in empty vector (Ad-dl703) and Ad-IxBa infected cells (Figure 5.6). The
efficiency of gene expression (Figure 5.7) and toxicity (Figure 5.8) were both
lowered by reducing the quantity of calcium making the precipitate. No information
relating to cell toxicity was presented in the original descriptions of the use of
adenovirus-CaPi coprecipitates in the 3T3 cell line and infection was also readily
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achieved in murine airway epithelium (Fasbender et al 1997; Fasbender et al 1998).
Precomplexing with lipofectamine produced similarly high levels of infection in both
cell types (Figures 5.9, 5.10) without the associated toxicity (Figure 5.11) suggesting
that the CaPi were responsible for the cytotoxic effect. It is postulated that CaPi are
internalised along with adenovirus. In an acidic endosome the CaPi may be rendered
soluble leading to a damaging influx of calcium (and phosphate) ions (Fasbender et
al 1997). The size of cationic polymer and the ratio of polymer to adenovirus have
been shown to affect the property of the complexes and resulting infection efficiency
(Fasbender et al 1997) and an optimal ratio of lipofectamine to adenoviral particles
was established (Figure 5.10).
Other more sophisticated methods have been used to specifically target
adenovirus to FlUVECs, including bispecific antibodies binding the adenoviral fibre
knob protein and epitopes on HUVECs (Nettelbeck et al 2001; Nicklin et al 2000).
These elegant approaches may have particular application where specific targeting is
necessary or desired in vivo.
However precomplexing with lipofectamine proved to be a cheap, simple and
effective method for facilitating adenoviral gene transfer in vitro and was therefore
used in the rest of the studies.
5.3.2. Ad-elafin and Ad-mSLPI reduce inflammatory cytokine production in
response to atherogenic stimuli by HUVECs and macrophages.
The mechanisms driving atherosclerotic plaque development have been
underpinned by in vitro studies demonstrating the inflammatory actions of oxidised
LDE on intimal cells (Claise et al 1996; Lei et al 2002). A possible contribution from
infectious agents or bacterial components such as LPS has been suggested by
detection ofChlamydia pneumoniae (Kuo et al 1993b; Kuo et al 1993a) and
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increased expression of the LPS receptor Toll like receptor-4 (Vink et al 2002), in
atherosclerotic specimens. These results are in agreement with the observation that
atheroma formation is accelerated in atheroma prone rabbits treated with LPS (Lehr
et al 2001).
Endothelial cells demonstrate increased chemokine expression during plaque
development (Koch et al 1993; Simonini et al 2000) and macrophages are the
predominant cell of the mononuclear cell infiltrate. Murine models of atheroma have
exemplified the importance of chemokine expression in atherogenesis. Indeed,
atherosclerosis susceptible, LDL receptor-deficient mice that were irradiated and
repopulated with marrow cells lacking the neutrophil chemokine receptor CXCR-2,
had reduced atheroma (Boisvert et al 1998). This body of data directed the study
towards endothelial cell chemokine production in response to oxidised LDL, TNF-a
and LPS. In accordance with previously published work (Claise et al 1996; Roebuck
1999), all three stimuli increased production of the neutrophil chemokine IL-8 in
endothelial cells (Figure 5.12A).
The effects of overexpression of elafin, its homologue mSLPI, previously
shown to inhibit LPS (Jin et al 1997; Zhu et al 1999) and IkBcx were compared in
HUVECs, macrophages and A549 cells. Adenoviral infection alone did not induce
inflammatory cytokine production. Ad-elafin and Ad-mSLPI along with Ad-lKBa
significantly reduced basal cytokine production in HUVECs (Figure 5.12B) whereas
only Ad-IxB reduced basal cytokine release in macrophages (Figure 5.13B) and
A549 cells (Figure 5.14B). Control vectors had no significant effect on basal
cytokine production in any of the cell types. This result conflicts with work that has
demonstrated inflammatory activation and TNF-a production following adenoviral
delivery in macrophages (Zsengeller et al 2000). There are several explanations for
this discrepancy. The macrophage cell type used was a cell line (RAW264.7), TNF-a
production was observed very early after infection (2 hours) and the method of
infection used virus alone giving very low infection efficiency (Zsengeller et al
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2000). The precomplexing protocol used in this thesis involved changing the medium
after a 2-hour incubation with the virus and this would cause early TNF-a production
to be missed. Adenoviral vectors carrying different genes were employed. Empty
viral vectors and a vector expressing a secreted protein (Ad-meotaxin) may be non¬
inflammatory compared to Ad-(3Gal which leads to expression and intracellular
accumulation of p galactosidase. Finally the studies differed in the method of
adenovirus delivery. Foxwell et al (1998) used recombinant GM-CSF treatment of
macrophages to increase expression of aV integrin co-receptors and observed no
excess basal TNF-a production in control vector cells, although again, this study
examined a later time point to that of Zsengeller et al (2000).
The question of inflammatory cytokine production in response to adenovirus is
important with respect to controlling safety and immune mediated inhibition of
adenoviral vectors and their transgenes. TNF-a is detected shortly after
administration of both wild type virus and defective vectors to mice (Ginsberg et al
1991). Interaction of adenovirus penton base with the plasma membrane and cellular
integrins leads to mitogen activated protein kinase activation and NF-kB mediated
IL-8 production as early as 20 minutes post-infection (Bruder et al 1997). In wild
type viruses, viral gene products from the El and E3 regions (the regions deleted in
the adenoviral vectors used in this thesis) modulate cell defence mechanisms
including NF-kB activation and TNF-a induced apoptosis (Russell 2000). El A gene
product from wild type adenovirus can bind to the p65 subunit ofNF-kB leading to
activation (Pahl et al 1996). The interplay between cellular proteins and (wild type)
viral gene products seeking to control cell survival and viral propagation is more
complex. ElA proteins may stimulate apoptosis by increasing production and
inhibiting proteosomal degradation of the key apoptotic factor p53 (Hale et al 1999).
By contrast, gene products from E1B 19K can inactivate members of the family of
pro-apoptotic proteins that interact with mitochondria and are involved in caspase
induction (Han et al 1996). Reduced Bax activity has also been postulated as a
mechanism of enhanced survival of cultured human endothelial cells following
infection with an El deleted replication deficient vector similar to the vectors used in
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this thesis although the mechanism was not described (Ramalingam et al 1999a).
T hese in vitro observations indicate that the outcome of adenoviral infection on cell
cytokine production and survival will depend on multiple (non-viral) factors
including cell type, stage of cell cycle and the signalling environment e.g. presence
of TNF-a or interferon y produced as part of the immune response to virus in vivo.
The latter statement is supported by the demonstration of altered signalling and
calcium regulated cytoskeletal protein gene expression in HUVECs but not in human
dermal fibroblasts or alveolar macrophages (Ramalingam et al 1999b).
Through facilitating adenoviral delivery by an alternative pathway that does
not result in increased basal cytokine production, lipofectamine precomplexing
provides the additional benefit of reducing the immune response to adenoviral
vectors.
In HUVECs, Ad-elafin and Ad-mSLPI significantly reduced IL-8 in response
to TNF-a, LPS and oxidised LDL (Figure 5.12C-E). Macrophage TNF-a production
in response to LPS was chosen as a model macrophage inflammatory response
(Figure 5.13A) and overexpression of elafin, mSLPI and IicBa significantly reduced
TNF-a production in response to LPS stimulation (Figure 5.13C-E). The magnitudes
of effect for both elafin and mSLPI were impressive compared to IxBa, a model
inhibitor of cytokine activation. There was a non-significant trend towards higher
degrees ofTNF-a inhibition with mSLPI (Figure 5.13C).
mSLPI's antagonistic action on LPS signalling was first identified using
differential display to compare two murine macrophage cell lines, one ofwhich
(C3H/HeJ) demonstrated hyporesponsiveness to LPS. Transfection with SLPI
converted macrophages from an LPS sensitive to LPS hyporesponsive phenotype
(Jin et al 1997). Subsequent work demonstrated that whereas transfection of a non-
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secretory form ofmSLPI into HeNC2 macrophages conferred protection form LPS
induced TNF-a production, addition of recombinant protein to the culture medium
had no inhibitory effect (Zhu et al 1999). Transfection of human cells with mSLPI
has not previously been performed although shortly after the original report by Jin et
al (1997), human peripheral blood monocytes cultured with exogenous human SLPI
were shown to have suppressed production ofmonocyte prostaglandin H synthase-2
and matrix metalloproteases 1 and 9 but not TNF-a in response to LPS (Zhang et al
1997). Although SLPI has been shown to bind to LPS (Ding et al 1999), SLPI-
containing medium is unable to transfer LPS-inhibiting activity to fresh cells, (Dr J
McMichael, from our laboratory, unpublished data) suggesting that extracellular
SLPI may not be able to interfere with LPS signalling. The different actions of
intracellular and extracellular SLPI will be discussed further in the following section
In addition to confirming the previously known anti-LPS activity ofmSLPI
these data establish for the first time the broad ranging antagonism of both elafin and
mSLPI against different stimuli suggesting a general role in dampening
inflammation.
Notably, Ad-elafin and Ad-mSLPI had no inhibitory effect on basal or LPS
induced IL-8 production by lung A549 epithelial cells, however, Ad-IxBa was
inhibitory (Figures 5.14B,C), possibly reflecting a cellular or organ specific action
for these antiproteases. Indeed, recent work from our group has demonstrated
enhanced neutrophil migration and a trend towards increased chemokine production
in murine lungs receiving Ad-elafin prior to LPS exposure (Simpson et al 2001a).
One investigative line under development is the possibility that elafin may modulate
inflammation differently on endothelial and epithelial surfaces, priming murine lung
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5.3.3. Mechanism of anti-inflammatory actions of Ad-elafin and Ad-mSLPI
Both IL-8 and TNF-a production are dependent on NF-kB regulated
transcription (Foxwell et al 1998; Mukaida et al 1994). An effect across 2 different
cell types against several different stimuli suggested an intracellular mode of action.
NF-kB activity is increased within the intimal cells of human plaques and is a
possible therapeutic target regulating the expression ofmany proatherogenic genes
(Brand et al 1996). Oxidised LDL increases endothelial cell production of reactive
oxygen species and activates NF-kB through interaction with the LOX-1 scavenger
receptor (Cominacini et al 2000). Oxidised LDL, LPS and TNF-a stimulation were
associated with increased activity of the pro-inflammatory transcription factor in
HUVECs (Figures 5.15. 5.16) (Flawiger et al 1999; Zen et al 1998). Following Ad-
elafin and Ad-mSLPI infection, NF-kB activity was reduced in LPS (Figure 5.15),
oxidised LDL (Figure 5.16A) and TNF-a stimulated HUVECs (Figure 5.16B). This
provides evidence lor an inhibitory effect prior to or at the level of gene transcription
for these stimuli. Ad-elafin and Ad-mSLPI also reduced LPS induced macrophage
NF-kB activation in accordance with their inhibitory action on production of the NF-
kB regulated pro-inflammatory cytokine TNF-a (Figure 5.17). Ad-lKB was a potent










Figure 5.19. Elafin and mSLPI modulate inflammatory signalling by TNF-a,
oxidised LDL and LPS.
Key to Figure 5.19. IRAK: Interleukin-1 receptor associated protein kinase.
TRAF: tumour necrosis factor receptor associated factors. NIK: NF-kB inducing
kinase. MAPK: mitogen activated protein kinases. LOX-1: lectin like oxidised LDL
receptor-1 (endothelial cells). TLR4: Toll-like receptor-4. MyD88: myeloid
differentiation protein 88. TNFR1: TNF-a receptor type-1. TRADD: TNF receptor-
associated death domain protein. RIP: receptor interacting protein. MAPK kinase:
mitogen activated protein kinase kinase. IKK: IkB kinase complex consisting of a, p
and y subunits. JNK/SAPK: c-Jun N-terminal kinase/stress activated protein kinase.
??: question marks are used to indicate that the signalling pathways linking oxidised
LDL and scavenger receptors to NF-kB have not been identified. This figure was
compiled from reviews by (Collins et al 2001) and (Ledgerwood et al 1999)
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Figure 5.19. Elafin and mSLPI modulate inflammatory signalling by TNF-a,
oxidised LDL and LPS.
Schematic diagram of signalling pathways for oxidised LDL, TNF-a and LPS in
endothelial cells leading to transcription factor activation and gene transcription.
Potential points where elafin and mSLPI may interact with these pathways are
numbered.
Binding of LPS to CD14 leads to association ofCD14 with TLR4. Signalling
depends on interaction of the intracellular TLR domain with adapter proteins
including MyD88. IRAK is phosphorylated and associates with TRAF-6, leading to
activation ofMAP kinases (p38 and JNK) and IKK. To induce NF-kB activation,
IKKs phosphorylate the inhibitory subunit (bound to inactive NF-kB) at its serine
residues. This 'targets' IkB for ubiquitination at lysine residues. The
polyubiquitinated IkB subunit is then degraded by the 26S proteosome and the active
NF-kB p65-p50 heterodimer is free to translocate to the nucleus and initiate
transcription. TNF-a signalling, similarly depends on interaction of the intracellular
domain of the active TNFR1 with the adapter proteins TRADD. TRAF-2 and RIP are
two proteins recruited to the TNFR-1 -TRADD complex. This coupling facilitates
p38 kinase. JNK and IKK activation. TNFR1 also transduces an apoptotic signal (not
shown) depending on the signalling context (other stimuli and the status of the cell).
Oxidised LDL binding to LOX-1 is associated with NF-kB and p38 MAPK
activation in endothelial cells although the mechanism of LOX-1 intracellular
transduction has not been elicited.
The points where elafin and mSLPI may be acting to inhibit signal transduction
and cytokine production are shown. The possibilities of an extracellular action (1) or
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In contrast to their effects in relation to IkBcx with respect to cytokine
inhibition, elafin and mSLPI were relatively weak inhibitors ofNF-kB activation.
The inhibitory action was lost with higher doses of LPS and TNF-a (Figures 5.15
and 5.16). Other transcription factors are involved in the regulation of IL-8
transcription and the findings presented here do not exclude the possibility that elafin
and mSLPI may interfere with more than one signalling pathway. IL-8 promoter
activity is regulated by differential activation and binding of activator protein-1 (AP-
1), nuclear factor IL-6 (NF-IL6) and NF-kB (Roebuck 1999). Activator protein-1
(AP-1) is a transcription factor composed of either Jun-Fos heterodimers or Jun-Jun
homodimers (Smeal et al 1989) that has been shown to contribute to IL-8 promoter
activity in human bronchial epithelial cells (Nakamura et al 1991). AP-1 may interact
synergistically with NF-kB (Stein et al 1993) or members of the cyclic AMP
response element-binding (CREB) and activating transcription factor-1 (ATF-1)
transcription factor families (Rabbi et al 1997) to heighten IL-8 gene expression
(Yasumoto et al 1992). Recently, a further transcription factor, signal transducer and
activator of transcription 3 (STAT3), was found to act co-operatively with c-src
kinase to induce IL-8 transcription in human aortic endothelial cells in response to an
oxidised phospholipid component of oxidised LDL (Yeh et al 2004).
The involvement ofmore than one transcriptional pathway may explain the
discrepancy between the magnitude of cytokine and NF-kB inhibition observed
following overexpression of elafin and mSLPI. Absolute inhibition ofNF-kB
activation would be undesirable, rendering the cell vulnerable to apoptotic death
(Barkett et al 1999). The latter property may be beneficial by providing a brake
against cytokine production rather than complete inhibition. The mechanism ofNF-
kB inhibition was further studied by Western Blot analysis, which demonstrated that
Ad-elafin and Ad-mSLPI reduced TNF-a and LPS induced iKBa degradation
(Figure 5.18). In macrophages, FcBa protein content was highest in the Ad-lKBa
infected cells (Figure 5.18) mirroring the EMSA results which showed that IKBa
was most efficient at down-regulating NF-kB activity (Figure 5.17). By contrast,
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HUVEC bcBa levels following Ad-lKBa infection were comparable to those
following Ad-elafin and Ad-mSLPI infection (Figure 5.18) despite Ad-lKBa being
more effective at suppressing NF-kB activation in response to TNF-a (Figure 5.16B,
upper panel). Samples for IkBcx immunoblots and NF-kB EMSAs were taken at 10
min and 1 h respectively and it is possible that the difference in magnitude between
elafin and mSLPI's inhibitory effect on NF-kB and preserving action on IkBo, in
HUVECs related to different time points in this cell type. Elafin and mSLPI may
have different actions on the various NF-kB inhibitory subunits and further studies of
IkBJI levels would be helpful (Lentsch et al 1999a, see below).
Consistent with its inhibitory activity on NF-kB demonstrated in the present
work, murine SLPI knockout macrophages demonstrate sustained increases in NF-
kB activation following LPS stimulation (Ashcroft et al 2000). Accordingly, Lentsch
et al (1999a) demonstrated that inhibition ofNF-kB activity in a rat immune complex
lung injury model, following administration of human SLPI, was associated with
increased levels of the IkBP inhibitory subunit (but not IkBcc) in lung homogenates.
In that model, mutated human SLPI sequences coding for proteins that lack trypsin
inhibitory activity failed to inhibit NF-kB activation (Mulligan et al 2000). More
recently, after completion of the work presented in this chapter, human SLPI was
demonstrated to reduce NF-kB activation in the human myelomonocytic U937 cell
line in response to LPS when added to the extracellular medium (Taggart et al 2002).
The anti-inflammatory activity against LPS was associated with protection from LPS
induced degradation of interleukin-1 receptor associated kinase (IRAK), IkBcx, and
IkB[1 and importantly, was shown to be inhibited by proteasome inhibitors.
Taken together these findings strongly suggest that mSLPI and by inference,
elafin inhibit NF-kB activation through an intracellular action involving protection of
the IkBoc (and possibly IkBP) from proteolytic degradation. Possible sites of action
are illustrated in Figure 5.19. Inhibitor studies have implicated serine proteases in
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IkB degradation (Henkel et al 1993). The observation that oxidative inactivation of
SLPI's antiprotease activity (Taggart et al 2002) disables its ability to protect against
IkB degradation is in agreement with previous observations by Mulligan et al (2000)
indicating that the mechanism requires intact protease inhibitory activity. Exogenous
serine protease inhibitors have previously been shown to block NF-kB activation
through inhibition of proteosomal proteases (Jobin et al 1999) and recently the serine
protease inhibitor antithrombin III was shown to block NF-kB activation in response
to LPS (Mansell et al 2001).
The findings presented in this chapter identify elafin as an inhibitor ofNF-kB
activation and add to the literature demonstrating a similar role for the closely related
protein mSLPI. Inhibition of cytokine production was more striking than the sole
suppression ofNF-kB activation (particularly for TNF-a stimulation in HUVECs:
Figures 5.12 and 5.16B). As discussed earlier it is important to underline that the
results do not exclude elafin and mSLPI interference with parallel pro-inflammatory
signalling pathways, a possibility not addressed in the current work.
5.3.4. Elafin and mSLPI are homologous proteins sharing broad innate immunity
roles and exhibiting potential as gene therapy targets for atherosclerosis.
In conclusion, the work in this chapter has demonstrated that Ad-elafin and
Ad-mSLPI block pro-inflammatory signalling in both endothelial cells and
macrophages and can, through NF-kB inhibition, attenuate inflammatory responses
to LPS, TNF-a and oxidised LDL.
Several important questions are worthy of further study. Firstly, where is (are)
the exact molecular site(s) of action of elafin and mSLPI? Several lines of evidence
currently point to an intracellular location of SLPI as a prerequisite for cytokine
blockade and inhibitory activity against a wide range of stimuli in the current work
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supports this view. NF-kB blockade has also been demonstrated following addition
of exogenous SLPI (Lentsch et al 1999a; Lentsch et al 1999b; Taggart et al 2002). In
Drosophila, LPS signalling involves an extracellular serine protease cascade that is
kept in check by serine protease inhibitors (Morisato et al 1994). There is no
evidence that such a cascade in mammals exists although Mansell et al (2001)
concluded that this was a possibility after observing inhibition ofNF-kB activation
by LPS with antithrombin III. These data are partly reconciled by the fact that SLPI
demonstrates cell membrane binding (McNeely et al 1997; Tseng et al 2000) and
may therefore be able to translocate across to the cytosol although no such binding
has been demonstrated for elafin. In human neutrophils, the majority of SLPI resides
in an active form within the cytoplasm (not within granules or a microsomal
subtraction) where there is clear potential for interaction with intracellular proteases
(Sallenave et al 1997).
Secondly, the extent to which NF-kB inhibition contributes to the innate
immunity role of endogenous elafin and SLPI is not known. The concept of secreted
serine protease inhibitors having direct influence on intracellular signalling pathways
is entirely novel and would require a reappraisal of their roles. Another secreted
microbicidal peptide with no sequence homology to elafin and SLPI, PR-39, has
recently been shown to inhibit TNF-a induced IkBo, degradation by the proteosomal
pathway by binding to the a7 subunit of the 26 S proteasome (Gao et al 2000).
Together elafin and SLPI form a paradigm, working as effectors of innate immunity
to protect tissues against maladaptive inflammatory responses. Their regulation and
multifaceted properties would make them ideal response molecules for checking
inflammation. They are up regulated by inflammatory stimuli (TNF-a and IL-ip)
and in addition to protease inhibition they both exhibit direct microbicidal activity
(Sallenave 2000).
Finally, these data indicate the suitability of elafin and SLPI as therapeutic
molecules for the treatment of atherosclerosis. Elafin is present within atherosclerotic
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tissue (Sumi et al 2002a) and may therefore have a role in checking endogenous
arterial wall inflammation. Although SLPI is produced by macrophages its role
within atheroma has not yet been characterised. The potential to focus the
inflammation damping properties of these peptides on atherosclerotic tissue through
gene therapy is attractive and certainly worthy of further study.
Chapter 5
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Chapter 6
Gene delivery of elafin reduces HNE mediated
endothelial cell injury and protects macrophages
from HNE mediated impairment of apoptotic cell
recognition.
6.1. Aims
The preceding chapter characterised the antinflammatory role for elafin and
murine SLPI against a range of atherogenic stimuli. Elafin was initially characterised
as a potent and specific inhibitor of both proteinase 3 and human neutrophil elastase
(HNE) (Sallenave et al 1991; Wiedow et al 1990) and SLPI has a broader range of
antiprotease activity including HNE, trypsin and chymotrypsin (Fink et al 1986;
Ohlsson et al 1976).
Until recently, neutrophils and their granule derived proteases were not
considered to play a prominent role in the development of atherosclerosis. The
demonstration of elafin within atherosclerotic plaques (Sumi et al 2002a) was
surprising given its strong association in the literature with the neutralisation ofHNE
in acute inflammatory processes not believed to be occurring within atheroma.
Recent reports have demonstrated evidence of neutrophil activation and
degranulation in patients with advanced atheroma and acute coronary syndromes
(Buffon et al 2002). Intriguingly, several neutrophil derived proteins have already
been demonstrated within atherosclerotic tissue and one of these, myeloperoxidase,
may mediate oxidative modification of low density lipoprotein (Daugherty et al
1994). Professor Libby's group recently extended these findings, demonstrating HNE
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in both fibrous and atheromatous plaques but not normal coronary arteries (Dollery
et al 2003).
The aim of this chapter is to characterise the effects ofHNE on the
inflammatory responses of human endothelial cells and macrophages. HNE is rapidly
inactivated by antiproteases including antitrypsin and macroglobulin contained
within the serum used to culture endothelial cells and macrophages (Travis et al
1983). The work in this chapter, examining HNE's actions, was therefore conducted
in serum-free conditions. That HNE can similarly function within the atherosclerotic
plaque in a microenvironment devoid of neutralising antiproteases is a central
assumption underlying the experiments. Myeloperoxidase catalyses inactivation of
protease inhibitors including antitrypsin in the low pH microenvironment associated
with neutrophil degranulation and inactivation of circulating and locally produced
antiproteases is one mechanism whereby HNE activity may persist (Shock et al
1988).
The effect of different concentrations ofHNE on the integrity of endothelial
monolayers was examined. A further aim was to examine to what degree adenoviral
mediated over-expression of elafin could protect endothelial cells and macrophages
from HNE injury.
At high concentrations, HNE has been shown to have cytopathic effects on
epithelial cells with lower concentrations signalling inflammatory cytokine
production (Sallenave et al 1994; Simpson et al 2001b; Walsh et al 2001). The
importance of inflammatory activation of endothelial cells with respect to the
initiation and progression of atheroma has been emphasised in earlier chapters.
Endothelial cell death may also contribute to both development and complications of
atheroma (Stoneman et al 2004). Loss of endothelium or denudation exposes a
thrombogenic surface (Davies 1994). Factors including HNE that facilitate loosening
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of endothelial cell-matrix attachments or endothelial cell death would be expected to
contribute to this process.
The work in this chapter confirms previously published observations that
monocytes and macrophages remain intact at HNE concentrations that cause
detachment and necrosis of epithelial cells and endothelial cells in vitro (Le Barillec
et al 1999b; Smedly et al 1986). HNE alters monocyte function in a more subtle
fashion by cleaving surface receptors responsible for recognition of bacterial
lipopolysaccharide (Le Barillec et al 1999) and macrophage recognition of apoptotic
cells (Vandivier et al 2002) prior to phagocytic engulfment. The resulting
functionally impaired macrophage is unable to mount an inflammatory cytokine
response to LPS or clear apoptotic cells from sites of inflammation. HNE is a potent
protease cleaving a range of surface receptors and extracellular proteins. The degree
to which this enzyme modulates macrophage function within the atherosclerotic
plaque is unknown although Dollery et al (2002) have indicated that HNE co-
localises and may indeed originate from macrophages in the vulnerable shoulder
regions of the plaque prone to rupture.
Work within our own group had already demonstrated the protective effects of
both recombinant elafin and adenovirus mediated overexpression of elafin on HNE
injury to epithelial monolayers (Simpson et al 2001b). The concept of a protease-
antiprotease balance within atherosclerotic plaques has previously been evoked as a
mechanism underlying the stability of the shoulder regions of plaques containing a
necrotic lipid core (Watanabe et al 2004). Given their presence together within the
atherosclerotic plaque, it was important to explore the possibility that elafin provided
protection from HNE injury to endothelial cells.
Similarly, apoptotic cell recognition was studied with respect to HNE
modulation ofmacrophage function. Apoptotic cell clearance, in particular, is a
central mechanism in the resolution of inflammation (Savill et al 2002) and
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impairment of apoptotic cell recognition is a feature of chronic inflammatory
pathologies such as cystic fibrosis and chronic obstructive airways disease (Hodge et
al 2003; Vandivier et al 2002). The technique of efficient adenoviral gene delivery to
macrophages described in chapter 5 was employed to discover whether elafin
overexpression could prevent HNE impairment of phagocytic function.
6.2. Results
6.2.1. The effect of Ad-elafin on HNE mediated endothelial cell injury.
HNE produced rounding and lifting of endothelial cells following incubations
for 8 hours in serum-free medium (Figure 6.1). The work in chapter 5 demonstrates
that Ad-elafin infection in conjunction with lipofectamine generates high
concentrations of elafin from HUVECs. Ad-elafin reduced the cytopathic changes in
response to HNE when compared to Ad-dl703 and Ad-GFP (Figure 6.1). These
adenoviruses were included to demonstrate the specificity of effect for Ad-elafin.
Ad-GFP was used in this experiment specifically to visualise both infection
efficiency and cell damage following HNE injury. Increasing concentrations of FINE
were associated with a decline in viable cell numbers measured by MTS assay
(Figure 6.2). Similarly, prolonged incubations with increasing HNE concentrations
led to increased LDH release into HUVEC culture supernatants indicating cell lysis
(Figure 6.3). HNE had no direct action on the tetrazolium colour indicator used in
this assay (data not shown). Ad-elafin was significantly more effective than Ad-GFP
or Ad-dl703 at preserving cell viability although both control viruses had
significantly higher viable cell counts than uninfected cells (Figure 6.4) following
FINE incubation.
HNE also increased endothelial cell IL-8 production during more prolonged
incubations at lower concentrations that were associated with less cytopathy (Figure
6.5). The increases in IL-8 production were modest compared to LPS or other
inflammatory stimuli (Figure 5.12A). In view of published reports indicating
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Figure 6.1. Incubation of endothelial cells with HNE led to a reduction in viable
cell numbers measured by MTS assay.
HUVECS were cultured in 96-well plates in serum-free conditions and incubated
with the concentration of HNE indicated for 24 h. Supernatants were removed
following the incubation and 120 pi serum-free endothelial culture medium with 20
pi MI'S Cell Titre reagent added according to the manufacturer's protocol. The MTS
tetrazolium compound is reduced by cells into a coloured formazan product that is
soluble in tissue culture medium. Production of the coloured agent can be measured
directly by recording absorbance at 490 nm giving an indirect measure of viable cell
number. Cells were incubated for 4 h and cell viability was determined from
measuring the absorbance at 490 nm. The absorbance from wells containing only
medium and MTS reagent was measured to provide a background for the corrected
absorbance shown. Results are mean and standard deviation from one experiment
performed in triplicate. Similar results were seen in two donors.
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Ad-dl703 Ad-GFP Ad-elafin
Figure 6.2. Overexpression of elafin protects HUVEC monolayers against HNE
damage
HUVECs were cultured and infected with Ad-dl703, Ad-elafin and Ad-GFP using
the lipofectamine protocol outlined in chapter 5. All HNE treatments were performed
24 h after viral infection. Photomicrographs of Ad-dl703, Ad-GFP and Ad-elafin
infected cells (all MOI 100), untreated and following incubation for 8 hours in
serum-free medium with HNE at the concentrations shown. Appearances of
uninfected cells were identical to Ad-dl703 infected cells (not shown).
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Figure 6.3. HNE induced release of cytosolic LDH into HUVEC culture
supernatants is concentration dependent.
HUVECS were cultured in 96-well plates in serum-free conditions and incubated
with the concentration of HNE indicated for 24 h. Supernatants were removed
following the incubation and supernatant LDH activity was expressed (after
correction for background within the culture medium) as a percentage of the activity
resulting from total cell lysis produced using 1% Triton X-100. Results are mean and






































Figure 6.4. The effect of adenoviral overexpression of elafin on HNE mediated
endothelial cell death.
Adenoviral infections were performed according to protocols outlined in figure 6.1 in
96-well plates. HNE incubations were set up and Cell Titre assays performed
according to protocols in figure 6.2. Data are means and standard deviations of 2
experiments performed in triplicate. *, significantly higher than Ad-GFP and Ad-
dl703, p < 0.01. **, significantly higher than uninfected cells, p < 0.01. ***,
significantly higher than uninfected cells, p < 0.05.
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Figure 6.5. IL-8 release by endothelial cells in response to incubation with HNE.
HUVECS were cultured in 96-well plates in serum-free conditions and incubated
with the concentration of HNE indicated for 24 h. Following incubation, supernatants
were removed and analysed for IL-8 content. Results are mean and standard
deviation form one experiment performed in triplicate.
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HNE mediated disruption of surface receptors and because HNE has been
demonstrated within atherosclerotic tissue, an experiment was devised to search for
any interaction between LINE and other inflammatory stimuli including oxidised
LDL, TNF-a and LPS. Because of the necessity to conduct HNE experiments in
serum-free conditions. HUVECs were incubated with HNE for 1 hour after which
serum-containing medium with the further stimulus was added.
Pre-incubation with HNE dramatically increased subsequent IL-8 release in
response to LPS and oxidised LDL (Figure 6.6). The effect was greater than the
summative effects of the individual stimuli (compare HNE alone and in combination
with oxidised LDL or LPS; Figures 6.6A, 6.6B and 6.6C) and there appeared to be a
dose effect for HNE with increasing preteatment doses leading to more IL-8
production in response to subsequent LPS or oxidised LDL. This suggested a
positive interaction or synergy between HNE pretreatment and these two stimuli. In
contrast, no such effect was observed for HNE pretreatment followed by TNF-a
stimulation. The latter stimulus produced a massive IL-8 response from endothelial
cells and this may have masked any effect from HNE pretreatment. Overexpression
of elafin led to a significant reduction in IL-8 production in response to HNE, HNE
and LPS in combination and, in agreement with results presented in chapter 5, in
response to LPS alone (Figure 6.7). Ad-IicBa that was included as a positive control
of cytokine inhibition reduced HUVEC IL-8 production in response to all three
combinations of stimuli (Figure 6.7).
6.2.2. Experiments examining the effect of Ad-elafin on HNE modulation of
macrophage function
HNE readily induced cytopathy and cell death in HUVECs and at lower
concentrations it stimulated IL-8 production. Both actions could be attenuated by
over-expression of elafin. In contrast, cultured macrophages were resistant to HNE
cytopathy at concentrations that would cause immediate lysis of HUVECs in serum-
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Figure 6.6. The effect of HNE pretreatment on endothelial cell IL-8 production
in response to oxidised LDL, LPS and TNF-a.
HUVECs were incubated in serum-free medium with the concentration ofHNE
indicated for 1 h. Supernatants were removed and replaced with normal serum
containing medium alone (HNE alone) or with oxidised LDL (100 pg/ml), LPS (100
ng/ml) and TNF-a (1 ng/ml) for 8 h before supernatants were removed for IL-8




Chapter 6: Gene delivery of elafin reduces HNE mediated injury
□ HNE 5 x 10"8M
23 HNE 5 x 10"8M + LPS lOOng/ml
















Figure 6.7. The effect of Ad-elafin on endothelial cell IL-8 production following
pretreatment with HNE alone, HNE pretreatment in combination with LPS
stimulation or LPS stimulation alone.
Adenoviral infections were performed according to the protocol in figure 6.1 and 24
h after infection HNE pretreatments, LPS stimulation and IL-8 assays were
conducted as for figure 6.6. Results are means and standard deviation from 3
experiments performed in triplicate. IL-8 production is expressed as a percentage of
production in uninfected cells (see Figure 6.6) *,** significantly lower than Ad-
dl703 infected cells p< 0.01. p< 0.001.
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Figure 6.8. The effect of HNE on macrophage production of TNF-a.
Human peripheral blood monocytes were cultured in 6-well plates and matured into
macrophages according to protocols described in the Materials and Methods chapter.
On culture day 4 macrophages were detached with ice cold PBS and replated (30000
cells/ well) in 96-well plates with serum-free X-vivo 10 medium. Experiments were
performed on culture day 7. HNE (1 pM) was added where indicated for 1 h after
which culture supernatant was removed and 10% autologous serum-containing
medium was introduced. Serum-free medium was also exchanged for serum
containing medium in wells that did not receive HNE pretreatments. LPS (100
pg/ml) was added where indicated for a further 4 h and culture supernatants were
removed for TNF-a quantification. Results are mean and standard deviation of an
experiment from one donor performed in quadruplicate.
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free conditions (data not shown). Reports had demonstrated that monocyte
responsiveness to HNE was reduced following incubation with HNE through a
mechanism involving cleavage of the CD14 receptor (Le Barillec et al 1999). The
responsiveness of macrophages to LPS as measured by TNF-a production was
reduced following incubation with PINE (Figure 6.8). This result contrasted with
HNE's facilitatory action on LPS induced cytokine production in endothelial cells.
HNE acted as a weak stimulus for macrophage TNF-a production (Figure 6.8) in line
with its effect on endothelial cell inflammatory cytokine production.
Dose finding pilot studies (data not shown) indicated that the minimum HNE
concentration (1 pM) required to produce a detectable reduction in macrophage
responsiveness after a 1 hour incubation was 100 fold stronger than the
concentrations that led to heightened LPS responsiveness in HUVECs.
Flow cytometry for CD 14 was performed to assess whether the reduced
responsiveness to LPS was associated with disruption of the receptor. HNE reduced
surface expression ofCD 14 (Figure 6.9) and overexpression of elafin significantly
attenuated this effect compared to control Ad-dl703 infected cells or uninfected cells
(Figure 6.10). This indicated that in addition to inhibiting LPS induced cytokine
production in endothelial cells and macrophages (Chapter 5), elafin overexpression
may preserve some aspects of CD 14 signalling in the context ofHNE injury. CD 14
expression was not completely restored in elafin expressing macrophages incubated
with HNE (mean 43% CD 14 expression compared to 66% prior to HNE) following
treatment (Figure 6.10E). When macrophages were infected with Ad-
elafin/lipofectamine, elafin supernatant levels were increased from 10.4 (± 4.11)
ng/ml with Ad-elafin alone to 232 (± 13.1) ng/ml (values are means and SDs derived
form a representative experiment performed in triplicate). Elafin was not detected in
the supernatant from uninfected cells. These levels of elafin production would not be
expected to neutralise the high concentration ofHNE used in this experiment.
Assuming a molecular weight for elafin of 9.9 kDa, the concentrations of elafin
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Figure 6.9. FACS analysis of macrophage surface CD14 expression following
HNE treatment.
Macrophages were prepared as for figure 6.8 except that on culture day 4 they were
transferred to 48-well plates (70000 cells/well). HNE incubations (1 pM) were
performed, where indicated, as before (see figure 6.8), supernatants removed and
cells washed and resuspended in ice cold PBS. Binding of 61D3 primary antibody
was used to determine cell surface CD14 expression. Cells were incubated with
61D3 for 30 min, washed twice and then incubated with phycoerythrin-conjugated
goat anti-mouse IgG secondary antibody for 15 min. Washed macrophages were then
analysed on a FACScan cytometer (Becton Dickinson and co.). Control cells were
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Figure 6.10. Ad-elafin reduces HNE mediated disruption of the macrophage
CD14 receptor.
Where indicated, macrophages were incubated with HNE (1 pM) for 1 h prior to
removal and binding of 61D3 antibody was analysed according to the protocol
described in figure 6.9. Adenovirus infections were performed 24 h prior to the HNE
incubation where indicated using the lipofectamine protocol outlined in the methods
chapter. A. Uninfected cells B. Ad-dl703 infected cells (MOI 100). C Ad-elafin
infected cells (MOI 100). D. Composite figure illustrating 61D3 binding in the
different conditions from a separate donor. E: Mean percent of macrophages staining
for CD14 ± SD. Data are from experiments performed on 2 separate donors. Data
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Figure 6.11. A comparison of the HNE inhibitory activity of macrophage culture
supernatants.
Macrophages were prepared and infected with adenovirus using the protocols
described in figure 6.10. Culture supernatants were removed for determination of
residual HNE activity following incubation for 1 h with HNE (1 pM). Supernatants
were transferred to a microtitre plate and cleavage of a chromogenic HNE substrate
was measured spectrophotometrically over time according to a protocol described in
the Methods section, r-elafin: truncated recombinant human elafin (15 pg/ml). Data
are mean and standard deviation from experiments performed on 3 separate donors. *
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produced would be expected to neutralise around 5% of the HNE. Figure 6.11
indicates that although residual supernatant HNE activity was significantly reduced
from wells with elafin expressing macrophages compared to control virus and
uninfected cells, the magnitude of reduction was modest. In contrast, a saturating
concentration of recombinant elafin effectively neutralised residual supernatant HNE
activity.
Having demonstrated HNE disruption of surface CD 14 on macrophages and
partial protection of CD14 through adeno-mediated overexpression of elafin, an in-
vitro system was devised to investigate the effects of elafin overexpression on
macrophage apoptotic cell clearance. CD 14 has been identified as a surface
recognition receptor for apoptotic cells. HNE impairment of macrophage apoptotic
cell recognition through cleavage of apoptotic cell recognition receptors has been
demonstrated (Vandivier et al 2002). In agreement with this work, incubation with
HNE significantly reduced apoptotic cell interaction with macrophages (Figure 6.12).
61D3, a CD 14 antibody with blocking activity against apoptotic cell recognition also
_ reduced macrophage interaction. This effect was increased in the presence ofHNE,
supporting the possibility that the combined treatments were affecting other
apoptotic cell recognition mechanisms in addition to CD 14. Apoptotic cell
recognition was relatively preserved in Ad-elafin infected macrophages in
comparison with viral control and uninfected cells.
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Figure 6.12. Ad-elafin protects macrophages from HNE-mediated impairment
of phagocytosis.
Macrophages were cultured and infected with adenovirus according to protocols
described in figure 6.10. Where indicated, HNE (lpM) and r-elafin (15 pg/ml) were
added in serum-free X-vivo 10 medium (Cambrex Bio Science) for 1 h prior to
adding the apoptotic Mutu (B cell) target cells with or without 61D3 antibody. After
fixing and staining, the percentage ofmacrophages interacting with apoptotic mutus
was calculated (% interaction). Interaction counts performed on macrophages that
had not been exposed to mutus (control) are also shown to exclude a significant
contribution from apoptotic macrophages originating from the culture. Data are mean
and standard deviation from experiments performed in quadruplicate on 3 separate
donors. * ,** significantly greater percentage phagocytic interaction than HNE
treated uninfected and Ad-dl703 infected cells,p < 0.05, 0.01.
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6.3. Discussion
The principle finding in this chapter relates to the significant protection against
HNE induced cell death, inflammatory activation and impaired cell function
conferred by overexpression of elafin. Discussion will focus on the relevance of
these findings from in-vitro models to inflammatory events occurring within the
atherosclerotic plaque.
6.3.1. Ad-elafin overexpression protects endothelial cells from the inflammatory
actions of HOME
The considerable genetic augmentation of elafin described in chapter 5 was
sufficient to ameliorate HNE induced cytopathic changes in HUVECs (Figures 6.1,
6.2 and 6.4). HUVEC cell counts were depleted in wells incubated with HNE (Figure
6.2). This reduction was quantified by MTS assay which measures the mitochondrial
activity within viable cells (Cory et al 1991). This result was compatible with two
possibilities: that HNE induces cell lysis directly or that it causes endothelial cell
detachment. The latter mechanism may have resulted in a decline in cell numbers
because detached cells were removed during the exchange ofmedium prior to
introducing the MTS reagent. Both detachment and cytolysis have been
demonstrated in cultured endothelial cells following incubation with HNE (Ballieux
et al 1994) or with degranulating neutrophils (Smedly et al 1986; Westlin et al 1993).
Subendothelial extracellular matrix proteins such as fibronectin and thrombospondin
are particularly susceptible to FINE cleavage, leading to cell retraction and rounding
(Bonnefoy et al 2000). The correlate of this process in vivo may be the appearance of
circulating endothelial cells and their fragments in various diseases characterised by
endothelial injury including atherosclerosis (Makin et al 2004; Mutin et al 1999). In
addition to membrane disruption and cytolysis, HNE has also been shown to induce
apoptotic cell death in bovine endothelial cells (Yang et al 1996a). As reported by
Ballieux et al (1994), it is likely that FINE concentration and period of incubation
combine to determine the predominant mechanism. In this work, the increased
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supernatant LDH activity (Figure 6.3) and propidium iodide uptake (data not shown)
indicated that cell lysis was occurring. The increases in LDH activity at higher
concentrations of FINE were modest (around 15% compared to untreated cells,
Figure 6.3) compared to the observed disruption of the HUVEC monolayer under
light microscopy. This result may reflect mixed mechanisms including cell
detachment, apoptosis and lysis. A direct effect ofHNE on liberated cytosolic LDH
can also not be excluded, possibly leading to reduced LDH activity and an under
estimation of cell lysis.
Both Ad-GFP and Ad-dl703 increased cell viability (Figure 6.4) and protected
endothelial cells from HNE damage (Figure 6.1) in comparison to uninfected cells.
This raised the intriguing possibility that viral infection was leading to upregulation
of an endogenous protecting factor against HNE. In contrast to epithelial cells,
cultured endothelial cells do not produce elafin (Figure 5.1) or SLPI (SLPI dot blots
performed on HUVEC culture supernatants, data not shown). Serine proteinase
inhibitory activity from cultured human and bovine endothelial cells has been
isolated by others against both HNE and trypsin (Hanley et al 1996; Rao et al 1995)
although the mediators involved were not identified and the capacity for the
endothelium to protect itself from HNE damage through upregulation of endogenous
antiproteases remained unknown. That protection was observed in both GFP
expressing cells and Ad-dl703 infected cells indicates that the virus effect was not
related to a specific transgene. A similar effect on HNE mediated injury has been
observed in epithelial A549 cells in our laboratory following infection with
adenovirus expressing B-galactosidase (Simpson 2001).
PINE incubation at concentrations below levels associated with immediate
cytopathy led to release of IL-8 into HUVEC culture supernatants (Figure 6.5). HNE
has previously been shown to augment IL-8 release from lung epithelial cells
(Sallenave et al 1994; Walsh et al 2001) and its ability to positively regulate
transcription and production of inflammatory mediators such as tissue factor in
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HUVECs has been demonstrated (Haubitz et al 2001). Proteinase 3, another
azurophil granule protease, has also been shown to positively regulate interleukin-8
in HUVECs (Berger et al 1996). The effect ofHNE pretreatment on HUVEC
responses to other inflammatory stimuli was investigated. The presence of several
potentially inflammatory stimuli within atherosclerotic tissue including oxidised
LDL and HNE (Dollery et al 2003) raises the question ofhow cells respond when
exposed to both stimuli. HNE has been shown to cleave surface CD 14 on monocytes
(Le Barillec et al 1999) and fibroblasts (Nemoto et al 2000). This action leads to
reduced inflammatory cytokine production in response to bacterial LPS (Le Barillec
et al 1999; Nemoto et al 2000).The concentrations ofHNE used in these studies were
relatively high (1 pM) and. whereas fibroblasts and monocytes remain intact in these
conditions, HUVECs detach and are lysed rapidly (the disruptive effect ofHNE at
5.0 X 10"8 M on HUVECs is shown in Figure 6.1). HUVECs were pretreated with
concentrations of HNE previously shown to induce IL-8 production and
subsequently exposed to inflammatory stimuli. Even short 1 hour treatments led to
significant increases in HUVEC IL-8 production without further inflammatory
stimuli (Figure 6.6). Pretreatment with HNE dramatically augmented subsequent IL-
8 production in response to oxidised LDL and LPS and there was an overall trend for
higher pretreatment concentrations ofHNE to lead to greater IL-8 release in response
to the same concentration of oxidised LDL or LPS (Figure 6.6). The results indicate
that a brief exposure to HNE (in which no morphological damage was observed, as
evidenced by absence of lifting and rounding of the HUVEC monolayer) not only led
to IL-8 production on its own but also primed the cells for subsequent stimulation by
other inflammatory stimuli.
This result contrasts with the negative actions on LPS signalling observed in
this work (Figure 6.7) and by others with monocytes (Le Barillec et al 1999) and
fibroblasts (Nemoto et al 2000) (with the caveat that the experiments on endothelial
cells in this chapter were performed with 100-fold lower concentrations ofHNE).
The increase in IL-8 production was in excess of the sum of either stimulus alone
indicating a synergistic effect. TNF-a produced a massive IL-8 response that was not
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increased by HNE treatment (Figure 6.6). This result may have reflected saturation
of the cellular IL-8 production machinery by TNF-a. Synergism between HNE,
oxidised LDL and LPS would be expected to lead to concentrated IL-8 production
and a focusing of the chemotactic signal to regions of atherosclerotic tissue where
both stimuli are present. Whereas this may be maladaptive in the context of
atherosclerosis and arterial wall inflammation, synergy between HNE and LPS
would serve a useful purpose in focusing recruitment of leucocytes to areas of
infection where both bacteria and degranulating neutrophils are present.
Having demonstrated the capability ofHNE to stimulate HUVEC IL-8
production, the effects of overexpression of elafin (a potent HNE inhibitor) and IkBoc
(an inhibitor of IL-8 transcription) were examined using adenoviral vectors. Elafin
significantly attenuated IL-8 production in response to HNE alone, HNE in
combination with LPS and, in agreement with data in chapter 5, in response to LPS
alone (Figure 6.7). Ad-lK"Ba similarly reduced IL-8 production to all three stimuli.
This result extends the role of elafin as a suppressor of inflammatory cytokine
production outlined in chapter 5. In addition to neutralising the disruptive effects of
HNE on cell components and the extracellular matrix (Figures 6.1, 6.4) elafin may
also exert anti-inflammatory actions through blocking FINE's facilitatory action on
IL-8 production. That IkBcc overexpression attenuated IL-8 production in response to
HNE, was in keeping with data indicating that HNE mediated IL-8 production in
epithelial cells is through a MyD88 IL-1R associated kinase-TNFR-associated-
factor-6-NF-KB pathway (Walsh et al 2001).The work presented in this chapter along
with recognition of specific cell signalling mechanisms and identification of Toll-like
receptor-4 as a receptor for HNE (Devaney et al 2003) broaden the perceived role of
this inflammatory mediator from an indiscriminate protease cleaving cellular and
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6.3.2. The inflammatory role of HNE on atherosclerotic plaque development.
It is important to consider the relevance of these in-vitro findings to
atherosclerotic plaque biology. The role of a neutrophil derived protein in an
inflammatory process, characterised histologically by a paucity of neutrophils, also
merits further discussion. Several lines of evidence point to a possible role for the
neutrophil and neutrophil derived proteins in the development of atheroma.
Epidemiological studies have repeatedly demonstrated a link between the circulating
leucocyte count and neutrophil differential and the subsequent development of
ischaemic heart disease (Friedman et al 1974; Sweetnam et al 1997). Neutrophils
from patients with advanced atheroma are more reactive and prone to degranulation
(Mohacsi et al 1996). Circulating concentrations ofHNE are higher in patients with
coronary artery disease (Amaro et al 1995; Kosar et al 1998). Perhaps the most
convincing evidence is the observation of neutrophil derived proteins within
atherosclerotic tissue. Large quantities of myeloperoxidase, a major neutrophil
protein, have been identified within atheroma. This enzyme may be an important
mediator of LDL modification within the plaque (Daugherty et al 1994; Hazen et al
1997). Neutrophil granule derived proteins, HNE and a-defensin, have also been
demonstrated directly within human atheroma (Barnathan et al 1997; Dollery et al
2003). The origin of these proteins has not been established. Macrophage production
has been proposed and there is some evidence that macrophages may produce
myeloperoxidase under certain conditions (Sugiyama et al 2001).
Neutrophil granule derived proteins becoming trapped within the neointima
following neutrophil degranulation seems a more likely explanation. Buffon et al
(2002) elegantly demonstrated the capacity for neutrophil degranulation with
myeloperoxidase depletion of neutrophils passing through an inflamed coronary
circulation. HNE is contained within the same azurophil granules as
myeloperoxidase and passage of both proteins into the subendothelial space may
occur following degranulation (Baldus et al 2001). The mechanism of
myeloperoxidase transcytosis across endothelial cells and its dependence on albumin
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and functioning caveolae has recently been elucidated (Tiruppathi et al 2004). Once
trapped within the neointima neutrophil derived proteins may exert their
inflammatory potential. In favour of such a hypothesis is the observation that HNE
can associate with connective tissue in humans (Watanabe et al 1990) and bound
HNE appears to be relatively resistant to inhibition (Morrison et al 1990).
Irrespective of the issues raised above, this chapter provides further evidence for the
inflammatory effects ofHNE on endothelial cells and demonstrates the protective
effect of elafin overexpression. This provided the impetus to examine the effects of
HNE injury on monocyte-derived macrophages. The macrophage has a central role
in plaque development (Glass et al 2001).
6.3.3. Ad-elafin rescues HNE mediated impairment of macrophage-apoptotic cell
recognition
Recognition of inflammatory stimuli and uptake of oxidised LDL or apoptotic
bodies within the plaque depend on functioning surface receptors. Previous work has
demonstrated cleavage of surface CD 14 from HNE treated human peripheral blood
monocytes (Le Barillec et al 1999) leading to reduced TNF-a production in response
to LPS. Following a 1 hour pretreatment with HNE, the responsiveness of peripheral
blood monocyte derived macrophages to LPS was similarly reduced (Figure 6.8).
The reduced TNF-a production was not a result of reduction in viable cell number
following FINE incubation as evidenced by propidium iodide staining and MTS
assay (data not shown). Pretreatment with FINE alone followed by replenishment
with serum containing medium produced a modest rise in TNF-a production (Figure
6.8). Inflammatory activation of a rat alveolar macrophage cell line by human
pancreatic enzymes including pancreatic elastase has previously been demonstrated
(Jaffray et al 2000). Pancreatic elastase increased TNF-a release through a
mechanism that involved NF-kB activation and selective degradation of cytoplasmic
IkB(3. Taken together, these findings suggest that the effect of FINE on macrophage
inflammatory programming is complex, stimulating TNF-a production directly but
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reducing TNF-a production in response to a second LPS stimulus in contrast to a
facilitatory action on endothelial cells (demonstrated earlier in the chapter albeit at
lower concentrations). The evidence presented in this chapter and observations by
others that specific transcriptional pathways are activated by HNE in a range of cell
types (Walsh et al 2001) indicates the possibility of specific receptor interactions.
It is worth comparing the results ofHNE pretreatment on subsequent responses
of endothelial cells and macrophages to inflammatory stimuli. HNE facilitation of a
subsequent LPS or oxidised LDL stimulus in endothelial cells (Figure 6.6) occurred
at concentrations 2 orders less than those associated with cleavage ofmacrophage
CD 14 and reduced LPS responsiveness (Figures 6.9, 6.8 respectively). HUVECS
have very low levels ofCD 14 expression (Jersmann et al 2001) and it is possible that
FINE'S facilitatory action on IL-8 production (at low concentrations) in HUVECs is
occurring through a separate signalling pathway. Interest in HNE as a ligand for
specific surface receptors has identified several candidates. FINE in a covalently
stabilised complex with its inhibitor a 1-antitrypsin is recognised by the serpin-
enzyme complex (SEC) receptor (Perlmutter et al 1990). The SEC receptor
transduces the chemotactic activity ofHNE-al antitrypsin complexes on neutrophils
(Joslin et al 1992). In addition, integrin CDllb/CD18 (Cai et al 1996) on neutrophils
and Toll-like receptor 4 (TLR4) on human bronchial epithelial cells (Devaney et al
2003) have been proposed as surface receptors for HNE. Toll-like receptors take part
in immune and inflammatory responses recognising microbial components with
activation of innate immune responses leading to development of adaptive immune
responses (Medzhitov et al 2000). TLR4 has been identified as a receptor for
bacterial LPS (Chow et al 1999; Hoshino et al 1999). HNE incubation led to
increased IL-8 release from human bronchial epithelial cells and human embryonal
kidney cells transfected with TLR4 at a similar concentration (50 nM) to that used on
HUVECs in this chapter (Devaney et al 2003). In contrast to the results for HUVECs
in Figure 6.6, Dr Devaney found that pretreatment with FINE led to reduced IL-8
production in response to a subsequent LPS stimulus. This was attributed to
internalisation or cleavage of TLR4 following interaction with HNE and was
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Figure 6.13. Inflammatory mechanisms of HNE, LPS and oxidised LDL
Key to Figure 6.13
IRAK: Interleukin-1 receptor associated protein kinase. TRAF: tumour
necrosis factor receptor associated factors. NIK: NF-kB inducing kinase. IKK: IkB
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Figure 6.13. Inflammatory mechanisms of HNE, LPS and oxidised LDL
(continued)
This diagram illustrates the relationship between HNE, LPS and oxidised LDL
signalling. HNE may stimulate IL-8 production directly through interaction (1) with
TLR4 (Devaney et al 2003) and activation of the Myd88-IRAK-TRAF pathway
(Walsh et al 2001). LPS attached to its circulating binding protein (not shown), binds
to CD 14 and this complex interacts with TLR4 on the membrane surface producing a
pro-inflammatory signal (Chow et al 1999). CD 14 also participates in apoptotic cell
recognition (not shown), an integral process for inflammatory resolution (Devitt et al
1998). Oxidised LDL binds to scavenger receptors and activates NF-kB through up¬
stream MAP kinases (Li et al 2003). FINE has an extensive list of substrates
including extracellular matrix proteins (2) and intercellular cadherins (3) (reviewed
by (Lee et al 2001). Disruption of these attachments leads to cell rounding, retraction
and lysis (4). HNE also cleaves a range of cell-surface proteins and receptors (5)
including CD 14 (Lee et al 2001; Vandivier et al 2002). The current work confirms
observations by others that pretreatment with HNE reduces LPS responsiveness (Le
Barillec et al 1999) and apoptotic cell recognition (Vandivier et al 2002) in
monocyte-macrophages. The work in this chapter also demonstrates enhanced IL-8
production in endothelial cells in response to LPS and oxidised LDL following
pretreatment with HNE (Figure 6.6). The mechanism involves activation ofNF-kB
(Figure 6.7), occurs at lower concentrations ofHNE than those associated with CD14
cleavage and may involve facilitation of surface or intracellular signalling pathways
by HNE or synergy between HNE-TLR4 and oxidised LDL or LPS signals.
Chapter 6
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proposed as a mechanism for desensitisation to LPS signalling (Devaney et al 2003).
The concentrations of LPS used to stimulate HUVECs and human bronchial
epithelial cells were different (100 ng/ml and 20 pg/ml respectively) in the two
studies. In addition, the duration ofHNE pretreatment was longer for human
bronchial epithelial cells (4 h compared to 1 h in HUVECs) and this may have
resulted in alterations in intracellular signalling such as the inhibition of LPS induced
NF-kB activation in monocytes that has been described following pre-incubation
with oxidised LDL (Brand et al 1997a). Figure 6.1 summarises putative receptor-
signalling pathways for HNE, LPS and oxidised LDL and illustrates the potential for
crossover and interaction between these pathways.
HNE reduced surface expression of CD 14 on human macrophages (Figure
6.10) in accordance with its action on other cell types (Le Barillec et al 1999;
Nemoto et al 2000). CD14 was previously considered only as a receptor for bacterial
LPS (Ulevitch et al 1995). More recently CD 14 has been shown to be involved in the
resolution phase of the inflammatory response, by acting as a cell surface receptor
for apoptotic cells (Devitt et al 1998). Macrophages are important phagocytic cells
involved in the recognition and removal of apoptotic cells, an integral process in the
resolution of the inflammatory response (Savill et al 2002). Recent data have
suggested that LINE, through cleaving key receptors, is responsible for the
impairment of apoptotic cell recognition by macrophages in inflammatory diseases
(Vandivier et al 2002). Although the list of receptors involved in apoptotic cell
recognition is increasing rapidly (Savill et al 2000) only the phosphatidylserine
receptor and CD 14 have previously been shown to be inactivated by HNE (on
macrophages and monocytes, respectively). Importantly, Vandivier et al (2002)
demonstrated that CD36 and CD32 expression and function were intact following
FINE treatment of human monocyte derived macrophages.
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Having established the disruptive activity ofHNE on macrophage CD 14
(Figure 6.9), a gene therapy strategy was devised to protect macrophages from HNE-
mediated shedding of CD 14 using Ad-elafin. The protocol to facilitate adenoviral
gene delivery to macrophages developed in chapter 5 was used to achieve high levels
of gene expression. Ad-elafin attenuated the decline in macrophage CD 14 levels
following HNE treatment compared to uninfected or control virus infected cells
(Figure 6.10). The preservation of CD14 expression was striking (Figure 6.10E)
although as reported in the results section, the quantities of elafin produced would be
expected to neutralise only approximately 5% of the HNE added. Examination of
residual supernatant HNE activity following the experiments demonstrated a modest
but statistically significant 20% decline in HNE activity from Ad-elafin wells
compared to Ad-dl703 or uninfected cells (Figure 6.11, columns d and f). It is
possible that elafin was bound to the extracellular matrix (Nara et al 1994) and that
the concentration of elafin within the supernatants did not accurately reflect the
quantity of active elafin present. This possibility could be explored by examining the
elafin content of cell lysates and immunostaining of the macrophage cultures to look
for evidence ofmatrix bound elafin.
An important question following on from these results was whether Ad-elafin
could protect macrophages from the HNE mediated impairment of phagocytic
function demonstrated previously (Vandivier et al 2002). In order to investigate this
further, a model of apoptotic cell clearance had to be established. A variety of cells,
such as lymphocytes and neutrophils are routinely used in experimental systems as
apoptotic target cells. Group I Burkitt lymphoma cells (Mutu I) were chosen over
neutrophils because of the absence of endogenous elastase in the former, which could
have interfered with the assay (Henriksen et al 2004). Macrophages were either
untreated/uninfected (control) or infected with Ad-elafin (Ad-dl703 as a control) and
incubated, where indicated, with FINE. In a variation of these experiments, the CD 14
blocking antibody 61D3 (Devitt et al 1998) was used to provide a positive control of
CD 14 blockade. Figure 6.12 shows that FINE treatment of uninfected cells inhibited
Mutu cell recognition by 54%, compared to uninfected cells alone. This level of
236
Chapter 6
Chapter 6: Gene delivery of elafin reduces HNE mediated injury
inhibition was comparable to that of 61D3 treatment. The prominent role of CD14
(the 61D3 antigen) for interaction and initial tethering of apoptotic Mutu cells with
human macrophages has previously been characterised (Flora et al 1994). Blocking
antibodies and peptides against the avP3 integrin (Vitronectin receptor) and CD36
produced little if any reduction of apoptotic Mutu cell interaction in this system
(Flora et al 1994). Interestingly, when 61D3 and HNE were used in combination
(Figure 6.12), a further decrease in recognition occurred, suggesting that the sites of
action of 61D3 and HNE are not identical. It is likely that in addition to cleaving
CD 14 (figure 6.9). HNE is interfering with additional (unidentified) surface receptors
in our system and notably the degree of inhibition never approached 100% even with
61D3 and HNE together. HNE cleavage of the phosphatidylserine receptor was
associated with reduced ingestion of apoptotic Jurkat cells by human macrophages
(Vandivier et al 2002) and the role of phosphatidylserine receptor cleavage in
reducing interaction in the experiments in this chapter is unknown.
When recombinant elafin was added extracellularly with HNE, macrophage
recognition was restored to normal values. Similarly, when macrophages were
transfected with Ad-elafin, prior to HNE challenge, a very significant increase in
macrophage recognition of apoptotic cells was obtained, compared to uninfected
cells and cells infected with Ad-dl703 demonstrating the elafin transgene specific
effect.
These results demonstrate that gene expression of elafin in macrophages
partially rescues their capacity to recognise apoptotic cells in the presence ofHNE.
The mechanism of elafin involves neutralisation of HNE activity and preserved
expression of recognition receptors including CD 14 (Figure 6.10). The discrepancy
between the degree ofHNE inhibition (Figure 6.11) and the preservation ofCD14
expression and apoptotic cell recognition (Figures 6.10E and 6.12) in Ad-elafin
infected macrophages has been discussed earlier. In contrast to Ad-elafin infected
macrophages, recombinant elafin produced complete neutralisation ofHNE activity
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(Figure 6.11) although there was little difference in apoptotic cell recognition activity
between Ad-elafm and recombinant elafin treated cells (Figure 6.12). CD 14
expression was reduced but still significantly higher in Ad-elafin infected
macrophages compared to control cells (Figure 6.10) despite the modest inhibitory
effect on supernatant HNE activity (Figure 6.11).
These important discrepancies are not fully explained from the data presented.
It may be that measurements of residual HNE supernatant activity do not reflect its
activity at the macrophage surface. Elafin's propensity to bind to matrix components
(Nara et al 1994) laid down by macrophages may produce an effective 'local' anti-
HNE shield. At first sight, Ad-elafin's action on apoptotic cell recognition does not
appear to be related to a direct effect of elafin overexpression in macrophages
because apoptotic cell recognition was not increased in Ad-elafin infected cells
compared to uninfected cells in the absence ofHNE (Figure 6.12). This finding does
not exclude the possibility that overexpression of elafin with its anti-inflammatory
actions, outlined in the earlier chapter, confers a beneficial signal to apoptotic cell
recognition in the context ofHNE injury.
In addition to removing cells before they undergo lysis, ingestion of apoptotic
cells by macrophages results in potent anti-inflammatory and immunosuppressive
effects through the production of anti-inflammatory cytokines such as Transforming
growth factor (TGF-pl) and Prostaglandin E2 and the suppression of release of pro¬
inflammatory IL-8, TNF-a and thromboxane A2 (Fadok et al 1998; Voll et al 1997).
Elafin and mSTPI overexpression were both shown to suppress LPS induced TNF-a
production by macrophages in chapter 5. In restoring apoptotic cell recognition in the
context ofHNE injury, elafin overexpression would reinforce the endogenous anti¬
inflammatory phenotype conferred by binding of apoptotic cells (Huynh et al 2002)
to macrophages that may otherwise be diminished by HNE.
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The recent finding that SLPI production is upregulated following macrophage
recognition of apoptotic cells is of particular interest (Odaka et al 2003). The slow
kinetics of production after the apoptotic cell recognition event suggests that SLPI is
unlikely to act in vivo at an autocrine level during the onset of the interaction but
rather in a paracrine fashion, during phagocytosis of incoming cells (Odaka et al
2003).
The work presented in this chapter sheds light on the extended pro¬
inflammatory effects of HNE on endothelial cells and macrophages. The ability of
Ad-elafin to rescue endothelial cells from HNE injury and inflammatory signalling
has been demonstrated. Ad-elafin also rescues macrophages from an HNE-induced
pro-inflammatory to an anti-inflammatory phenotype, favouring apoptotic cell
recognition and clearance. These findings raise two exciting possibilities. Firstly, the
potential for systemic delivery of macrophages transfected ex-vivo with anti¬
inflammatory genes. This approach has been demonstrated in murine
glomerulonephritis (Kluth et al 2001; Zernecke et al 2001) and this methodology
may prove useful in inflammatory conditions where direct use of adenovirus gene
vectors is precluded because of their intrinsic immunogenicity. Secondly, the data
further strengthen the case for targeted overexpression of elafin within arterial
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CONCLUSION AND FUTURE DIRECTIONS
The experiments described in this thesis have illustrated the utility of
modelling atherosclerotic endothelial cell injury using cultured human umbilical vein
endothelial cells. Incubation with oxidised LDL led to production of the
inflammatory chemokines IL-8 and MCP-1 and activation of the inflammatory
transcription factor NF-kB. These findings parallel changes observed in endothelial
cells within atherosclerotic coronary arteries.
Gene expression profiling using commercial nylon miniarrays was performed
on oxidised LDL treated endothelial cells. Limitations of this approach were
encountered including the finding that a large majority of genes varied little in
expression between different treatment conditions. Reproducibilty between
hybridisations was poor for many genes emphasising the importance of a robust
array platform and use of repeat hybridisation that was not feasible with the nylon
miniarrays.
Angiopoietin-2 was the only target form the array experiments successfully
verified using ribonuclease protection assays and semiquantitative PCR. Production
of this angiogenic factor was increased in HUVECs incubated with oxidised LDL
and TNF-a and intense expression was seen within the neointima of atherosclerotic
plaques. Additional possible stimuli for angiopoietin-2 production include VEGF and
a relatively hypoxic microenvironment within the plaque. The process of neointimal
angiogenesis contributes to plaque growth through providing a plexus of blood
vessels facilitating passage of inflammatory cells and mediators within the
neointima. Angiopoietin-2 expression might be expected to confer leakiness and
these vessels are prone to bleeding. Both properties may give rise to (sudden) plaque
expansion or rupture. In animal models, VEGF infusions are associated with
accelerated plaque growth and increased plaque density of endothelial cells and
macrophages (Celletti et al 2001). Similarly, treatment with angiogenesis inhibitors
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attenuates plaque growth (Moulton et al 1999). These findings have led to concerns
that attempts to increase angiogenesis within ischaemic tissues using direct or genetic
delivery of angiogenic factors may cause plaque expansion or destabilisation.
Whereas these concerns have not been realised in the clinical trials, the contribution
of neointimal angiogenesis to plaque growth and complications is significant and
further understanding of mechanisms driving new vessel formation and factors
governing their integrity within the atherosclerotic plaque are important goals.
Gene expression profiling failed to identify a candidate athero-protective
mediator and focus therefore turned to elafin, a pleiotropic anti-inflammatory
antiprotease previously identified within human atherosclerotic coronary arteries.
The effects of adenoviral overexpression of elafin were examined. Development of a
simple protocol involving precomplexing adenoviral vectors with lipofectamine
enhanced gene delivery to endothelial cells and facilitated gene delivery to human
macrophages, a notoriously difficult cell type to transfect. The mechanism of
improved gene delivery was not examined in detail but may involve improved uptake
of virus. Methods to augment adenoviral gene delivery in vivo are attractive through
reducing viral dosing and toxicity. Previous work employing adenovirus in complex
with calcium precipitates has demonstrated enhanced delivery of adenovirus to the
murine airway epithelium and the work here indicates that in vivo studies examining
the effects of adenovirus in complex with lipofectamine, a relatively non-toxic lipid,
would be valuable.
Overexpression of elafin and the related protein SLPI led to reduced
inflammatory cytokine production in response to atherogenic stimuli by human
endothelial cells and macrophages. This activity was associated with inhibition of
NF-kB activation and preservation of the inhibitory IkBcx, subunit. Overexpression of
elafin also protected endothelial cells form HNE mediated injury and inflammatory
cytokine production. Elafin protected macrophages from TINE mediated disruption
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of surface CD 14 expression and this was associated with preserved interaction of
apoptotic cells following HNE injury.
These experiments expand our understanding of elafln and SLPI biology,
firmly identifying them as powerful modulators of inflammation with properties
extending beyond neutralisation ofHNE and other proteases. The findings leave
several important questions and avenues for further research.
The mechanism of elafin and SLPI upregulation of IkBcc has not been
identified at the molecular level. Although both proteins have well defined roles as
secreted antimicrobial and antiprotease agents, our results identified an additional
intracellular mode of action, possibly interfering with IkBoc degradation through
blockade of the proteosome. This work did not include control experiments with
exogenously added elafin and SLPI although similar experiments performed on other
cell types within our group failed to show broad ranging cytokine inhibition with
addition of recombinant elafin and SLPI to the culture medium. Analysis of mutated
proteins has pointed strongly to an intracellular mode of action for SLPI requiring
antiprotease activity (Zhu et al 1999) and similar confirmatory experiments with
elafin should be performed. The selectivity of elafin and SLPI blockade of
inflammatory cytokines following overexpression and whether it is truly cell type
specific merits further investigation (indeed, no anti-inflammatory effect was
observed in epithelial cells). Study of a potential elafin and SLPI interaction with
proteosomal subunits would be a logical starting point.
The ability of elafin overexpression to preserve macrophage surface CD14
expression and interaction with apoptotic cells was striking compared to the
relatively modest inhibitory effect against the concentrations ofHNE used, further
analysis of cell lysates from elafin infected macrophages may provide information on
matrix bound elafin, not measured in the supernatants but contributing to a local
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HNE shield. Although there was no suggestion of heightened apoptotic cell
recognition or increased CD 14 expression in elafin expressing macrophages, the
possibility that elafin confers a pro-apoptotic cell recognition message in the context
ofHNE injury was not excluded. Future work should examine the expression and
activity of other apoptotic cell recognition receptors.
Finally, the in vitro biological effects of elafin and SLPI beckon the question of
whether gene delivery could modulate the development of atherosclerosis in vivo.
Several murine models of atherosclerosis exist and a direct extension of this work
would be to examine systemic delivery of Ad-elafin and Ad-mSLPI through tail vein
delivery in mice. Subsequent hepatic expression would be expected to augment
circulating levels of elafin and SLPI and the effect of transient increases in
production on atherosclerotic plaque progression could be examined. If the anti¬
inflammatory effect is dependent on intracellular expression and cannot be achieved
by remote production then targeting of viral vectors to atherosclerotic endothelium
could be employed. This question could also be addressed with transgenic lines given
the availability of mice expressing elafin under the control of the mCMV (Sallenave
et al 2003) and endothelin (Zaidi et al 1999) promoters.
In conclusion, the findings described in this thesis have added to our
understanding of neointimal angiogenesis by identifying oxidised LDL as a stimulus
for endothelial cell production of the angiogenic factor angiopoietin-2 and
demonstrating intense expression of this angiogenic factor within human
atherosclerotic plaques. An extended role for elafin and SLPI in the innate immune
response has been identified. Adenoviral overexpression of these proteins suppressed
NF-kB activation and inhibited inflammatory cytokine production in endothelial
cells and macrophages. These properties suggest a therapeutic potential for
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Abstract
The number of cardiovascular publications featuring gene expression profiling technologies is growing rapidly. This article introduces
four profiling techniques; serial analysis of gene expression, differential display, subtractive hybridisation and DNA microarrays.
Illustrations of their application towards cardiovascular research are given and their potential for gene discovery and improving our
understanding of gene function is discussed. © 2002 Elsevier Science B.V. All rights reserved.
Keywords: Gene expression; Sequence (DNA/RNA/prot)
1. Introduction
Despite intensive studies, the mechanisms behind com¬
mon cardiovascular diseases such as hypertension and
atherosclerosis are poorly understood. The precise combi¬
nation of environmental and genetic factors responsible for
these disorders may vary between patients, producing
phenotypically similar manifestations but requiring differ¬
ent interventions to correct them. More detailed characteri¬
sation of pathological processes at the molecular and
cellular levels will enhance understanding of underlying
mechanisms. Cellular phenotype is determined to a large
extent (although not completely) by the set of proteins that
are expressed in the cell. Ideally a description of cellular
phenotype would include information on every protein
expressed, its intracellular localisation, and biological
activity. This task is beyond the reach of current ex¬
perimental techniques. New methodologies have provided
the opportunity to analyse and in some cases to quantify
simultaneously, thousands of messenger RNA (mRNA)
transcripts. This type of analysis has been termed gene
expression profiling [1], Databases generated by genome
sequencing programs, have facilitated the identification of
genes by relatively short sequences within their transcripts
and global expression profiling in simple organisms like
'Corresponding author. Tel.: +44-131-651-1194; fax: +44-131-650-
6527.
E-mail address: yuri.kotelevtsev@ed.ac.uk (Y. Kotelevtsev).
yeast has yielded information on the regulation of gene
expression in response to different stimuli [2], Medical
researchers are now using expression profiling to sys¬
tematically characterise molecular events pertaining to
complex multifactorial diseases. Serial analysis of gene
expression (SAGE), differential display, subtraction sup¬
pression hybridisation, and DNA microarrays are four
major methods used for expression profiling.
This review aims to provide an introduction to these
methods and gives illustrations of their application towards
cardiovascular research. We examine the potential for gene
discovery and highlight the limitations. The number of
cardiovascular publications describing expression profiling
strategies is growing rapidly and some of these have been
reviewed recently [3-5].
2. Methods used for expression profiling
2.1. Serial analysis of gene expression
SAGE is a technique for determining mRNA expression
levels by sequencing cDNA molecules produced by re¬
versed transcription [6], The method is based on tagging
sequences inside cDNA with specific oligonucleotides
bearing recognition sequences for a restriction enzyme that
Time for primary review 28 days.
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cuts DNA 9-13 bases away from its recognition site. The
next step involves joining these short fragments together in
concatamers. Sequencing several thousand cloned con-
catamers comprising 20-30 tags and scoring the sequences
corresponding to each mRNA provides a direct measure of
mRNA abundance in a given sample.
For known genes, the 9-10 base pair oligos are often
sufficient for identifying the cDNA of origin using Gen-
Bank. Although SAGE can be performed with small
amounts of starting mRNA, the quantity of sequencing
required and difficulty in reproducing protocols for con-
catamer formation have limited its uptake as an expression
profiling technique. A detailed review of SAGE meth¬
odology is given elsewhere [7],
2.2. Differential display
Differential display will detect mRNA sequences that
are absent or expressed at very low levels in one sample in
comparison with another. This technique is therefore
limited to detecting large variations in the amount of
mRNA present. The first step involves reverse transcrip¬
tion with an oligo (dT) primer ending with C, G or A at
the 3' end [8], This splits the resulting cDNA sample into
three pools according to the final primer nucleotide and
these are amplified in a polymerase chain reaction (PCR)
with a mix of arbitrary 5' primers designed to yield several
hundred PCR products. Radionucleotides are incorporated
during the reaction and the PCR products are resolved by
electrophoresis on a polyacrylamide gel. Bands present in
one sample that are absent from another are candidates for
differentially expressed genes. This method is relatively
simple and has the advantage of facilitating comparison of
most cDNAs from a given cell type using several 5'
arbitrary primer combinations and small samples of
mRNA. Detected bands are anonymous and therefore
require purification, subcloning and sequencing. The PCR
step generates a significant rate of false positives based on
Northern blot analysis and although modifications may
reduce this problem [9], differential display has largely
been superseded by the development of more sensitive
techniques below.
2.3. Subtraction suppression hybridisation
This approach improves sensitivity for low abundance
transcripts by 'equalising' their concentration with high
abundance transcripts through a hybridisation step [10,11],
Two cDNA populations termed 'tester' and 'driver' are
made using reverse transcription from the two mRNA
samples to be compared. The tester cDNA is split further
into two pools and two different oligos containing motifs
that can be recognised by special primers are ligated onto
the 5' ends. Through a serious of hybridisation steps,
sequences equally represented in the 'tester' and 'driver'
populations are subtracted out leaving differentially ex¬
pressed sequences that can be amplified by PCR using
primers complementary to the attached oligos. As with
differential display the final PCR product may be sub-
cloned for sequencing and compared to Gen-Bank de¬
posited sequences. The technique is not demanding in
terms of resources and can lead to identification of novel
genes. It is not however, suited to systematic profiling
owing to difficulties in standardising the hybridisation
steps and the high rate of false positives [12],
2.4. Microarrays
Microarrays facilitate parallel quantification of
thousands of specific mRNAs in a sample through hybridi¬
sation to complementary sequences placed at specified
positions on glass or silicon supports [1,13], In contrast to
differential display and subtractive hybridisation the se¬
quence of the target gene or expressed sequence tag (EST)
is known. Recently, two different techniques for high
density spotting of DNA molecules on glass or silicone
surfaces became available. One format involves robotic
deposition of PCR fragments amplified from cDNA clones
and was developed at Stanford University [13]; 10 000
genes may be arrayed on a compact area of 3.6 cm".
Affymetrix apply an alternative approach based on photo¬
lithographic synthesis of oligonucleotides in situ. Ultra¬
violet light is used to direct base by base synthesis, in
parallel, for up to 400 000 oligos on one silicone chip [14],
Specific oligo design allows the user to avoid regions of
repetitive or homologous sequence between different
genes. Microarrays work on a reverse principle to Northern
blot analysis. Instead of labelling a specific cDNA probe
and hybridising to a pool of mRNAs immobilised on a
membrane, a pool of labelled mRNAs is hybridised to
numerous cDNA probes immobilised on a solid support in
specific positions. The cDNA populations from two ex¬
perimental samples are labelled with different fluorescent
dyes and hybridised to the same microarray allowing direct
comparison of signal intensity. Smaller amounts of RNA
are required for the analysis of a greater number of genes
than is possible with Northern blotting without a big loss
of sensitivity. In one study comparing the two methods, a
microarray was able to detect 90% of the expression
changes demonstrated in one sample by Northern blotting
[15], Microarray technology is expensive to set up but
expression profiling has become possible for many re¬
search groups through the development of centralised
facilities within academic institutions and the availability
of commercial microarrays.
The array fabrication technique is critical for producing
high resolution and minimising background 'noise' and
cross hybridisation signals. For cDNA arrays, signals vary
depending on the slide surface and spotting buffer and the
temperature and humidity during array printing [16],
Robotic systems for microarraying are commercially avail¬
able and the design of the original robot at Stanford
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University is available online (http://cmgm.stanford.edu.p-
brown/mguide/index.html). Following hybridisation and
image processing the data must be normalised to adjust for
labelling and detection efficiencies for different fluorescent
labels and differences in the quantity of starting RNA
between samples. Normalisation strategies (reviewed in
Ref. [16]) include correcting for total intensity by assum¬
ing that although fluorescence varies between individual
transcripts, this should even out over many thousands and
be identical for the same quantity of RNA labelled with
two different fluorescent markers. A second approach
utilises the signal ratio of the gene of interest to that of
housekeeping genes (the expression levels of which are
assumed not to vary between samples). A third uses the
fact that the predicted slope of a scatterplot of housekeep¬
ing and added equimolar controls for the two probes
should be unity. The data can be rescaled using this slope
with regression analysis.
The data of hybridisation experiments with cDNA arrays
can be presented as a matrix of fluorescent intensities, each
value corresponding to a spot on the microarray. In a given
matrix, rows may represent genes and columns may
represent cDNA samples. In a simple analysis there will be
only two columns comparing gene expression in two
different samples. This is the commonest form of data
presentation, particularly for clinical specimens. Experi¬
ments in cell culture may involve different treatments with
extended time points. More detailed analysis of the re¬
sulting vast data sets may help to uncover common
mechanisms of gene regulation or improve functional
understanding by grouping expression changes in terms of
time and magnitude or according to designated gene
function groups. Algorithms comparing the data between
rows (genes) and columns (samples) have been developed.
Once a measure of similarity (or distance) between in¬
dividual gene profiles has been assigned, these may be
divided into groups or clusters. Brazma et al. [17] have
provided a comprehensive review of clustering algorithms
in the analysis of expression data. Clustering was first
described by DeRisi et al. [2], who discovered that genes
with similar expression profiles during metabolic shift in
yeasts were functionally related and shared transcription
factor binding sites in their promoter regions.
3. Applications of gene expression profiling to
cardiovascular disease
An overview of recent cardiovascular publications using
gene expression profiling is provided in Table 1 where
studies are classified according to disease model, ex¬
perimental sample and profiling method.
3.1. Atherosclerosis and endothelial dysfunction
3.1.1. Celt culture models
The above techniques have wide applications in the
study of developmental and pathophysiological processes
in the cardiovascular system. Difficulties may arise in the
interpretation of gene profiles from tissues containing
multiple cell types and this may be circumvented in part by
using cell culture models described below.
Gimbrone's group used differential display to isolate
genes that are up-regulated in cultured endothelial cells
(ECs) in response to laminar or turbulent flow shear stress
[18], The genes for manganese superoxide dismutase and
cyclooxygenase-2 (COX-2) were up-regulated in cells
exposed to laminar shear stress and these findings were
confirmed by Northern blotting. Importantly, the inves¬
tigators confirmed that enhanced gene expression was
translated into increased protein synthesis by immuno-
blotting. The contribution of turbulent flow to endothelial
dysfunction and atheromatous plaque development at
'lesion prone areas', such as arterial bifurcations and
curvatures, is well established. The putative protective
effects of an antioxidant enzyme and prostacyclin (the
major product of endothelial COX-2), induced by laminar
shear stress are particularly interesting in this regard. The
failure of differential display to detect enhanced expression
of endothelial cell nitric oxide synthase (demonstrated by
Northern analysis) in ECs exposed to laminar flow illus¬
trated the limited sensitivity of this technique. The in¬
fluence of mechanical stimuli has also been studied on
vascular smooth muscle cells grown on fibronectin coated
supports using cDNA microarrays [19], Only a handful of
the 5000 genes monitored at two time points after the onset
of mechanical stretch varied by more than the 2.5-fold
threshold change in expression set by the investigators.
Applying this threshold may facilitate more reproducible
results although the majority of genes varied by less than
2-fold in their expression and quantitatively small but
functionally important changes in expression may have
been overlooked. Plasminogen activator inhibitor-1 (PAI-
1) and Tenascin-C were induced following stretch. These
findings were confirmed with Northern blotting, ELISA
and Western blotting for corresponding changes in mRNA
and protein production. PAI-1 secreted within the vascular
wall may regulate extracellular matrix proteolysis and
vascular repair. Tenascin-C is also prominent in remodel¬
ling tissues and has anti-adhesive properties. The func¬
tional impact of these mediators on the atherosclerotic
plaque is harder to predict. Expression of PAI-1 may act to
strengthen the surrounding extracellular matrix and could
render a fibrous cap less prone to rupture. It may also
favour the accumulation of matrix and subsequent plaque
growth. Whether a stretch stimulus applied to ECs growing
in a monolayer reproduces the mechanical environment of
a vessel wall is also questionable and studies on ex vivo
vessel preparations would be instructive.
Oxidised low density lipoprotein (Ox-LDL) is another
central influence in atherosclerotic plaque development.
Monocytes become engorged with cholesterol within the
plaque forming foam cells and this process has been
modelled by incubating the monocytic THP-1 cell line
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Table 1
Summary of recent applications of expression profiling to cardiovascular disease
Examples of genes identified
by expression profiling
Sample type and method of expression profiling Ref.





Early growth response gene-1 (Egr-1) and Egr-1
inducible genes: 1CAM-1, CD44, TNFa, IL-2,
PDGFa, TGF-pl and TGF-(32 were more highly
expressed within the fibrous cap compared to the
adjacent media.
T expression of IL-8, MCP-i, VCAM-1, PA1-I,
VE-cadherin and Gro-a in activated compared to
quiescent ECs
T expression following incubation with oxidised
LDL: adipophilin, heparin-binding epidermal growth
factor like growth actor, thrombomodulin, CD73 and
nuclear receptors LXRa, RXRa and PPAR-y.
i expression: CD 64, carbonic anhydrase,
cytochrome 6-245 and Rnase A2
T expression of plasminogen activator inhibitor 2
in both monocytes from patients with Lipoprotein (a)
hyperlipidaemia and healthy donor monocytes
incubated with plasma lipoprotein (a).
T expression in Chlamydia-'mfected cells: IL-8, IL-1(3,
bFGF, PDGF-(3, MCP-1 and IFN-a receptor.
T expression of the chemokine, eotaxin
following TNFa treatment.
T expression: manganese superoxide dismutase and
cyclooxygenase-2 in response to laminar shear stress.
T expression with strain: cyclooxygenase-1, tenascin-C
and plasminogen activator-1. I expression of matrix
metalloprotease-1 and thrombomodulin.
Identification and cloning of gene 2A3-2, homologous
to human translational elongation factor in highly
proliferating vascular smooth muscle cells.
T expression in restenotic tissue: thrombospondin-1,
heat shock protein B, cyclooxygenase-1 and FK506
binding protein-12. i expression of desmin and
mammary derived growth inhibitor.
Texpression following ischaemia-reperfiision: inhibitor
of apoptosis (IAP), PAI-1, PAI 2, heat shock proteins
70, 28 and 22, elongation Factor la and connective
tissue growth factor.
T expression following myocardial infarction: fibronectin,
laminin, fibrillin, fibulin and decorin. TIMP 2 and
osteoblast-specific factor 2.
i expression: CD36, lipoprotein lipase and long
chain acyl-CoA synthase.
The ACE inhibitor captopril, normalised the increased
expression of monoamine oxidase and cytochrome P450
following myocardial infarction and reduced the induction
of thrombospondin-4 and TGF binding protein-2
like protein.
T embryonal expression compared to healthy adult
myocardium: ANP, BNP, fibronectin and collagen III,
osteopontin, superoxide dismutase.
T expression in infarcted myocardium: ANP, BNP,




on a high cholesterol
diet.
SAGE analysis of human ECs
activated with conditioned
monocyte medium.
The human THP-1 macrophage
cell line response to oxidised LDL
was characterised using a DNA array.
Corroborative experiment examining
healthy donor monocytes incubated
in medium containing high Lp(a).
DNA array analysis of a human
micovascular endothelial cell line
response to infection with
Chlamydia pneumoniae.
The response of cultured human
aortic smooth muscle cells to
TNFa characterised using
a microarray.
Differential display analysis of
ECs exposed to laminar shear stress.
DNA array analysis of human VSMC
responses to biaxial cyclic strain.
Subtractive hybridisation analysis
was employed to compare a highly
proliferating rat VSMC line with
























of a rat model of MI.
DNA array investigation
of ACE inhibition following
MI in rats.
DNA array comparison
of rat embryonal and
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Table 1. Continued
Examples of genes identified
by expression profiling
Sample type and method of expression profiling
Tissue culture In vivo Human derived
Ref.
Heart failure T expression in failing hearts: Gelsolin, myomesin
and ubiquitin.
1 expression in failing hearts: striated muscle LIM
protein-1 (SLIM-1) and al Antichymotrypsin.
Cardiac hypertrophy T expression during induction of hypertrophy: JAK 3
protein tyrosine kinase, vasopressin receptor and
SPARC cystine rich glycoprotein.
i during hypertrophy: PAI-2 and desmoplakin.
T expression during regression of hypertrophy:











with Ox-LDL and comparing expression profiles to un¬
treated cells using microarrays [20], Of the 6805 genes
arrayed, 268 (4%) altered their expression, a minimum of
2-fold, at one of the time points ranging up to 4 days. Data
was presented in clusters according to temporal expression
patterns and results were confirmed using quantitative real
time PCR. In this method, reverse transcribed mRNA is
PCR-amplified with gene specific primers in the presence
of a probe containing a quenched fluorescent dye. The 5'
exonuclease activity of the polymerase is utilised to release
fluorescent dye from the target probe facilitating continu¬
ous monitoring of the reaction against a reference probe
such as 18S RNA. Genes previously demonstrated to be
responsive to Ox-LDL loading of macrophages such as
thrombomodulin, were induced in the THP-1 cells, offer¬
ing some validation of the model. The scavenger receptors
A and CD 36 involved in Ox-LDL uptake were up-
regulated along with nuclear receptors that control lipid
metabolism reflecting a lipid storage phenotype similar to
maturing adipocytes. Vascular smooth muscle cell (VSMC)
behaviour in an atheromatous plaque has been modeled by
treating cultured VSMCs with the cytokine, tumor necrosis
factor a [21], Eotaxin, a chemokine characterised by its
chemotactic properties for eosinophils, was induced more
than 20-fold on a cDNA microarray. Eosinophils are not
present within atherosclerotic plaques and the finding
prompted immunohistochemical studies to localise eotaxin,
which was expressed in plaque smooth muscle cells and its
receptor, present on plaque macrophages and mast cells.
This study demonstrated how transcriptional profiling can
complement traditional, hypothesis driven research through
producing unexpected findings, in this case the presence of
a signalling pathway in atherosclerotic plaques.
The above studies illustrate the contribution expression
profiling can make to the molecular dissection of cellular
responses to specific stimuli. Comparison between differ¬
ent cell lines or cells grown in different matrix environ¬
ments has also provided valuable information. Primary rat
VSMCs were compared to a transformed proliferating rat
VSMC line using differential display [22] in an ingenious
model of smooth muscle cell proliferation occurring during
restenosis. Differential up-regulation of one of the isolated
clones was confirmed by in situ hybridisation in rat carotid
arteries following angioplasty but the full gene could not
be identified from the 3' sequence alone. Further cloning
steps were required to determine the full sequence that had
homology with human translational elongation factor,
coding for a protein involved in protein synthesis.
Finally, coordinating expression profiling with gene
mapping led to the identification of the Tangier disease
gene coding for the ABC1 transporter [23]. Cells from
subjects with Tangier disease are defective in the process
of apolipoprotein mediated removal of cholesterol and
phospholipids. Microarrays were used to compare gene
expression in fibroblasts from Tangier patients with heal¬
thy controls under conditions known to induce cholesterol
efflux. Probing of samples from three patients identified
several under expressed genes including one that mapped
to a large genetic locus independently characterised by
positional cloning. The confirmation of point mutations in
this gene in Tangier patients, the absence of mutations in
healthy controls and the observation that overexpression of
ABC1 resulted in enhanced cholesterol efflux indicated
that ABC1 is the Tangier genetic defect.
3.1.2. Analysis of atherosclerotic tissue
Expression profiles from cell culture models of re¬
stenosis and atherosclerosis have led to the identification of
novel genes and the demonstration of their expression in
clinical specimens and tissue samples from animal models
of these diseases. Flowever, complex interactions between
multiple cell types and matrix are lost with in vitro systems
and further information may be gained by summative
expression profiles obtained directly from animal model
tissues or clinical specimens. The complexity of expression
profiling of patient tissue samples is compounded by the
additional variables of different genetic backgrounds,
aetiology of underlying disease and preceding drug treat¬
ments.
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Profiling of human atherosclerotic plaques is limited by
the availability of tissue. To overcome the technical
problem of limited mRNA, novel methods of cDNA
amplification have been applied [24] to use cDNA arrays
to probe neointimal tissue obtained following atherectomy
of in-stent restenosis. This study highlighted the problem
of choosing an appropriate control tissue to compare
against neointimal tissue. Tunica media samples form
coronary and gastrointestinal arteries were taken as con¬
trols and observed differences may therefore not be
specific to the process of restenosis that was the target of
the study. Carotid endarterectomy samples consist of larger
pieces of tunica media gouged from the arterial wall during
revascularisation. cDNA array profiling identified heig¬
htened activity of the Early growth response gene-1 (Egr-
1) transcriptional pathway in these lesions compared to
media from non-diseased arteries [25], Egr-1 modulates a
group of stress responsive genes including platelet-derived
growth factor and transforming growth factor (3 that may
contribute to plaque growth and smooth muscle cell
recruitment. A fundamental role for this pathway in
atheroma development was suggested by the additional
finding of Egr-1 activation in early atherosclerotic lesions
from cholesterol fed LDL receptor knockout mice.
3.2. Heart failure
The heart is an organ with areas of regional specialisa¬
tion, composed of multiple cell types including car-
diomyocytes, fibroblasts, endothelial and neuroendocrine
cells. Expression profiles from diseased myocardium will
therefore reflect the response from these different cells
types as well as leucocytes recruited during inflammatory
processes. Yang et al. [26] compared expression profiles
from end stage heart failure patients suffering from is-
chaemic cardiomyopathy and dilated cardiomyopathy to
non-diseased myocardium. The authors argued that com¬
paring end-stage heart failure myocardium with different
underlying aetiologies would identify shared expression
profiles that may be fundamental to the failing myocar¬
dium. Only 12 of 7000 arrayed genes were identified with
similar expression changes in both types of heart failure in
addition to five genes expressed uniquely in failing and
two genes expressed in non-failing hearts. Shared changes
included functional themes such as reduced expression of
the structural and contractile proteins (3-actin and striated
muscle LIM protein-1. It is not clear to what degree the
lack of similarity between heart failure specimens repre¬
sented different underlying disease aetiology, severity or
other variables. Expression profiles are meaningful only in
the context of experimental conditions in which they have
been measured. In order to apply this technology to human
specimens, new methods of detailed characterisation and
annotation of the clinical background will be needed to
compare results between centres.
3.3. Cardiac hypertrophy
Cardiac hypertrophy is characterised by alterations in
cardiomyocyte metabolism, contractile proteins and the
extracellular matrix. It may result from a familial disorder
or occur as an adaptive response, following stresses such
as haemodynamic overload and myocardial infarction
(MI). Hwang et al. [27] compared EST frequency between
three pooled human hypertrophic ventricle cDNA libraries
with more than 70 000 myocardial ESTs generated from
human fetal, adult and hypertrophied hearts. The estab¬
lished association with high levels of natriuretic peptide
expression (atrial natriuretic peptide and brain natriuretic
peptide) was observed in all three hypertrophic samples. In
addition there was a striking up-regulation of genes
associated with the cellular response to injury including a
heat shock protein, a-(3-crystallin, not previously impli¬
cated in hypertrophy. Only 64 genes were identified as
being potentially overexpressed, demonstrating the limita¬
tion of large scale EST sequencing to detecting statistically
significant changes only in moderately abundant tran¬
scripts. The Toronto group used this extensive EST library
to create a large 'Cardiochip' cDNA array to probe
samples from patients with hereditary hypertrophic ob¬
structive cardiomyopathy [28], Genes for tropomyosin and
thymosin beta4, a regulator of actin polymerization, were
differentially expressed in keeping with disruption of the
sarcomere and cytoskeleton in this disorder. Although the
contribution of these expression changes to function and
phenotype remains to be elucidated the potential for
detailed characterisation of patients with this disorder was
demonstrated.
3.4. Myocardial infarction
Rodent models of MI result in inflammatory and fibrotic
repair responses within necrotic myocardium in addition to
compensatory hypertrophy of the remaining viable ventri¬
cle. Stanton et al. [29] examined expression of 7000
cDNAs in the infarcted left ventricular (LV) free wall and
interventricular septum at five different time points after
surgical induction of Ml in the rat. Approximately 7000
clones were isolated from a rat LV cDNA library and
probed with fluorescently labelled cDNA from both sites,
at each time point in infarction and sham operated animals.
The authors chose an arbitrary threshold of 1.8-fold
increase or decrease in expression and sub-arrayed these
genes for repeat analysis. Over 700 genes were shown to
have reproducible patterns of differential expression. In
addition to identifying genes previously described as
having altered expression in myocardial infarction, new
genes were implicated in the processes of repair and
remodelling. That no gene exhibited unique changes in
expression within the interventricular septum compared to
the LV free wall was surprising considering that they were
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subjected to different stress environments. The effective¬
ness of clustering expression profiles in time and mag¬
nitude of response to provide clues to the roles of poorly
characterised genes was demonstrated. Osteoblast-specific
factor-2 was thought to be unique to osteoblasts. This gene
had heightened expression in a cluster with collagen,
laminin and fibronectin suggesting a role in the matrix
deposition and remodelling occurring after infarction.
Finally, the reduced expression of several enzymes in¬
volved in the (3-oxidation pathway provided a possible
insight into the metabolism of injured myocardium, mov¬
ing away from fatty acid substrates. Models of reversible
ischaemia or ischaemia-reperfusion injury allow assess¬
ment of early changes occurring before the onset of
necrosis. An intriguing theme of cytoprotective gene
expression was demonstrated using subtractive hybridisa¬
tion within the myocardium following transient coronary
occlusion in pigs [30]. Anti-apoptotic factors and heat
shock proteins were expressed along with growth factors
that may act as survival signals. The profile is no more
than a catalogue of expression events but it provides
insight into the critical balance that exists between life and
death following ischaemia-reperfusion and begs the ques¬
tion whether augmentation of survival factors improve
functional outcome following ischaemia.
Models of cardiac hypertrophy and failure are character¬
ised by reexpression of fetal genes. However, the conse¬
quences of gene expression during development are very
different from those initiated following injury. Sehl et al.
[31] used microarrays to compare expression profiles
during myocardial development and infarction. The arrays
consisted mainly of cDNA clones produced by subtractive
hybridisation of sham operated and Ml samples. This
approach has the advantage of enriching the array for
differentially expressed genes, decreasing the examination
of multiple housekeeping or 'non varying' genes [32], In
addition, the subtractive technique generates clones from
any part of the mRNA and allows identification of
differentially expressed genes that have not been cloned
previously. For developmental profiling, embryonic and
1-day old neonatal myocardial samples were compared
with healthy adult rat myocardium. Ventricular tissue was
harvested at multiple time points after coronary artery
ligation and compared to sham operated tissue for stress
response profiling. The greatest contrast was seen when
comparing neonatal with adult myocardium and, as ex¬
pected, this reflected higher expression of signal transduc¬
tion and growth regulatory proteins such as p21 in the
developing heart. Twelve genes previously described as
being expressed during myocardial development were
identified together with ten uncharacterised ESTs and 36
genes not previously associated with cardiac development.
Although the array consisted largely of cDNA clones
derived by subtractive hybridisation of infarcted myocar¬
dium only 63 of the 989 clones representing 14 different
genes had demonstrable differential expression following
myocardial infarction. Previously described shared gene
expression patterns between cardiac development and
injury, including increased atrial natriuretic peptide, fibro¬
nectin and collagen III expression were confirmed. How¬
ever, these were in a small subset and the discordant
regulation of the majority of genes suggested that a shift to
the fetal gene program is not a general characteristic in
failing hearts.
No information was given on the structural or inflamma¬
tory cell types contributing to the changes in gene expres¬
sion within the myocardial tissue in these models of
myocardial ischaemia and infarction. In addition, the array
used by Stanton et ai. [29] was biased against genes
expressed in infiltrating leucocytes or genes with very low
basal expression levels because the arrayed genes were
taken from a normal LV cDNA library that would not
represent genes from these cell populations. This could be
why monocyte expression of cathepsin B following MI
was detected by Sehl et al. [31] but not in the former
study.
Expression profiles from specific cell types, harvested
from tissues, can be obtained using laser capture mi¬
crodissection [33,34], Laser capture allows precise identifi¬
cation, dissection and retrieval of pure cell populations that
are more reflective of the disease process in vivo. Luo et
al. [34] compared gene expression in large and small
neurons within rat dorsal root ganglia with RNA extracted
from 1000 captured neurons of each size. The small
quantity of RNA generated required further linear amplifi¬
cation with T7 RNA polymerase before hybridisation. The
investigators were able to demonstrate reproducible pat¬
terns of gene expression, using microarrays that were
subsequently confirmed by immunohistochemistry. One
possible application in the cardiovascular field would be
the selection of macrophage foam cells from atheros¬
clerotic plaque specimens.
4. Conclusions: cautious optimism
The interpretation of data from any expression profiling
technique requires caution. The risk of false positive
signals or bands is high. In microarray studies this may
arise through cross hybridisation of homologous or con¬
served repeat sequences. Lee et al. [35] demonstrated that
for a specified cDNA sample the ability of a DNA chip to
distinguish correctly the presence of any sequence was
90% per run. Costly repeat analysis of the same sample is
therefore required and ideally all findings should be
confirmed in a separate system such as Northern blotting.
Secondly, attaching functional significance to changes in
gene expression level alone is difficult. No information is
provided on post-translational modifications or the rate of
protein degradation. An alteration in expression and pro¬
tein synthesis of any given gene may represent an adaptive,
compensatory response or contribute to disease progres¬
sion. Profiling merely provides a further level of charac-
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terisation for pathophysiological processes without offering
information on the role of individual genes. Finally, levels
of mRNA do not always correlate with protein synthesis.
Studies in yeast indicate that expression of important
growth regulatory genes may not vary between quiescent
and proliferative conditions [36], Expression analysis is
complicated further by the fact that functionality and not
protein level is the critical issue. If receptors or ligands are
expressed but not functional, the value of gene expression
and protein analysis is disputable and may be misleading.
Bearing these caveats in mind, the potential uses for
systematic expression profiling on a genome wide scale in
cardiovascular research are clear. Further studies will
enhance our understanding of the relationship between
expression level and functional consequence for individual
genes. Computational approaches such as clustering, out¬
lined above, will allow some degree of functional interpre¬
tation through linking the expression of unknown or poorly
characterised genes with better known ones and through
identifying patterns of genes regulating certain functions
such as signalling or metabolic pathways. Profiling in¬
formation provides a rich source of additional questions
and hypotheses. Further experiments are often required to
examine whether expression profiles translate from in vitro
to in vivo models or from transgenic mice with a certain
disease phenotype to diseased human tissue. Association of
particular profiles with specific disease phenotypes may
have future diagnostic [37] or prognostic value as well as
allowing the design of specific experiments to examine in
detail, the functional roles of individual genes within these
profiles. The enormous amount of data produced by
profiling studies poses challenges for publication and
journals frequently use supplemental web pages to fully
release data. The development of expression databanks
akin to the sequence databanks already available will
facilitate more rapid comparisons between cells and tissues
in health and disease. The Stanford Microarray Database is
endeavouring to provide an online, searchable, public
interface for the dissemination of microarray studies [38].
Such enhanced facilities for the comparison and pattern
recognition of gene expression profiles will give research¬
ers powerful tools for gaining further insights into gene
function.
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Adenoviral Gene Delivery of Elafin and Secretory Leukocyte
Protease Inhibitor Attenuates NF-KB-Dependent Inflammatory
Responses of Human Endothelial Cells and Macrophages to
Atherogenic Stimuli1
Peter A. Henriksen,*1 Mary Hitt,* Zhou Xing,1 Jun Wang,* Chris Haslett,*
Rudolph A. Riemersma,18 David J. Webb,1 Yuri V. Kotelevtsev,1 and Jean-Michel Sallenave2*
Atherosclerosis is a chronic inflammatory disease affecting arterial vessels. Strategies to reduce the inflammatory responses of
endothelial cells and macrophages may slow lesion development and prevent complications snch as plaque rupture. The human
protease human neutrophil elastase (HNE), oxidized low density lipoprotein, LPS, and TNT-a were chosen as model stimuli of
arterial w all inflammation and led to production of the chemokine II.-8 in endothelial cells. To counteract the activity of HNE, w e
have examined the effects of adenoviral gene delivery of the anti-elastases elafin, previously demonstrated w ithin human atheroma,
and murine secretory leukocyte protease inhibitor (SLPI), a related molecule, on the inflammatory responses of human endothelial
cells and macrophages to atherogenic stimuli. We developed a technique of precomplexing adenovirus with cationic lipid to
augment adenoviral infection efficiency in endothelial cells and to facilitate infection in macrophages. Elafin overexpression
protected endothelial cells from HNE-induced 11.-8 production and cytotoxicity. Elafin and murine SLPI also reduced endothelial
1L-8 release in response to oxidized low density lipoprotein, LPS, and TNF-a and macrophage TNF-a production in response to
LPS. This effect was associated with reduced activation of the inflammatory transcription factor NF-kB, through up-regulation of
in both cell types. Our work suggests a novel and extended anti-inflammatory role for these HNE inhibitors working as
effectors of innate immunity to protect tissues against maladaptive inflammatory responses. Our findings indicate that elafin and
SLPI may be gene therapy targets for the treatment of atheroma. The Journal of Immunology, 2004, 172: 4535-4544.
Early atherosclerotic lesion development results from en¬trapment and subsequent oxidation of low density li¬poprotein (LDL)3 within the intimal space of arterial ves¬
sel walls. Atherosclerosis may be considered a chronic disease
caused by inflammatory interactions among oxidized LDL, inflam¬
matory cells recruited to the lesions, and the normal cellular ele¬
ments of the vessel wall, namely endothelial cells and smooth mus¬
cle cells (I). Cytokines such as TNF-a have an established role in
plaque inflammation (2) and. more recently, bacterial components
including LPS have been implicated as causative agents (3-5).
The neutrophil chemokine IL-8 is increased in atheroma (6, 7),
and neutrophils from patients with multiple atherosclerotic plaques
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and widespread coronary inflammation demonstrate evidence of
increased degranulation, becoming depleted of myeloperoxidase
(8). Human neutrophil elastase (HNE) is contained in and released
from the same azurophil granules as myeloperoxidase, and its
damaging effects on endothelial monolayers have been described
previously (9). Therefore, we have chosen to study HNE, in ad¬
dition to oxidized LDL, TNF-a, and LPS, as model stimuli of
endothelial cell injury in atherosclerosis.
Elafin, a specific HNE inhibitor, has been identified within hu¬
man coronary artery intima (10). Recent work has suggested ex¬
tended anti-inflammatory roles for murine secretory leukocyte pro¬
tease inhibitor (mSLPI), an inhibitor of HNE sharing homology
with elafin (11). Murine SLPI has been shown to attenuate inflam¬
matory cytokine production by macrophages in response to bac¬
terial LPS (12, 13). Human SLPI has been demonstrated to prevent
activation of the inflammatory transcription factor NF-i<B (14, 15).
Therefore, we hypothesized that overexpression of elafin and
mSLPI using adenoviral vectors may reduce the inflammatory re¬
sponses of endothelial cells and macrophages to atherogenic
stimuli.
The relative accessibility of vessels affected by atherosclerotic
disease makes gene therapy attractive, and strategies directed at
reducing inflammation within the vessel wall may slow plaque
progression and prevent rupture and ensuing coronary thrombosis.
We developed a technique to increase adenoviral gene delivery in
human endothelial cells and to facilitate infection of macrophages,
a cell type lacking natural tropism for adenovirus.
Our studies show for the first time that: 1) overexpression of
elafin protects human endothelial cells from HNE-induced damage
and 2) both elafin and mSLPI have broad-ranging anti-inflammatory
0022-1767/04/S02.00
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activity, reducing endothelial cell IL-8 production in response to
TNF-a, LPS, and oxidized LDL and TNF-o: production by human
macrophages in response to LPS. It is noteworthy that both of
these anti-inflammatory actions were associated with reduced ac¬
tivation of the transcription factor NF-kB and concomitant in¬
crease in IkBck protein. Our findings extend the observed potential
of elafin augmentation in models of arterial wall inflammation,
including vein graft degeneration (16) and transplant arterio¬
sclerosis (17). They indicate that gene augmentation of both




HNE was obtained from Elastin Products (Owensville, MO). LPS was
from Escherichia coli serotype 0127:B8 (Difco Laboratories, Detroit, MI).
Endothelial basal medium-2 (EBM2) and growth supplements were ob¬
tained from Clonetics (BioWhittaker, Wokingham, U.K.). Penicillin G,
streptomycin sulfate, DMEM, and IMDM were obtained from Life Tech¬
nologies (Paisley, U.K.). Falcon tissue culture material was from A. & J.
Beveridge (Edinburgh, U.K.). ELISAs for IL-8, TNF-a, and murine
eotaxin (m-eotaxin) were obtained from R&D Systems Europe (Abingdon.
U.K.). All other chemicals were purchased from Sigma-Aldrich (Poole,
U.K.).
LDL: isolation and oxidation
Human plasma was obtained from the Department of Transfusion Medi¬
cine, Royal Infirmary ofEdinburgh (U.K.). LDL was isolated by sequential
ultracentrifugation, followed by dialysis against PBS and 0.2 g/L chelex
(pH 7.4). The LDL was oxidized against CuCL and the degree of oxidation
was monitored by the formation of conjugated dienes at 234 nm (18). At
maximum absorbance (usually 60-90 min after initiation), oxidation was
terminated by the addition of 10% excess EDTA. Both native and oxidized
LDL were concentrated in an ultrafiltration unit (Amicon 52; Millipore,
Watford, U.K.) using polyethersulfone membranes (diameter, 44.5 mm;
nominal molecular weight limit, 30,000; Millipore) to yield 5 ml of con¬
centrated material. Traces of Cu2+ were then removed by gel filtration
chromatography over a Sephadex G25 column (PD-10; Amersham Phar¬
macia, Uppsala, Sweden). Protein concentrations were measured by the
Lowry method (19). The endotoxin concentration of native and oxidized
LDL at working dilutions was measured by the Limulus amebocyte lysate
assay (Chromogenix, Charleston, SC) and was found to be <100 pg/ml or
0.01 endotoxin U/ml.
Murine SLPJ oligonucleotides
Murine SLP1 oligonucleotides were obtained from MWG Biotech (Milton
Keynes, U.K.). A forward oligonucleotide (5'-GCTCTAGAGCTTCAC-
CATGAAGTCCTGCGG-3') was engineered to contain an Xhal site (5'-
GCTCTAGAG-3') and oligonucleotides 6-26 from the mSLPI cDNA se¬
quence containing the endogenous Kozak's sequence and coding for the
first 4 aa (20). The reverse oligonucleotide (5'-GGAATTCCTTTGCATA-
GAGAAATGAATGCG-3') was designed to contain an ZjcoRI site (5'-
GGAATTCC-3') and oligonucleotides 634-655 from the cDNA sequence.
The two oligonucleotides were designed to span introns and to amplify a
667-bp product (containing a poly(A) signal and 265 bp of 3' untranslated
region).
RNA preparation and cloning ofmSLPI
A fresh lung from a murine C57BL6/CBA hybrid was obtained and snap-
frozen in liquid nitrogen, and total RNA was prepared using TRIzol reagent
(21). RNA was quantified in the final solution (0.29 /xg/'/xl) and used as a
template for reverse transcription (RT) and PCR (all reagents from Pro-
mega. Southampton, U.K.). Briefly, 1 /xg of total RNA was used in the RT
reaction (37°C for 45 min) with 5 ng//xl reverse primer, 0.5 mM dNTPs, 10
U//xl reverse transcriptase (Moloney murine leukemia virus), and 2 U//xl
RNasin in PCR buffer containing 3 mM MgCL. After a 5-min incubation
at 95°C, the RT mixture was added for PCR (final volume. 100 /xl of PCR
buffer: 1 ng//xl reverse and forward primers. 0.03 U/'/xl Taq polymerase,
and 0.5 mM MgCL). Thirty cycles of amplification were conducted in a
thermal cycler (DNA Engine; MJ Research, Cambridge, MA) using the
following conditions for each cycle: 94°C for 30 s, 55°C for 30 s, and 72°C
for 1 min. Amplified products were then analyzed on 0.8% agarose gels,
cut from the gel, purified, and ligated by conventional methods into pGEM
T-easy (Promega). An £LoRI mSLPI cDNA digest was then subcloned into
pDK6. The correct orientation was assessed and sequencing was performed
to rule out any unwanted mutagenesis. Further directional cloning was
performed by subcloning the Xhal-EcoRV mSLPI cDNA fragment into
Nhel-EcoRV digested plRESGFP2 (gift from F. Graham and R. Marr,
Department of Biology, McMaster University, Hamilton, Ontario. Canada)
to generate plRESmSLPI-GFP2.
RNA preparation and cloning ofm-eotaxin
Murine eotaxin cDNA was amplified by RT-PCR from total RNA ex¬
tracted from female BALB/c murine lung that had been subjected to in¬
duced allergic airway eosinophilia (22). RT was conducted with random
hexamers and PCR was performed (as above) using a primer pair contain¬
ing restriction sites EcoRI and BamUl on forward and reverse primers,
respectively (forward, 5'-CGGAATTCCGGTAACTTCCATCTGTCTCC-
3'; reverse, 5'-CGGGATCCCGGTCCCTGTTTCAA ACAAGC-3'). An
800-bp EcoRVBamYW fragment of full-length m-eotaxin was isolated from
a 1% agarose gel and ligated into the multicloning site of the shuttle vector
pDK6 to generate pDK6-m-eotaxin (23).
Adenovirus (Ad) constructs
El, E3-deleted Ad encoding mSLPI cDNA (Ad-mSLPI). pIRES-mSL.Pl-
GFP2 and pBHGIoxAEl,3Cre were used to cotransfect 293 cells. Cre-
mediated, site-specific recombination (24) resulted in the generation of
Ad-mSLPI. Ad-mSLPJ was purified and titered by conventional methods
(23). The integrity of mSLPI and its activity in HUVECs were assessed by
dot blot analysis (using anti-mSLPI polyclonal Abs) and anti-HNE activity,
respectively (data not shown).
Ad-m-eotaxin. The pDK6m-eotaxin plasmid was cotransfected into 293
cells along with the rescuing vector pBHGK). Homologous recombination
resulted in the generation of Ad-m-eotaxin. HUVECs were infected with
Ad-m-eotaxin, and m-eotaxin production was verified by EL1SA (data not
shown). The Ad-m-eotaxin virus was purified, titered, and stored as above
(23).
Ad-lKBoL Construction of the vector expressing a mutant form of IkBo
protein (in which serines 32 and 36 are replaced by alanine residues, there¬
fore preventing inducible IkBo phosphorylation) has been described before
(25).
Ad-elafin. The Ad vector encoding for the 95-aa elafin molecule has been
described before (26). El, E3-deleted empty adenoviral vector (Ad-dl703)
coding for no transgene was described before (27).
Ad expressing green fluorescent protein (Ad-GFP) was a gift from F.
Graham and R. Man-.
Cell isolation and culture
HUVECs. Ethical approval was obtained from Lothian Research and Eth¬
ics Committee (2001/R/UO/01) for the procurement of human umbilical
veins from healthy term pregnancies during elective cesarean sections. Hu¬
man umbilical cord was digested using collagenase type IV according to
published protocols (28), and HUVECs were grown in EBM2 culture me¬
dium containing growth supplements at 37°C, 5% C02. Cells were not
grown beyond six passages.
PBMC-derived macrophages. Mononuclear cells were isolated from pe¬
ripheral blood as described (29). Freshly citrated blood was centrifuged at
400 X g for 20 min, and the platelet-rich plasma supernatant was used to
prepare autologous serum by addition of CaC"l2 (10 mM final concentra¬
tion). Leukocytes were isolated after removal of erythrocytes by sedimen¬
tation using 6% (w/v) dextran T500 in saline by fractionation on a discon¬
tinuous gradient of isotonic Percoll solutions made in Ca2+/Mg2*-free
PBS. Percoll concentrations of 55, 68, and 79% were used, and the leu¬
kocytes were centrifuged at 700 X g for 20 min. Mononuclear cells were
aspirated from the 55/68% interface and were washed three times in Ca2%
Mg2+-free PBS before culture. Monocytes were enriched from the mono¬
nuclear fraction by selectively attaching them to 48- or 12-well plates for
40 min at 37°C. Nonadherent lymphocytes were removed and adherent
monocytes were washed twice in PBS. Monocytes were then cultured in
IMDM containing 10% autologous serum, penicillin G (final concentration
100 U/ml), and streptomycin sulfate (final concentration 100 /xg/ml) at
37°C in a 5% C02 atmosphere. Maturation into macrophages with this
culture protocol has previously been demonstrated using myeloid-specific
markers, including CD 16 and CD51/CD61 (29).
A549 lung epithelial cells. A549 lung epithelial cells (30) were incubated
in DMEM containing 10% FCS, penicillin G (final concentration 100
U/ml), and streptomycin sulfate (final concentration 100 /xg/ml) and were
grown to confluence in 48-well plates 37°C in a 5% C02 atmosphere.
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Incubations with HNE, TNF-a, LPS, and oxidized LDL
For FINE-mediated injury experiments. HUVECs were washed with PBS
to remove serum (because of the presence of HNE inhibitors in serum) and
were incubated in serum-free EBM2 containing HNE for 8 h, after which
photomicrographs were taken. For HNE pretreatment studies, HUVECs
were washed in PBS and preincubated with HNE for 1 h before replen¬
ishment with serum-containing EBM2 containing the second LPS or oxi¬
dized LDL stimulus. All incubations with TNF-a and oxidized LDL were
for 8 h. When LPS was the sole stimulus, it was incubated with HUVECs
and A549s for 8 h and with macrophages for 3 h.
Ad infection protocols
To augment adenoviral gene transfer in HLVECs, we adapted a protocol
involving precomplexing adenoviral vectors with the cationic liposome
lipofectamine (31). We also tested this protocol for gene delivery on human
monocyte-derived macrophages, a notoriously difficult cell type to trans-
feet (32). HUVECs and A549 cells were grown to confluency and one well
was used for cell count determination. Ad was dosed for each experiment
at 100 PFU/cell. Ad vectors were preincubated for 15 min at room tem¬
perature in OptiMEM I reduced serum medium (Invitrogen, Paisley, U.K.)
with lipofectamine (Invitrogen) at a ratio of 5 X 104 lipofectamine mole¬
cules to each adenovirus particle. Ad particle concentration was determined
from absorbance at 260 nm for each Ad construct, according to published
protocols (33). HUVECs, peripheral blood-derived macrophages, and
A549s were incubated in the virus-containing medium for 2 h before re¬
plenishment with their respective normal growth media.
Preparation ofnuclear extracts and EMSAs
Nuclear extracts were prepared after 1-h treatments from HUVECs and
macrophages according to the method of Staal et al. (34). Briefly, cells
were scraped and lysed in 400 /xl of buffer A (10 mM HEPES, 10 mM KC1,
2 mM MgCl2 1 mM DTT, 0.1 mM EDTA, 0.4 mM PMSF, 0.2 mM NaF,
0.2 mM Na,V04, and 1 /xg/ml leupeptin), to which was added 25 /xl of
buffer B (10% Nonidet P-40), and the nuclei were collected by centrifu-
gation (10,000 X g for 2 min). Nuclei were resuspended in 50 /xl of buffer
C (50 mM HEPES, 50 mM KCI, 10% glycerol, 0.2 mM NaF, and 0.2 mM
Na3V04) and agitated for 20 min at 4°C, followed by centrifugation
(10,000 X g for 5 min). Nuclear proteins (7 /xg) were incubated with 5X
binding buffer (50 mM Tris-HCl, 0.5 M KCI, 5 mM EDTA, 2.5 mM
MgCL, 40% glycerol) and [y-32P]-labeled NF-kB consensus oligonucleo¬
tide and were electrophoresed on a 6% nondenaturing polyacrylamidc gel.
The NF-kB (5'-AGTTGAGGGGACTTTCCCAGGC-3') oligonucleotide
was obtained from Promega. DNA binding was assessed by autoradiogra¬
phy. Quantitative analysis was performed with a Storm 860 Phosphorlm-
ager using ImageQuant software (Molecular Dynamics, Buckinghamshire,
U.K.). A mutant NF-kB oligonucleotide (ANF-kB) with a "G" —> "C"
substitution in the NF-kB/RcI DNA binding motif (Santa Cruz Biotech¬
nology. Santa Cruz, CA) was used to establish the specificity of the sample
nuclear protein binding to NF-kB.
Western blot analysis for IkB protein content in HUVECs and
macrophages
Total cell (HUVECs and macrophages) extracts were prepared with cell
lysate buffer (10% glycerol, 2% SDS, 62.5 mM Tris-Cl, 2 /xg/ml leupeptin,
2 /xg/ml aprotinin, and 1 mM PMSF) after 10 min of LPS (100 ng/ml) or
TNF-a (100 pg/ml) stimulation. Cell extracts were analyzed for IkBot pro¬
tein content by SDS-PAGE. Briefly, equal volumes were loaded onto a
12% Bis-Tris/MES polyacry!amide gel (Invitrogen) and electrophoresis
was performed. Electroblotting was then conducted on nitrocellulose (Arn-
ersham Pharmacia, Buckingham, U.K.), and membranes were treated with
rabbit anti-lKBa Ab, 1/1000 dilution (Cell Signaling Technology, New
England Biolabs, Hitchin, U.K.), for either 16 h at 4°C or 2 h at room
temperature and subsequently with goat anti-rabbit, 1/2000 dilution
(DAKO, Ely. U.K.) for 1.5 h at room temperature. The Western blots were
then developed by ECL (Western Lightning Chemiluminescence Reagent
Plus; Perkin-Elmer Life Sciences, Cambridge, U.K.) according to the man¬
ufacturer's instructions.
Statistics
Results are presented as mean ± SD. and differences between treatments
were tested using the Student / test.
Results
The effects ofoxidized LDL, LPS, TNF-a, and IINF. on IL-8
production by HUVECs
To validate our in vitro model. HNE. LPS, oxidized LDL, and
TNF-a were chosen as stimuli relevant to endothelial injury oc¬
curring during the development of atherosclerosis. HUVECs pro¬
duced the chemotactic cytokine IL-8 (pg/ml) as follows: 92.7 ±
7.05 (untreated), 126 ± 9.65 (post 100 /ug/ml native LDL), 317 ±
38.2 (post 100 /xg/ml oxidized LDL), 608 ± 144 (post 100 ng/ml
LPS), 5144 ± 721 (post 1 ng/ml TNF-a), 126 ± 8.45 (post 2.5 X
1(TS M HNE), 145 ± 14.4 (post 5.0 X 1(T8 M HNE). Nonoxi-
dized, native LDL was included as a control and in agreement with
the literature (35) produced a small increase in IL-8 production
over untreated cells. This increase was considered negligible com¬
pared with the 3-fold increase over basal levels observed with
oxidized LDL (36). Results pertaining to native LDL therefore are
not shown in the rest of the manuscript. Addition of low concen¬
trations of HNE for I h followed by replacement of the HNE-
containing medium with serum-containing medium led to a small
increase in IL-8 production. In addition, a 1-h HNE pretreament
led to increased IL-8 response after subsequent stimulation with
both LPS and oxidized LDL. The data, expressed as a percentage
of non-HNE-prctreated cells (Table I), show a dose-dependent ef¬
fect for FINE pretreatment. Our results indicate that a brief expo¬
sure to HNE (in which no morphological damage was observed, as
evidenced by absence of lifting and rounding of the HUVEC
monolayer; data not shown) not only induced IL-8 production on
its own but also primed cells to further stimulation by LPS and
oxidized LDL.
Precomplexing Ad with cationic liposomes dramatically
enhanced infection efficiency in HUVECs and macrophages
As a marker for our Ad-lipofectamine infection method, we chose
to measure levels of the HNE inhibitor elafin. Endogenous elafin
could not be detected in the supernatants from uninfected
HUVECs or macrophages in the presence or absence of stimuli
(data not shown). In contrast, elafin levels in the supernatants from
HUVECs and macrophages as measured by ELISA (37) were dra¬
matically increased after infection with Ad-elafin that had been
precomplexed with lipofectamine compared with infection with
Ad-elafin alone. Indeed, HUVEC elafin production, after infection
with Ad-elafin at an multiplicity of infection of 100 in the absence
and presence of lipofectamine, was 61.7 (±6.82) ng/ml and 782
(±27.5) ng/ml, respectively. Lipofectamine also had a facilitatory
Table 1. HUVEC IL-8 response to LPS and oxidized LDL after HNE
pretreatment"









2.5 X 10"* M 193 (45.9) 213 (27.8)
5 X 10 " M 316(50.0)'' 228 (32.6)
1 X 10 7 M 248 (29.4) 332 (26.3)'
" HUVECs were grown to confluency in 48-well C'ostar plates (Cambridge, MA).
HNE stimulations were performed in serum-tree I.BM2 for I It, after which the
HNE-eontaining medium was replaced with EBM2 containing 2.5% ECS. I.PS or
oxidized LDL was added in serum-containing medium and supernatants were har¬
vested for 11.-8 determination after 8 h. Data are means and St), from three separate
experiments performed in triplicate. 11,-8 is expressed as a percentage of production
in non-HNE-pretreated ceils.
h Significantly higher than 2.5 X 10 * M ItNE/I.PS; p < 0.05.
'' Significantly higher compared with 2.5 X 10 K M HNE/oxidized LDL;p < 0.001.
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effect on Ad infection ofmacrophages, increasing production from
17.1 (±3.71)ng/ml to 250 (± 18.3) ng/ml. A549 elafin production
was 571 (±23.1) ng/nl, increasing to 893 (±34.1) ng/ml with li-
pofectamine (all values are means and SDs derived from one rep¬
resentative experiment performed in quadruplicate).
Ad-elafin reduced HNE induced injury and cytokine production
by HUVECs
Having demonstrated the inflammatory effects of oxidized LDL.
LPS, and HNE on HUVECs and having established an efficient
Ad-infection method (see above), we hypothesized that elafin may
modulate the responses to these stimuli by both inhibiting FfNE
activity and interfering with LPS signaling in a similar fashion to
mSLPl (13). Ad-mediated overexpression of elafin reduced the
rounding and lifting observed in HUVEC monolayers after an 8-h
incubation with HNE (2.5 X 1(FS M) (Fig. la). Ad-dl703 and
Ad-GFP were included to demonstrate the specificity of effect for
Ad-elafin. Ad-GFP was used in this experiment specifically to vi¬
sualize both infection efficiency and cell damage after HNE injury
(Fig. In) and was not used further in our study. Ad-I«Ba was
included as a positive control of cytokine inhibition and reduced
HUVEC IL-8 production in response to HNE, HNE and LPS in
combination, and LPS alone (Fig. 1/?). Ad-elafin also inhibited
. /
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FIGURE 1. Overexpression of elafin protected HUVEC monolayers
against HNE damage and inhibited HNE- and LPS-induced 1L-8 produc¬
tion. HUVECs were cultured and infected with Ad-elafin, Ad-dl703 (an
empty viral construct containing no transgene), and Ad-GFP (100 PFU/
cell) according to the protocols in Materials and Methods. All experiments
were performed 24 h after Ad infection, a, Photomicrographs of Ad-elafin-,
Ad-dl703-, and Ad-GFP-infected cells untreated (upper pane!) and after
incubation for 8 It with HNE (lower paneI) in serum-free medium. Ap¬
pearances of uninfected cells were identical with those of Ad-dl703-in-
fected cells (data not shown). />, HUVEC IL-8 production after pretreat-
ment with HNE alone. HNE pretreatment in combination with LPS
stimulation, or LPS stimulation alone. HNE pretreatments were conducted
as in Table I. and cells were replenished with serum-containing medium
after HNE pretreatment. Results are means and SD of three experiments
each performed in triplicate. IL-8 production is expressed as a percentage
of production in uninfected cells (see Table 1). *,p < 0.01; **.p < 0.001;
significantly lower than Ad-dl703-infected cells,.
IL-8 production after a brief exposure to HNE alone (5 X 1(T 8 M
for I h), after FINE pretreatment followed by LPS, and. most no¬
tably, after LPS stimulation in isolation (Fig. 1 b). An extended
anti-inflammatory role for elafin was suggested by its disruptive
effect on LPS signaling, and the remainder of the study focused on
investigation of this property.
Ad-elafin and Ad-mSLPI reduced cytokine production by
endothelial cells and macrophages, but not lung epithelial cells
The anti-inflammatory activities of elafin were further studied on
HUVECs, macrophages, and lung alveolar epithelial cells (A549
cells). Epithelial cells are not relevant to atherosclerosis and were
included to test whether the inhibitory effect demonstrated cellular
specificity. The effects of both Ad-elafin and Ad-mSLPI, a closely
related antiprolease, were examined on responses to LPS, TNF-a,
and oxidized LDL. In addition to the empty Ad construct Ad-
dl703, we included a further control Ad expressing m-eotaxin (Ad-
m-eotaxin), a secreted chemokine of similar molecular mass to
elafin and mSLPI (38), with no known anti-inflammatory activity
in the cell types studied. In HUVECs, Ad-elafin and Ad-mSLPI
produced small but significant reductions in basal IL-8 production,
an effect not observed in Ad-I(<Ba-infected cells (Fig. 2b). Ad-
elafin and Ad-mSLPI had comparable inhibitory effects to Ad-
IicBa after stimulation of HUVECs with LPS (Fig. 2d, same data
as Fig. \ti) and oxidized LDL (Fig. 2e) when compared with con¬
trol vectors. TNF-a stimulation led to a large increase in IL-8
production that was significantly attenuated by Ad-IxBa, Ad-
mSLPI, and Ad-elafin (Fig. 2c). TNF-a was chosen as a marker for
the ability of macrophages to respond to LPS, and stimulation of
macrophages with LPS produced a response in both uninfected and
virally infected cells (Fig. 3a). In contrast with IL-8 production in
HUVECs (Fig. lb), there was no significant difference in the basal
level of TNF-a production among the five adenovirus constructs
(Fig. 3b). Ad-mSLPI and Ad-elafin significantly reduced the
TNF-a response to LPS compared with Ad-dl703 and Ad-m-
eotaxin (Fig. 3c).
In comparison with their inhibitory effect on stimulated cytokine
production in HUVECs and macrophages. Ad-elafin and Ad-
mSLPI had no effect on IL-8 production by A549s in basal con¬
ditions or after stimulation with LPS (Fig. 4, b and c). However,
Ad-Ii<Ba retained an inhibitory effect, significantly reducing basal
IL-8 production and attenuating the response to LPS in A549 cells.
Ad-elafin and Ad-mSLPI reduced NF-kB activation in HUVECs
and macrophages by reducing luBa degradation
In HUVECs and macrophages, the level of NF-kB activity in un¬
stimulated cells was very low. There was no difference between
virally infected and uninfected cells (data not shown). In
HUVECs, stimulation with LPS led to an increase in NF-kB ac¬
tivity that was significantly reduced by Ad-elafin and Ad-mSLPI,
but only at the lowest concentration of LPS used (100 ng/ml) (Fig.
5a). Inhibitory effects disappeared at higher LPS concentrations
(1-5 /xg/ml) by comparison with the inhibitory effect of Ad-IxBa,
which remained constant (Fig. 5a).
A similar result was seen after incubation of HUVECs with
oxidized LDL (Fig. 6a). Ad-IxBa was most inhibitory, but both
Ad-elafin and Ad-mSLPI attenuated NF-kB activation signifi¬
cantly compared with control vectors. Similarly, the rise in NF-kB
activity after stimulation with TNF-a (100 pg/ml) was reduced in
Ad-elafin- and Ad-mSLPI-infected cells. In parallel with their in¬
hibitory effects on LPS signaling (Fig. 5a), this effect disappeared
with a higher concentration (1 ng/ml) of TNF-a (Fig. 6b). In con¬
trast, the inhibitory effect of Ad-I«Ba was retained at the higher
TNF-a concentration.
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FIGURE 2. Ad-elafin and Ad-mSLPl reduced IL-8
production in HUVECs in basal (untreated) conditions
and after stimulation with TNF-a. LPS, and oxidized
LDL. HUVECs were grown to confluency in 48-well
plates and were infected with Ad as in Fig. ]. Stimuli
were applied 24 h after infection and left for 8 h before
removal of conditioned medium for IL-8 ELISA. Ad-
m-eotaxin and the empty viral construct containing no
transgene (Ad-dl703) were included as controls for the
effects of adenoviral infection. Ad-LB was included
as a positive control of cytokine inhibition, a, IL-8
response to the three stimuli (see Results), b, Ad-ela-
fin. Ad-mSLPl, Ad-dl703, Ad-UBa, and Ad-m-
eotaxin-infected cells under basal (untreated) condi¬
tions. c, TNF-a, 1 ng/ml. <7, LPS, 100 ng/ml (Ad-
elafin/LPS data are the same as in Fig. 1 b). e, Oxidized
LDL, 100 jug/ml. IL-8 production is expressed as a
percentage of uninfected cells. Data in b—e are means
and SDs from three separate donors performed in qua¬
druplicate. *,p < 0.05; **.p < 0.01; ***,p < 0.001;



































































In macrophages, Ad-elafin and Ad-mSLPl significantly attenu¬
ated NF-kB activity after LPS stimulation when compared with
control vectors, although Ad-It<Ba was the most effective (Fig. 7).
The mechanism of NF-kB inhibition by Ad-elafin and Ad-
mSLPl was further studied by stimulating Ad-infected HUVECs
and macrophages with TNF-a and LPS, respectively. Total cell
lysates were then analyzed for I«Ba content by Western blot
analysis.
Fig. 8 shows that Ad-mSLPI and Ad-elafin significantly pro¬
tected HUVECs and macrophages from TNF-a- and LPS-induced
IxBa degradation, respectively. Ad-I«Ba produced overexpres-
sion of mutated IkBot (as evidenced by its higher m.w.), but in
accordance with other studies it did not completely prevent en¬
dogenous I«Ba degradation.
Discussion
The mechanisms driving atherosclerotic plaque development have
been underpinned by in vitro studies demonstrating the inflamma¬
tory actions of oxidized LDL on intimal cells (35, 36, 39). A pos¬
sible contribution from infectious agents or bacterial components
such as LPS has been suggested by detection of Chlamydia pneu¬
moniae (40) and increased expression of the LPS receptor Toll-like
receptor-4 (3) in atherosclerotic specimens. These results are in
agreement with the observation that atheroma formation is accel¬
erated in atheroma-prone rabbits treated with LPS (4).
At the molecular level, endothelial cells demonstrate increased
adhesion molecule and chemokine expression during plaque de¬
velopment (7, 41), and macrophages are the predominant cell of
the mononuclear cell infiltrate. Murine models of atheroma have
exemplified the importance of chemokine expression in atherogen-
esis. Indeed, atherosclerosis-susceptible, LDL receptor-deficient
mice that were irradiated and repopulated with marrow cells lack¬
ing the neutrophil chemokine receptor CXCR-2 had reduced ath¬
eroma (42). This array of data prompted us to examine endothelial
cell chemokine production in response to oxidized LDL, TNF-a,
and LPS. We demonstrate here that all three stimuli increased pro¬
duction of the neutrophil chemokine IL-8 (Table I and Fig. 2a) in
endothelial cells. We also show for the first time that brief expo¬
sure to the neutrophil enzyme HNE increases endothelial cell IL-8
production (see Results) in a similar fashion to its previously pub¬
lished effects on lung epithelial cells (43, 44) and that HNE prc-
treatment potentiated the IL-8 response to subsequent stimulation
by LPS and oxidized LDL (Table I). In accordance with previously
published work (9), we found that a more prolonged incubation of
HNE with endothelial cells was cytotoxic (Fig. 1 a). Although neu¬
trophils are not present in large quantities within atherosclerotic
plaques, myeloperoxidase, a major neutrophil protein, has been
identified as a key mediator of plaque development (45, 46). The
observation that a defensin, a further neutrophil granule-derived
protein, is present within the coronary artery intima (47) and may






























FIGURE 3. Ad-elafin and Ad-mSLPI reduced macrophage TNF-a pro¬
duction in response to LPS stimulation. Adenoviral infections were per¬
formed (100 PFU/cell) as described in Materials and Methods, and LPS
was added on day 7 of culture. Conditioned medium was removed after 3 h
for TNF-a EL1SA. a, Representative experiment from one donor (mean
and SD from triplicate wells) showing TNF-a production from untreated
cells and the response after stimulation with LPS (1 ng/ml) in uninfected
and Ad-dl703-infected macrophages, b, TNF-a production in infected,
nonstimulated cells, c, TNF-a production in response to infected and LPS-
stimulated macrophages (1 ng/ml). TNF-a production is expressed as a
percentage of uninfected cells. Data in b e are means and SDs from three



































FIGURE 4. Ad-elafin and Ad-mSLPI had no effect on IL-8 production
by A549 epithelial cells in response to LPS stimulation, A549s were grown
to confluence in 48-well Costar plates, infected with adenovirus vectors
(100 PFU/cell), and stimulated with LPS using the HUVEC protocol de¬
scribed in Fig. I. a, IL-8 production in response to LPS stimulation (100
ng/ml). Data represent the mean and SD from triplicate wells, ft, Basal IL-8
release from infected nonstimulated A549s. c, IL-8 production from in¬
fected A549s in response to LPS (100 ng/ml). Data represent the means and
SDs from three experiments performed in triplicate. IL-8 concentration is
expressed as a percentage of uninfected cells. *,p < 0.05; **,p < 0.001;
significantly lower than Ad-m-eotaxin-infected cells.
interact with LDLs (48), supports our hypothesis that neutrophil-
derived HNE augments endothelial cell inflammatory responses to
oxidized LDL and LPS.
We chose, therefore, to investigate whether Ad-mediated over-
expression of HNE inhibitors would modulate the inflammatory
responses of endothelial cells observed in the first part of our
study. Elafin and mSLPI are cationic low-m.w. protease inhibitors
with spectrums of antiprotease activity that include HNE, protein¬
ase 3, and porcine pancreatic elastase for elafin and LINE, trypsin,
and chymotrypsin for mSLPI (1 1). In humans, these protease in¬
hibitors show 40% protein sequence homology and have been
characterized from a variety of epithelial lining fluids (49). SLP1
and elafin are present in monocytes, alveolar macrophages, and
neutrophils, albeit to varying degrees (II, 50). The N-terminal of
elafin provides a substrate for transglutamination and binding to
interstitial molecules, potentially accounting for the colocalization of
elafin with tissue transglutaminase in human coronary arteries (10).
Using a novel technique involving precomplexing of adenovirus
with cationic liposomes, we were able to significantly augment Ad
gene delivery in HUVECs. Other workers have also demonstrated
that precomplexing cationic compounds, including calcium phos¬
phate precipitates and liposomes with Ad, augment gene delivery
both in vivo and in vitro (31, 51-53). Using our methodology,
Ad-mediated elafin overexpression in HUVECs prevented direct
HNE damage (Fig. lcr) and inhibited HNE-induced IL-8 produc¬
tion (Fig. 1ft). Remarkably, the elafin inhibitory effect was com¬
parable to that of the NF-kB inhibitory subunit IkBo, suggesting
that elafin and IkBo may share a common HNE inhibitory path¬
way. Walsh et al. (44) have recently shown that HNE signals
through the MyD88-IL-lR-assoeiated kinase-TNFR-associated
factor-6-NF-«B pathway, and a recent report has demonstrated
Toll-like receptor 4-mediated IL-8 induction by HNE (54). Our
new findings extend in endothelial cells the above-mentioned ob¬
servations in epithelial cells and support promoter mutation studies
indicating that NF-kB is the predominant as-acting element in
IL-8 gene expression (55).
Importantly, Ad-elafin has modulatory effects even in the ab¬
sence of HNE (Fig. 1ft), suggesting that elafin may be exerting
additional anti-inflammatory effects beyond neutralization of
HNE. This possibility was tested further in a range of cell types by
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FIGURE 5. Ad-elafin, Ad-mSLPI, and Ad-IxBa
reduced NF-kB activation in HUVECs after stimula¬
tion with LPS. Cells were grown to confluence in 24-
well Costar plates and infected with adenovirus vec¬
tors (100 PFU/cell) according to the protocols in Fig.
1, and nuclear proteins were prepared for EMSA 1 h
after stimulation with LPS. Specificity of binding was
demonstrated by disappearance of the NF-kB band
with a mutated NF-kB oligo (A probe). Nuclear pro¬
teins from two separate experiments were run in pairs
on the same gel. £/, EMSAs of nuclear proteins (7 /xg)
from cells infected with Ad vectors and stimulated
with LPS at 100 ng/ml, 1 /xg/ml, and 5 /xg/ml. b, The
mean intensities of the corresponding NF-kB bands for
uninfected and adenovirus-inlected cells were deter¬
mined using ImageQuant software and expressed as
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FIGURE 6. Ad-elafm, Ad-mSLPI, and Ad-lkba
reduced NF-kB activation in HUVECs after stimula¬
tion with oxidized LDL and TNF-a. EMSAs were per¬
formed on nuclear proteins prepared according to the
protocols in Fig. 5. a, Oxidized LDL-stimulated cells
(100 ng/ml). b, TNF-a-stimulated cells. EMSAs arc
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FIGURE 7. Ad-elafin, Ad-mSLPI, and Ad-1kBo
reduced NF-kB activation in macrophages after stim¬
ulation with LPS. Macrophages were cultured in 12-
wcll Costar plates and infected with adenovirus vec¬
tors as in Fig. 3. Cells were stimulated with LPS (1
ng/ml) for I h on day 7. and EMSAs were performed
on nuclear extracts (7 p.g) as in Fig. 5 (representative
gel from an experiment repeated on two separate do-
















comparing the anti-inflammatory actions of elafin, its homologue
mSLPI (previously shown to inhibit LPS) (12, 13), and ]«Ba. In
HUVECs, Ad-elafin and Ad-mSLPI significantly reduced IL-8
production in basal conditions and in response to TNF-a. LPS, and
oxidized LDL (Fig, 2, a-d). Because human macrophages are
relatively refractory to Ad infection expressing low levels of
adenoviral receptors (56), we used our Ad-lipofeclamine technique
on these cells and showed that elafin expression was increased
vastly (see Results). Overexpression of elafin, mSLPI, and I«Ba
significantly reduced macrophage TNF-a production in response
to LPS stimulation (Fig. 3c). These results confirm the previously
known anti-LPS activity of mSLPI (12, 13) using a different
approach and establish for the first time the broad-ranging antag¬
onism of elafin and mSLPI against different stimuli, suggesting a
general role in dampening inflammation.
Interestingly, Ad-elafin and Ad-mSLPl had no inhibitory effect
on basal or LPS-induced IL-8 production by lung epithelial cells;
however, AcI-IkBo was inhibitory (Fig. 4, a and b). possibly re¬
flecting a cellular or organ-specific action for these antiproteases.
Indeed, recent work from our own group suggests that overexpres¬
sion of elafin is not anti-inflammatory and may prime murine lung
innate immune responses after an LPS challenge (57, 58).
Because both IL-8 and TNF-a production are dependent on NF-
KB-regulated transcription (59), we investigated whether elafin
could also interfere with the NF-kB pathway. NF-kB activity is
increased within the intimal cells of human plaques and is a pos¬
sible therapeutic target regulating the expression of many
proatherogenic genes (60). We performed EMSAs to examine the
effects of the Ad vectors on NF-kB activation in HUVECs and
macrophages. Oxidized LDL increases endothelial cell production
of reactive oxygen species and activates NF-kB through interac¬
tion with the lectin-like oxidized LDL receptor 1 scavenger recep¬
tor (61), and oxidized LDL, LPS, and TNF-a stimulation were
associated with increased activity of the proinflammatory tran¬
scription factor in HUVECs (Figs. 5 and 6) (62. 63). After Ad-
elafin and Ad-mSLPI infection, NF-kB activity was reduced in
LPS- (Fig. 5). oxidized LDL- (Fig. 6a), and TNF-a-stimulated
HUVECs (Fig. 6b). This provides evidence for an inhibitory effect
before or at the level of gene transcription for these stimuli. Ad-
elafin and Ad-mSLPI also reduced LPS-induced macrophage
NF-kB activation in accordance with their inhibitory action on
production of the NF-kb-regulatcd proinflammatory cytokine
TNF-a (Fig. 7). This was further studied by Western blot analysis,
which showed that Ad-elafin and Ad-mSLPI inhibited NF-kB ac¬
tivity by reducing TNF-a- and LPS-induced IkBo degradation
(Fig. 8). Interestingly, and as demonstrated by others (64), Ad-
IkBc* did not prevent endogenous IkBc* degradation, confirming
that overcxpression of IkB« can saturate the endogenous IkBu
degrading cellular machinery. iKBa protein content was highest in
the Ad-lKBa-infected cells (Fig. 8) mirroring the EMSA results,
which showed that IkBo was most efficient at down-regulating
NF-kB activity (Figs. 6 and 7). Consistent with its inhibitory ac¬
tivity on NF-kB in the present work, SLPI murine macro¬
phages demonstrate sustained increases in NF-kB activation after
LPS stimulation (65). Accordingly, Lentsch et al. (14) demon¬
strated that inhibition of NF-kB activity in a rat immune complex
lung injury model, after administration of human SLPI, was asso¬
ciated with increased levels of the IkB/3 inhibitory subunit. In that
model, mutated human SLPI sequences coding for proteins that
lack trypsin inhibitory activity failed to inhibit NF-kB activation
(66). Although SLPI has been shown to bind physically to LPS
(67), Jin et al. (12) as well as J. McMichael (unpublished obser¬
vations) in our group have reported that SLPl-containing medium
was unable to transfer LPS-inhibiting activity to fresh cells, sug¬
gesting that extracellular SLPI may not be able to interfere with
LPS signaling. Two reports have supported an intracellular mode
of action for this secreted protein. Zhu et al. (13) showed that a
SLPI construct lacking a leader sequence and hence coding for a
nonsecrcted protein was still able to exert its anti-LPS effect and
subsequent NF-kB activity. More recently (68), SLPI's anti¬









figure 8. Ad-elafin, Ad-mSLPI. and Ad-lkba protected HUVECs
and macrophages from 1kB« degradation. HUVECs and macrophages (un¬
infected or infected with Ad constructs) were stimulated with TNF-a (100
pg/ml, upperpanel) or LPS (1 ng/ml, lower panel), respectively, for 10 min
(preliminary experiments were performed to determine optimal timing:
data not shown). Total cell extracts were obtained and Western blot anal¬
ysis was performed for I kBu content as outlined in Materials and Methods.
Ad-derived IkBo migrates slightly behind endogenous Ik Bo Results are
representative of experiments performed in duplicate.
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proteasome inhibitors. In addition to SLPI and elafin, other serine
protease inhibitors have been shown to block NF-kB activation
through inhibition of proteosomal proteases (69. 70).
Our results do not exclude elafin and mSLPI interference with
parallel proinflammatory signaling pathways activated by TNF-a,
LPS, and oxidized LDL because inhibition of cytokine production
was more striking than was the sole suppression of NF-kB acti¬
vation (particularly for TNF-a) supporting this possibility.
In conclusion, our experiments have shown for the first time that
overexpression of HNE inhibitors is protective against HNE-me-
diated endothelial cell damage and proinflammatory signaling in
both endothelial cells and macrophages and can, through NF-kB
inhibition, attenuate inflammatory responses to LPS. TNF-a, and
oxidized LDL. Overall, our data support the concept of endoge¬
nous defense molecules such as elafin and SLPI working as elfec-
tors of innate immunity to protect tissues against maladaptive in¬
flammatory responses. We believe that the properties of these
molecules make them attractive anti-inflammatory agents in a
range of diseases, including arterial wall inflammation occurring
during atherosclerosis.
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Abstract The resolution of inflammation is dependent on
recognition and phagocytic removal of apoptotic cells by
macrophages. Receptors for apoptotic cells are sensitive to
degradation by human neutrophil elastase (HNE). We show iu
the present study that HNE cleaves macrophage cell surface
CD 14 and in so doing, reduces phagocytic recognition of
apoptotic lymphocytic cells (Mutu 1). Using an improved
method of adenovirus-mediated transfection of macrophages
with the HNE inhibitor elafin, we demonstrate that elafin
overexpression prevents CD14 cleavage and restores apoptotic
cell recognition by macrophages. This approach of genetic
modification of macrophages could be used to restore apoptotic
cell recognition in inflammatory conditions.
© 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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1. Introduction
The removal of cells undergoing apoptosis or programmed
cell death is an essential step in the resolution phase of the
inflammatory response. Macrophages are particularly impor¬
tant in the processes of recognition and engulfment of apop¬
totic cells [1,2] and inflammatory mediators may impair these
processes prolonging inflammation and tissue injury. Human
neutrophil elastase (HNE) is a potent protease released by
neutrophils during acute inflammation and mediates both di¬
rect tissue damage and the upregulation of pro-inflammatory
cytokines such as interleukin (IL-8) [3-5], HNE has also re¬
cently been demonstrated to impair apoptotic cell recognition
by cleaving the phosphatidylserine receptor (PSR) on the
surface of macrophages [6], A variety of macrophage receptors
have been implicated in apoptotic cell recognition, such as the
'Corresponding author. Fax: +44-1-31-650-4384.
E-mail address: jsallena@staffmail.ed.ac.uk (J.-M. Sallenave).
Abbreviations: HNE, human neutrophil elastase; 61D3, monoclonal
blocking antibody against CD 14; IL, interleukin; Ad, adenovirus; Ad-
dl703, control (empty) adenoviral vector; PBS, phosphate-buffered
saline; PSR, phosphatidylserine receptor; TNFcr, tumour necrosis
factor-oc GFP, green fluorescent protein
PSR and CD 14 [6,7] and from these the former has been
shown to be inactivated by HNE in patients with pulmonary
inflammation [6], Similarly, HNE has been shown to degrade
CD14 on the surface of human peripheral blood monocytes
and fibroblasts [8,9],
We have chosen to focus the present study on CD 14 and
reasoned that a strategy aiming at protecting CD 14 from
cleavage by HNE would be beneficial, favouring apoptotic cell
removal in an inflammatory environment. For that purpose,
we used an adenovirus (Ad) gene-transfer methodology in¬
volving complexing a recombinant Ad with the cationic lipo¬
some lipofectamine. Using this technique, we show that the
HNE-mediated cleavage of CD14 and ensuing impairment of
apoptotic cell recognition are inhibited by Ad-mediated over-
expression of human elafin, a potent HNE inhibitor. Inhibitors
of HNE are thought to comprise part of the human innate
immune system. Elafin [10,11] is a potent inhibitor of HNE
and proteinase 3 produced in the skin and airways, which is
upregulated in response to early inflammatory cytokines such
as tumour necrosis factor (TNF) and IL-1 [4]. Our group has
recently demonstrated elafin as a multi-faceted molecule ex¬
hibiting direct antimicrobial activity [12] and an inhibitory
effect on NF-kB mediated inflammatory cytokine production
[13].
We demonstrate here for the first time that human macro¬
phages can be genetically reprogrammed to overexpress elafin,
from an HNE-mediated inflammatory phenotype, associated
with apoptotic cell recognition deficiency, to a phagocytic
competent phenotype. These findings have implications for the
use of adenovirus in ex vivo applications of macrophages in
inflammatory disorders.
2. Materials and methods
2.1. Reagents
HNE was obtained from Elastin Products (Owensville, MO). Re¬
combinant elafin was a gift from Dr. J. Fitton, Astra-Zeneca (Mac¬
clesfield, UK). The monoclonal blocking antibody against CD 14 (mAb
61D3) hybridoma (IgGl mouse anti-human) was originally obtained as
a gift from J.D. Capra [14], Penicillin G, streptomycin sulfate, and
Iscove's modified DMEM were obtained from Life Technologies
(Paisley, UK). X-Vivo 10 serum free culture medium was obtained
from Cambrex Bio Science (Wokingham, UK). Falcon tissue culture
material was from A.&J. Beveridge (Edinburgh, UK). 6-well, 48-well
and 96-well tissue culture plates were obtained from Corning Costar
0014-5793/S22.00 © 2004 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved,
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(High Wycombe, UK). All other chemicals were purchased from Sig¬
ma Chemicals (Poole, UK).
2.2. Adenovirus (Ad) constructs
The generation of El, E3 deleted Ad constructs Ad-elafin and Ad-
dl703 ("empty" Ad control) has been described previously [15,16],
2.3. Macrophage isolation and FACS analysis
Mononuclear cells were isolated from peripheral blood as follows:
freshly citrated blood was centrifuged at 400 x g for 20 min and the
platelet-rich plasma supernatant was used to prepare autologous se¬
rum by addition of CaCh (10 mM final concentration). Leukocytes
were isolated after removal of erythrocytes by sedimentation using 6%
(w/v) dextran T500 in saline by fractionation on a discontinuous gra¬
dient of isotonic Percoll solutions made in Ca2+/Mg2+-free phosphate-
buffered saline (PBS) (CMF-PBS). Percoll concentrations of 55%, 68%
and 79% were used and the leukocytes were centrifuged at 700 x g for
20 min. Mononuclear cells were aspirated from the 55%/68% interface
and washed three times in CMF-PBS prior to culture. Monocytes were
enriched from the mononuclear fraction by selectively attaching them
to 6-well plates for 40 min at 37 °C. Non-adherent lymphocytes were
removed and adherent monocytes were washed twice in PBS. Mono¬
cytes were then cultured in Iscove's modified DMEM containing 10%
autologous serum, penicillin G (final concentration 100 U/ml) and
streptomycin sulfate (final concentration 100 pg/ml) at 37 °C in a 5%
CCA atmosphere. Maturation into macrophages with this culture
protocol has previously been demonstrated using myeloid-specific
markers, including CD16 and CD51/CD61 [17]. On culture day 4,
macrophages were removed with cold CMF-PBS and plated at 70000
cells/well on 48-well plates in X-Vivo 10 serum free culture medium.
On culture day 6, Ad vectors were preincubated for 15 min at room
temperature in X-vivo 10 medium with lipofectamine (Invitrogen,
Paisley, UK) at a ratio of 5 x 104 lipofectamine molecules to each Ad
particle (Ad particle concentration was determined from absorbance at
260 nm for each Ad construct according to established protocols) and
added to day 6 macrophages at a multiplicity of infection (MOl) of
100. Macrophages were incubated in the virus-containing medium for
2 h before replenishment with X-vivo 10 growth medium.
Where indicated, HNE (1 pM) was added directly the following day
and incubated for I h prior to removal. Following HNE treatments,
cells were washed with ice cold CMF-PBS and suspended in 2% goat
serum (Serotec Ltd, Oxford, UK). Cells were incubated with 61D3, a
CD 14 blocking monoclonal antibody [7], for 30 min, washed twice and
then incubated with phycoerythrin-conjugated goat anti-mouse IgG
secondary antibody for 15 min. Washed macrophages were then
analysed on a FACScan cytometer (Becton Dickinson and Co.).
2.4. HNE inhibition assay
The HNE activity of macrophage supernatants, following incuba¬
tion with HNE, was examined to determine any inhibitory effect
conferred by infection with Ad-elafin or incubation with r-elafin. The
HNE activity assay has been described in detail elsewhere [18]. Briefly,
all dilutions were performed in assay buffer (50 mM Tris, 0.5 M NaCl
and 0.1% Triton X-100, pH 8.0). Cell culture supernatant (90 pi) was
incubated in a 96-well microtitre plate for 30 min at 37 °C before
addition of the chromogeneic substrate /V-methoxysuccinyl-Ala-Ala-
Pro-Val-p-nitroanilide. The change in absorbance measured spectro-
photometrically at 405 nm (MR5000 Plate Reader, Dynatech, Dynex,
Billinghurst, UK) was expressed as a function of time. In a separate
experiment to measure HNE activity within apoptotic Mutu cells, two
independent batches of apoptotic Mutu cells (3 million cells) were
pelleted and washed with PBS and lysed in 0.4 ml of HNE buffer assay.
Cell lysate (50 pi) was added to a microtitre plate and HNE activity
recorded according to the protocol described above.
2.5. Apoptotic cells recognition assays
Macrophages were prepared and Ad infections performed in X-vivo
10 serum free medium as above in 48-well plates. Where indicated,
HNE (I pM) and r-elafin (15 pg/ml = 2.5 pM) were added directly for
I h prior to the interaction assay with apoptotic cells. The group I
Burkitt lymphoma cell line Mutu I, induced into apoptosis by 16 h
incubation with I pg/ml of the calcium ionophore ionomycin (Cal-
biochem, Nottingham, UK), was used as a source of apoptotic cells.
Typically, around 70% of cells were apoptotic following this treatment
as determined by FACS analysis of annexin V staining. For some
experiments, the 61D3 CD14-blocking monoclonal antibody was
mixed with the apoptotic Mutu cells. The culture medium was removed
and 750000 apoptotic Mutu cells were added to each 48-well for 1 h at
37 °C before being washed extensively with ice cold CMF-PBS to re¬
move unbound apoptotic cells. Cells were then fixed in 1% parafor¬
maldehyde and stained with Diff-quick for counting. Cultures were
scored by light microscopy according to the proportion of macro¬
phages that had internalised or bound apoptotic Mutu cells by
established criteria [7,19], At least 300 macrophages were assessed
per sample.
2.6. Statistics
Results are presented as means ±S.D. and differences between
treatments were tested using the Student's t test.
3. Results and discussion
Macrophages are important phagocytic cells involved in the
recognition and removal of apoptotic cells, integral processes
in the resolution of the inflammatory response [1,2], Recent
data have suggested that HNE, a pro-inflammatory enzyme
released during uncontrolled inflammation [3], may be re¬
sponsible for the impairment of apoptotic cell recognition by
macrophages, by cleaving key receptors on these cells [6], The
100 A 1 ll uninfected
80 Jh\ 1 no HNE
60 ll 11 2 HNEW J H ,
40 / I'
20 V \V \






c i | Ad-clufin
\)\ 5 no HNE
f H « HNE
\rf 4
I 10 I (XI 1000 HX) 1000
1 uninfected
2 uninfected + HNF
3 Ad-dl703
4 Ad-dl703 + HNE
5 Ad-elafin
6 Ad-elafin + HNE







20 40 60 80 KM)
Cells staining for CD 14 (c/< )
Fig. 1. The effect of HNE on surface expression of CD 14 on human
macrophages. Where indicated, macrophages were incubated with
HNE (1 pM) for 1 h prior to removal. Binding of the 61D3 (anti-
CD 14) antibody was then analysed by flow cytometry. Adenovirus
infections were performed at an MOI of 100 using the protocol with
lipofectamine described in Section 2. (A) Uninfected cells. (B) Ad-
dl703-infected cells (MOI 100). (C) Ad-elafin infected cells (MOI 100).
(D) Composite figure illustrating 61D3 binding in the different con¬
ditions from a separate donor. (E) Mean percent of macrophages
staining for CD14±S.D. Data are from experiments performed on
two separate donors.
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PSR was susceptible to HNE cleavage although the expression
of other apoptotic cell recognition receptors, CD36 and CD32,
was relatively preserved. We have demonstrated that CD 14, a
receptor with susceptibility to HNE, participates in the reso¬
lution phase of the inflammatory response as a cell surface
receptor for apoptotic cells [7] in addition to acting as a re¬
ceptor for bacterial lipopolysaccharide [20], To test whether
HNE could cleave macrophage CD14, we treated this cell type
with purified HNE and analysed CD14 cell surface expression
by FACS analysis. Compared to untreated cells, HNE-treat-
ment drastically reduced the level of cell surface CD 14
(Fig. 1A).
We decided to target HNE because of its deleterious action
in inflammatory conditions and its central role in cleaving a
variety of apoptotic cell receptors (CD 14 and phosphatidyl-
serine [6] being two out of a list likely to grow). We designed a
gene therapy strategy to protect macrophages from the HNE-
mediated cleavage of surface receptors. Traditional gene
transfer vectors have proven disappointing for the transfection
of macrophages [21] and we have previously developed a hy¬
brid method, involving pre-complexing of adenovirus with
cationic liposomes (lipofectamine) [13], This method greatly
enhances transfection in other cell types both in vitro and in
vivo [22,23], We have adapted this method for peripheral
blood monocyte-derived macrophages and show here an im¬
pressive increase in transfection levels using green fluorescent
protein (GFP) as a gene reporter (Fig. 2). Using this technique,
92% of macrophages exhibited GFP expression 24 h after in¬
fection with Ad-GFP (counting in a low power field). Simi¬
larly, when macrophages were infected with Ad-elafin/
lipofectamine, elafin supernatant levels were increased from
10.4 (±4.11) ng/rnl with Ad-elafin alone to 232 (±13.1) ng/ml
(values are means and S.D. derived from a representative ex¬
periment performed in triplicate). Elafin was not detected in
the supernatant from uninfected cells. Having established the
disruptive activity of HNE on macrophage CD 14 in our Sys¬
tem (see above. Fig. 1A), we demonstrated that Ad-elafin in¬
hibited HNE-mediated shedding of CD14 compared to
macrophages infected with Ad-dl70/3, an Ad vector with no
Fig. 2. Lipofectamine facilitates Ad-GFP infection of macrophages.
Peripheral blood monocyte-derived macrophages were infected on
culture day 6 with Ad-GFP (100 PFU/cell). Where indicated, virus was
precomplexed with lipofectamine (+) according to protocols in Section
2. Photomicrographs were taken 24 h after Ad infection and GFP
fluorescence was observed. (A) No filter and (B) green filter.
transgene cassette (Fig. 1B and C). When serum-free super-
natants were tested for HNE activity, most HNE was inhibited
when a saturating concentration of r-elafin was added extra-
cellularly (Fig. 3). Although Ad-elafin was efficient in pre¬
serving CD 14 expression, it conferred by contrast a relatively
modest, albeit significant, inhibition of HNE when compared
to Ad-dl70/3 (Fig. 3). This result was predicted from the elafin
concentrations in Ad-elafin infected cell supernatants that were
theoretically not high enough to neutralise the quantity of
HNE added.
Finally, we investigated the effect of HNE on macrophage
apoptotic cell recognition and whether Ad-elafin had a pro¬
tective role. A variety of cells, such as lymphocytes and neu¬
trophils, are routinely used in experimental systems as
apoptotic target cells. We chose Group 1 Burkitt lymphoma
cells (Mutu I) over neutrophils because of the absence of en¬
dogenous HNE in the former (HNE levels were below the
levels of detection from apoptotic mutu cell lysates, see Section
2), which could have interfered with our assays. Previous work
has demonstrated that binding of viable Mutu cells is negli¬
gible in this system and any interaction that does occur is with
spontaneously apoptotic Mutu cells [19], Macrophages were
either untreated/uninfected (control) or infected with Ad-elafin
(Ad-dI70/3 as a control) and incubated where indicated with
HNE. In a variation of these experiments, the CD 14 blocking
antibody 61D3 [7] was used in order to provide a positive
control of CD14 blockade. Fig. 4 shows that HNE treatment
of untransfected cells inhibited Mutu cell recognition by 54%,
compared to untransfected cells alone. This level of inhibition
was comparable to that of 61D3 treatment. The prominent
role of CD14 (the 61D3 antigen) for interaction and initial
tethering of apoptotic Mutu cells with human macrophages















































Fig. 3. Comparison of HNE inhibitory activity of macrophage culture
supernatants. Macrophages were prepared and infected with Ad-vec¬
tors using the protocols described in Fig. 1. Following incubation with
HNE, culture supernatants were removed for determination of residual
HNE activity. Supernatants were transferred to a microtitre plate and
cleavage of a chromogenic HNE substrate was measured spectropho-
tometrically over time. P values are given for the comparisons of Ad-
dl703 (control adenovirus) and uninfected cells to Ad-elafin. Data are
means ± S.D. from experiments performed in triplicate on three sep¬
arate donors (n = 3).
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Fig. 4. Elafin protects macrophages from HNE-mediated impairment of Mutu cell recognition. Macrophages were cultured and infected with Ad
vectors using the same protocol from Fig. 1. Where indicated, HNE (1 gM) and r-elafin (2.5 pM) were added in serum free X-vivo 10 medium for 1 h
prior to adding the apoptotic Mutu target cells with or without 61D3 (CD 14 blocking monoclonal antibody). After fixing and staining, the per¬
centage of macrophages interacting with apoptotic Mutu cells was calculated. Interaction counts performed on macrophages that had not been
exposed to Mutu cells are also shown to exclude any significant contribution from apoptotic cells originating from within the culture. P values are
given for each comparison. Data are means ±S.D. from experiments performed in quadruplicate on three separate donors (n = 3).
peptides against the otvp3, integrin (Vitronectin receptor) and
CD36 produced little if any reduction of apoptotic Mutu cell
interaction in this system [19]. Interestingly, when 61D3 and
HNE were used in combination, a further decrease in recog¬
nition occurred, suggesting that the sites of action of 61D-3
and HNE are not identical. It is likely that in addition to
cleaving CD 14 (Fig. 1), HNE is interfering with additional
(unidentified) surface receptors in our system and notably the
degree of inhibition never approached 100% even with 61D3
and HNE together. HNE cleavage of the PSR was associated
with reduced ingestion of apoptotic Jurkat cells by human
macrophages [6] and the role of PSR cleavage in reducing in¬
teraction in our system is unknown.
When r-elafin was added extracellularly with HNE, macro¬
phage recognition was restored to normal values. Similarly,
when macrophages were transfected with Ad-elafin, prior to
HNE challenge, a very significant increase in macrophage
recognition of apoptotic cells was obtained, compared to un-
transfected cells and cells transfected with Ad-dl70/3, demon¬
strating the elafin transgene specific effect (Fig. 4). In addition,
Ad-transfection on its own (Ad-dl70/3 and Ad-elafin) did not
influence apoptotic cell recognition. HNE, Ad-elafin and Ad-
dl703 had no effect alone on the background rate of apoptotic
cell recognition in the absence of apoptotic Mutu cells (Fig. 4;
2nd, 3rd and 4th bars from the left).
These results illustrate the potential of elafin gene therapy to
rescue the capacity of macrophages to recognise apoptotic cells
in the presence of HNE. Although expression of CD14 was
relatively preserved in Ad-elafin infected macrophages
(Fig. 1C), the effect on residual supernatant HNE activity was
less marked (Fig. 3) indicating the possibility that elafin may
facilitate apoptotic cell recognition through additional mech¬
anisms. Indeed, we have shown that elafin has broad ranging
anti-inflammatory properties, inhibiting the action of the
transcription factor NF-kB and the release of pro-inflamma¬
tory cytokines such as TNF and IL-8 [13], Since HNE has been
shown to have pro-inflammatory signalling effects [4,5], it is
likely that the Ad-elafin transfection of macrophages provides
a further anti-inflammatory signal beneficial to apoptotic cell
recognition. This signal would reinforce the endogenous anti¬
inflammatory phenotype conferred by binding of apoptotic
cells to macrophages [24] that may otherwise be diminished by
HNE. Interestingly, the endogenous synthesis of another
neutrophil elastase inhibitor, secretory leukocyte protease in¬
hibitor (SLPI), has recently been shown to be up-regulated
following macrophage recognition of apoptotic cells [25],
However, as pointed out by Odaka et al. [25], the slow kinetics
of production of SLPI after the apoptotic cell recognition
event suggests that SLPI is unlikely to act in vivo at an au¬
tocrine level during the onset of the interaction but rather in a
paracrine fashion, during phagocytosis of incoming cells.
In summary, we show here that using adenovirus as a gene
transfer vector in a hybrid method with lipofectamine as a
facilitating agent, it is possible to very efficiently transfect
monocyte-derived macrophages ex vivo with elafin, a potent
elastase inhibitor. This rescues these cells from an HNE-in-
duccd pro-inflammatory to an anti-inflammatory phenotype
favouring apoptotic cell recognition and clearance. The po¬
tential for systemic delivery of macrophages transfected ex
vivo with antinflammatory genes has been demonstrated in
murine glomerulonephritis [26,27] and this methodology may
prove useful in inflammatory conditions where direct use of
adenovirus gene vectors is precluded, because of their intrinsic
immunogenicity. Cystic fibrosis, characterised by an excessive
load of unchecked HNE and a recognised "paralysis" of innate
immune mechanisms [28], provides a fascinating model in
which to test this paradigm.
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